<SEC-DOCUMENT>0001711279-22-000058.txt : 20221107
<SEC-HEADER>0001711279-22-000058.hdr.sgml : 20221107
<ACCEPTANCE-DATETIME>20221107071156
ACCESSION NUMBER:		0001711279-22-000058
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221107
DATE AS OF CHANGE:		20221107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		221363700

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krys-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e,d:558d66f804d0487883dba3662b46c183--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:krys="http://www.krystalbio.com/20220930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl8zLTEtMS0xLTMyMzA5_9e2bc651-42d9-4835-9417-b6cee774c5a8">false</ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl81LTEtMS0xLTMyMzA5_d2a6a1d1-78de-422a-a600-d48fe7262915">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl82LTEtMS0xLTMyMzA5_29396079-5fce-463c-978a-b0315ec22d28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl85LTEtMS0xLTMyMzA5_3aca8c7a-1f97-4b35-ae80-4a709ec0cfec">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl8xMC0xLTEtMS0zMjMwOQ_662ff818-0ed0-4e09-b8ea-e131278b999d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i486816b282c448beb5dfc59d3dd09a4b_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjAw_1d212468-e6cb-466c-91ca-14c8b3f2974b">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d41541995b4fe2ab20091cba0c85c2_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775193c878c44f59b88bf9723aa001a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd74b71c5964f71aee86633bf510cf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2775a9a719c3456a9237c8c0bfe82b9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152425a33b7e4cbcb9970cc97b2cace5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3634606c684047bba8c4d34eaa98022c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840b1bacbbf34eb686c537dd492045ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8eec4dac16a4daab1a85db49aaf6f9f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2f3d8999c54a118d9796dcfca0feaf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10b23711a0741f5a1c060825f98ba98_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f996c6f367a493784f701839cfebdee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60635a52ed064f588cfe46ee6683334f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf27db60a1c497cbf41c87a9b613266_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3185b9d4440145839e7322dfeaf5e54a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895df53b1ba54daab24b6813c0528941_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fd3e7bf09145a0ba746d34252ffa18_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa7c0396011440f81f7befcb8eedf7d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9c70f6616c4a18acab21995ed3bd27_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ca242fc83249a2920e7e8a2eeda3fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5edf79ca55d4b1c92d3dde303374d72_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0c84181c984977949009a857d8fa3c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57a417ebdc84df6a8e2b1cade9e5951_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2883f5567f477db55ba6210ef2d8ef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72689f291e4242d5be528af1c05de8d9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4ab7f7eb574fbebd360c4189819573_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1651b324e8e341258e711103298899a6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia512091aa9cc474e8677a732ef039459_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b263a75424b4a47848e30c65da9385e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20636276ad04e9d896807348404d0a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ad0ed0f0ad43ed8c2ee76bcadd6adc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8627db24c8ef4f7e8eb028920efbc320_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97649db97aba4548addc129f6b210a44_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b37f8044404214ab59a210c61d1bf8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2cb27f4b2244b9482d9a7a4799cb32e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890467fedbdd4ba3aa14064c4d4782fb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07652d3bbafc4de89373f4382ad0adeb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2bd578d48664208ba4ed1ca9a668b4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecc2576a4cf40d2a8e639f2124feb66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3dd1fba9fd4476eacb885999e7f77e7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ea41483449459b936d6bca734640e9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b6c2cb1c8a494fa13868c00724fde9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6cdd346df1c4094b1949ffe62f42958_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219a217858014087b2e593831b4b4195_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e8f6cac3a6489e8ba7ec64fc5e26ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbe031717624bf18894ff53096917ee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09fb66d89a964f519eef9b01dd2a64dd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i804e7ae90e0c4170b9443943d0900e79_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59b3698ee4784a65906fc83187b5d36a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30cb962689ff4c3aa3dbddb683a95c6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9eca0e9d35b487a8f129507b42cea8c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b010cf48b94020be75c64bcf4ef43e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90cb5ac5c4eb41499523aaf1cda7629c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ce97a3eb9f46338729167ca12679df_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6597ad2d405542ce9626662507030a7e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="id2aebf72749342469c8fe09700344c6b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120f39a8c06046dc8927af6d7756608e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54b929ec80d44839ff7152507ca4c1c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86399381f2054cfb96cf8e0c08c527fa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf8290ed1234e40ae5260bc12184c04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ce38678ccd4f96b65c96b347657521_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2711458b1a41d6b98bc1413bdbc152_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b2986e81f44720abbc09b89ba3a446_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57420e235a64a5fb3a723c554ea7d5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdca84ad76694a69aee10fc9cfd0e0f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8f94d206814d259cc04e6134260599_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0521592fe8214fdcbf9363ed85d04e75_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8fa447f8214bfe917bfea3629882f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e1c1e1be2f4fca992ef8ae2c01448e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2564b238dda24ae892c179c7d56fe33c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed83ef245114b17b4ec315c5b79e99a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if128286fde8e48bda27846143219a6a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b0d7eff19849baad70f4c1ccf194fb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6efb41c0e52f44a8bf5e1dc4ac1647b2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ecfa420d4d405385cf50e5cbda74b6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a570d866504e0a94f3b9b2a20a2f8d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9e5b5c9da54691afa3f377ff8c028f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030326b8c06846669784eeba5596ca2f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3954f8ffb03540639aa7f22b7c875a2a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i375366091dbe420e8154d3503d92c83c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b32c1a4a1954edc8663be651ea566e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b3fa0dd16b46198ffe62a62527cae5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6644b768bf541ba8408590ac2dd5956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51fb68a8e9dd42179b7f44937fd02d2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d41d0a58bfe460d9793cfbb8d115862_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55754357bb34466811d0d9b089fbfb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77eb6667d87d4a48a23a1c05f70f0054_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8814b6e4d26342739fbd6b838acaa863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6166c735944a67af8bad5424f2374d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c0695b52704d2aab04ad37cd4579dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7c1ee294504734a051a54cc80afd33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132a91679b794ea4b461110cc358acba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1c894de1ca4c588bcceda18014bc3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6bc2ff934854878b2f463664d5a6acc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c13850920c64e95897ca644335b133d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169676a81ad4497aa2d1347caf2c7e5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae71768f86a84ff38722ac63232d8be0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0eecdcc8e5048a587e31bc5751ed3fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39c0b6bc40a420b862bc4cf852d00bb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idff5589cd93c46cb87913f248b6eb315_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff436f8b9563446293b5781dc7e26b82_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574448c6d24c4a17ad6bf5c2ba879888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce49bed180d47aaa7a25633ed9e0d0a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2103bb237f91481a841947ba35171c0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1647014b96864f48aa14287e6d16e887_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687bee7c6c9147be9f354df54817d16e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3928d17425554a3a99f3ba2ebcf67515_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7df56418f54686af3bd73d39453c69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib688aa903552456cb0df8bb52f2a6c35_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753b83af693442cdaf1ec67d12b5d9a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i389d7854847544d0bf805ab6494af671_I20160526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i51995febb28d40aca39ea569c56e2121_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ShortTermAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c7af875bb2430591fb076cbadd84fd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7872ff13c54442a94e52d5702cac2a_I20201005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7d043bf3db47c0ad21c9a2482c6d41_I20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1c15e03628914d43970aaad1d2908cff_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42838452e79140c2a17a6b085770b63a_I20220516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84afbfefdee44283aad3240ba9ff5307_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee48ed1af849452cb48d2605517b57ce_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a5f95e9ca04dbeaedc4b0678713b09_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d346d3ba744ec1b1737860d62e3b84_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b281ab636c94ea6bd90e055d3589ac1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc55688aaad54360ab017dae30869a94_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185716a2727648acad1bd93183ea6948_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c7ee9b693a458cb42ad232c2bffc54_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3429310d21c54f51b8a52e3cdd70ecaf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e01a31d978c42ffbd78aa936eef3109_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61a04c79d69473eb9ccc0fb8188c965_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf130c14e7754e39a5e8a947488cdf56_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6103d6d6474ab09e162650723b7b42_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1e5a79af6a486eb62a8e55c89d9956_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>krys:milestone</xbrli:measure></xbrli:unit><xbrli:context id="ic785c649e5754160bc5a5ec1d8456f79_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c03d6d59cb46e1980e5371e1219705_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5333910ddc449b91395b95aedb3b6e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic437ced0a09847f29ac47c72470b481a_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880fa33842f74d9c9c0071788d237821_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6402aea5802416894421190b1b7c2aa_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia911f16a65084debb3a3812c943cd418_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afdf84dc726448aad231c9d735efdf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9468c5dcd0a64aaaad772669a3b8abe9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9295b53dfb2645f78dbe60fefa07587f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fb2504463a49eda96d3323c25ec8da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1559256d15ff46e2b6b221d76549e677_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0041f489e334ddba2da2707d6d6515d_I20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce1955630ff46e58df59ed150227ca5_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543a231c136d4fbea8192a671046f7d2_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6a49f61bf04d37ad841675aa460161_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486816b282c448beb5dfc59d3dd09a4b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5d78fd59e541a99ea4c0f4e1de1d37_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bafc7ab51364dee96000779f13a8763_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b84e5d94eed444397515564515f6e25_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554b9366933442a2aa09ffe226b09237_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4944831e440c4e57954464b8eac273a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id88546130308412087cf656552ac4dad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4673f017ae43eaa5817b3e918cb7df_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38e44d1e815453f9fa009b512d8c70b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f08e8bf17b425f835e3620c83e2398_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2103c585e344ff197ab0e7bb4cc2ae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bd4f06054f4551a0c04a0a482190a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i977428fb79094a95b2d8d909cdd22eaf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id108621ccf904c55942c6ee24593df70_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0e76d9070c4128b90730ceba7e6793_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9ff3681fe9437586096cd7401ca9ce_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7d2608b4e8487e85fca38da9b0a67c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8420fcd5952417fa51cddbbcf6d44b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312172e49cc6483fb8ba4c537f5a773e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09e88a222d54915b2b03b547c38c599_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c42738289064a8ea522bd02105cc6c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf80894786944bc1920dbabf15657881_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327eb87761364089af22aa767f369073_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124dbd40c51a45a2bf0196c7305130a2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3ffb69ea7a49f2a999c26d33b7fd55_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4fe3e9d3d544384841d12bece5bca42_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e6fb6eea9d48e1a6a317593df48bf6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia304daa15c32499381cbc07b635d095c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec14cf55416487cb3ce5a09f7e544f7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i558d66f804d0487883dba3662b46c183_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYx_4387d276-1b65-4f66-9808-d4328e11d48c">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6OGRhZTIwM2MxNDA1NDkwMzhkOWVjNzk4ZWJlZjZmZjUvdGFibGVyYW5nZTo4ZGFlMjAzYzE0MDU0OTAzOGQ5ZWM3OThlYmVmNmZmNV8wLTAtMS0xLTMyMzA5_35de4c8b-9067-4895-8457-acb1ad1904e7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDI_f0ca4eeb-dfa6-48b4-b035-24b232edd8cf">September&#160;30, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6OWI4ODJiM2ZlMjY5NDg5NTkxMjdjZTE3MzFiZDJhMTQvdGFibGVyYW5nZTo5Yjg4MmIzZmUyNjk0ODk1OTEyN2NlMTczMWJkMmExNF8wLTAtMS0xLTMyMzA5_939c5a24-4f90-46d1-b4ca-10b8ca4ca6c3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY4_405e9160-4ed9-4979-8fc1-969cde95b3d7">001-38210</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcw_a15fdc6b-bd6e-416a-8d19-038571a6d208">Krystal Biotech, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ZTU1MjQ4MzY0ZDQxNDc4OWI4YzE2N2VjOTFhMjUwODgvdGFibGVyYW5nZTplNTUyNDgzNjRkNDE0Nzg5YjhjMTY3ZWM5MWEyNTA4OF8wLTAtMS0xLTMyMzA5_8f90a640-f724-4faa-a32c-85b54268f25a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ZTU1MjQ4MzY0ZDQxNDc4OWI4YzE2N2VjOTFhMjUwODgvdGFibGVyYW5nZTplNTUyNDgzNjRkNDE0Nzg5YjhjMTY3ZWM5MWEyNTA4OF8wLTItMS0xLTMyMzA5_3d048021-fbca-4707-9331-ea0264ab55a4">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU3_f207589b-e058-4f08-861e-c16185df9c4b">2100 Wharton Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY0_a57b5655-861f-4ea3-8fc0-b08606af9dc6">Suite 701</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcz_6122b57b-f6bc-4424-9b15-ded1c3955c86">Pittsburgh</ix:nonNumeric>, <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYz_307c4c40-b298-49b0-8f00-a9680fb6492a">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF81OTk_7ecdc0b0-01e1-4df7-9e85-f12156459c31">15203</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU4_dc414435-5c05-45de-a638-b6d380072715">412</ix:nonNumeric>) <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY1_867072c3-73f0-400e-a94d-5ea344734534">586-5830</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTAtMS0xLTMyMzA5_ebc3d989-abe6-4bee-a54d-bcc1a8a42042">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTEtMS0xLTMyMzA5_fdd512ec-3436-4124-87db-e957ea945032">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTItMS0xLTMyMzA5L3RleHRyZWdpb246NTc3MmE3MTUyMmMxNDI0OThiN2FkOWRjNDIxNTJhYmFfNA_b56a20e1-677a-4fea-b807-0962a3034a15">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU5_36f5f773-474e-4d42-9d8c-f6fa4e910396">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY2_0c31382a-f634-4403-8dcf-06f4c59fffc9">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ODgxODZkYWM5MWY3NDI4MWFmN2YyN2Q5NjA1Nzc3ZTMvdGFibGVyYW5nZTo4ODE4NmRhYzkxZjc0MjgxYWY3ZjI3ZDk2MDU3NzdlM18wLTAtMS0xLTMyMzA5_21f6ed6a-a763-45e3-bb6e-8824d3e71afa">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ODgxODZkYWM5MWY3NDI4MWFmN2YyN2Q5NjA1Nzc3ZTMvdGFibGVyYW5nZTo4ODE4NmRhYzkxZjc0MjgxYWY3ZjI3ZDk2MDU3NzdlM18xLTYtMS0xLTMyMzA5_2be27b02-cafc-4edd-8bdb-6c4118b255ef">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYw_08a72298-8a8d-4d62-a80e-27b2b8e16f7a">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcx_73bdb9e1-e09e-449a-ab30-825b1711032b">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of October&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="if9d41541995b4fe2ab20091cba0c85c2_I20221031" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF81NDk3NTU4MTY0MzM_2570e3d7-a887-4281-8e27-d7e538cc9289">25,747,647</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_13">Financial Statement</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_13">s</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_16">Condensed Consolidated Balance Sheets as of </a>September&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_16"> and </a>December&#160;31, 2021 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the </a>Three and Nine<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_19"> Months Ended </a>September&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_19"> and </a>2021 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the </a>Three and Nine<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_22"> Months Ended </a>September&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_22"> and </a>2021 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_25">Condensed Consolidated Statements of Cash Flows for the </a>Nine Months Ended<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_25"> </a>September&#160;30, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_25">  and </a>2021 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_58">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_58">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_82">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_82">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_85">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_91">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_94">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_100">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_106">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_106">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_109">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_109">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i558d66f804d0487883dba3662b46c183_112">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i558d66f804d0487883dba3662b46c183_112">34</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i558d66f804d0487883dba3662b46c183_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i558d66f804d0487883dba3662b46c183_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNC0xLTEtMS0zMjMwOQ_be1601b4-bd8d-4990-9513-7126cdd368e5">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNC0zLTEtMS0zMjMwOQ_e63d77b7-2151-419d-ad3d-6862ed88b152">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNS0xLTEtMS0zMjMwOQ_a2e570d2-b604-48bd-8646-1521de805e36">208,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNS0zLTEtMS0zMjMwOQ_aac274b3-35bd-4def-bf41-77724364f177">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNi0xLTEtMS0zMjMwOQ_ea33eec0-e766-4888-b392-52eb81d121d5">3,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNi0zLTEtMS0zMjMwOQ_1c359b13-f5be-4509-b37b-2ae59c4c11c4">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNy0xLTEtMS0zMjMwOQ_3fa69c20-fe92-496c-8c07-90d65502f5be">397,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNy0zLTEtMS0zMjMwOQ_aae909ce-b890-4a9e-80de-007e0fbbbce0">442,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOC0xLTEtMS0zMjMwOQ_29e9b2af-a61b-4c7e-b4f9-67bf937a6b25">157,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOC0zLTEtMS0zMjMwOQ_4864a833-7e4a-4220-9d8f-d08b937f7cb5">112,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOS0xLTEtMS0zMjMwOQ_a4fb1b9d-6949-43ae-97b4-fef69acfce65">12,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOS0zLTEtMS0zMjMwOQ_69017f24-c9e2-4375-a6b0-197a7c9c7087">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTAtMS0xLTEtMzIzMDk_6c71d2c7-7383-4f63-ab17-624f0fc86be4">8,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTAtMy0xLTEtMzIzMDk_0c3e7594-0462-4ad1-9819-37feafd56786">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTEtMS0xLTEtMzIzMDk_cd8e9edb-24ed-40cf-8275-626ae8eb6893">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTEtMy0xLTEtMzIzMDk_8794b393-e7a6-436b-bcbf-12f83d545f34">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTItMS0xLTEtMzIzMDk_6d54c019-a6c4-4370-ae74-6f9cac8e95e4">576,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTItMy0xLTEtMzIzMDk_fbc62f8e-e082-4ee5-9030-1063d6838d1d">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTUtMS0xLTEtMzIzMDk_f164211c-faa1-4695-8035-41dbd0e3d45e">5,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTUtMy0xLTEtMzIzMDk_04fd0183-e658-4f56-bee0-711781205bdd">8,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTYtMS0xLTEtMzIzMDk_e1ded526-dc64-4e8d-a1c3-e45e3c19414f">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTYtMy0xLTEtMzIzMDk_2ccba2a2-356e-4af7-b999-0eb4fcf72881">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTctMS0xLTEtMzIzMDk_0aff9081-56b5-49ef-9f21-3e12c4e453ea">20,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTctMy0xLTEtMzIzMDk_6fa9f1c1-0f6b-4e99-9a83-931b4f3ecd92">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTktMS0xLTEtMzIzMDk_221597f5-4985-40f2-997a-8abce13b0487">28,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTktMy0xLTEtMzIzMDk_a6a19c95-8d12-4b37-9f23-36d30dd115b1">25,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjAtMS0xLTEtMzIzMDk_443f9f77-9519-4fb7-81d6-d84a1fa52cfb">7,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjAtMy0xLTEtMzIzMDk_fed7f12f-2ba0-440f-9b9f-a991d1331160">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjEtMS0xLTEtMzIzMDk_dfb06761-6750-4417-98c0-7943e1d523ee">35,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjEtMy0xLTEtMzIzMDk_422c9734-548d-4fc2-be8a-5d0f6bc8dbe5">32,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjItMS0xLTEtMzIzMDk_6920e9bf-df3d-4162-81cd-f84bd2d4f523"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjItMy0xLTEtMzIzMDk_a3d27136-e57b-465d-9ebc-a29a85eb9e6c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18yMQ_74ad305a-9f1b-410f-ad9b-1a60dccc51f4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18yMQ_79a47d81-eda6-431e-b19d-1b56e33016d5">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18zNQ_43263da8-6dae-4a94-8eff-963a9f4defde"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18zNQ_d4636e66-b4bc-4c9f-81c0-a6b6062bb9bb">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; September&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N184NQ_45cb5986-a277-46b0-99d4-65d9cbc67cf0"><ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N184NQ_c96703f8-d0ad-499f-bd50-ffc61006cb73">2,061,773</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued, and <ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18xMTA_1ed14507-88b0-404a-a370-735cbff1958d"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18xMTA_7cd93131-b99a-4d73-b1d3-549263b6e77c">no</ix:nonFraction></ix:nonFraction> shares outstanding at September&#160;30, 2022</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMS0xLTEtMzIzMDk_0159f434-8799-4a6c-9df1-dbac47aa3641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMy0xLTEtMzIzMDk_48fafd8b-40ce-4507-adee-9e5eb3325228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xOA_222ba38b-0a72-471e-b447-4310e928ae86"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xOA_3fb8305b-45f7-4aa3-a6f2-3c12e3fa7641">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18zMg_aaf8b6fc-398f-43ef-bc78-d204dc504bd5"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18zMg_e7f55288-5968-441a-a032-b11a3b6b1828">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized a  September&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y184Mg_0ae5042a-52f8-442a-bd35-c4e84ceffb4f"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y184Mg_3c983527-c1aa-460d-b6c5-5c7138befe57">25,709,664</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2022; and <ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xNDQ_3aa9e5f4-32dc-4ccb-a7bf-bbf2a4f1cefd"><ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xNDQ_a6fad967-2ce3-4db9-99c3-07e954cf8b43">25,207,985</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMS0xLTEtMzIzMDk_884c2db8-33f0-4a4f-af3a-55d5ca5a1fb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMy0xLTEtMzIzMDk_3eb44ec4-a74a-48c8-ac03-63108ef6207e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjYtMS0xLTEtMzIzMDk_0f00d53d-8acc-463c-9f7b-df2fa22f85e1">790,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjYtMy0xLTEtMzIzMDk_712bbe3f-35dc-4800-bcf3-0cbdac2cc4ec">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjctMS0xLTEtMzIzMDk_63606665-5d0d-4231-baab-5ff4c6a7bee7">1,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjctMy0xLTEtMzIzMDk_0a34d048-121e-4e1f-ab24-2515d3c8670d">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjgtMS0xLTEtMzIzMDk_01d5176f-4a9c-4e9d-9cbc-2f0d3d70b933">248,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjgtMy0xLTEtMzIzMDk_cff64c0f-ede2-44f9-a8f1-5b5cac4629d0">140,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjktMS0xLTEtMzIzMDk_1911299c-210a-41d6-8919-7930d91afb66">540,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjktMy0xLTEtMzIzMDk_3e3ba1e8-14d1-490a-bcf3-e934888028a1">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMzAtMS0xLTEtMzIzMDk_60dc698b-b854-4bf0-80e6-c565e16dcec1">576,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMzAtMy0xLTEtMzIzMDk_006e34ce-b6bb-401a-b1bc-53990fdb47b4">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:38.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy0xLTEtMS0zMjMwOQ_5482876b-8624-409c-a92b-beb6fda01cc6">11,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy0zLTEtMS0zMjMwOQ_3616e6f9-965f-4069-8100-6041b68c2b6f">6,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy01LTEtMS0zMjMwOQ_9fbda636-067b-4705-b72d-3adbc9f28d74">31,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy03LTEtMS0zMjMwOQ_bbb4bc54-3d13-4619-a6a4-626929ebd5b8">18,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC0xLTEtMS0zMjMwOQ_8d77b4aa-ea07-45cf-b296-7a2a949f806f">19,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC0zLTEtMS0zMjMwOQ_7e1242cb-cc68-4bff-9188-0cedfb098b3e">9,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC01LTEtMS0zMjMwOQ_d3d35b9f-fe35-408d-a033-c75c130ffd5d">53,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC03LTEtMS0zMjMwOQ_f2f856d4-54ea-40fb-8ceb-1497dcb2d868">27,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS0xLTEtMS0zMjMwOQ_5795b03d-12c5-4e3b-8b32-f9531a0822cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS0zLTEtMS0zMjMwOQ_1e7b240d-1e03-4a23-bda0-5f85bb8f65c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS01LTEtMS0zMjMwOQ_b54454f9-1f54-4ce3-a961-bbd2388aa49a">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS03LTEtMS0zMjMwOQ_aa5cc2fc-8b34-4173-803f-d4677ac590e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi0xLTEtMS0zMjMwOQ_b43cb4ac-e55f-4038-ae57-1e70d77df1ec">31,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi0zLTEtMS0zMjMwOQ_edcbd204-7cfc-4738-a5c1-5560c2ae5adc">15,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi01LTEtMS0zMjMwOQ_9693abaa-3b9d-4b30-aba3-79e900061383">110,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi03LTEtMS0zMjMwOQ_93d0b8da-8d95-42b0-899e-2bed8cd67127">46,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy0xLTEtMS0zMjMwOQ_4c045473-614d-41e3-9169-9f3626f941b7">31,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy0zLTEtMS0zMjMwOQ_982681cd-be9a-4a5f-aa59-1205c17abd87">15,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy01LTEtMS0zMjMwOQ_4056f963-6057-4b0c-ade9-0514a5e5e266">110,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy03LTEtMS0zMjMwOQ_6fc94f5b-a70b-48cc-a804-044c28a60f3f">46,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS0xLTEtMS0zMjMwOQ_6bdad474-0413-4bf7-87f3-fdccd7dc1390">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS0zLTEtMS0zMjMwOQ_26e3a281-90dd-452f-b7a3-7602715c327b">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS01LTEtMS0zMjMwOQ_95114045-ad8e-4b96-80fb-08164203f70e">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS03LTEtMS0zMjMwOQ_a3ef526b-ed03-4dfe-bb80-339b7420ffca">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtMS0xLTEtMzIzMDk_8d96324b-ff0d-4d5d-9f4d-9969b9ce1dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtMy0xLTEtMzIzMDk_d16e5eb0-5bbc-43df-885a-073f967b5e18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtNS0xLTEtMzIzMDk_2df8a70e-6051-4ffa-83a6-6b967980ff31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtNy0xLTEtMzIzMDk_f5539d6a-cb0f-49b4-8a1f-e619d0088131">1,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtMS0xLTEtMzIzMDk_74dae3ac-7eff-473a-9861-70b8663af050">29,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtMy0xLTEtMzIzMDk_c106287e-1330-40ea-8e2b-f6bff7b8f6f8">15,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtNS0xLTEtMzIzMDk_d9f264dd-3810-4673-b9ea-1d3c7aa2682d">107,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtNy0xLTEtMzIzMDk_5778562b-a077-4ab9-8261-27e90db9a6aa">47,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItMS0xLTEtMzIzMDk_5230b510-eb4f-4260-8a0b-56bef4bfc039">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItMy0xLTEtMzIzMDk_7c2c06c3-c76f-4d34-994a-9834b6531663">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItNS0xLTEtMzIzMDk_6fadbd6c-f609-403f-9639-fa583916409f">1,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItNy0xLTEtMzIzMDk_51a9c904-5590-4755-8540-5443f460b3cc">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtMS0xLTEtMzIzMDk_52bf958d-5f1f-480d-9cbe-915c8b853c5d">29,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtMy0xLTEtMzIzMDk_cad20700-80a1-49e6-b6c6-d884ae651789">15,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtNS0xLTEtMzIzMDk_5e8f6933-596c-4809-b8db-594bc850cfb6">109,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtNy0xLTEtMzIzMDk_76da43f6-ebdc-464a-93a4-1d62544d9acd">47,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMS0xLTEtMzIzMDk_3bdafda1-5f71-4d77-96e3-64fc88c63f29"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMS0xLTEtMzIzMDk_501b7ace-92fd-4f86-9e30-09658267ebd6">1.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMy0xLTEtMzIzMDk_92d29c3e-e0bc-4e33-9a31-5f2580bdfd09"><ix:nonFraction unitRef="usdPerShare" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMy0xLTEtMzIzMDk_d818ee47-0fb2-4ddd-9ee5-6084bbf2ad32">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNS0xLTEtMzIzMDk_418b413e-03f4-499c-8729-877d941625da"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNS0xLTEtMzIzMDk_b041ae85-01fc-4d53-b5d7-c6be253c4b80">4.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNy0xLTEtMzIzMDk_2636aa88-4066-4211-87d9-5c6d57cb8f5b"><ix:nonFraction unitRef="usdPerShare" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNy0xLTEtMzIzMDk_a40b114d-59f0-4b88-9622-2b7473304576">2.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMS0xLTEtMzIzMDk_402b2894-cc13-4489-b2c2-e65d84c5f2a9"><ix:nonFraction unitRef="shares" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMS0xLTEtMzIzMDk_b3d8d660-281d-4c90-ba08-9a9350df584e">25,619,125</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMy0xLTEtMzIzMDk_1d16f6f4-2db2-45b7-8a29-87abec89b4b5"><ix:nonFraction unitRef="shares" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMy0xLTEtMzIzMDk_27b379fc-073b-4b8c-9766-b83fa7ff0851">22,212,266</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNS0xLTEtMzIzMDk_ab13f971-dbb6-4468-afed-6d5359e5eb7f"><ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNS0xLTEtMzIzMDk_fb666474-4aa4-4bf4-ab61-e3f6ec261ffa">25,428,097</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNy0xLTEtMzIzMDk_d1062314-81c1-4e3b-8123-ce1fa4b54ddd"><ix:nonFraction unitRef="shares" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNy0xLTEtMzIzMDk_d37b974b-bee1-42f9-865e-7d07187b02e7">21,893,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i775193c878c44f59b88bf9723aa001a7_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0xLTEtMS0zMjMwOQ_a5b7de49-9798-4342-95fc-ce5def0be4c9">25,207,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775193c878c44f59b88bf9723aa001a7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0zLTEtMS0zMjMwOQ_b4e04624-d652-4bb0-9b06-3833db95532a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd74b71c5964f71aee86633bf510cf2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy01LTEtMS0zMjMwOQ_a6672d90-e08c-4ac4-b6b7-945370ef8069">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2775a9a719c3456a9237c8c0bfe82b9c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy03LTEtMS0zMjMwOQ_d1e07850-8d89-4a2f-bb52-f075b262c53a">163</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i152425a33b7e4cbcb9970cc97b2cace5_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy05LTEtMS0zMjMwOQ_c533aabf-affd-4e24-bd59-5344ce2e8cef">140,784</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0xMS0xLTEtMzIzMDk_bd2bb63c-bc2c-42d1-913a-6ceaf992555d">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC0xLTEtMS0zMjMwOQ_5737c8f5-fc26-4bd0-b908-8757a46b103c">1,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC01LTEtMS0zMjMwOQ_1697b4f8-0bec-4af5-929c-8e253e7ed1d7">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC0xMS0xLTEtMzIzMDk_d3d85730-2a50-4738-9a03-31b5615045f9">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS0xLTEtMS0zMjMwOQ_373cd35f-f01a-4833-9260-ff0a0bc93d00">10,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS01LTEtMS0zMjMwOQ_2141eead-9c28-474d-882e-5e03a28bd990">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS0xMS0xLTEtMzIzMDk_249e59b0-c0f3-435e-a76f-d76cb8a162e4">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNi01LTEtMS0zMjMwOQ_3e4fa06e-8e60-41cb-a707-9c4b8f99e996">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNi0xMS0xLTEtMzIzMDk_cbced6ab-a480-4327-bbbc-83bd33a4506d">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3634606c684047bba8c4d34eaa98022c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNy03LTEtMS0zMjMwOQ_b7f693ec-111a-466e-a18a-9319b3646aec">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNy0xMS0xLTEtMzIzMDk_d7303f78-ee5c-415d-8562-ea3b3a895811">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i840b1bacbbf34eb686c537dd492045ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOC05LTEtMS0zMjMwOQ_edacbd0c-d2b9-4154-8aeb-45d67254ec71">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOC0xMS0xLTEtMzIzMDk_65d264a5-61e8-4288-ae93-93fabbca8ecb">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0xLTEtMS0zMjMwOQ_ee06bb32-87ab-4d59-9010-d43e0d5aa3c6">25,199,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0zLTEtMS0zMjMwOQ_1e1331aa-549f-4ad9-9e89-46c05ccc6cc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8eec4dac16a4daab1a85db49aaf6f9f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS01LTEtMS0zMjMwOQ_f1ebc9e3-9bee-4b50-9224-bcf597e4010c">740,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea2f3d8999c54a118d9796dcfca0feaf_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS03LTEtMS0zMjMwOQ_d223106b-844d-491b-a548-56ed686bb070">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie10b23711a0741f5a1c060825f98ba98_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS05LTEtMS0zMjMwOQ_fb641333-1ce2-4e47-950c-bad675b1f93c">190,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f996c6f367a493784f701839cfebdee_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0xMS0xLTEtMzIzMDk_293fbaf6-6f06-434f-98ff-95cc520c8cef">548,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60635a52ed064f588cfe46ee6683334f_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtMS0xLTEtMzIzMDk_da57cb18-3bdc-4f9b-9816-b8051f9d1319">472,706</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtNS0xLTEtMzIzMDk_ce8686b5-2b68-41b6-8fd9-e8e74384c6fb">30,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtMTEtMS0xLTMyMzA5_b25b35a0-9d73-454c-8ddb-68ddb3d46c8e">30,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTEtMS0xLTEtMzIzMDk_88b0a64e-b80b-436e-8728-6ac45e0ff8eb">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTItNS0xLTEtMzIzMDk_7a1f0e14-f90d-42ec-a5b6-98fadbda2158">8,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTItMTEtMS0xLTMyMzA5_353cc4e4-0b97-4cb1-b2a5-cd2e01dd7b8d">8,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf27db60a1c497cbf41c87a9b613266_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTMtNy0xLTEtMzIzMDk_05c82cd1-14b2-43b9-b9b0-30809a5f6967">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTMtMTEtMS0xLTMyMzA5_74760308-e0ad-4c75-96d0-96d32f5c0370">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3185b9d4440145839e7322dfeaf5e54a_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTQtOS0xLTEtMzIzMDk_bb7fdb83-89ef-4195-905a-5b8b390153b3">28,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTQtMTEtMS0xLTMyMzA5_e74076cc-9b58-49ef-b9ee-91321c2a10a1">28,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i895df53b1ba54daab24b6813c0528941_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMS0xLTEtMzIzMDk_2975ebac-6c32-4a94-9ef1-ff0d0c24fe21">25,664,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895df53b1ba54daab24b6813c0528941_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMy0xLTEtMzIzMDk_098e6c82-838b-4354-8e4d-c4f2e904ee35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fd3e7bf09145a0ba746d34252ffa18_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtNS0xLTEtMzIzMDk_6e5e4b76-3890-4189-8c9a-2eb1ba3129ed">779,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa7c0396011440f81f7befcb8eedf7d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtNy0xLTEtMzIzMDk_dc77fb0a-ef2c-40b6-b929-c03903584031">1,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9c70f6616c4a18acab21995ed3bd27_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtOS0xLTEtMzIzMDk_d8fa805d-d646-4d09-bbda-add2be114611">218,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ca242fc83249a2920e7e8a2eeda3fc_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMTEtMS0xLTMyMzA5_3084a7e3-babe-4688-b983-18129bcd8d79">559,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5edf79ca55d4b1c92d3dde303374d72_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtMS0xLTEtMzIzMDk_4515b419-c088-402f-a855-fda56a8e54e3">45,377</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtNS0xLTEtMzIzMDk_44801026-7621-45ad-98dd-e3d8367ee1be">2,176</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtMTEtMS0xLTMyMzA5_6e084f40-3468-4d79-ac41-bfeaa19e76dc">2,176</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTctNS0xLTEtMzIzMDk_e8730c00-8afb-46f0-9799-db6ebdb31f6b">9,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTctMTEtMS0xLTMyMzA5_a7db328f-2487-4458-a6ec-5e4fcdefb2d3">9,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0c84181c984977949009a857d8fa3c_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTgtNy0xLTEtMzIzMDk_28d6282f-40a7-4577-8648-a45f2439e8b6">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTgtMTEtMS0xLTMyMzA5_6d79ab1b-5eca-4c6b-b986-586f67d7ec41">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57a417ebdc84df6a8e2b1cade9e5951_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTktOS0xLTEtMzIzMDk_9e1a5b64-03f8-46f5-9ffe-2a593fed94ea">29,850</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTktMTEtMS0xLTMyMzA5_80676a72-0bc2-4fab-a4f5-66c77a05d92f">29,850</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2022</span></div></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c2883f5567f477db55ba6210ef2d8ef_I20220930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMS0xLTEtMzIzMDk_c10f4fe0-1006-423f-9772-5ed8efe82e01">25,709,664</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2883f5567f477db55ba6210ef2d8ef_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMy0xLTEtMzIzMDk_50d4da83-506b-412c-9d07-65eaf6a417a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72689f291e4242d5be528af1c05de8d9_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtNS0xLTEtMzIzMDk_0f25833b-0438-47a1-a682-44cef4be8584">790,954</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4ab7f7eb574fbebd360c4189819573_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtNy0xLTEtMzIzMDk_d0db8166-7eff-4e6a-9dcc-7a08ecbf9d29">1,475</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1651b324e8e341258e711103298899a6_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtOS0xLTEtMzIzMDk_c3059603-3561-4347-9964-912aa6ec574e">248,707</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMTEtMS0xLTMyMzA5_bb3c93e0-8217-4e8c-9d12-b8be2907213e">540,772</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia512091aa9cc474e8677a732ef039459_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0xLTEtMS0zMjMwOQ_ce5239bb-0678-41c5-9d21-2b225c53c21c">19,714,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia512091aa9cc474e8677a732ef039459_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0zLTEtMS0zMjMwOQ_93491fd4-e461-45c4-b130-1e320dc337e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b263a75424b4a47848e30c65da9385e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy01LTEtMS0zMjMwOQ_80d43b50-7ab7-4eab-bdfa-c3572bea3992">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20636276ad04e9d896807348404d0a1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy03LTEtMS0zMjMwOQ_b8ab6127-300e-4db8-b05f-943fe7b26173">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ad0ed0f0ad43ed8c2ee76bcadd6adc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy05LTEtMS0zMjMwOQ_f7a17f31-b8d4-4b54-bb4d-2c5dc7ab8121">71,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0xMS0xLTEtMzIzMDk_df2c5041-65c7-462a-ae74-644423b3b7cb">292,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8627db24c8ef4f7e8eb028920efbc320_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC0xLTEtMS0zMjMwOQ_d0e2876a-edba-4f3d-b2ae-670e1d50ad1f">2,489,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97649db97aba4548addc129f6b210a44_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC01LTEtMS0zMjMwOQ_abf2d031-90de-4fda-8fd8-75134e724859">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC0xMS0xLTEtMzIzMDk_f83c423f-60c1-4b58-9425-37cddc37f4b1">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97649db97aba4548addc129f6b210a44_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNS01LTEtMS0zMjMwOQ_ebcb3d3d-dc46-4292-9583-0310b04cec23">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNS0xMS0xLTEtMzIzMDk_95028779-38cf-469c-a5e1-c531d594a62f">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b37f8044404214ab59a210c61d1bf8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNi03LTEtMS0zMjMwOQ_237e6212-e239-4cb8-8ff5-d937bc1915bc">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNi0xMS0xLTEtMzIzMDk_935035c2-213c-4cb8-8650-e92c9080e0f7">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2cb27f4b2244b9482d9a7a4799cb32e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNy05LTEtMS0zMjMwOQ_c9e6d898-bc7f-4e79-ac71-61c294392960">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNy0xMS0xLTEtMzIzMDk_f2d9f195-eb02-4be0-8a88-cfebfe92e5fc">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0xLTEtMS0zMjMwOQ_a683fa73-a5d9-428c-b687-c61cf347ec62">22,204,057</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0zLTEtMS0zMjMwOQ_4403b45b-2622-40c2-9b5c-ac42c609b0aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890467fedbdd4ba3aa14064c4d4782fb_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC01LTEtMS0zMjMwOQ_b388236b-354c-4973-8f72-dc13cf900b64">517,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07652d3bbafc4de89373f4382ad0adeb_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC03LTEtMS0zMjMwOQ_2291ad48-0ef3-49c0-bc56-e6d1833c9530">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2bd578d48664208ba4ed1ca9a668b4a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC05LTEtMS0zMjMwOQ_76b605c7-ee3b-45e8-99b9-81fa27f21a2c">87,026</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecc2576a4cf40d2a8e639f2124feb66_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0xMS0xLTEtMzIzMDk_6f85ccf2-62e6-4a76-a4e8-ab4e62ab1788">430,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3dd1fba9fd4476eacb885999e7f77e7_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS0xLTEtMS0zMjMwOQ_854f423a-85de-48ff-a340-8bd549a9469c">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS01LTEtMS0zMjMwOQ_7368e51f-9bcb-4757-aa9f-056c240c0483">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS0xMS0xLTEtMzIzMDk_30dc60e9-fdbd-4a5c-84ab-431aed621aa5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTAtNS0xLTEtMzIzMDk_0855ab30-f02b-40da-9392-bef8ba3ab72d">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTAtMTEtMS0xLTMyMzA5_97616d89-8c45-4e78-84fe-25cc8f3044bd">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b6c2cb1c8a494fa13868c00724fde9_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTEtNy0xLTEtMzIzMDk_dd9b6616-30b1-47c6-9e65-16a75d1d9afc">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTEtMTEtMS0xLTMyMzA5_463dd646-be9c-43e1-bb74-0700423dcdfc">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6cdd346df1c4094b1949ffe62f42958_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTItOS0xLTEtMzIzMDk_86ee2f67-3de8-45ad-ae05-ca7c9b8bc4c9">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTItMTEtMS0xLTMyMzA5_8fa288ce-914a-4779-af01-2d803a788e60">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i219a217858014087b2e593831b4b4195_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMS0xLTEtMzIzMDk_7e7783e2-1783-482f-b724-539718ab9685">22,205,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219a217858014087b2e593831b4b4195_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMy0xLTEtMzIzMDk_d398ef09-915e-427b-ade9-ad8e653bef26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e8f6cac3a6489e8ba7ec64fc5e26ad_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtNS0xLTEtMzIzMDk_0f941240-2eeb-45e2-a626-104d107f99d2">521,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdbe031717624bf18894ff53096917ee_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtNy0xLTEtMzIzMDk_6646d728-a28a-4a90-99ec-b51feb662882">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09fb66d89a964f519eef9b01dd2a64dd_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtOS0xLTEtMzIzMDk_6f1b39b1-cbc8-4882-97cb-96c3e73bf74a">103,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804e7ae90e0c4170b9443943d0900e79_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMTEtMS0xLTMyMzA5_111e6ba9-ff0f-478e-b380-99e6343a5234">418,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59b3698ee4784a65906fc83187b5d36a_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtMS0xLTEtMzIzMDk_47713a87-ff88-44f7-b10d-8fa3a3c2feab">32,952</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtNS0xLTEtMzIzMDk_a62916da-107f-41ce-b444-9c4a32634d8f">1,534</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtMTEtMS0xLTMyMzA5_5c2df853-6895-481d-9a0c-1bb578fddf7c">1,534</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTUtNS0xLTEtMzIzMDk_d524679e-863f-4360-bdf3-47e7e44200ae">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTUtMTEtMS0xLTMyMzA5_883b11bc-4dfd-47a8-86e3-c84b26789854">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb962689ff4c3aa3dbddb683a95c6a_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTYtNy0xLTEtMzIzMDk_68c5aaa7-5a58-44b7-b04f-79f7e564bf82">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTYtMTEtMS0xLTMyMzA5_7a79aa27-2383-4d84-8138-b32c42e18809">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9eca0e9d35b487a8f129507b42cea8c_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTctOS0xLTEtMzIzMDk_c174441f-bf6f-41a8-b727-61a0767d42b1">15,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTctMTEtMS0xLTMyMzA5_9ebc6cf1-8534-4682-bda3-574a92b1178f">15,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2021</span></div></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMS0xLTEtMzIzMDk_104c61a6-ca76-4a0e-8559-49b396d8be0a">22,237,984</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMy0xLTEtMzIzMDk_28b68cff-c0fe-465d-ba9d-cf69fe6cc25a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b010cf48b94020be75c64bcf4ef43e_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtNS0xLTEtMzIzMDk_22991c1c-ae43-46e7-bab2-3711b9132545">527,229</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90cb5ac5c4eb41499523aaf1cda7629c_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtNy0xLTEtMzIzMDk_44ee6467-7db4-44c6-a0a9-4e461e52b458">14</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60ce97a3eb9f46338729167ca12679df_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtOS0xLTEtMzIzMDk_a99e9f70-1836-4d92-a06b-684810e3679f">118,978</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6597ad2d405542ce9626662507030a7e_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMTEtMS0xLTMyMzA5_8268b2ca-928d-4de2-b73b-272105d4cff1">408,237</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMy0xLTEtMS0zMjMwOQ_7934f721-a8cc-48ea-8bae-2abacd24cec3">107,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMy0zLTEtMS0zMjMwOQ_f573bb13-c3bd-4f87-9296-3a04715e79f2">47,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNS0xLTEtMS0zMjMwOQ_508e0117-6aa4-4ed7-9b24-317ff112de44">2,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNS0zLTEtMS0zMjMwOQ_2110b8d8-dc0e-4a48-b7e3-663a1cb05eb7">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNi0xLTEtMS0zMjMwOQ_d16c31a2-8e0e-4f3c-be20-ae2adad72e23">23,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNi0zLTEtMS0zMjMwOQ_04b28d67-fcd5-4501-88f2-f483a83cbe6e">10,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposals of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnSalesOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNy0xLTEtMS00MjU2Nw_2ef5535b-165d-4b2a-8d6e-1350c7787c00">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:GainsLossesOnSalesOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNy0zLTEtMS0zMjMwOQ_88d46287-065c-4e9d-ba55-3536889ed1a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfOC0xLTEtMS0zMjMwOQ_c95f7815-3312-41d0-a8aa-a931947cfd76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfOC0zLTEtMS0zMjMwOQ_e66c0614-6b32-4adc-b69a-b7277b063f10">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTAtMS0xLTEtMzIzMDk_bb914e1a-b7b1-4fd8-bd31-f3c79c5fa5bc">224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTAtMy0xLTEtMzIzMDk_057fee9d-923a-48d5-b6fc-1053bab2bcce">224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTItMS0xLTEtMzIzMDk_c0b080b7-9fc7-43a2-b752-a35dcfee82c5">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTItMy0xLTEtMzIzMDk_3474db78-94a7-464a-8bb8-fa41e2c9ccfe">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTQtMS0xLTEtMzIzMDk_923a5ca7-81b5-4023-98f7-070973085b94">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTQtMy0xLTEtMzIzMDk_9c9d6b33-fa29-4692-b120-8b91f1ee3c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTUtMS0xLTEtMzIzMDk_91a34a12-4d09-4996-851a-68d0ce55074e">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTUtMy0xLTEtMzIzMDk_d9b61652-67f0-4f9f-8755-10c2e84de9e9">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTYtMS0xLTEtMzIzMDk_823a583d-5ff3-4217-867a-79c113e25fc8">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTYtMy0xLTEtMzIzMDk_4d3f7b34-0ba4-4886-b67a-a138395592c0">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTctMS0xLTEtMzIzMDk_8a834e57-201a-4020-8750-8c7e20b1942a">3,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTctMy0xLTEtMzIzMDk_fb5bbd6b-ca26-4b1b-9cec-eed3e082a48c">6,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMS0xLTEtMzIzMDk_6b0af62c-24fa-4d51-93a8-334c907e00e0">78,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMy0xLTEtMzIzMDk_8bf34fd1-1f41-46e9-ae34-4b41ec212a26"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMy0xLTEtMzIzMDk_9df6e537-0fbb-4eea-83eb-5357bdaf6b0e">27,038</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjItMS0xLTEtMzIzMDk_40c3014e-d5ed-421d-9e8a-1b39430f4173">47,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjItMy0xLTEtMzIzMDk_bb63658a-a72e-4fce-ac8d-86166ab9735f">27,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjMtMS0xLTEtMzIzMDk_b6fe30da-ebb6-4492-94ca-4214f29cc3da">214,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjMtMy0xLTEtMzIzMDk_5d8f3217-5fd5-420e-8322-733e72decf16">83,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjQtMS0xLTEtMzIzMDk_154757f1-46d8-452b-9ea2-bc6df3a4c9ae">153,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjQtMy0xLTEtMzIzMDk_e0ea3e86-84a6-49ee-9293-7759367199a0">11,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjYtMS0xLTEtMzIzMDk_22e90e6c-96fa-42ac-9674-c0e7010bb98b">108,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjYtMy0xLTEtMzIzMDk_bc75969f-21c0-4675-8654-31dbc9b26837">100,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjktMS0xLTEtMzIzMDk_db24319d-3903-4b99-9499-e4a7f314e236">32,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjktMy0xLTEtMzIzMDk_4fb71095-511f-4116-b300-9630fc2fb381">153,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to settlement of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzAtMS0xLTEtMzIzMDk_001bdce8-e17d-4bcb-b4f1-d6668c79fde7">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzAtMy0xLTEtMzIzMDk_dfad460f-b98f-47dc-9bcf-1997b97eef96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of ASTRA build to suit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzEtMS0xLTEtMzIzMDk_3e32abad-b43c-47d8-98bb-90f71df09cf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzEtMy0xLTEtMzIzMDk_85c747a5-dc86-4643-a2c6-47a3f130455f">7,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzItMS0xLTEtMzIzMDk_59aad973-9006-490a-85c6-e13c5c1a2947">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzItMy0xLTEtMzIzMDk_2dd6edb3-cfa8-44be-bae9-9fef2d9e83bb">145,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzQtMS0xLTEtMzIzMDk_31534241-3170-4f66-a18c-d24b2f473eda">154,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzQtMy0xLTEtMzIzMDk_f2835d24-94b1-466e-8952-f8ffddefa54d">18,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzYtMS0xLTEtMzIzMDk_a0a88ded-d0d5-4540-b82d-220f1883167d">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzYtMy0xLTEtMzIzMDk_fae957fa-165d-4b90-b870-182a4d7d8f7d">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzctMS0xLTEtMzIzMDk_c7d3afdd-9c3f-47d7-b6ca-902a55e96d38">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6597ad2d405542ce9626662507030a7e_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzctMy0xLTEtMzIzMDk_ca32d3de-1f8a-411a-a30e-aa657fc63b43">286,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDAtMS0xLTEtMzIzMDk_023bebc9-ca96-47fb-8c64-f75e73c9a587">15,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDAtMy0xLTEtMzIzMDk_3cd38222-958f-437b-8e08-00bc91a2f7f5">23,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDEtMS0xLTEtMzIzMDk_5f2bc107-5a5d-4ac1-96fc-da037328ef13">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDEtMy0xLTEtMzIzMDk_2fb6f8c3-1899-4343-95c0-18d5e0bdfba3">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i558d66f804d0487883dba3662b46c183_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMzQ2OA_0bb5bd6b-9ecc-45e7-96e7-e60af875c89e" continuedAt="ie652551ed5be4a2886019d9b9f6671dd" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="ie652551ed5be4a2886019d9b9f6671dd"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 23, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022 and August 25, 2022, the Company incorporated Krystal Biotech Switzerland GmbH and Krystal Biotech Netherlands, B.V., respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMTkzMA_79c428a4-7330-4e73-b268-80bdd17b3b70">248.7</ix:nonFraction> million. With the net proceeds raised from its public offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMjExMA_cd5b89f3-aef8-46e7-8420-2d67f4f2f2c2">394.4</ix:nonFraction> million as of September&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div></ix:continuation><div id="i558d66f804d0487883dba3662b46c183_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDA_96d5ee78-3878-401e-9db3-76463ef149fb" continuedAt="ic81438b5a2354d0cab1247e17c8857e5" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic81438b5a2354d0cab1247e17c8857e5" continuedAt="i9b7a670da5864648847265694eab6f1e"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDE_0cc912b7-812d-409c-ad82-acdb2f607e76" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i9b7a670da5864648847265694eab6f1e" continuedAt="i39fe4c1cdc7440a3967c5a666b61a43f"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="krys:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDI_937ab71f-aae2-4fba-8cf3-9e7cf7cbc6d3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzU_b342c623-48a5-41c3-96a8-b95632f73beb" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDQ_ca410790-90ef-412c-acdb-e79050db081d" continuedAt="i972bd0d29bce41cfb902d617e34f5a1e" escape="true">Segment and Geographical Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i972bd0d29bce41cfb902d617e34f5a1e">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfNDE5NQ_713975f2-a8f2-4c85-a89a-cf7d7f7c01f2">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceutical products.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzQ_532d132a-e9b1-4b57-94c6-6eb8cf30f0e6" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzY_5bcd3852-912a-4973-9491-8ec584ffdd17" continuedAt="ie3e1346bed8c4bcfbce4d01a2774aa69" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie3e1346bed8c4bcfbce4d01a2774aa69">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i39fe4c1cdc7440a3967c5a666b61a43f" continuedAt="ib816af52dfa84279b7b43bf8c5bbf2d7"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzc_08405c21-7f98-415d-af35-ca795a32fe9c" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDk_7d62e5ac-f7ee-4806-bffa-a0da616e5165" continuedAt="i7b8af65421fc4605bf8a47d14f01344d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzg_f5a6cd98-3e40-441d-9ee1-d852d83a8451" continuedAt="i4341aca1efc8403ea07b92f686a702eb" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="i4341aca1efc8403ea07b92f686a702eb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2aebf72749342469c8fe09700344c6b_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMC0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjAwNzkzZGFhMDBmYTRkZmFiOTkwYzZkNDgwNGQwNWI2XzQ_b230b809-8b5c-46b8-aca8-ce07a1e27bee">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i120f39a8c06046dc8927af6d7756608e_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMC0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjAwNzkzZGFhMDBmYTRkZmFiOTkwYzZkNDgwNGQwNWI2Xzk_4888b859-70e5-4ccb-8fed-2156a8241d1d">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib54b929ec80d44839ff7152507ca4c1c_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMS0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOmZmNjMwNjc1MzdiYzQ4OThiNzMyMzNlYjRhMjBlM2NmXzQ_a49ca620-f498-4eec-a59d-0c0113f68165">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i86399381f2054cfb96cf8e0c08c527fa_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMS0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOmZmNjMwNjc1MzdiYzQ4OThiNzMyMzNlYjRhMjBlM2NmXzk_75fd958e-b9ee-4aea-939c-5f6e547e96ec">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf8290ed1234e40ae5260bc12184c04_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMi0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjNiYzYxMjU4YTc1OTQyNTI4NTFhNTdlMmY1M2RjNzkzXzQ_486a264e-4c91-4538-ba4d-960d65f08fe5">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i05ce38678ccd4f96b65c96b347657521_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMi0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjNiYzYxMjU4YTc1OTQyNTI4NTFhNTdlMmY1M2RjNzkzXzk_2258a2dc-5d64-4b02-bdc1-e2f8bccf14d1">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from <ix:nonNumeric contextRef="i8e2711458b1a41d6b98bc1413bdbc152_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY0OTI2NzQ3MDI1Nw_96f28f6a-87f2-4696-8881-faeed8048238">7</ix:nonNumeric> to <ix:nonNumeric contextRef="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY0OTI2NzQ3MDI2NA_ca78295d-6108-4898-8e1c-6d9333dc0c0f">15</ix:nonNumeric> years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b8af65421fc4605bf8a47d14f01344d">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ib816af52dfa84279b7b43bf8c5bbf2d7" continuedAt="i18bd1d49c61c4d4a844463e91f9abc41"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDU_67b8d913-7e0e-451f-ac42-51e907b274f8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has <ix:nonFraction unitRef="usd" contextRef="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_37ad0c03-fe12-40ed-a5c7-e7e5d57f2293"><ix:nonFraction unitRef="usd" contextRef="ia6b2986e81f44720abbc09b89ba3a446_D20220101-20220930" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_864304c0-7b9b-45cd-863b-f3f9236a5d30"><ix:nonFraction unitRef="usd" contextRef="ic57420e235a64a5fb3a723c554ea7d5a_D20210701-20210930" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_87b17ece-6594-4d24-984f-c9f4da86e859"><ix:nonFraction unitRef="usd" contextRef="icdca84ad76694a69aee10fc9cfd0e0f8_D20210101-20210930" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_f988792e-f414-42e7-b173-010a2a4ec891">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized any impairment losses for the three and nine months ended September&#160;30, 2022 and 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzk_b8042016-120e-4901-bc6c-0480addf714c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDc_0eedf3c6-f3f7-4b2d-a912-9b9a9a67e199" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDY_e0b39fbd-61d9-430c-9426-4fdea0526359" continuedAt="i5d5dadb680a84aa58fdcea4a37fda7c9" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i18bd1d49c61c4d4a844463e91f9abc41"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d5dadb680a84aa58fdcea4a37fda7c9" continuedAt="i947ff75ad8de48aa940afaa5a7b3b148">obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i947ff75ad8de48aa940afaa5a7b3b148">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDg_846f9803-ba32-4d7d-9d76-56cf1ec71e3b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDM_a2288690-408b-49c9-9037-ec9e16129f51" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i558d66f804d0487883dba3662b46c183_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfOTU4_042cb5df-4ae1-40ed-9741-3a6e85c28315" continuedAt="i9f144dd13007428d953b7c64f0c254b0" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i9f144dd13007428d953b7c64f0c254b0"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfNjYz_507b9ffd-5617-4993-b985-8d94463123ba">3,565,110</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfNjcw_5cf77683-bf1f-4755-a424-b34b2857fddf">1,900,638</ix:nonFraction> common share equivalents outstanding as of September&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfOTU5_386e2d5e-6840-462c-8a96-05cc1c027f0c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:53.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC0xLTEtMS0zMjMwOQ_1d703960-3073-4ad8-831c-d71696c428c2">29,850</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC0zLTEtMS0zMjMwOQ_aec034b8-37db-4b16-9875-a2d74f2797c1">15,589</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC01LTEtMS0zMjMwOQ_d9f264dd-3810-4673-b9ea-1d3c7aa2682d">107,923</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC03LTEtMS0zMjMwOQ_5778562b-a077-4ab9-8261-27e90db9a6aa">47,764</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0xLTEtMS0zMjMwOQ_52dea3c7-a5a1-41f5-88d9-545fceb17f3e"><ix:nonFraction unitRef="shares" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0xLTEtMS0zMjMwOQ_62acd11e-994a-44ea-814d-dfd8da28ba34">25,619,125</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0zLTEtMS0zMjMwOQ_0101e373-9abf-4e95-a83f-4bc14fe8b488"><ix:nonFraction unitRef="shares" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0zLTEtMS0zMjMwOQ_404c1125-9ba2-4d6a-9847-7e5748149d80">22,212,266</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi01LTEtMS0zMjMwOQ_ab13f971-dbb6-4468-afed-6d5359e5eb7f"><ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi01LTEtMS0zMjMwOQ_fb666474-4aa4-4bf4-ab61-e3f6ec261ffa">25,428,097</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi03LTEtMS0zMjMwOQ_d1062314-81c1-4e3b-8123-ce1fa4b54ddd"><ix:nonFraction unitRef="shares" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi03LTEtMS0zMjMwOQ_d37b974b-bee1-42f9-865e-7d07187b02e7">21,893,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0xLTEtMS0zMjMwOQ_561d2099-208f-422f-996e-757ced4e6c87"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0xLTEtMS0zMjMwOQ_f060c097-72fa-46bf-abd3-bd14d7d928dc">1.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0zLTEtMS0zMjMwOQ_2053b537-525b-4bd2-968e-6158c6781cfa"><ix:nonFraction unitRef="usdPerShare" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0zLTEtMS0zMjMwOQ_c0ae468e-bf0b-49d2-8d97-3fb935511392">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy01LTEtMS0zMjMwOQ_418b413e-03f4-499c-8729-877d941625da"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy01LTEtMS0zMjMwOQ_b041ae85-01fc-4d53-b5d7-c6be253c4b80">4.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy03LTEtMS0zMjMwOQ_2636aa88-4066-4211-87d9-5c6d57cb8f5b"><ix:nonFraction unitRef="usdPerShare" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy03LTEtMS0zMjMwOQ_a40b114d-59f0-4b88-9622-2b7473304576">2.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfNTAz_1ef593aa-b7d4-4f27-a943-5d4f477d6885" continuedAt="ia9dd63ab23f242d287d9dc8bc7022d77" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><ix:continuation id="ia9dd63ab23f242d287d9dc8bc7022d77"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfNTA0_de36dd1c-2027-467e-80a0-5021f212b723" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f94d206814d259cc04e6134260599_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC0xLTEtMS0zMjMwOQ_f6003d6c-863f-441d-93a2-dff678e75050">186,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f94d206814d259cc04e6134260599_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC03LTEtMS0zMjMwOQ_6ffcc009-9c61-4d3b-8537-ebd0706ae0d6">186,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0521592fe8214fdcbf9363ed85d04e75_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC05LTEtMS0zMjMwOQ_3858d694-1fcf-46e4-aff5-7c37cfa6e6cd">186,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8fa447f8214bfe917bfea3629882f2_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS0xLTEtMS0zMjMwOQ_44296eb7-2b1d-4ba5-9a20-a51d385dbc9b">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8fa447f8214bfe917bfea3629882f2_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS03LTEtMS0zMjMwOQ_c079868b-b294-4156-a712-8c3db788091b">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e1c1e1be2f4fca992ef8ae2c01448e_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS05LTEtMS0zMjMwOQ_2508bdd4-9019-4000-8cf1-5adb7e64e19c">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xLTEtMS0zMjMwOQ_39953141-9a3f-4cc0-812c-a50d8d4d190a">52,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0zLTEtMS0zMjMwOQ_bdcc488c-a5fe-4761-bb3d-54f43620a97f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC01LTEtMS0zMjMwOQ_b8596556-c42a-4030-b173-004d39511fa0">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC03LTEtMS0zMjMwOQ_a789ffe7-c959-4430-9a95-e1e66636fe3d">52,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed83ef245114b17b4ec315c5b79e99a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xMS0xLTEtMzIzMDk_62acea09-18be-4ab8-9b3c-78b6045cf843">52,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if128286fde8e48bda27846143219a6a1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xMy0xLTEtMzIzMDk_ceec016c-9fab-4af8-998b-fd14618a96a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xLTEtMS0zMjMwOQ_2d6cb470-defd-4f12-ba67-4a34b9ce5225">94,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0zLTEtMS0zMjMwOQ_e29ea89a-a832-4572-818b-0a8a55aca5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS01LTEtMS0zMjMwOQ_3ba24749-5e21-46fc-94ef-528918523c49">886</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS03LTEtMS0zMjMwOQ_541aa614-fb0e-414b-b190-2b74a58b557c">93,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efb41c0e52f44a8bf5e1dc4ac1647b2_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xMS0xLTEtMzIzMDk_2bef598c-0365-446d-bea7-8c268edffac8">87,291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ecfa420d4d405385cf50e5cbda74b6_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xMy0xLTEtMzIzMDk_5733b99f-11df-4b5e-803d-27b67cce227e">6,238</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMS0xLTEtMzIzMDk_1530d664-7ad6-47bd-bf8d-9169d00c7f67">74,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMy0xLTEtMzIzMDk_00861ad7-f071-4ca3-8bb1-f1e17a381fbc">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtNS0xLTEtMzIzMDk_f67bb216-d23e-46cf-b745-2460bac9d5b2">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtNy0xLTEtMzIzMDk_9e1bef0a-588a-494f-ba33-0752dd98fb35">74,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a570d866504e0a94f3b9b2a20a2f8d_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMTEtMS0xLTMyMzA5_d0a0ac1b-10cf-40d8-a673-aec8330f521e">67,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9e5b5c9da54691afa3f377ff8c028f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMTMtMS0xLTMyMzA5_7a5572c9-b501-4dc7-9f56-8d4577831e43">6,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030326b8c06846669784eeba5596ca2f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMS0xLTEtMzIzMDk_7c1921f4-9a0e-4e6e-89c7-b4f31d93a71c">222,016</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030326b8c06846669784eeba5596ca2f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMy0xLTEtMzIzMDk_271e384e-3ce3-4cca-9457-a914e7555971">38</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030326b8c06846669784eeba5596ca2f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtNS0xLTEtMzIzMDk_606f7658-58aa-4cc3-93b1-f751c1c16b11">1,486</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030326b8c06846669784eeba5596ca2f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtNy0xLTEtMzIzMDk_4fbad7bd-001b-4f68-9206-16f7af45617e">220,568</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMTEtMS0xLTMyMzA5_f9dc5c61-f2b7-46df-9aa8-23956375fb2e">208,011</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3954f8ffb03540639aa7f22b7c875a2a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMTMtMS0xLTMyMzA5_a4a9da1c-6633-4a3f-8574-1a27ba179a3a">12,557</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMS0xLTEtMzIzMDk_20dd6fe3-fa1f-4b92-a1f0-74d83b6bba1b">408,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMy0xLTEtMzIzMDk_d23bb6f0-46ce-46bd-889a-0f3bef5967a7">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItNS0xLTEtMzIzMDk_b624fca5-7fbe-4605-9afc-41d8c8fff8d1">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItNy0xLTEtMzIzMDk_f30777aa-1856-4792-a27c-577e77b89d6f">406,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375366091dbe420e8154d3503d92c83c_I20220930" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItOS0xLTEtMzIzMDk_fae7d934-ccae-4f80-9208-35410ea27bab">186,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b32c1a4a1954edc8663be651ea566e8_I20220930" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMTEtMS0xLTMyMzA5_069c13ac-3e47-4160-ba21-94a04c8d4598">208,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b3fa0dd16b46198ffe62a62527cae5_I20220930" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMTMtMS0xLTMyMzA5_bc9c31d4-a177-4318-a8c2-b072062ae25e">12,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.100%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6644b768bf541ba8408590ac2dd5956_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy0xLTEtMS0zMjMwOQ_7f7733e1-1981-4e08-92a9-916aa88a6486">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6644b768bf541ba8408590ac2dd5956_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy03LTEtMS0zMjMwOQ_137431b4-b3b6-4d9b-92ca-936eeec4841c">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fb68a8e9dd42179b7f44937fd02d2a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy05LTEtMS0zMjMwOQ_e42e5b20-aed3-42d5-8700-fddaa706fc53">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS0xLTEtMS0zMjMwOQ_d6bfcbc3-3f99-4413-8be9-53bbc1c87423">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS03LTEtMS0zMjMwOQ_bf1dfa82-56b7-434b-a7ef-65f2746f2f84">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d41d0a58bfe460d9793cfbb8d115862_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS05LTEtMS0zMjMwOQ_c6af172e-a5fb-4fe2-8495-df8a130ffad2">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xLTEtMS0zMjMwOQ_651f3432-c46e-49c4-ad2f-a0861c81e22a">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0zLTEtMS0zMjMwOQ_78ce6479-2dce-4c6e-bd3d-cbe1b15d81da">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy01LTEtMS0zMjMwOQ_0cbdc0d6-958f-4eb4-8e7f-5a62a79de95f">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy03LTEtMS0zMjMwOQ_4d26b013-12cd-4042-8958-ead8956168f3">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77eb6667d87d4a48a23a1c05f70f0054_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xMS0xLTEtMzIzMDk_997f8b6b-6255-49ec-a1d5-ca70f81b3029">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8814b6e4d26342739fbd6b838acaa863_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xMy0xLTEtMzIzMDk_4ab38b61-a131-4625-a509-a41368ba64d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xLTEtMS0zMjMwOQ_fde0c520-4929-40c8-bfc5-61bf65a12011">83,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0zLTEtMS0zMjMwOQ_88c103ac-ee6e-4dd4-b774-39fc46020695">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC01LTEtMS0zMjMwOQ_171975db-a213-4513-9dd4-fe119d9d7b59">114</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC03LTEtMS0zMjMwOQ_23a87595-a68d-4e9e-9c24-573d3c76cf16">83,196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6166c735944a67af8bad5424f2374d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xMS0xLTEtMzIzMDk_8e7d5da5-efb2-4793-b3b0-1847fa60753e">35,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c0695b52704d2aab04ad37cd4579dc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xMy0xLTEtMzIzMDk_3232b653-0c68-4d74-bd93-78e50927af7f">47,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xLTEtMS0zMjMwOQ_dc3f4523-2706-421a-b5bb-adb277c34f7d">37,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0zLTEtMS0zMjMwOQ_db4bc97b-7cfb-4f98-b0d2-7d5eefd916ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS01LTEtMS0zMjMwOQ_885fcacf-c4eb-4e4b-8d89-fbefc99b1056">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS03LTEtMS0zMjMwOQ_48cbc2a0-368b-482f-9248-72a6199c3cd2">37,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132a91679b794ea4b461110cc358acba_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xMS0xLTEtMzIzMDk_d0d4e4dc-7eea-428d-9332-37f657d94cc9">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1c894de1ca4c588bcceda18014bc3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xMy0xLTEtMzIzMDk_41b2b41b-1195-44a2-a733-d546aec583e3">16,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMS0xLTEtMzIzMDk_38b47082-7423-40bf-b9d2-e36f2302a35a">161,390</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMy0xLTEtMzIzMDk_2dd7fded-88db-4421-9418-0a9f214ddc70">11</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtNS0xLTEtMzIzMDk_7aa4dc67-ffef-43ff-a731-ffaafab235e6">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtNy0xLTEtMzIzMDk_822171ec-9876-4637-ab2c-517caf984ffe">161,221</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bc2ff934854878b2f463664d5a6acc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMTEtMS0xLTMyMzA5_568638dc-2a93-425d-bc33-4f86d8a9a4bd">96,850</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c13850920c64e95897ca644335b133d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMTMtMS0xLTMyMzA5_064cdab6-d233-417d-9db8-ae4f1d178e5b">64,371</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMS0xLTEtMzIzMDk_3a1e3ead-f94e-4321-a8dd-ffa6ac9e383e">502,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMy0xLTEtMzIzMDk_1e03fbf8-4345-4116-9094-f727aeb9077d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtNS0xLTEtMzIzMDk_9127c0c7-670e-4783-b930-918d5ea47e27">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtNy0xLTEtMzIzMDk_249b7f4a-7f8d-4630-a532-04d3c791938d">502,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169676a81ad4497aa2d1347caf2c7e5f_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtOS0xLTEtMzIzMDk_3579be58-b57d-440a-93ca-56fef0a6859c">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae71768f86a84ff38722ac63232d8be0_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMTEtMS0xLTMyMzA5_bf50aeb9-4a17-430f-9a2b-a9e04839734e">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eecdcc8e5048a587e31bc5751ed3fe_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMTMtMS0xLTMyMzA5_9fcee2a0-5985-44e9-8b0c-0e49b0a666c0">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMjcy_14c657fb-a1f9-4660-9cba-4e80749fd7c4">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between <ix:nonNumeric contextRef="ie39c0b6bc40a420b862bc4cf852d00bb_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMzQ1_61969a78-9774-47c8-b9f3-cb96540a764e">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="idff5589cd93c46cb87913f248b6eb315_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMzUy_9201be19-95cb-4f64-80c7-47e00b6e1f0f">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzg4_2962c23b-aa2a-4554-a1c1-bc9de6c187e5" continuedAt="ia966e509e6c3498ca4171621ac8c07b6" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ia966e509e6c3498ca4171621ac8c07b6"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzg5_49d12821-33c3-404a-b275-fe6746128ac6" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff436f8b9563446293b5781dc7e26b82_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMi0xLTEtMS0zMjMwOQ_9885203a-1dcb-4e7a-910d-98cc65a1d312">130,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574448c6d24c4a17ad6bf5c2ba879888_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMi0zLTEtMS0zMjMwOQ_f3c2f698-32b6-4f70-836a-d4acb246cd4a">104,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce49bed180d47aaa7a25633ed9e0d0a_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMy0xLTEtMS0zMjMwOQ_5e4a8ec2-fe75-4c8f-934c-5a2e96fd9aa2">21,503</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2103bb237f91481a841947ba35171c0e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMy0zLTEtMS0zMjMwOQ_557fe7e4-aa3b-4247-a9f3-9154790e8482">5,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1647014b96864f48aa14287e6d16e887_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNC0xLTEtMS0zMjMwOQ_ee817eb5-e36a-47c7-8749-3f74a181867b">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687bee7c6c9147be9f354df54817d16e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNC0zLTEtMS0zMjMwOQ_4718516e-8faa-493b-8cd1-c3b66a774065">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3928d17425554a3a99f3ba2ebcf67515_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNS0xLTEtMS0zMjMwOQ_e1e77131-4b91-4152-9329-90310b7d46dc">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7df56418f54686af3bd73d39453c69_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNS0zLTEtMS0zMjMwOQ_96fc969b-57af-4311-85e3-67affe5fdaf0">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib688aa903552456cb0df8bb52f2a6c35_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNi0xLTEtMS0zMjMwOQ_5b03dda9-8c1a-4a4d-98f8-765b9c26624b">10,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753b83af693442cdaf1ec67d12b5d9a3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNi0zLTEtMS0zMjMwOQ_6a08d154-5c8d-4ec0-afd6-fa45d2ae7b87">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNy0xLTEtMS0zMjMwOQ_09e7619d-2446-49b3-b3f5-7fd95de660ad">163,587</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNy0zLTEtMS0zMjMwOQ_8cacb562-28c4-45e6-8573-b0dab284d62f">116,569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOC0xLTEtMS0zMjMwOQ_b67a6b7d-dfec-4e16-acd3-98b34a7f38bc">5,801</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOC0zLTEtMS0zMjMwOQ_4856252a-810e-4ff5-ba6d-959a9ff666ef">4,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOS0xLTEtMS0zMjMwOQ_b67a2443-54d4-47bd-bfff-8c514161c1a7">157,786</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOS0zLTEtMS0zMjMwOQ_487a83c4-1799-43ef-81e2-88eadd10379d">112,355</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTU3_ce380f64-94dd-4f29-858d-4813dcdaf611">669</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTY0_f6db0d16-f7f2-4ae2-9e89-a9eecbf6f1c5">1.6</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTk4_0fa48764-6fb4-4461-8573-55162e557f48">474</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMjA1_9e9f36a5-c0e9-4d6f-84c9-e5a641dfa3f3">1.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzkw_c3676749-9a25-48a6-89cf-7a7d222555b4" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMi0xLTEtMS0zMjMwOQ_41c80a80-454e-465e-b1ad-5cf2fb3778e4">10,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMi0zLTEtMS0zMjMwOQ_e71e8f38-e246-4fac-ae58-cbff552f8c25">9,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMy0xLTEtMS0zMjMwOQ_a8a06a56-d0d4-4951-8a78-bb1ce1e8e718">2,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMy0zLTEtMS0zMjMwOQ_53f09a3c-7f21-41ba-b67d-70a0d38cfe43">2,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNC0xLTEtMS0zMjMwOQ_abe4dba7-8881-430d-b5dc-800dc34c8312">3,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNC0zLTEtMS0zMjMwOQ_6a594adc-d95a-4221-8249-4d655b0dd710">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNS0xLTEtMS0zMjMwOQ_15fe12ab-51c6-4ed4-9fe3-e35bb154661f">2,325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNS0zLTEtMS0zMjMwOQ_647ff41e-442b-4a3b-b90d-e0efdd674d57">1,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNi0xLTEtMS0zMjMwOQ_343740d0-8cdb-4f37-a6a4-40aa56ab19e0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNi0zLTEtMS0zMjMwOQ_20458e50-27f1-432c-865d-3d8320a279a7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNy0xLTEtMS0zMjMwOQ_3ea37770-5618-4bef-8315-e9ea78b580b3">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNy0zLTEtMS0zMjMwOQ_89b50c50-4904-403b-ab53-7fd4cbd85e1d">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfOS0xLTEtMS0zMjMwOQ_e5274027-1271-4059-a3f9-3393508b04f0">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfOS0zLTEtMS0zMjMwOQ_be4b65c1-6555-43f6-946f-b323ee5b6cfc">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMTAtMS0xLTEtMzIzMDk_ba8ae902-8ff6-42a7-885e-19b0ed759a31">20,724</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMTAtMy0xLTEtMzIzMDk_908ed7fb-f5b3-48bf-8499-d35ee999f1c8">16,297</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i558d66f804d0487883dba3662b46c183_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzQ_311f26dd-bd72-4def-8219-63c3e7c4791a" continuedAt="i57df497e0a2c49649137270c60eb80f2" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i57df497e0a2c49649137270c60eb80f2" continuedAt="iebf166c619f54e45981de2004b238ef5"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i389d7854847544d0bf805ab6494af671_I20160526" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMzc4_0d17ca30-cb03-4d39-ae88-d0dfd37c6438">47,000</ix:nonFraction> square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. On September 30, 2022, the Company amended the 2016 Lease ("Short-Term Amendment") to add a short-term lease for additional office space that commenced on October 1, 2022 and expires on September 30, 2023. The amendment increased the area leased by approximately <ix:nonFraction unitRef="sqft" contextRef="i51995febb28d40aca39ea569c56e2121_I20220930" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODI0NjMzNzIyNDg5Nw_e2e69085-83eb-413e-8e05-a65c6b9de518">7,000</ix:nonFraction> square feet through September 30, 2023, resulting in a total area leased of approximately <ix:nonFraction unitRef="sqft" contextRef="i84c7af875bb2430591fb076cbadd84fd_I20220930" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODI0NjMzNzIyNDkwNA_60e82c67-ddf3-4014-8ece-f8701e653628">54,000</ix:nonFraction> square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="iebf166c619f54e45981de2004b238ef5" continuedAt="i0451cf05bb1f47719238ff0906a78766"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $<ix:nonFraction unitRef="usd" contextRef="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTc0NA_beb76c81-d386-4fc8-a9ac-33c8c04f56fd">9.4</ix:nonFraction>&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjAzOA_9df19561-d728-4c70-8ee3-7adf872f0626"><ix:nonFraction unitRef="usd" contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjAzOA_df173c30-a9c8-4c70-92f4-192c53709122">10.0</ix:nonFraction></ix:nonFraction>&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $<ix:nonFraction unitRef="usd" contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjE5Mg_ec949c50-a6a8-4de8-91e5-5515bbecd416">2.4</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjQwOQ_97170f0e-88b5-47e8-8ee3-fd46e850b409">9.4</ix:nonFraction>&#160;million. The Company held approximately $<ix:nonFraction unitRef="usd" contextRef="icd7d043bf3db47c0ad21c9a2482c6d41_I20201015" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjQ0NA_724e8338-bcb2-48d5-9839-dc1feffb89c2">1.5</ix:nonFraction>&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed in 1H 2023.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="krys:LessorOperatingLeaseLiabilityAnnualLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDMwMA_645dfb25-f023-44a1-b626-01ed8a0c9a2e">82</ix:nonFraction>&#160;thousand, and are subject to a cumulative <ix:nonFraction unitRef="number" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="krys:CumulativeEscalationClausePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDMzNg_10d48fed-7f28-462d-8de5-fe932b5c4de6">10</ix:nonFraction>% escalation clause every <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="krys:CumulativeEscalationClauseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDM2Mw_9248c05b-4059-445a-9b94-b5c3eba28fab">5</ix:nonNumeric> years through 2071. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a <ix:nonNumeric contextRef="i1c15e03628914d43970aaad1d2908cff_I20211215" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDQzMA_a3d4670b-0aa2-49d6-9a20-24913b6b8d0f">3</ix:nonNumeric> year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into a <ix:nonNumeric contextRef="i42838452e79140c2a17a6b085770b63a_I20220516" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI3MTcy_81a0d963-cb14-47a8-bd1c-0bd6fb542042">16</ix:nonNumeric> month lease agreement for the Zug, Switzerland office that commenced on September 1, 2022 and expires December 31, 2023.</span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzU_b97a88a2-edf5-47b5-a4a4-95e83ff72112" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:85.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.760%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMS0xLTEtMS0zMjMwOQ_00b1865f-9a9a-4b7d-a6c4-69fe3e8e8606">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMi0xLTEtMS0zMjMwOQ_c670dc8d-a77b-4717-a8af-2bd45c53280c">1,640</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMy0xLTEtMS0zMjMwOQ_63e3bc84-5939-4dca-9597-17208f4d8967">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNC0xLTEtMS0zMjMwOQ_29135f8d-b9df-48a9-9fc4-8e4338b245db">1,277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNS0xLTEtMS0zMjMwOQ_8952ac97-4f37-47d6-a4f0-d3276022c99c">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNi0xLTEtMS0zMjMwOQ_4443ffd6-661c-403a-9f80-45216fe7693a">12,062</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNy0xLTEtMS0zMjMwOQ_25a9449b-a54e-4a4f-b542-e8c8212837ec">18,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfOC0xLTEtMS0zMjMwOQ_b3f2f67e-a956-4e31-9347-20696226502e">9,077</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfOS0xLTEtMS0zMjMwOQ_8378a6de-47b5-424e-a154-cb32f5aa9e7b">9,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Short-Term Amendment not exceeding twelve months, the Company has not recorded a right-of-use asset or corresponding lease liability for the amendment as of September 30, 2022. Future minimum remaining operating lease payments under this amendment are $<ix:nonFraction unitRef="usd" contextRef="i84afbfefdee44283aad3240ba9ff5307_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI5MDk0_2f1025b9-6ad5-421e-811e-dbda103d6ff7">40</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="iee48ed1af849452cb48d2605517b57ce_I20231231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI5MDc5_d0ab9448-f427-4ee7-850d-bad559373099">121</ix:nonFraction>&#160;thousand for the years ending December 31, 2022 and 2023, respectively. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i0451cf05bb1f47719238ff0906a78766" continuedAt="ia20e7da9b5f7413f9a183d0cff62b3b7"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzY_2368d432-4ba2-4bc6-acfa-a2690a37abaa" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfMy0xLTEtMS0zMjMwOQ_a9cf8d76-6a2e-41ca-b936-fc4cce44dfc1">8,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfMy0zLTEtMS0zMjMwOQ_02b16c7c-f04f-4b73-836f-62f964cd16c9">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNC0xLTEtMS0zMjMwOQ_0896e064-1b00-433a-a973-046bc3349a9d">1,547</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNC0zLTEtMS0zMjMwOQ_b3c4de5c-1234-4696-829b-5f4c3663e64b">1,041</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNS0xLTEtMS0zMjMwOQ_02d891e1-43f7-4f97-ade8-6aa67120dc73">7,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNS0zLTEtMS0zMjMwOQ_993e54ac-4d13-46d1-b3ce-fdef8a65db1d">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNi0xLTEtMS0zMjMwOQ_2a99f8df-8f44-42ac-9e65-b91b61a5012f">9,122</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNi0zLTEtMS0zMjMwOQ_9dece3e8-771c-4896-a9a7-b9f12f4d6d6d">8,024</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNy0xLTEtMS0zMjMwOQ_e9694614-90f6-4069-b4a5-070a2cc33191">12.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNy0zLTEtMS0zMjMwOQ_b24783a9-135b-4325-a40e-90d4c9cb19c7">14.4</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfOC0xLTEtMS0zMjMwOQ_2eead473-4c31-4238-a5c7-be5211061342">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfOC0zLTEtMS0zMjMwOQ_e9b08bd4-2fa8-4f29-b516-2880e8b74e14">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTY0OTI2NzQ1NTY1Mw_a0b2e3bf-3940-485c-af04-10714ea3293f" escape="true"><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC0xLTEtMS0zMzQxOQ_16c8af71-c7c7-4602-bbf8-6e34caeaad53">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC0zLTEtMS0zMzQwMA_e66120b8-c07a-466f-bd10-20edfe9233fd">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC01LTEtMS0zMzQyMQ_fa38a7b1-fc8a-47f3-aed8-576b82e9315d">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC03LTEtMS0zMzQwMw_ef8b4e8c-a210-48b4-a1da-a38f17dd5809">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS0xLTEtMS0zMzQyMw_4d59234a-91bf-4d9c-90e7-cf73d4bf1aef">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS0zLTEtMS0zMzQwNg_33974e68-54b0-4f93-971e-1b0d88a8b0a6">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS01LTEtMS0zMzQyNQ_8055539a-f301-40a5-bb33-bc648f33754c">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS03LTEtMS0zMzQwOQ_200f5d9b-59df-4aea-a56b-7dd742da22e1">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi0xLTEtMS0zNDkzNw_0aec91c6-6218-42e6-b3dd-4e0042191c52">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi0zLTEtMS0zNDk0MQ_14b27905-cc32-43e9-ba69-917af22e4a66">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi01LTEtMS0zNDk0Mw_c4cd17cc-0971-4b08-a03a-fda9e15410bd">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi03LTEtMS0zNDk0NQ_98f1dc1c-9c13-41a3-bc0f-6500638e65c6">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2022 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="i91a5f95e9ca04dbeaedc4b0678713b09_I20220930" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjQyOA_93d4d964-8d3a-4eb1-bac4-f788d1ab53bf">2.4</ix:nonFraction> million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="i02d346d3ba744ec1b1737860d62e3b84_D20220701-20220930" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjYzNw_fbd8e312-7cfe-4385-94f7-15db2ab930e7">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6b281ab636c94ea6bd90e055d3589ac1_D20220101-20220930" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY0NA_2078ac48-1ee3-48db-91c9-446866feffa8">5.1</ix:nonFraction> million for each of the three and nine months ended September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="idc55688aaad54360ab017dae30869a94_D20210701-20210930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY4Ng_218b5612-61f7-48ed-8fde-e1333e60209c">744</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i185716a2727648acad1bd93183ea6948_D20210101-20210930" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY5Mw_9fdce779-19db-4462-8f7c-54a0a73d15e6">3.3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i01c7ee9b693a458cb42ad232c2bffc54_I20220930" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzExNw_0e6db719-1f25-45af-af62-412740ecec4d">6.2</ix:nonFraction> million. The Company has incurred expenses under these activities of $<ix:nonFraction unitRef="usd" contextRef="i3429310d21c54f51b8a52e3cdd70ecaf_D20220701-20220930" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzE4MQ_63db0664-3e89-4957-9ea4-00472d833b66">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e01a31d978c42ffbd78aa936eef3109_D20220101-20220930" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzE4OA_4d718002-1b3f-4808-aace-c47cd12c1a8f">9.5</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ia61a04c79d69473eb9ccc0fb8188c965_D20210701-20210930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzIyMg_55971c8b-c5e9-4942-ab7a-23ce986a5ba4">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf130c14e7754e39a5e8a947488cdf56_D20210101-20210930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzIyOQ_fbe7599f-08d9-4b6a-adb7-382dbca18033">4.1</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzc0MQ_f5e7d62f-f14f-4f81-9661-90f688b3150d">10.3</ix:nonFraction> million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the interior construction of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ia20e7da9b5f7413f9a183d0cff62b3b7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to <ix:nonFraction unitRef="number" contextRef="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930" decimals="INF" name="krys:CostOfWorkPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODM1Nw_38d6233c-9bc3-4703-99fb-0afffa735d38">1.75</ix:nonFraction>% of the cost of work. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $<ix:nonFraction unitRef="usd" contextRef="i2c6103d6d6474ab09e162650723b7b42_I20210913" decimals="-5" name="krys:LossContingencyGuaranteedMaximumPriceToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODc0NA_67ba7d9c-db84-4ee3-82a6-b4db6ccd8f2c">84.1</ix:nonFraction>&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ibb1e5a79af6a486eb62a8e55c89d9956_D20220428-20220428" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTA4MjA_7ce9892e-37f4-4e29-97a2-5bdfbda26fcf">25.0</ix:nonFraction>&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $<ix:nonFraction unitRef="usd" contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTExODE_b01c5216-7b21-4212-875f-8be5574818d7">12.5</ix:nonFraction>&#160;million, followed by <ix:nonFraction unitRef="milestone" contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930" decimals="INF" name="krys:NumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTExOTc_3172b1a5-a9b1-421c-85c9-73f287402ec7">three</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="ic785c649e5754160bc5a5ec1d8456f79_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_0ee125a6-7a63-4699-8385-93086e45b15f"><ix:nonFraction unitRef="usd" contextRef="i22c03d6d59cb46e1980e5371e1219705_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_2cae2ded-b2dc-4546-9ae6-96469a717b1f"><ix:nonFraction unitRef="usd" contextRef="i5d5333910ddc449b91395b95aedb3b6e_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_506e62c9-d825-4e25-b478-a25daafb4293">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million contingent milestone payments upon reaching $<ix:nonFraction unitRef="usd" contextRef="ic437ced0a09847f29ac47c72470b481a_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyNTg_808fa8e7-d25e-4e0b-b185-b4b2fe7ac169">100.0</ix:nonFraction>&#160;million in total cumulative sales, $<ix:nonFraction unitRef="usd" contextRef="i880fa33842f74d9c9c0071788d237821_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyODg_56cd3743-715f-4024-9665-d1bad389c60f">200.0</ix:nonFraction>&#160;million in total cumulative sales and $<ix:nonFraction unitRef="usd" contextRef="ic6402aea5802416894421190b1b7c2aa_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEzMjE_7258f6bd-4175-4aa5-94de-9da6c49f0c74">300.0</ix:nonFraction>&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $<ix:nonFraction unitRef="usd" contextRef="ia911f16a65084debb3a3812c943cd418_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementTotalConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTE3MjQ_08e7d493-40da-4dc5-b038-442325d93709">75.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTE3NTM_0da9ae89-8998-4628-9815-7220fdde05bd">25.0</ix:nonFraction>&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of September&#160;30, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTY0OTI2NzQ2Mjg0OQ_2e632f87-f0e2-4cdd-abf4-d0b984ecb887">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTIxMTc_64710123-f5d8-4ed4-807e-74443f16615e">768</ix:nonFraction>&#160;thousand of insurance proceeds during the three and nine months ended September&#160;30, 2022  and Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTIyMDg_b1dba55f-35dc-4b60-97e2-c2f28da7abb4">372</ix:nonFraction>&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div></ix:continuation><div id="i558d66f804d0487883dba3662b46c183_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMjA1OQ_cd056650-ad2f-489f-8679-ff15f9052116" continuedAt="i98509c2fac7e47c387e3f078d3c1ca2b" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="i98509c2fac7e47c387e3f078d3c1ca2b" continuedAt="i7bb6a3bceae0484f8305d32871a39019"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="i2afdf84dc726448aad231c9d735efdf6_I20201231" decimals="-5" name="krys:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfNTMx_3c6c0127-b3d0-4fe8-a1d9-b95b189b902a">150.0</ix:nonFraction>&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i7bb6a3bceae0484f8305d32871a39019"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i9468c5dcd0a64aaaad772669a3b8abe9_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfNzc0_267c3e91-91bc-4e82-a1a1-907274196da4">262,500</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9295b53dfb2645f78dbe60fefa07587f_I20211231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfODMx_5a081d78-f2d2-451c-a9b5-9a341d6277f4">66.50</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfODY0_92a1b434-fcf2-4e00-bdca-180ff6863572">16.9</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfOTIw_910a52c4-c59c-4ffc-a349-ce5593d286ec">524</ix:nonFraction>&#160;thousand. During the nine months ended September&#160;30, 2022, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfOTk1_fa335cc3-9a64-4b1a-b6d4-54e3de42f057">434,782</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i66fb2504463a49eda96d3323c25ec8da_I20220930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTA1Mg_1b09ab6d-c92d-475d-a844-7398ea41276a">69.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTA4NQ_9232e550-fd0e-4d9e-b7b6-b7853d6d599b">29.1</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTE0MQ_56ad5566-fed0-4f06-a163-49cf31dab8f0">900</ix:nonFraction>&#160;thousand, resulting in a remaining $<ix:nonFraction unitRef="usd" contextRef="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930" decimals="-5" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTE3MA_1a847894-88e3-4f38-b329-6725a6a9c763">102.5</ix:nonFraction>&#160;million available for issuance under the ATM Program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTI5Nw_fd730e1f-22d2-41c8-90f9-34e75550e0ec">2,866,667</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i1559256d15ff46e2b6b221d76549e677_D20211203-20211203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTMzOA_71b177d8-52ae-4f2f-90bc-80fce3a92a09">200,000</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="id0041f489e334ddba2da2707d6d6515d_I20211203" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTQzNw_bf841359-07d2-4cca-aa6e-8e3e8ff29fe4">75.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTUwMw_89d08d41-591f-422d-9971-a2505eb5dc20">201.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTU3OA_8941a8e6-d812-4f35-93f4-3e52e9c3b77b">12.9</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTYzNg_cc54d1e7-127d-421f-9717-8f3d399d05ec">227</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTcxOA_07451b56-3216-453e-96a1-4a32479a549e">2,211,538</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i7ce1955630ff46e58df59ed150227ca5_D20210201-20210201" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTc1OQ_db36f542-e989-4c84-a90e-b884a4dd7a5c">288,461</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i543a231c136d4fbea8192a671046f7d2_I20210201" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTg1OA_07116f60-ccb0-4762-8317-9ac62e820aa2">65.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTkyNA_411b517c-56b0-49a5-b23a-a78125276cd4">134.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTk5OQ_c2e164cd-83ef-4711-88f7-521e4db0c2db">8.6</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="iae6a49f61bf04d37ad841675aa460161_D20210201-20210201" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMjA1Nw_c04c811b-b8a9-4248-b35c-db20e174d686">198</ix:nonFraction>&#160;thousand.</span></div></ix:continuation><div id="i558d66f804d0487883dba3662b46c183_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5NQ_03cab727-7f0b-4799-952c-99ddd635ae2e" continuedAt="i45fafe1402204d29be0e4c299f03c3fc" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i45fafe1402204d29be0e4c299f03c3fc" continuedAt="id12e4df1e88341b8b5e6ad13e4f20e3e"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over <ix:nonNumeric contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMA_e37a14a5-7410-4d36-ad10-d1b7c631c538">four-year</ix:nonNumeric> periods and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjAw_1d212468-e6cb-466c-91ca-14c8b3f2974b">one</span>-year to <ix:nonNumeric contextRef="iac5d78fd59e541a99ea4c0f4e1de1d37_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5Ng_78967b9d-39d0-4e3b-9f16-b1425dcbc8da">four-year</ix:nonNumeric> periods. Stock options have a life of <ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjU3_77534f8c-e534-455c-aac4-5b700057a71e">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i9bafc7ab51364dee96000779f13a8763_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjgy_ca0f7ec6-2cb9-40c6-868b-915e75083688">189,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0b84e5d94eed444397515564515f6e25_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjg5_33d76108-f494-44f5-9ed4-5f2c6f706f69">1,913,000</ix:nonFraction> stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="i554b9366933442a2aa09ffe226b09237_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzk3_9384b1c8-9e39-4f2d-9c8c-f833d84a857e">297,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4944831e440c4e57954464b8eac273a8_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNDA0_8db48e52-e724-49e4-bf20-de41656688f9">799,950</ix:nonFraction> stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="id88546130308412087cf656552ac4dad_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTI4_b67778a5-59d7-4846-b8db-61499bbac79e">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ife4673f017ae43eaa5817b3e918cb7df_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MTg4_49ddd8c6-988f-494c-9f05-a4ee873054d6">45,000</ix:nonFraction> stock options to non-employees during the three and nine months ended September&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="ib38e44d1e815453f9fa009b512d8c70b_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNjEx_50c1579b-fce6-4027-ae80-f42476c952de"><ix:nonFraction unitRef="shares" contextRef="i41f08e8bf17b425f835e3620c83e2398_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNjEx_e00f8bb7-2466-4f1d-a529-27b4d57a61d2">50,000</ix:nonFraction></ix:nonFraction> stock options to non-employees during the three and nine months ended September&#160;30, 2021, respectively.</span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMQ_569f184d-edaa-4d73-8417-0d70ba0e78f8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.885%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS0xLTEtMS0zMjMwOQ_97d34e75-3437-4088-9f28-4c8ffd13eacc">2,043,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS0zLTEtMS0zMjMwOQ_219b929d-4b48-47c6-af0a-5f65aa232459">57.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2103c585e344ff197ab0e7bb4cc2ae9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS01LTEtMS0zMjMwOQ_df280fdc-216c-473d-b270-89e71f9e9018">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS03LTEtMS0zMjMwOQ_5016839f-f052-4ea6-80dd-eb2102f2996f">31,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMi0xLTEtMS0zMjMwOQ_bb546585-7824-495e-91fa-16ca99cb07d2">1,958,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMi0zLTEtMS0zMjMwOQ_b741e891-3f30-447d-b755-f7945e3e0abe">63.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMy0xLTEtMS0zMjMwOQ_fb7bdc31-5ad5-450b-9594-ae2dd36adc3c">84,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMy0zLTEtMS0zMjMwOQ_eedf8371-dfdc-48a4-81bf-c87a097bce75">46.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNC0xLTEtMS0zMjMwOQ_c145460e-842a-4087-b004-5ecd05692e4b">412,892</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNC0zLTEtMS0zMjMwOQ_c72e5a2d-e9e9-40cb-b432-f95ebe22ad04">58.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNS0xLTEtMS0zMjMwOQ_a0959137-c178-42be-8a7c-c44692d5092f">5,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNS0zLTEtMS0zMjMwOQ_6c5a8998-e354-4a84-9b7e-03ec5c9dcc32">78.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi0xLTEtMS0zMjMwOQ_26f634cd-37c4-4a72-a9aa-d62076ba18a2">3,498,510</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi0zLTEtMS0zMjMwOQ_8559e15c-3336-477d-a918-f0263c69a96a">60.38</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi01LTEtMS0zMjMwOQ_01f30d76-40bc-49e3-a033-9d6d35b2ffdf">8.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi03LTEtMS0zMjMwOQ_fb497463-577c-44e0-b664-428faaf06e6e">37,213</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy0xLTEtMS0zMjMwOQ_bec94b6b-b525-461d-a00e-0db26579aacb">637,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy0zLTEtMS0zMjMwOQ_dbdd4ccf-1d4c-4441-8e1e-81cbb64f8a12">48.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy01LTEtMS0zMjMwOQ_25f4a38c-30bb-49da-808a-fd56a413b230">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy03LTEtMS0zMjMwOQ_32a676d9-d2bd-4c0a-b8ef-618f652b9190">14,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTA4OQ_0c37207e-0b39-4776-98e3-9160e9ea0d7d">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTA5Ng_26cf2e1b-5c3f-489f-8731-cb85b302f60e">2.1</ix:nonFraction>&#160;million, respectively, and during the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTE1Mg_590cf20f-809e-4aaa-b5da-6ef69772fc3b">64</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTE1OQ_3fbb1449-eb5e-4e4f-9bfe-add0aad7c52d">872</ix:nonFraction>&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTMyNg_bda613d6-6ec5-4323-9ac5-4d25286b195a">49.59</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTMzMw_606985f1-f25d-46b0-91de-04b8266a0c73">43.66</ix:nonFraction>, respectively, and during the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTM4OQ_92e73f4a-0af3-4e6d-b2fa-9b80a0a8e7a7">34.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTM5Ng_6c46ce20-de00-4ef9-850e-84fcb960ae8f">43.31</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i22bd4f06054f4551a0c04a0a482190a8_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTQyNA_af9d2762-b0a7-4ce9-bf37-c46722ea1da7">105.5</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i977428fb79094a95b2d8d909cdd22eaf_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MzIy_08831858-e43d-48af-b81d-a764dc39f84d">3.1</ix:nonNumeric> years as of September&#160;30, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="id12e4df1e88341b8b5e6ad13e4f20e3e" continuedAt="i50b80b60b90c4024a377a1a9a3902d99"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5Nw_48d3ad03-54a4-44e4-ab0b-89e130cced00" continuedAt="i47c9b0eb67244466ba93e72d3c461581" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.519%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id108621ccf904c55942c6ee24593df70_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy0xLTEtMS0zMjMwOQ_dc17d115-3604-45d0-9b5d-d6390c373e2a">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0e76d9070c4128b90730ceba7e6793_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy0zLTEtMS0zMjMwOQ_11e9669e-9cc6-44b8-8168-792093b2caea">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9ff3681fe9437586096cd7401ca9ce_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy01LTEtMS0zMjMwOQ_a2dbff45-9aa0-47b3-b7ca-7d3d9de59cad">5,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7d2608b4e8487e85fca38da9b0a67c_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy03LTEtMS0zMjMwOQ_333a0fb3-aac8-4de7-a4a4-27794f728633">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8420fcd5952417fa51cddbbcf6d44b9_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC0xLTEtMS0zMjMwOQ_67de97e1-1795-4aa9-85dc-cd84ace325b1">6,433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312172e49cc6483fb8ba4c537f5a773e_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC0zLTEtMS0zMjMwOQ_740ea7cd-e3bf-4353-81af-77267502f885">2,502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09e88a222d54915b2b03b547c38c599_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC01LTEtMS0zMjMwOQ_b52b7545-b5a3-4847-a5d2-7e0ab1b31b54">16,791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c42738289064a8ea522bd02105cc6c5_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC03LTEtMS0zMjMwOQ_b299b86d-c1e2-49cc-8efc-c3abb31ca9f6">6,742</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS0xLTEtMS0zMjMwOQ_6f4d2ef7-3fa6-4cfe-b7fc-67c60677c0b9">8,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS0zLTEtMS0zMjMwOQ_370a1def-b2db-48d0-9942-2b4c35fef988">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS01LTEtMS0zMjMwOQ_d88af8bc-6985-4484-b20a-196f096abc4a">22,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS03LTEtMS0zMjMwOQ_a5ffd906-a335-4fbe-b41a-585b18253587">9,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $<ix:nonFraction unitRef="usd" contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTk5MQ_c51e02a8-2d78-478d-abe3-42f52133cab6">137</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTk5OA_8d2af610-8189-43fe-986d-69986db72f8e">423</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjA5NQ_442e5e0b-c25e-4b91-8940-ac1c3bf2238e">79</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjEwMg_b6b3ddef-ca3e-4bc5-9c7c-f8efd43fd75d">182</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively. </span></div><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5OA_bb41fbfa-bae4-4bb7-a293-a467f9ec199b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.935%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi0xLTEtMS0zMjMwOQ_3c702666-8467-4387-9706-4101ccba26e6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi0zLTEtMS0zMjMwOQ_622c74a3-3f48-4331-a07e-b5365f6c8493">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi01LTEtMS0zMjMwOQ_a86829e5-582a-4e91-b5f0-f75f556e0c7a">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi03LTEtMS0zMjMwOQ_dfc08568-0886-4033-b561-694b8a526e38">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy0xLTEtMS0zMjMwOQ_cf93fb60-baad-47b0-9e96-a0257507d1b7">6.23</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy0zLTEtMS0zMjMwOQ_ca3bc21e-22b7-4c94-9c98-7077817e8ce9">6.10</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy01LTEtMS0zMjMwOQ_70778106-984d-4087-abf3-df28ffd80c0b">6.21</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy03LTEtMS0zMjMwOQ_bd7f2a5e-b84c-4ac4-8b2d-70a37a4cd4c5">6.18</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC0xLTEtMS0zMjMwOQ_850773dc-b3fb-41f2-ba5a-b6d811a715d4">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC0zLTEtMS0zMjMwOQ_00f0f804-dcee-4c92-84d5-fc81eb5166b2">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC01LTEtMS0zMjMwOQ_dee1cf7b-d048-4122-8f26-e1a38fd3afa4">2.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC03LTEtMS0zMjMwOQ_a00c0436-146a-4205-aef0-2be8349a6acc">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS0xLTEtMS0zMjMwOQ_cbfef293-f43b-4ed6-98ff-97c3355c43fd">70.91</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS0zLTEtMS0zMjMwOQ_51b7dbbe-fe59-490a-bb5a-73ce978df141">53.69</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS01LTEtMS0zMjMwOQ_6a3ba2cb-62ac-47e8-b3ab-4eeaa0e406e1">63.03</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS03LTEtMS0zMjMwOQ_0e229d5a-bfbe-48ab-88dd-4c3614255b28">67.15</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi0xLTEtMS0zMjMwOQ_a298db2d-7228-4be1-ba80-cecd279907d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi0zLTEtMS0zMjMwOQ_04cc98df-2499-4782-80e6-4a35f2b8d7c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi01LTEtMS0zMjMwOQ_f66182d2-8b4f-4a5b-9a2d-8f72dca0ba45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi03LTEtMS0zMjMwOQ_99632cba-9387-4a8f-b6d9-eb78de9a4d44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <ix:nonNumeric contextRef="ibf80894786944bc1920dbabf15657881_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5NA_d4554253-347d-4893-9b1b-3cb694cc8d0c">four-year</ix:nonNumeric> period. The Company granted <ix:nonFraction unitRef="shares" contextRef="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjUxNg_edb6a3af-dc6b-4767-b9b6-5bae9452006a"><ix:nonFraction unitRef="shares" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjUxNg_f676f4d9-1469-4582-bba4-afd50d37e003">zero</ix:nonFraction></ix:nonFraction> RSAs to employees of the Company during the three and nine months ended September&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="i327eb87761364089af22aa767f369073_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjYwMQ_44e529ae-2b39-49a8-9783-81df831298fe">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjYwOA_4f5fa0c7-6e59-4547-ae75-2bc028796dda">98,800</ix:nonFraction> RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMg_98819bdf-aec2-45f5-8b89-eec8986a037d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMS0xLTEtMS0zMjMwOQ_2252d26e-a204-432a-a901-3471951151f4">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMS0zLTEtMS0zMjMwOQ_f15bc920-36b6-49e5-a08c-5138cec29b3f">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMi0xLTEtMS0zMjMwOQ_04ab2b63-e7fe-4c1c-8064-e2feae886122">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMi0zLTEtMS0zMjMwOQ_eacdeac8-ac83-4a31-9f6f-596b86f288cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMy0xLTEtMS0zMjMwOQ_f1015323-742c-4bad-8653-2397cf56fd2c">14,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMy0zLTEtMS0zMjMwOQ_79e649f0-cec5-4c75-bd07-e40368754759">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNC0xLTEtMS0zMjMwOQ_7efc2747-9cb2-42b5-91e5-b83a83c36b35">17,879</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNC0zLTEtMS0zMjMwOQ_4067f7d1-8bb9-42b0-91a5-66397f0d180c">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNS0xLTEtMS0zMjMwOQ_9479a4bb-8d41-4fe5-9fbf-f4b94e548e15">66,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNS0zLTEtMS0zMjMwOQ_eba85b0c-b928-4c5d-9e92-dc41455c5cd4">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjcwMQ_4b3f582d-fe50-4b34-b7b0-930106ea0f8a">4.2</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MzE0_c96ca4b8-47ce-4227-bc90-f12a56e3f23c">2.4</ix:nonNumeric> years as of September&#160;30, 2022.</span></div><ix:continuation id="i47c9b0eb67244466ba93e72d3c461581"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124dbd40c51a45a2bf0196c7305130a2_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy0xLTEtMS0zMjMwOQ_24d9b885-8541-4c0d-be2f-481932680d01">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3ffb69ea7a49f2a999c26d33b7fd55_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy0zLTEtMS0zMjMwOQ_29705c05-273d-4c86-b398-1aab8c55991e">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fe3e9d3d544384841d12bece5bca42_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy01LTEtMS0zMjMwOQ_c55ee2ab-1a67-4ddc-96ac-3be16a5e2afa">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6fb6eea9d48e1a6a317593df48bf6_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy03LTEtMS0zMjMwOQ_8c41a670-9575-4acf-ba26-5131c3f7a48b">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC0xLTEtMS0zMjMwOQ_468ac5b6-bcc6-4159-9d10-a27378d5ca46">441</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i327eb87761364089af22aa767f369073_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC0zLTEtMS0zMjMwOQ_c54b9d64-87ca-414a-8a0c-ad9ec3177707">491</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC01LTEtMS0zMjMwOQ_d4520611-da53-4a8c-8253-2231689cb17d">1,340</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC03LTEtMS0zMjMwOQ_62bee555-dcb7-4256-95d0-34a903dabc79">1,159</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50b80b60b90c4024a377a1a9a3902d99">Shares remaining available for grant under the Company&#8217;s stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="ia304daa15c32499381cbc07b635d095c_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzEzNA_83644775-2c5b-467a-85c8-da107039a5f1">607,366</ix:nonFraction>, with a sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i1ec14cf55416487cb3ce5a09f7e544f7_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE4NQ_48ca5486-248a-4978-a667-f98c88f60022">7,223</ix:nonFraction>, at September&#160;30, 2022.</ix:continuation></span></div><div id="i558d66f804d0487883dba3662b46c183_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181NS9mcmFnOjZiMjIzOTE2MzAyOTQ0NjZiNDkwNjI1MzFiZTIwMzUzL3RleHRyZWdpb246NmIyMjM5MTYzMDI5NDQ2NmI0OTA2MjUzMWJlMjAzNTNfMzcw_74094f9b-8d35-424a-a2a6-f5cc313c3245" continuedAt="i26455721da9d4a00be19ed930e0983c1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i26455721da9d4a00be19ed930e0983c1">The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.</span></div><div id="i558d66f804d0487883dba3662b46c183_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, cost, progress and results, of our research and development activities, preclinical studies and clinical trials for B-VEC (previously &#8220;KB103&#8221; and now known as Vyjuvek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), KB105, KB104, KB407, KB408, KB301, KB303, and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact that the COVID-19 pandemic and measures implemented to prevent its spread may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final US Food and Drug Administration (&#8220;FDA&#8221;), marketing and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates regarding the potential market opportunity for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to fund our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs associated with our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully develop and commercialize our product candidates, including B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business model and strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of building a medical affairs and commercial organization, including a sales force in anticipation of commercialization of B-VEC and any additional product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully avoid or resolve any litigation, intellectual property or other claims, that may be brought against us;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic conditions, including the recent rise in inflation and interest rates; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Form 10-Q, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale cGMP manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><img src="krys-20220930_g1.jpg" alt="krys-20220930_g1.jpg" style="height:809px;margin-bottom:5pt;vertical-align:text-bottom;width:642px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments</span></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dermatology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beremagene geperpavec ("B-VEC"), our lead product candidate is a topical gel containing our novel vector designed to deliver two copies of the COL7A1 transgene for the treatment of dystrophic epidermolysis bullosa ("dystrophic EB" or "DEB").  DEB is a group of heritable skin diseases characterized by skin fragility, blister formation, milia, and scarring that affects approximately 10,000 patients worldwide.  In June 2022, we filed a Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") seeking approval of B-VEC for the treatment of patients with dystrophic EB with a request for six-month priority review.  In August 2022, the FDA accepted the BLA and granted priority review with a Prescription Drug User Fee Act target date of February 17, 2023.  In September 2022, we were informed that Vyjuvek (our priority name for B-VEC) was acceptable to the FDA. In September 2022, we received a positive opinion from the European Medical Agency (EMA) Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of DEB with no additional studies required. We also plan to submit a market authorization application, or MAA, to the European Medicines Agency, or the EMA, in Q4 2022.  We have exclusive, worldwide commercialization rights for B-VEC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB105 is a topical gel containing our novel vector designed to deliver two copies of the TGM1 transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. In July 2021, we announced data from the fourth patient dosed in the trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response.  Faced with competing priorities during the BLA review cycle and initiation of the cystic fibrosis clinical program, the Company anticipates patient dosing in the ongoing Phase 1/2 clinical trial of KB105 for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis in 1H 2023. Details of the Phase 1/2 study can be found at www.clinicaltrials.gov under NCT identifier NCT04047732.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the SPINK5 transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. We expect to initiate a Phase 1 clinical study in the first half of 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length cystic fibrosis transmembrane conductance regulator ("CFTR") transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated CFTR gene. In August 2022, we announced that the FDA had accepted our KB407 Investigational New Drug ("IND") application. We plan to initiate a Phase 1 clinical study ("CORAL-1/US study") of inhaled KB407 in patients with cystic fibrosis ("CF") in the U.S. in the fourth quarter of 2022. Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier NCT05095246. Previously, in September 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study ("CORAL-1/AU study") of inhaled KB407 in patients with CF. We have begun screening patients for enrollment in the CORAL-1/AU study and plan to initiate dosing in the fourth quarter of 2022.</span></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aesthetics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary Jeune Aesthetics, Inc. ("Jeune"). Jeune's leading product candidate, KB301, is a novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. On March 22, 2022, we announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301. Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier NCT04540900. In Q2 2022, subjects from the PEARL-1 Cohort 2 trial were enrolled in a durability trial to evaluate duration of treatment effect, reduction of the unevenness in placebo treated sites, and long term safety monitoring. We anticipate announcing data from the durability trial in Q4 2022. The Company intends to start a Phase 2 clinical study (PEARL-2) for the treatment of wrinkles and improvements in skin quality attributes in 1H 2023 following agreement with the FDA on measurement of primary efficacy endpoints.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune has several other aesthetic medicine product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Highlights and Recent Developments</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In October 2022, following our mid-cycle BLA review of B-VEC, we were informed that the FDA does not plan to hold an Advisory Committee meeting and has not identified a need for Risk Evaluation and Mitigation Strategies (REMS) for this application.  </span></div><div style="margin-top:3pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In August 2022, we incorporated Krystal Biotech Netherlands, B.V., for the purpose of establishing operations in Europe.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date the impact of the COVID-19 pandemic on our business and clinical trials in the U.S. has been minimal. We will continue to assess the potential impact of the pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. Outside of the U.S., we have experienced pandemic-related delays in clinical trial initiation in Australia, and we will continue to closely monitor the impact that future pandemic developments have on this and our other clinical trials, going forward. For additional information regarding the impact of the coronavirus pandemic, please see "Risk Factor - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business." in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span></div><div id="i558d66f804d0487883dba3662b46c183_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third-party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension study for B-VEC, resume dosing with KB105 Phase&#160;1/2 clinical trial, initiate a Phase 2 trial for KB301, initiate a Phase 1 trial for KB407, initiate a Phase 1 trial for KB104, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation for personnel in our executive, commercial, business development and other administrative functions. General and administrative expenses also include professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include travel expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and to operate as a public company. These increases will likely include increased costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate that we will increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we closed on the purchase of the building that was constructed to house our second cGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who manages the construction of ASTRA.  Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct the facility, which is expected to be completed in 1H 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes during the three and nine months ended September&#160;30, 2022 to our critical accounting policies, significant judgments and estimates as disclosed in our management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:56.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,451)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,799)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,261)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $5.4 million in the three months ended September&#160;30, 2022 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September&#160;30, 2021. Higher research and development expenses were due to increased preclinical, clinical and pre-commercial manufacturing activities of $635 thousand, increased payroll related expenses of $3.0 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $1.5 million increase in stock-based compensation, an increase in outsourced research and development activities of $1.0 million and increased other research and development expenses of $842 thousand, primarily due to depreciation, license and regulatory fees, and software related costs. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $10.4 million in the three months ended September&#160;30, 2022 as compared to the three months ended September&#160;30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $7.7 million, which was primarily driven by an increase in headcount in our executive, commercial, and other administrative functions to support overall growth, and includes a $3.9 million increase in stock-based compensation, increased commercial preparedness expenses of approximately $922 thousand, a net increase of $804 thousand, which consists of a decreased legal and professional fees of $766 thousand offset by a decrease in litigation proceeds of approximately $1.6 million, due primarily to the settlement of the PeriphaGen litigation, increased travel related activities of $140 thousand, an increase in medical affairs costs of $159 thousand, and increased other administrative expenses of $1.2 million, primarily due to increased utilities, taxes, and IT costs. These increases were offset by a net decrease in business development costs of $351 thousand and a decrease in software related costs of $202 thousand.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the three months ended September&#160;30, 2022 and 2021 was $1.6 million and $63 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. The increase in interest and dividend income is the result of increased investment activity and increased interest rates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine Months Ended September&#160;30, 2022 and 2021</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.381%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,425)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,026)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,159)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $12.8 million in the nine months ended September&#160;30, 2022 compared to the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $3.2 million, increased payroll related expenses of $6.4 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $3.3 million increase in stock-based compensation, increased outsourced research and development activities of $1.9 million and an increase in other research and development expenses of approximately $1.4 million, primarily due to software related costs and rent and depreciation. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $26.2 million in the nine months ended September&#160;30, 2022 as compared to the nine months ended September&#160;30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $19.8 million, which was primarily driven by an increase in headcount in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $10.2 million increase in stock-based compensation, commercial preparedness expenses of approximately $4.1 million, medical affairs costs of $495 thousand, increased travel related activities of $329 thousand, increased software related costs of $92 thousand, and other administrative expenses of $2.2 million, primarily due to rent, utilities, taxes, recruiting and conference expenses. These increases were offset by a net decrease of $845 thousand, which consists of a decrease in legal and professional fees of $1.8 million offset by an increase in litigation proceeds of approximately $993 thousand, due primarily to the settlement of the PeriphaGen litigation.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation settlement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement for the nine months ended September&#160;30, 2022 and 2021 was $25.0 million and zero, respectively, and consisted of the settlement of litigation with PeriphaGen. See "Legal Proceedings" in Note 6 of the notes to condensed consolidated financial statements included in this Form 10-Q for more information.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the nine months ended September&#160;30, 2022 and 2021 was $2.5 million and $127 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. The increase in interest and dividend income is the result of increased investment activity and increased interest rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September&#160;30, 2022 and 2021 was zero and $1.5 million, respectively, and related to accretion of the financial obligation for the build to suit lease liability during the nine months ended September&#160;30, 2021 to a balance that equaled the purchase consideration for ASTRA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, our cash, cash equivalents and short-term investments balance was approximately $394.4 million. Since operations began, we have incurred operating losses. Our net losses were $29.9 million and $107.9 million for the three and nine months ended September&#160;30, 2022, respectively, and $15.6 million and $47.8 million for the three and nine months ended September&#160;30, 2021, respectively. At September&#160;30, 2022, we had an accumulated deficit of $248.7&#160;million. With the net proceeds raised from our previous public and our ability to issue additional shares under our current ATM  program, we believe that our cash, cash equivalents and short-term investments as of September&#160;30, 2022 will be sufficient to allow us to fund operations for at least 12 months from the filing date of this Form 10-Q. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support our cost structure. Furthermore, we expect to incur increasing costs associated with satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned clinical and preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues until 1Q 2023, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out some of our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to continue to incur significant manufacturing and commercialization expenses as we prepare for product sales, marketing, commercial manufacturing, packaging, labeling and distribution. Furthermore, pursuant to our settlement agreement with PeriphaGen, we will be required to pay $12.5 million upon the approval of our first product by the FDA, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales.  Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third-party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, payments of settlement amounts to PeriphaGen and general overhead costs.  In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeline and cost of our OLE study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results and costs of our Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of manufacturing of B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing of an IND application for future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining our own commercial-scale cGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the nine months ended September&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2022 was $78.2&#160;million and consisted primarily of a net loss of $107.9&#160;million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of $26.4&#160;million, and including net changes in operating assets and liabilities of approximately $3.2&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2021 was $27.0&#160;million and consisted primarily of a net loss of $47.8&#160;million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of approximately $11.9&#160;million and build to suit interest expense of $1.5&#160;million, including net changes in operating assets and liabilities of approximately $7.1&#160;million. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2022 was $108.9&#160;million and consisted primarily of expenditures of $47.8&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $214.7 million on the purchase of short-term and long-term investments, partially offset by proceeds of $153.6&#160;million received from the maturities of short-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2021 was $100.2&#160;million and consisted primarily of expenditures of $27.5&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $83.8 million on the purchase of short-term and long-term investments, partially offset by proceeds of $11.0&#160;million received from the maturities of short-term investments.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2022 was $32.3&#160;million and consisted primarily of proceeds of $32.9&#160;million received from our ATM Program and exercises of stock options and offset by $649&#160;thousand used for the employee tax withholding payment for settlement of vested restricted stock awards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, we issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting underwriting discounts and commissions of approximately $900&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2022, we received proceeds of $3.6&#160;million&#160;from the exercise of stock options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2021 was $145.6&#160;million and consisted primarily of proceeds of $153.6&#160;million received from our ATM Program, a public offering, and exercises of stock options, partially offset by $8.0&#160;million used for the purchase of the ASTRA building. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, we completed a public offering of 2,211,538 shares of our common stock at $65.00 per share. Net proceeds from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million and other offering expenses of approximately $198&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, pursuant to the ATM Program we issued 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand. We also incurred $172 thousand of other offering expenses related to the ATM Program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2021, we received proceeds of $1.9 million&#160;from the exercise of stock options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $394.4 million at September&#160;30, 2022, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that the investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.</span></div><div id="i558d66f804d0487883dba3662b46c183_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we implemented the first phase of our enterprise resource planning software, Microsoft Dynamics D365 (&#8220;Dynamics&#8221;), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years as the Company grows and as we move towards commercialization of our initial product candidate, B-VEC. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to continue to strengthen our internal financial controls. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.  As we are still in the process of implementing these additional phases, no change in our internal control over financial reporting occurred during the quarter ended September&#160;30, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i558d66f804d0487883dba3662b46c183_91"></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.</span></div><div id="i558d66f804d0487883dba3662b46c183_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in "Summary Risk Factors" and "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There have been no material changes from the risk factors previously disclosed in such filing.</span></div><div id="i558d66f804d0487883dba3662b46c183_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i558d66f804d0487883dba3662b46c183_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i558d66f804d0487883dba3662b46c183_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i558d66f804d0487883dba3662b46c183_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220930ex311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220930ex312.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220930ex321.htm">Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2022, are formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL. </span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i558d66f804d0487883dba3662b46c183_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.240%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;7, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>krys-20220930ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5f54c0766d5f4f23981da2bb31378680_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>krys-20220930ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i933c5cba4e1046df9be7f015d7346ceb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>krys-20220930ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i88d6d134fa6b42a0a69b69c4f8af44db_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended September&#160;30, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended September&#160;30, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>krys-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>0000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>0000010 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>0000011 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>0000013 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>0000014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>0000015 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>0000018 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>0000019 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>0000020 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>0000022 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>0000023 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>0000026 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>0000028 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>0000028 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>0000029 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>0000030 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000032 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseCostsDetails" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>0000036 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000037 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>0000038 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>0000040 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
        <link:definition>0000041 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_LitigationSettlementTotalConsideration" abstract="false" name="LitigationSettlementTotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SwitzerlandLeaseMember" abstract="true" name="SwitzerlandLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CostOfWorkPercentage" abstract="false" name="CostOfWorkPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CumulativeEscalationClausePercent" abstract="false" name="CumulativeEscalationClausePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_TwoThousandSixteenLeaseAgreementMember" abstract="true" name="TwoThousandSixteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PaymentToEscrowForReducingLeaseRentals" abstract="false" name="PaymentToEscrowForReducingLeaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_ShortTermAmendmentMember" abstract="true" name="ShortTermAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AdditionalAreaOfRealEstatePropertyLeased" abstract="false" name="AdditionalAreaOfRealEstatePropertyLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_NumberOfMilestones" abstract="false" name="NumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LitigationSettlementMilestonePaymentsSalesThreshold" abstract="false" name="LitigationSettlementMilestonePaymentsSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" abstract="false" name="LessorOperatingLeaseLiabilityAnnualLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_OtherContractualObligationsMember" abstract="true" name="OtherContractualObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedFinancingFeesCurrent" abstract="false" name="AccruedFinancingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LossContingencyGuaranteedMaximumPriceToBePaid" abstract="false" name="LossContingencyGuaranteedMaximumPriceToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_PeriphaGenMember" abstract="true" name="PeriphaGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_BostonMassachusettsLeaseMember" abstract="true" name="BostonMassachusettsLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressCurrent" abstract="false" name="AccruedConstructionInProgressCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PurchasePriceOfPotentialBuildingPurchase" abstract="false" name="PurchasePriceOfPotentialBuildingPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClauseTerm" abstract="false" name="CumulativeEscalationClauseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_PaymentsForSuitLiability" abstract="false" name="PaymentsForSuitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>krys-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_73080954-b013-46fd-bd56-e3af2bd592d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:to="loc_us-gaap_PreferredStockValue_73080954-b013-46fd-bd56-e3af2bd592d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ba40af2a-d67b-47cd-84da-5623c922c419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:to="loc_us-gaap_CommonStockValue_ba40af2a-d67b-47cd-84da-5623c922c419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e9d536c9-ec34-48ab-a4c0-633ddd2dbd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e9d536c9-ec34-48ab-a4c0-633ddd2dbd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e282707c-7475-41a0-bdce-2243efd59437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e282707c-7475-41a0-bdce-2243efd59437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31d251d6-0202-41e5-b39f-8f465d12caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c085548d-5edd-458f-aca1-78a3d0c479e7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31d251d6-0202-41e5-b39f-8f465d12caac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7fd8a37e-f32f-4f82-8624-40bfb12dd324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_853d7854-2dde-47b2-b2e0-67fba8b3f622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7fd8a37e-f32f-4f82-8624-40bfb12dd324" xlink:to="loc_us-gaap_Liabilities_853d7854-2dde-47b2-b2e0-67fba8b3f622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d8532f75-596d-4851-8176-31ec861ed421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7fd8a37e-f32f-4f82-8624-40bfb12dd324" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d8532f75-596d-4851-8176-31ec861ed421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7feb30b-8e21-47de-8a95-4825ce63e4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7fd8a37e-f32f-4f82-8624-40bfb12dd324" xlink:to="loc_us-gaap_StockholdersEquity_b7feb30b-8e21-47de-8a95-4825ce63e4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2310b8e4-6331-4827-83fd-61474ef60db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:to="loc_us-gaap_AssetsCurrent_2310b8e4-6331-4827-83fd-61474ef60db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6c59f86e-602d-4bcb-bb11-a08e0ab244bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6c59f86e-602d-4bcb-bb11-a08e0ab244bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f30ec4c0-9e29-4082-99d8-790b011763f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:to="loc_us-gaap_LongTermInvestments_f30ec4c0-9e29-4082-99d8-790b011763f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_81875808-0235-45e9-a646-04aa8d60791d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_81875808-0235-45e9-a646-04aa8d60791d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_52d64ecf-0369-4b31-8964-461c7348849d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81614e0c-bc8f-42b6-ac08-ff635c588713" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_52d64ecf-0369-4b31-8964-461c7348849d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4215f995-9650-48ce-ab69-c3124b30f986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8a57261a-4420-4e6c-8596-759abb8eee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4215f995-9650-48ce-ab69-c3124b30f986" xlink:to="loc_us-gaap_LiabilitiesCurrent_8a57261a-4420-4e6c-8596-759abb8eee5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73970b32-9fff-46a0-88f6-80034d8ed2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4215f995-9650-48ce-ab69-c3124b30f986" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73970b32-9fff-46a0-88f6-80034d8ed2ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8bb52c85-c75d-465a-85c1-165e90331dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_427e271a-87aa-4610-b068-25c04af88a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb52c85-c75d-465a-85c1-165e90331dd8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_427e271a-87aa-4610-b068-25c04af88a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1f139cdc-ed41-48db-beff-b00c04dbe593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb52c85-c75d-465a-85c1-165e90331dd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1f139cdc-ed41-48db-beff-b00c04dbe593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb8f8959-cd44-4810-8739-bf3890b4b988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb52c85-c75d-465a-85c1-165e90331dd8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb8f8959-cd44-4810-8739-bf3890b4b988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ee7e660-a17b-4864-aa4a-f42ab969a356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d85e302-734d-4941-8c06-dff63934c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ee7e660-a17b-4864-aa4a-f42ab969a356" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d85e302-734d-4941-8c06-dff63934c298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_133e60a8-700c-4aa0-995a-99f852c6aaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ee7e660-a17b-4864-aa4a-f42ab969a356" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_133e60a8-700c-4aa0-995a-99f852c6aaf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ee77af89-1fed-4995-b2e3-75bf593e6190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ee7e660-a17b-4864-aa4a-f42ab969a356" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ee77af89-1fed-4995-b2e3-75bf593e6190" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3dee8196-a696-481b-8091-c690a5a48013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a6aefa84-0dd4-468c-8a19-fb3d58a28233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3dee8196-a696-481b-8091-c690a5a48013" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a6aefa84-0dd4-468c-8a19-fb3d58a28233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ed9763ba-2ae2-40a7-9de8-b13c00af9c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3dee8196-a696-481b-8091-c690a5a48013" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ed9763ba-2ae2-40a7-9de8-b13c00af9c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_9738cba2-23e2-4c4d-9509-d915809ac7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3dee8196-a696-481b-8091-c690a5a48013" xlink:to="loc_us-gaap_LitigationSettlementExpense_9738cba2-23e2-4c4d-9509-d915809ac7bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc99391e-c015-4781-957a-53d6f84d1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_264e166d-baa9-4b11-8d78-93fa5de1898d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bc99391e-c015-4781-957a-53d6f84d1a8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_264e166d-baa9-4b11-8d78-93fa5de1898d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_b0cb86c5-fe7d-4f83-8fbf-7032edee0580" xlink:href="krys-20220930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bc99391e-c015-4781-957a-53d6f84d1a8e" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_b0cb86c5-fe7d-4f83-8fbf-7032edee0580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8a3c45bb-5e35-4ef4-beaf-d6e8516a1d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bc99391e-c015-4781-957a-53d6f84d1a8e" xlink:to="loc_us-gaap_InterestExpense_8a3c45bb-5e35-4ef4-beaf-d6e8516a1d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_14361665-f1b5-4b2f-93d1-a675424e9462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17c971e5-9301-41d6-be53-96eeebd1e68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_14361665-f1b5-4b2f-93d1-a675424e9462" xlink:to="loc_us-gaap_NetIncomeLoss_17c971e5-9301-41d6-be53-96eeebd1e68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2d25cb12-5a35-4cdd-84be-76bf1961b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_14361665-f1b5-4b2f-93d1-a675424e9462" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2d25cb12-5a35-4cdd-84be-76bf1961b5d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2f83b1f-cdb1-4b34-a109-aa3d00716dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_633bbd89-56d3-4d0e-9683-a0196390591a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c2f83b1f-cdb1-4b34-a109-aa3d00716dd4" xlink:to="loc_us-gaap_OperatingExpenses_633bbd89-56d3-4d0e-9683-a0196390591a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43c0d497-4c14-4727-8b26-7a4aa8dc1e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea040c12-1d98-4bb1-a750-7f9c0e702429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43c0d497-4c14-4727-8b26-7a4aa8dc1e17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea040c12-1d98-4bb1-a750-7f9c0e702429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c078ecb4-0a8f-4c91-afff-8883496d0571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43c0d497-4c14-4727-8b26-7a4aa8dc1e17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c078ecb4-0a8f-4c91-afff-8883496d0571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77dd3738-ac2f-4ee7-bef2-ab5dff3b0690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43c0d497-4c14-4727-8b26-7a4aa8dc1e17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77dd3738-ac2f-4ee7-bef2-ab5dff3b0690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36d731cb-1f33-4136-9175-21cfa40c745d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_36a7f3ba-7f65-43d3-9cbd-da7a8ab68b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36d731cb-1f33-4136-9175-21cfa40c745d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_36a7f3ba-7f65-43d3-9cbd-da7a8ab68b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_7ac2448a-b5f9-4289-98e1-ed57142d1b5f" xlink:href="krys-20220930.xsd#krys_PaymentsForSuitLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36d731cb-1f33-4136-9175-21cfa40c745d" xlink:to="loc_krys_PaymentsForSuitLiability_7ac2448a-b5f9-4289-98e1-ed57142d1b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_191d1ae1-83bc-4f2b-9c4a-d271d317e0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36d731cb-1f33-4136-9175-21cfa40c745d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_191d1ae1-83bc-4f2b-9c4a-d271d317e0b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d384b34-27be-4f48-9061-693f7bc6c3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_NetIncomeLoss_5d384b34-27be-4f48-9061-693f7bc6c3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_4448c054-08f8-40be-82ca-3ab265eb19fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_DepreciationAndAmortization_4448c054-08f8-40be-82ca-3ab265eb19fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c1875b7e-d3fe-48bb-b515-7f91a8392e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_ShareBasedCompensation_c1875b7e-d3fe-48bb-b515-7f91a8392e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_86454dde-668f-4600-b015-7d43ad7f18db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_OtherNoncashExpense_86454dde-668f-4600-b015-7d43ad7f18db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2bb11ce-66f3-4a88-bf1c-30c5f7adc284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2bb11ce-66f3-4a88-bf1c-30c5f7adc284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_1c49638d-f8f1-482e-bcd1-fdcd8f2c7028" xlink:href="krys-20220930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_1c49638d-f8f1-482e-bcd1-fdcd8f2c7028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_74cc466b-3db8-4042-aa7c-f283053d8efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_74cc466b-3db8-4042-aa7c-f283053d8efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2cb95da4-705c-4ae4-9ae5-35e25f08e5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2cb95da4-705c-4ae4-9ae5-35e25f08e5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1d7245d8-4a96-4334-868c-c6a093f5ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1d7245d8-4a96-4334-868c-c6a093f5ae8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f8d5f447-891d-4da1-bc90-d6a740050ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f8d5f447-891d-4da1-bc90-d6a740050ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_9df2dbd3-f609-441b-87fa-661c60aa56ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a2d636a-8c90-49f4-b697-61d0521c368d" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_9df2dbd3-f609-441b-87fa-661c60aa56ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_994b37ec-53a5-40a5-940f-68f3498e93a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d046637b-5dbc-491f-bbbf-42564eb96b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_994b37ec-53a5-40a5-940f-68f3498e93a6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d046637b-5dbc-491f-bbbf-42564eb96b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bb2350b2-5f9a-4e40-91e3-cdb13443dad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_994b37ec-53a5-40a5-940f-68f3498e93a6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bb2350b2-5f9a-4e40-91e3-cdb13443dad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_5c0991aa-00cf-47e5-9b9e-f33c9170b616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_994b37ec-53a5-40a5-940f-68f3498e93a6" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_5c0991aa-00cf-47e5-9b9e-f33c9170b616" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_09c9dc20-af26-4210-971d-9b1aaaba0ab4" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a964ace6-68c9-49a8-b523-23b0791cb66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_09c9dc20-af26-4210-971d-9b1aaaba0ab4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a964ace6-68c9-49a8-b523-23b0791cb66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c9bf041-5898-48d9-8cee-eddce91f5f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_09c9dc20-af26-4210-971d-9b1aaaba0ab4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c9bf041-5898-48d9-8cee-eddce91f5f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_005916f2-b953-4504-9b1a-c70d8224f2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ffdde1f0-53c2-4559-b04d-3baa452d2831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_005916f2-b953-4504-9b1a-c70d8224f2b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ffdde1f0-53c2-4559-b04d-3baa452d2831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff7fcd90-8c1e-4f75-b6e1-77828ea44374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_005916f2-b953-4504-9b1a-c70d8224f2b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff7fcd90-8c1e-4f75-b6e1-77828ea44374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2892b944-e008-4a62-a1b3-67f56aeb4f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_005916f2-b953-4504-9b1a-c70d8224f2b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2892b944-e008-4a62-a1b3-67f56aeb4f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a95a9783-e8c1-4d51-aaa3-c2742c4325b7" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea6df26b-6a5a-453d-99f0-b5a4aa8db605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a95a9783-e8c1-4d51-aaa3-c2742c4325b7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea6df26b-6a5a-453d-99f0-b5a4aa8db605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d7a04d45-17b3-4087-93cc-f150e705fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a95a9783-e8c1-4d51-aaa3-c2742c4325b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d7a04d45-17b3-4087-93cc-f150e705fd16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_943c3ab8-f8a7-42d8-b046-d444eda375f2" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27cd21c3-fb31-4f2b-be98-7b8900bc28a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_943c3ab8-f8a7-42d8-b046-d444eda375f2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27cd21c3-fb31-4f2b-be98-7b8900bc28a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_5e024fad-2594-4343-bfad-c7953c8ec108" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_943c3ab8-f8a7-42d8-b046-d444eda375f2" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_5e024fad-2594-4343-bfad-c7953c8ec108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1a1e8dba-c9cf-4a52-9efb-46f0dd6a799a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_943c3ab8-f8a7-42d8-b046-d444eda375f2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1a1e8dba-c9cf-4a52-9efb-46f0dd6a799a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5924d13c-750e-4c52-ae52-e65e2a6d1ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94acb551-4f4f-4d71-9ef0-1ed75515cc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5924d13c-750e-4c52-ae52-e65e2a6d1ce5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94acb551-4f4f-4d71-9ef0-1ed75515cc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_da508757-b462-4697-8266-d25f4a7ed971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5924d13c-750e-4c52-ae52-e65e2a6d1ce5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_da508757-b462-4697-8266-d25f4a7ed971" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:href="krys-20220930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_e993841f-ff7a-4eec-9099-4b87675bc7b5" xlink:href="krys-20220930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_e993841f-ff7a-4eec-9099-4b87675bc7b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_183584b0-715d-4cb6-86b7-e171df4bf15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_183584b0-715d-4cb6-86b7-e171df4bf15c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_e7100993-58b4-4681-8927-76a6211fa1ed" xlink:href="krys-20220930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_krys_AccruedPayrollAndBenefits_e7100993-58b4-4681-8927-76a6211fa1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_a3f24081-645c-40f8-a310-5c3eb684eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_us-gaap_AccruedIncomeTaxes_a3f24081-645c-40f8-a310-5c3eb684eaaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_39b4626c-66ac-488a-a48f-f30fb1125c2b" xlink:href="krys-20220930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_39b4626c-66ac-488a-a48f-f30fb1125c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_3d01b5dd-510e-4523-a3f8-f8986da1b22c" xlink:href="krys-20220930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_krys_AccruedFinancingFeesCurrent_3d01b5dd-510e-4523-a3f8-f8986da1b22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_05010537-9241-4dd1-a48b-ac688198f087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d46d59ad-6170-48bd-ad19-c379f8adf68f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_05010537-9241-4dd1-a48b-ac688198f087" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cf600c5-7753-46ae-8f8b-9ddecb40c91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bced5b48-8df2-4a38-986d-9764bb13e481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cf600c5-7753-46ae-8f8b-9ddecb40c91e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bced5b48-8df2-4a38-986d-9764bb13e481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_754d2c84-8760-452a-be1a-c060383371c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cf600c5-7753-46ae-8f8b-9ddecb40c91e" xlink:to="loc_us-gaap_OperatingLeaseLiability_754d2c84-8760-452a-be1a-c060383371c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1246e40b-0afd-4b07-8e54-b878c502cca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1246e40b-0afd-4b07-8e54-b878c502cca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa5badab-7c8a-4fde-b968-b58ce90cf473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa5badab-7c8a-4fde-b968-b58ce90cf473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12dc624d-d701-4706-be4d-0a918702a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12dc624d-d701-4706-be4d-0a918702a470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_71b3a0cb-15e0-4cc7-be87-85021edde1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_71b3a0cb-15e0-4cc7-be87-85021edde1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_964f7a49-101a-4ece-9a1f-7b9250aa0384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_964f7a49-101a-4ece-9a1f-7b9250aa0384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eb563978-e9d7-4080-ab50-6a2896738f5d" xlink:href="krys-20220930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fb2bd89-2063-46c6-ac89-80914a86ef6d" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eb563978-e9d7-4080-ab50-6a2896738f5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dc74e42f-c65e-4e8e-8858-68c6453f07e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f065860c-8009-4631-94ca-b62e70e0769b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dc74e42f-c65e-4e8e-8858-68c6453f07e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f065860c-8009-4631-94ca-b62e70e0769b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ed1d9c0-bc0e-49be-b0eb-5d4276352b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dc74e42f-c65e-4e8e-8858-68c6453f07e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ed1d9c0-bc0e-49be-b0eb-5d4276352b3b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>krys-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended" id="i814f54300052412da8a416b7efaeff78_CondensedConsolidatedStatementsofStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c8ac235c-b146-48ce-aeee-70d0eaa85b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_SharesOutstanding_c8ac235c-b146-48ce-aeee-70d0eaa85b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7afcf02-f9cb-406a-87d3-61e34f041bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockholdersEquity_c7afcf02-f9cb-406a-87d3-61e34f041bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a1821cc-fe16-4a07-9d31-de970af00e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a1821cc-fe16-4a07-9d31-de970af00e36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8724c86d-5452-4dac-8b41-2b815fea7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8724c86d-5452-4dac-8b41-2b815fea7ed3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b6782b21-90a9-47d7-8f9c-b80f417411af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b6782b21-90a9-47d7-8f9c-b80f417411af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ada748cc-62f1-4923-9275-996d166de975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ada748cc-62f1-4923-9275-996d166de975" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_182f414a-fcf2-4794-91a6-c9a4623676e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_182f414a-fcf2-4794-91a6-c9a4623676e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1f0a1091-bfe6-4145-ab10-6b7b51828d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1f0a1091-bfe6-4145-ab10-6b7b51828d54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_041383c8-5dae-4209-b67e-dcd92b9662b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_NetIncomeLoss_041383c8-5dae-4209-b67e-dcd92b9662b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_744534d3-4704-427b-b0de-88cee8424cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_871b94e0-ad59-4c93-855f-448f62d3f114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:to="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d8eb606-4872-45a1-b65a-e10a781380c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:to="loc_us-gaap_EquityComponentDomain_9d8eb606-4872-45a1-b65a-e10a781380c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:to="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9326b77c-0706-49c7-a3bb-73ac89a388f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_CommonStockMember_9326b77c-0706-49c7-a3bb-73ac89a388f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_849f7569-c886-462a-aa8e-505266c87146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_849f7569-c886-462a-aa8e-505266c87146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72f87e1a-31df-40cf-9410-662ce5966bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72f87e1a-31df-40cf-9410-662ce5966bb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_12f3f360-76b1-4cd6-80e0-56c7c00880d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_RetainedEarningsMember_12f3f360-76b1-4cd6-80e0-56c7c00880d0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i8842c58deed6497197d13f0cd1981a0a_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_920ed22f-6252-430d-bb40-f16d3843e0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_920ed22f-6252-430d-bb40-f16d3843e0c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d80a9609-2496-4ae9-9662-5ead33925ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d80a9609-2496-4ae9-9662-5ead33925ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bf22d4f3-57b8-4cbd-82a5-6bea9ab617c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bf22d4f3-57b8-4cbd-82a5-6bea9ab617c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56b1502a-dbab-4292-8e56-7511d4b01037_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56b1502a-dbab-4292-8e56-7511d4b01037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1f481870-ae8a-42a3-945e-90f1539a9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:to="loc_us-gaap_EquipmentMember_1f481870-ae8a-42a3-945e-90f1539a9cd8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="i92476212b4bb439da4bfc9209407c138_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b76b182-a7fd-4e0f-a87d-5bbfb9b9fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b76b182-a7fd-4e0f-a87d-5bbfb9b9fa98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03a74a2f-9899-40b4-8ab0-012868a3fb00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03a74a2f-9899-40b4-8ab0-012868a3fb00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_039c7be2-49ab-48a8-a47f-0d5ed91b7d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_ComputerEquipmentMember_039c7be2-49ab-48a8-a47f-0d5ed91b7d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_9ac51bd1-7218-4d2d-9308-f4c7b7a84490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_EquipmentMember_9ac51bd1-7218-4d2d-9308-f4c7b7a84490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a779784c-27b6-4008-b848-3186866ac256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a779784c-27b6-4008-b848-3186866ac256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:to="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_026916ca-45f5-4e54-a2c8-81fc9833ee9e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:to="loc_srt_RangeMember_026916ca-45f5-4e54-a2c8-81fc9833ee9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:to="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22883078-2614-465c-a2bf-a117c9326f9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:to="loc_srt_MinimumMember_22883078-2614-465c-a2bf-a117c9326f9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e1df297b-01ff-4e7f-ba3c-ec0c690abe26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:to="loc_srt_MaximumMember_e1df297b-01ff-4e7f-ba3c-ec0c690abe26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="ie9d158d810e24b41b8b9b9afa1d0bf67_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bffa8c60-190a-450e-bb32-e6377ec56944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bffa8c60-190a-450e-bb32-e6377ec56944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_884f0fc1-d558-4d5d-bf11-14e8c7173a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_884f0fc1-d558-4d5d-bf11-14e8c7173a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2ac060ae-52a9-450c-8b01-9ca5e4581f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2ac060ae-52a9-450c-8b01-9ca5e4581f99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08645950-9ca8-48fa-a716-b2f29fe6e589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08645950-9ca8-48fa-a716-b2f29fe6e589" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_002c906b-27e8-439e-b524-42d9b24a35f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_002c906b-27e8-439e-b524-42d9b24a35f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fb1c039-6514-4dd8-bdca-19827adaa255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fb1c039-6514-4dd8-bdca-19827adaa255" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c16cc48e-69b5-4a6d-8143-1bf3a162e9d6" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c16cc48e-69b5-4a6d-8143-1bf3a162e9d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_659f79dc-1662-4765-a4c0-0c6462916de2" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_659f79dc-1662-4765-a4c0-0c6462916de2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_43c5902d-5f0e-454e-af20-b71b0fb439a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_43c5902d-5f0e-454e-af20-b71b0fb439a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_311f9ebf-89cf-4147-9416-400d5a3de83c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_311f9ebf-89cf-4147-9416-400d5a3de83c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1e2b5662-cba9-4f38-b3db-26acaf2eeebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:to="loc_us-gaap_CashMember_1e2b5662-cba9-4f38-b3db-26acaf2eeebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_398bd513-79a1-49b3-b1c2-2ca9ef933154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_398bd513-79a1-49b3-b1c2-2ca9ef933154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_630f9988-91c9-4551-88b1-901a9b5e0851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_630f9988-91c9-4551-88b1-901a9b5e0851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_add61d9a-a4d0-4c27-911e-f4711d6b1a52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_add61d9a-a4d0-4c27-911e-f4711d6b1a52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6fd011d3-4419-4ee9-a279-83009bca30da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6fd011d3-4419-4ee9-a279-83009bca30da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_0f063dfd-dd9a-44ed-8aec-0df279bc22d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_0f063dfd-dd9a-44ed-8aec-0df279bc22d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_9627c429-5137-4cba-b6f6-c6bd96113cfd" xlink:href="krys-20220930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_9627c429-5137-4cba-b6f6-c6bd96113cfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57b70116-b90e-41a4-b6ef-b80186672665_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:to="loc_srt_RangeMember_57b70116-b90e-41a4-b6ef-b80186672665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:to="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_254093af-57cd-40ae-9b23-188f315580c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:to="loc_srt_MinimumMember_254093af-57cd-40ae-9b23-188f315580c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c18a9fb0-88c9-414b-b38c-cd6e7d8a6739" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:to="loc_srt_MaximumMember_c18a9fb0-88c9-414b-b38c-cd6e7d8a6739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9c9f23a-12a0-4799-84bd-bc47083e3b30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9c9f23a-12a0-4799-84bd-bc47083e3b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9fdbe7f2-7aa9-4888-88cb-3020e2c5b7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_CommercialPaperMember_9fdbe7f2-7aa9-4888-88cb-3020e2c5b7d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_88a5e7c5-a5d2-4a3f-905d-e0041a8bba47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_88a5e7c5-a5d2-4a3f-905d-e0041a8bba47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a95a8dbc-76a0-452d-8084-4ec286ba5250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a95a8dbc-76a0-452d-8084-4ec286ba5250" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="ic2bf1213fc1949689987fd2c0291408a_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_192584af-8e3a-461a-8448-9b3065a7e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_192584af-8e3a-461a-8448-9b3065a7e5b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f72a9cf-cfce-4efa-b0a1-0f0b151bcb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f72a9cf-cfce-4efa-b0a1-0f0b151bcb92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0562dd8-35e9-4d5b-a2d8-96a2133b7b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0562dd8-35e9-4d5b-a2d8-96a2133b7b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c41ea7-39bd-4690-b5cf-e7231ecb2aec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c41ea7-39bd-4690-b5cf-e7231ecb2aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7dbf3c63-f03b-422f-817f-04fc7999641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_ConstructionInProgressMember_7dbf3c63-f03b-422f-817f-04fc7999641e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_591cd124-24dc-406c-8f2c-b1f492fbbe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_591cd124-24dc-406c-8f2c-b1f492fbbe8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_20605d7b-b613-4acb-9765-6a72ad7e355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_20605d7b-b613-4acb-9765-6a72ad7e355f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_868f16be-289c-4092-9bfe-033a5819cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_ComputerEquipmentMember_868f16be-289c-4092-9bfe-033a5819cc7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_f5db44cf-c7f3-4dce-862b-5cdd7eb61b6a" xlink:href="krys-20220930.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_krys_LabEquipmentMember_f5db44cf-c7f3-4dce-862b-5cdd7eb61b6a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i218ff1a31a26481db85e0fb69ab3d0d6_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_c201aa79-c49f-4782-a723-e4b8bff362a5" xlink:href="krys-20220930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_c201aa79-c49f-4782-a723-e4b8bff362a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_c00c2f86-4b7d-4d1c-a46b-4db2f77bd823" xlink:href="krys-20220930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_c00c2f86-4b7d-4d1c-a46b-4db2f77bd823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_3afa80fd-8785-4d3f-83b9-7772d6c5504e" xlink:href="krys-20220930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_3afa80fd-8785-4d3f-83b9-7772d6c5504e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ea450e36-4163-4992-9370-1e7797037a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ConstructionInProgressGross_ea450e36-4163-4992-9370-1e7797037a82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_4fa06f3a-1c86-4a9e-858a-87d04377da09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_FinanceLeaseLiability_4fa06f3a-1c86-4a9e-858a-87d04377da09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2d2b167b-143e-4580-9ba5-fcfc2e5dd3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_EscrowDeposit_2d2b167b-143e-4580-9ba5-fcfc2e5dd3e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fac1eca0-65e0-43e8-b046-db97c39134a5" xlink:href="krys-20220930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fac1eca0-65e0-43e8-b046-db97c39134a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_6702dee3-6bbd-4a68-9a32-1958d6dd0c34" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CumulativeEscalationClausePercent_6702dee3-6bbd-4a68-9a32-1958d6dd0c34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_63fb9eaa-5434-4278-8555-6c9d040838bf" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CumulativeEscalationClauseTerm_63fb9eaa-5434-4278-8555-6c9d040838bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7f82856-68d8-41cb-81ab-c38f7ce63254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7f82856-68d8-41cb-81ab-c38f7ce63254" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecc9538d-6941-4c90-bc20-3a8ece7f0546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecc9538d-6941-4c90-bc20-3a8ece7f0546" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_a4a2f644-23cc-4285-b320-9aacf67c8d88" xlink:href="krys-20220930.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_RemainingCommitmentAmount_a4a2f644-23cc-4285-b320-9aacf67c8d88" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_27a7f65c-a7e0-4771-b486-1afac98a5bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ProfessionalFees_27a7f65c-a7e0-4771-b486-1afac98a5bf1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d6e5744c-620f-4525-a1ff-0b1c1b94e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ContractualObligation_d6e5744c-620f-4525-a1ff-0b1c1b94e7c0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_8e542b18-7dff-4560-b407-f11231584d86" xlink:href="krys-20220930.xsd#krys_CostOfWorkPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CostOfWorkPercentage_8e542b18-7dff-4560-b407-f11231584d86" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_23f561d0-5334-45d4-bf7f-4ca585a234d8" xlink:href="krys-20220930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_23f561d0-5334-45d4-bf7f-4ca585a234d8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_fd9a4617-3d63-4fe0-a8c3-1ac472fa362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LitigationSettlementExpense_fd9a4617-3d63-4fe0-a8c3-1ac472fa362b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c0774018-c10e-4731-a3a9-22e88bf72dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c0774018-c10e-4731-a3a9-22e88bf72dca" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_35896730-3ef7-488c-a84d-d5ba7042ca3d" xlink:href="krys-20220930.xsd#krys_NumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_NumberOfMilestones_35896730-3ef7-488c-a84d-d5ba7042ca3d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2f6a0884-5fbc-4982-836c-8573707d6a2e" xlink:href="krys-20220930.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2f6a0884-5fbc-4982-836c-8573707d6a2e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_d4379931-cfdb-4aca-b829-7de3b51300c0" xlink:href="krys-20220930.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LitigationSettlementTotalConsideration_d4379931-cfdb-4aca-b829-7de3b51300c0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83d42c9a-d024-4456-bb4d-9d38647df05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83d42c9a-d024-4456-bb4d-9d38647df05f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b9ea1d48-e3cc-4450-933e-f243d927940a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b9ea1d48-e3cc-4450-933e-f243d927940a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_caf38e0c-31d9-452f-a70f-faa2d2d74997_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_caf38e0c-31d9-452f-a70f-faa2d2d74997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_1db170b2-ebc2-40f5-b045-3645e23c0aa2" xlink:href="krys-20220930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_1db170b2-ebc2-40f5-b045-3645e23c0aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember_3ec7697b-2289-4f9b-a561-07ba48eeb40d" xlink:href="krys-20220930.xsd#krys_ShortTermAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_ShortTermAmendmentMember_3ec7697b-2289-4f9b-a561-07ba48eeb40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_03940f16-8a67-4a1d-ae67-4adcdcf6c4af" xlink:href="krys-20220930.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_BostonMassachusettsLeaseMember_03940f16-8a67-4a1d-ae67-4adcdcf6c4af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_2c5f4ea5-e227-4238-a138-c3a23a077864" xlink:href="krys-20220930.xsd#krys_SwitzerlandLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_SwitzerlandLeaseMember_2c5f4ea5-e227-4238-a138-c3a23a077864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_314df9f6-c1bd-4a97-b63a-6530a9829198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_314df9f6-c1bd-4a97-b63a-6530a9829198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_49d5e058-a2b7-4d0d-9e4a-3b293ede3987" xlink:href="krys-20220930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_ClinicalSupplyAgreementMember_49d5e058-a2b7-4d0d-9e4a-3b293ede3987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_8be51faa-1121-41e7-bcee-3092f4ed68f9" xlink:href="krys-20220930.xsd#krys_OtherContractualObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_OtherContractualObligationsMember_8be51faa-1121-41e7-bcee-3092f4ed68f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_b68d1937-adf2-46df-a477-60af177ca3fc" xlink:href="krys-20220930.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_ASTRAFacilityMember_b68d1937-adf2-46df-a477-60af177ca3fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_458d68cf-a889-4180-bc27-541fb42b29cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:to="loc_srt_LitigationCaseTypeDomain_458d68cf-a889-4180-bc27-541fb42b29cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:to="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_28051688-cf7d-4f9b-a9f9-c2575f204832" xlink:href="krys-20220930.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:to="loc_krys_PeriphaGenMember_28051688-cf7d-4f9b-a9f9-c2575f204832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:href="krys-20220930.xsd#krys_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_55f84bad-bb90-43c6-ac60-dadfc0f13864_default" xlink:href="krys-20220930.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:to="loc_krys_MilestonesDomain_55f84bad-bb90-43c6-ac60-dadfc0f13864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:href="krys-20220930.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:to="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_d01622b8-db2e-45b2-b760-4cb0b59de8ae" xlink:href="krys-20220930.xsd#krys_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneTwoMember_d01622b8-db2e-45b2-b760-4cb0b59de8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_f7e44867-bc75-4455-94fb-1137282bc309" xlink:href="krys-20220930.xsd#krys_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneThreeMember_f7e44867-bc75-4455-94fb-1137282bc309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_30fc5f40-b340-46be-88b5-693f625c7309" xlink:href="krys-20220930.xsd#krys_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneOneMember_30fc5f40-b340-46be-88b5-693f625c7309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_29c425ee-c351-49cb-a2c7-d785800a7923_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:to="loc_srt_ScenarioUnspecifiedDomain_29c425ee-c351-49cb-a2c7-d785800a7923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3aece7b4-7164-44a2-a555-8c2b3ce66dd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:to="loc_srt_ScenarioForecastMember_3aece7b4-7164-44a2-a555-8c2b3ce66dd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="i5eab6cb2f98046aab519e1a1c5acd6e5_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_7a26cd00-625f-41a8-ae1f-89689cfee801" xlink:href="krys-20220930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_7a26cd00-625f-41a8-ae1f-89689cfee801" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a682206-eb90-42fd-a5de-dafe9078d8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a682206-eb90-42fd-a5de-dafe9078d8ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f80d5bf2-31f5-49e2-be7b-5daf002a6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f80d5bf2-31f5-49e2-be7b-5daf002a6f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a260eb86-ffaa-4fa0-9441-a7d643e9e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a260eb86-ffaa-4fa0-9441-a7d643e9e316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_612fbd85-c689-4417-90ae-c30941234f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_612fbd85-c689-4417-90ae-c30941234f23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_091fd860-a74a-493c-b0b2-2df1b068ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_091fd860-a74a-493c-b0b2-2df1b068ea58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_7e5ea09a-cc10-4d47-9b95-22cbadc86e42" xlink:href="krys-20220930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_7e5ea09a-cc10-4d47-9b95-22cbadc86e42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f8c1b791-cdb1-4d3c-a98b-a7feb1ab3731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f8c1b791-cdb1-4d3c-a98b-a7feb1ab3731" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d488d6-e95f-465f-8b1b-9ffdb78e9a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d488d6-e95f-465f-8b1b-9ffdb78e9a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_132e724c-f88a-4e0b-84f2-3873c6d89042" xlink:href="krys-20220930.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_PlacementSharesMember_132e724c-f88a-4e0b-84f2-3873c6d89042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_0456d499-5a17-44e7-b91a-87156d452873" xlink:href="krys-20220930.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_PublicOfferingMember_0456d499-5a17-44e7-b91a-87156d452873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_4499dcf1-feb2-429f-aa0f-a53acd1da285" xlink:href="krys-20220930.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_ATMProgramMember_4499dcf1-feb2-429f-aa0f-a53acd1da285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_eff4cb1f-6453-41ad-be51-ea9b969f3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_us-gaap_OverAllotmentOptionMember_eff4cb1f-6453-41ad-be51-ea9b969f3ea3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i915ff4461ecb4216906dc238df4f4cf3_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24d83c13-9c65-405a-b2c2-aef9d7eacac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24d83c13-9c65-405a-b2c2-aef9d7eacac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540ad6be-4c15-4114-88fc-91dd27f544aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540ad6be-4c15-4114-88fc-91dd27f544aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e664f-12d9-4b2a-81d0-bc4aad34d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e664f-12d9-4b2a-81d0-bc4aad34d62d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c79b351-5de5-4f3b-8f5c-7d78ae08c568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c79b351-5de5-4f3b-8f5c-7d78ae08c568" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e036333b-56ca-4d5b-b95c-c2366f2df7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e036333b-56ca-4d5b-b95c-c2366f2df7f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f11f36-fc57-4761-8b9b-6561b460a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f11f36-fc57-4761-8b9b-6561b460a93a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc8f45d5-281e-4fcc-8c3a-bf7da9549ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc8f45d5-281e-4fcc-8c3a-bf7da9549ebe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_34e2a182-9bdd-4d0f-8ea4-04fe6b26e8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_34e2a182-9bdd-4d0f-8ea4-04fe6b26e8c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5793940d-877d-4482-a85e-56c3ebf4aa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5793940d-877d-4482-a85e-56c3ebf4aa01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b18e3783-f69b-4b1c-939d-2f48d98fe2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b18e3783-f69b-4b1c-939d-2f48d98fe2e4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1736726b-a17f-4809-a113-691cae15de0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1736726b-a17f-4809-a113-691cae15de0d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82fb5f72-7847-493f-a818-eb5e72554f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eafa5a68-286e-4d9e-9d8d-7436b6a48f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eafa5a68-286e-4d9e-9d8d-7436b6a48f1b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9189d3c-2fee-4c93-a1f3-0b63dd54026a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9189d3c-2fee-4c93-a1f3-0b63dd54026a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a529d750-6649-4b43-ab8b-ebfd921b9ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a529d750-6649-4b43-ab8b-ebfd921b9ccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_cca818af-077b-4719-b4cd-f44667ee4de1" xlink:href="krys-20220930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_krys_NonEmployeeStockOptionMember_cca818af-077b-4719-b4cd-f44667ee4de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e1ed89b3-42fd-461d-8cce-b3591f3f4fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_us-gaap_RestrictedStockMember_e1ed89b3-42fd-461d-8cce-b3591f3f4fd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_ecfe0a4d-9adb-4c44-a519-bc2c24d078c8" xlink:href="krys-20220930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_krys_IncentiveStockOptionsMember_ecfe0a4d-9adb-4c44-a519-bc2c24d078c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df9666bb-8f7b-4864-a0ac-0a5218854bb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:to="loc_srt_RangeMember_df9666bb-8f7b-4864-a0ac-0a5218854bb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:to="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02a048c2-250f-4e9c-b06e-c299096b07a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:to="loc_srt_MinimumMember_02a048c2-250f-4e9c-b06e-c299096b07a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_333809db-82dc-4904-907c-07b4e9f9dec6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:to="loc_srt_MaximumMember_333809db-82dc-4904-907c-07b4e9f9dec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0f1a83f1-cb21-4283-8573-c1fc25351bfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:to="loc_us-gaap_PlanNameDomain_0f1a83f1-cb21-4283-8573-c1fc25351bfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:to="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_18cfd9ea-3979-4d3e-bbf4-3af03e6d8829" xlink:href="krys-20220930.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:to="loc_krys_StockIncentivePlanMember_18cfd9ea-3979-4d3e-bbf4-3af03e6d8829" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1aa468a6-6875-4948-8097-9ce0e42da896_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1aa468a6-6875-4948-8097-9ce0e42da896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_bf71cb66-d2ef-431a-9e3c-c6aa69eee6b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:to="loc_srt_DirectorMember_bf71cb66-d2ef-431a-9e3c-c6aa69eee6b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_8b215b5b-81c1-4b0c-ac3c-97b8fdad6fd8" xlink:href="krys-20220930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:to="loc_krys_NonEmployeeStockOptionMember_8b215b5b-81c1-4b0c-ac3c-97b8fdad6fd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended" id="i92dc36725de24164be42502634dc7a31_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5c52a6e1-d255-4649-9b14-6d28a548a199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5c52a6e1-d255-4649-9b14-6d28a548a199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_957b6887-3fbb-40d4-8eeb-33e45997af85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_957b6887-3fbb-40d4-8eeb-33e45997af85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d29a3da-68d1-4dd0-9335-629d9dad122f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d29a3da-68d1-4dd0-9335-629d9dad122f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4123add-7c49-4dd0-ba8b-d7dbf4147bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4123add-7c49-4dd0-ba8b-d7dbf4147bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:to="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac4f0748-8041-4fdb-b323-2315e9e0946f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac4f0748-8041-4fdb-b323-2315e9e0946f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bee9d83-be07-4852-a479-06261d0300fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bee9d83-be07-4852-a479-06261d0300fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d97e2e69-85ad-47c0-935f-36bf56fc0564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:to="loc_us-gaap_RestrictedStockMember_d97e2e69-85ad-47c0-935f-36bf56fc0564" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="i27c1012f6a6a4778ae09c1932b07972b_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd77b320-cf72-497b-be0c-716263415766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd77b320-cf72-497b-be0c-716263415766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99ca0c29-f51c-4ca3-adcb-b42346ea40a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99ca0c29-f51c-4ca3-adcb-b42346ea40a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_676028e1-275e-4fee-ab7c-a6c995fd45ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_676028e1-275e-4fee-ab7c-a6c995fd45ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_52451773-37fe-499e-8e5f-7deddcf543df" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_52451773-37fe-499e-8e5f-7deddcf543df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_da1bc160-f83b-4b71-a2bd-597fa82d6b71" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_da1bc160-f83b-4b71-a2bd-597fa82d6b71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:to="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9445c167-45eb-4474-9f3b-9786863c1fb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9445c167-45eb-4474-9f3b-9786863c1fb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35c64bb3-8080-4123-806f-c0de5d02db17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35c64bb3-8080-4123-806f-c0de5d02db17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended" id="i3121f4e533284e7fb3fd6f50eeca671e_StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a216a361-1859-48c2-a2b5-5b49a790d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a216a361-1859-48c2-a2b5-5b49a790d6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_44e49895-0d71-40d6-9217-612bd4d0a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_44e49895-0d71-40d6-9217-612bd4d0a31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b97acb0a-2158-47ac-b10a-b354f1b9c122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b97acb0a-2158-47ac-b10a-b354f1b9c122" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f15c4f6-212b-4931-8bb6-cb545ba844dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f15c4f6-212b-4931-8bb6-cb545ba844dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3b5082f5-cb33-4d5c-bc87-ad2584a0635c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_151a6e5f-e90e-4fca-b08e-ca44433537a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_151a6e5f-e90e-4fca-b08e-ca44433537a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_376c5ac3-ff83-4b2d-8aa8-47b94b9fcd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_376c5ac3-ff83-4b2d-8aa8-47b94b9fcd18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be955ccb-677b-4a09-8e71-5c8cdeed93e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be955ccb-677b-4a09-8e71-5c8cdeed93e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46928743-4b39-4eae-8276-8e88c3c16e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46928743-4b39-4eae-8276-8e88c3c16e50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4150c7e-4987-45a0-b93a-df1d7f60b535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:to="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17267af9-c622-4119-9bcf-554c387e2629_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17267af9-c622-4119-9bcf-554c387e2629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9ea04e55-138f-4c10-ac47-ecb0fdc83bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:to="loc_us-gaap_RestrictedStockMember_9ea04e55-138f-4c10-ac47-ecb0fdc83bb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>krys-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_222d8d3e-4727-44f8-bd59-81dfa70a713e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_808b398c-0147-452a-8bf1-b7afeec0152d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_49848195-2dba-4d0e-b583-388a8fc97f22_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20220930.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_214a9163-43ee-4619-bc00-b1f496a6d7f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad39e43e-9e1f-4fa3-b8d1-52582d20fc49_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_81fecfe9-3e2e-4e8b-8a75-9862bb6ab6ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3a71affb-34d5-44ce-9208-54e07d8cd9f5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_abc3b8c8-1f72-41d8-9880-58afc7d72470_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_36d6b2f4-bd86-403a-9db1-6e07ebaf0747_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4ebc8aef-82cf-45f4-baf4-eca7b669b255_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_467c9b08-f9ba-411c-b3a7-57bf00de3303_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a20f0f2f-b40a-4ce2-b46b-a47317e4363c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8210b2a7-886b-46a8-973d-d7a9e414aa18_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_026ca126-ad24-4838-b79c-27c0778b9ae8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_217b4b51-4218-435d-abb5-ef0203403c89_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35cdc5f8-770b-4f6a-8b6d-2dab82e9777c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a1b4a86c-321c-4aae-8adb-b9108580d012_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c33c53ca-38f3-4067-9e85-09192089e10f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fa37175-bde7-406b-b75a-d0362ce3283e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5fdfd584-3424-43a9-91f3-7262b56caf16_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f5a9df3-a5b1-4a64-947a-77c6f9df8b5c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_9c1fce9e-b0ca-4ecf-8956-387edb912c34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_424e6f5e-1b00-4702-836e-8cd81ba79b91_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_f0551da9-563b-4a26-9f55-1e01afdc34af_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_925cce3a-799c-49b7-8975-10a2c4e56119_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_0ee1274e-fb30-4ef7-a822-f36a0c1c6d29_terseLabel_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, liability, annual lease payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_label_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_documentation_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:href="krys-20220930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:to="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_994c3bbd-6f24-46f1-ab30-b9b6cbb306a2_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20220930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_456154cb-fff5-4d63-b0f1-cdc7a5f82388_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_8bc336cc-8ad0-44f9-8e95-68f257f3546b_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems" xlink:to="lab_krys_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_56f4888e-63d7-48d6-aa12-8b3732677a4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aae9bdc9-124a-463c-abe0-c468c953bdb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized a September&#160;30, 2022 and December&#160;31, 2021; 25,709,664 shares issued and outstanding at September&#160;30, 2022; and 25,207,985 shares issued and outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_47f4ca0f-9b13-4364-a927-91745255cdec_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_f6d723ff-2d35-4db6-a15f-6db9ba9bf9b0_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental condensed consolidated balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20220930.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SwitzerlandLeaseMember_d673709e-11d8-4a64-b8f4-e90b5a7bc6f3_terseLabel_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_label_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease [Member]</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_documentation_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember" xlink:href="krys-20220930.xsd#krys_SwitzerlandLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SwitzerlandLeaseMember" xlink:to="lab_krys_SwitzerlandLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3d9b760c-9336-4f4e-90bd-3221307d38b9_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53ad9806-bcc6-41cb-88b6-aaefbce9d1e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_481760b4-8986-434c-8d5c-b8e99b184a1d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_00190c11-8139-4779-a14e-12ca8e748ca3_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f991d6ba-68f2-46d0-92ba-f66c04cd7493_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesDomain_40ba106a-6fa3-4aeb-b5bb-a43a2f645698_terseLabel_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_label_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_documentation_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain" xlink:href="krys-20220930.xsd#krys_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesDomain" xlink:to="lab_krys_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_22c35cf9-7118-4cca-9b30-ee0ee1901f96_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5195aa3d-43b9-464c-9ff7-3d4c49e01e8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at September 30, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_bea40908-2fb3-4e96-bab7-0d7e5df1b204_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20220930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03347265-d3b2-41a0-8231-5ce3ae8a1189_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_95574d69-5e18-4e9c-8a0d-c71444fad5b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22263b81-4eae-4087-ac94-a214a32a21c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be60a009-03fe-4889-a696-ec541424a582_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f3f6a91-2345-4d1a-bac8-577f67558d31_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_fc807ab3-cd97-4be6-9d58-daa32a396d62_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20220930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_71bb8a58-39ae-4b64-9d48-7ab0a099e468_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0fec1f60-e770-410d-90e8-2b84dc498ab7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f0f57db-c14c-4ea5-a037-ace3dd901ec3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_05155284-d9ae-47ba-98a4-e2460f15be50_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_401aa4af-0d7f-4296-b3bf-a84a0b5307c3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d3a2422c-2878-42b3-b329-e9722fd91f56_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c3738ab-0540-462f-b916-482887f328b1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_e65cfce1-aa88-4c2b-9669-88a3e8a50a6b_terseLabel_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_label_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease [Member]</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_documentation_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember" xlink:href="krys-20220930.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BostonMassachusettsLeaseMember" xlink:to="lab_krys_BostonMassachusettsLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0a6b6e12-a1b7-4474-9b00-b0b1652f1613_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d5076907-6ec7-4af9-a0e4-e67fe0773187_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_234e318d-b26b-42ec-ab36-442df3226de7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9b4c7f84-56d8-4181-afb1-7bd1ea3140aa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b2eea136-0d14-40e9-8e1e-297ac4a3f4aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99e51e1b-9000-4515-abb0-81b8c3d959d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d4bc50d6-0de0-4e3e-8f6a-26f25b4940d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_4a67e9da-e2c0-4979-a216-6ff7a1af0426_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_26be0343-da00-449e-8e74-9bbeb40e46ef_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_54fb5ecd-6c93-4aef-9d64-8c27755ebac9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_14a564e7-d621-4487-afc4-56501c6bac9a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneThreeMember_2358ba8b-94e4-4650-8564-5880806ed40a_terseLabel_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_label_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_documentation_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember" xlink:href="krys-20220930.xsd#krys_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneThreeMember" xlink:to="lab_krys_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_760b981a-cfac-45c2-ab71-e479cec57125_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0fa3b765-86d9-4061-b35e-b695623826f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e7f1584-7284-479a-bd2b-722b55e1be3a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5ed49c51-927c-4e98-b80e-8c2de2b6f749_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1a9dc687-2d23-47c5-9b2d-4e1ac23374f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c583c6cc-9a3b-4a19-b1d2-156f90da1ae2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2e198d2-4a5d-4f90-aedf-20f94f733212_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NumberOfMilestones_1d90715f-d913-4717-9d47-32ad25fd48e2_terseLabel_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_label_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_documentation_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones" xlink:href="krys-20220930.xsd#krys_NumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NumberOfMilestones" xlink:to="lab_krys_NumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_bec20f3c-ea2d-4620-b011-1c32f5ca6590_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_86cc40e9-6020-42f8-ad12-1ecdd5fcbe05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_69d83e7b-f3a6-4343-b575-4e1a3a67a09c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_977e0d9f-c4dd-4dee-9e7e-23d4b8580979_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d30b9f7b-5345-4f7c-a662-f797bd6b4662_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ff18084-7545-4092-a305-2c4b1765cdc4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4664a222-0de8-4692-a5fb-1b2bde4576a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d86f3688-74bd-44fe-bce5-1b70f0e75c05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9c05fb0f-772a-435e-b362-ef133abcd1c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_6d6734e0-1445-4f1f-9dd2-979187400098_terseLabel_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contribution</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_label_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Escrow For Reducing Lease Rentals</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_documentation_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to escrow for reducing lease rentals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:href="krys-20220930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:to="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf230d6c-eede-4905-9776-f882074f8873_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4df2280b-2f96-4cf0-9c23-bdf6cb03efce_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39e897c6-6c33-4480-9fce-87eaa21b0e1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_659d5cea-2ac0-4247-89c7-a6c2312a9cd4_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20220930.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e7aeb4f0-02fa-475c-84ca-f6898358be89_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fff9c2fb-b0a8-45c8-9c0d-0cae08a3983a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7850621-cf4c-4be0-adec-4f33f834c934_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_70a666ce-e3c4-45b5-a59d-60010c19f9de_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_ccea4994-12f0-4c8b-85e7-c783bf059f6b_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20220930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_03439460-6647-4746-ae13-550e7c9ad87b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ef3ac519-3c3b-4c15-a229-49fe981c7930_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_728dae6c-7310-4787-9ace-e19f63d5072f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_26a1fda6-384b-40eb-9cc6-5d3762ddf636_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b03ebe41-cc1d-46fd-b59e-248c476ff4a6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8369bca1-022e-4e08-a8ce-3b987660291f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9ad02f13-c6a4-46e2-b1a3-40d5c56cc33b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2a82ede8-0cbe-4505-a07e-b192de3142aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14459493-fddd-4d29-ae11-76e1be2dd524_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_fd71eb48-8147-429a-af8f-8686a5807d24_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20220930.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c5823852-0253-415d-a68a-ebdda5cd7573_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2dba0917-f540-4967-b36e-62a9c9405f49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_892f4538-a682-4ff0-8e64-17fdec43ca33_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1570e93e-c998-4369-8ea5-b5f841a3047c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_07d26aff-62fc-4d4b-a80b-4eab384e48c7_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20220930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e20c554e-6214-44cd-83be-7ba1cadfb45f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_086bbaf7-c23a-4127-abad-e2c33abcb617_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bbe4db8e-2c49-45fb-8923-48973f9acf21_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3f862db9-f660-460e-bf10-d0ae26cad9fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e3c22a14-becf-430a-9630-d2dcbf37b5bc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_26612d20-141e-4aba-9b47-4789d95e44e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49133548-9687-4106-b00e-559334da9f75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_39bfc9bd-26c7-4caa-af0e-85d7fc2de225_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_07d722d0-8d3c-4444-9403-ca85b6a8e8f0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a222ad5e-3980-4804-a675-a68b05c430fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d71b3438-de92-4e1b-a629-a80b9e429d6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ab8ddf3e-3101-4361-aeee-ab91d1ba6ffa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fe78d9a6-a26b-4df9-a068-a044a2b33512_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_36610007-08fd-4b51-979d-ffc5eecf5c31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bbde37e2-4dd0-45a6-8beb-3d357b18e245_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854a7739-ecd5-4284-8598-622931e3c88d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bcf13c0c-34bc-447e-8c0b-15f70204dbad_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_173c344e-e19d-46d4-a24a-d2c656861673_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_291f0c64-e88b-47f1-aa7d-35b8a763cdde_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cd5d6936-d34d-4863-8abc-db421a7b6cfd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c9201e12-be55-48c3-b5e1-b4053fbbf6dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1c4aa673-3c68-4e83-9bd4-00fce1923ae6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9deb847c-9419-44ff-a641-c76ad12b2988_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_9b254c77-3330-418d-a614-5bba2191a040_terseLabel_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued financing costs</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_label_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_documentation_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent" xlink:href="krys-20220930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedFinancingFeesCurrent" xlink:to="lab_krys_AccruedFinancingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7d8a328-dd76-415b-b5c4-2fea6852ad40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_17f03e0e-53bc-4302-a067-78ee8ca4379c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ce66da51-faca-4351-8e15-01e6c82674d4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c615284a-3629-44ad-847a-f4d5bcb17988_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_07d42f73-8ea7-4eb5-978f-5eeb76a9e18a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_b81309e5-90f9-47ae-a956-54b956813e6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f58651f1-8cb1-4a0b-955e-4220c112730f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_44509130-4baa-4f05-9edb-43458b7ba435_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_23ddcf68-acfe-4228-ba58-1ecfe416aec8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_14f1a022-db81-4978-8346-69a34d7e39f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f18397d-5867-4f31-a1c2-5c2a19e7fff0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56c85284-a580-4bd6-8a17-92e582c5e784_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3a875454-898f-4e70-9b67-755ca023757d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PeriphaGenMember_d916ea3e-863e-4936-bf0f-a34c97f9042b_terseLabel_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:label id="lab_krys_PeriphaGenMember_label_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen [Member]</link:label>
    <link:label id="lab_krys_PeriphaGenMember_documentation_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember" xlink:href="krys-20220930.xsd#krys_PeriphaGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PeriphaGenMember" xlink:to="lab_krys_PeriphaGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2d2adc1b-16a9-4d66-858c-8e25ecfd2fd8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_ead0cc80-d2f0-4a9e-a9b3-d606afc02892_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_349459e5-2365-4893-a338-b47f637d07c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_cfed05ef-abe3-4e66-bec1-ce3e90519fb7_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20220930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_357b1a10-f088-451e-9577-5e051f57b855_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, total consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_label_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_documentation_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration" xlink:href="krys-20220930.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementTotalConsideration" xlink:to="lab_krys_LitigationSettlementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_66b53a56-4c05-4d15-bd3a-29d6208d47e5_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20220930.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ce3ffebe-6084-452c-88e5-96a689489c69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b6386338-12ce-4642-9d58-b0a997720c89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b9b90043-c3b9-4147-b503-bc7f4e394df3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f0e21a40-d8bf-4686-8f9e-f537765fe442_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9c29684e-047d-4eca-86c8-84669c02520a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_a6422037-eb0c-4310-8bc5-c57f048d3204_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_label_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClausePercent" xlink:to="lab_krys_CumulativeEscalationClausePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ba24528c-02f2-46d2-94d4-c80aa680dd8d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_bd5bd4cf-5056-418b-84a3-c536fdf66391_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_a1e7fbe6-ca51-4597-a810-fca95dd1e1bd_terseLabel_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of potential purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_label_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_documentation_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:href="krys-20220930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:to="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3bd0dc94-ff47-49bc-847c-d52d4a00b37d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d2656846-08f4-4d27-aec5-fee6064d02be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c3bbe0ab-5cb7-40de-8538-8343af5e00fa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_1750598c-d5d5-4fa9-a44c-a6b9a4200ffd_terseLabel_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, guaranteed maximum price to be paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_label_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_documentation_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:href="krys-20220930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:to="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentsForSuitLiability_4ac8c76d-95fb-475d-bcd0-fffa3fc0d305_negatedTerseLabel_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of ASTRA build to suit liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_label_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_documentation_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability" xlink:href="krys-20220930.xsd#krys_PaymentsForSuitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentsForSuitLiability" xlink:to="lab_krys_PaymentsForSuitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ff05a492-2e02-4da5-925e-c4df006e3358_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2a6b9f96-ae3b-4a11-9bea-1d5cca5fdb82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1ee8c65f-5eb2-47a7-bdcc-2981eea9a217_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_21cbd0f2-8891-428d-9c65-40f1433eb344_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_4c53a897-d1b1-4d31-b5e1-09e4bf3b1ff3_terseLabel_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Lease Agreement</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_label_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Lease Agreement [Member]</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_documentation_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:href="krys-20220930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:to="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_788881ce-233b-492e-8c97-676d630c574e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_683ef05d-3659-426c-aa4c-d8244833ae15_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_label_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClauseTerm" xlink:to="lab_krys_CumulativeEscalationClauseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_099fa70c-78e2-4f8e-9741-fd4001f798aa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d5ac55a1-501d-48d2-a6bc-38ee4e0752ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b1332a5d-ee76-4655-94d2-9c942bd24e13_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b918849-24c3-49bd-9ad5-98dd20723524_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27f55080-48cc-427f-aa4d-5a0d04a8344c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef6d645-21ce-414b-870e-2c5f44915df9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_49944330-e818-44aa-96c7-2fb495c15e02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a0f28520-c8ec-41e3-a243-655208b018a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ebf46df4-34b4-49c2-b1d1-0cbaa34499dc_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_dfd8405a-a69d-4b07-872a-2342f106a848_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_601e3861-df35-4377-8305-4a236f9bdc95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_02bf3a0d-ea22-4cff-a522-cb680b51fbad_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20220930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ccbd9bac-4f31-4acb-bcb2-d22be2b43404_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_3578ff69-5543-49ce-801c-4a96cc4f88b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShortTermAmendmentMember_463b311a-5e6c-48e7-9898-ef677af50b11_terseLabel_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment</link:label>
    <link:label id="lab_krys_ShortTermAmendmentMember_label_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment [Member]</link:label>
    <link:label id="lab_krys_ShortTermAmendmentMember_documentation_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember" xlink:href="krys-20220930.xsd#krys_ShortTermAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShortTermAmendmentMember" xlink:to="lab_krys_ShortTermAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_65aa0f9a-be7a-4f2c-b2c8-734cebd99208_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_099da4e9-1296-44db-a9f7-75f783639fd2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b08e15fa-4dbb-40bb-a5d8-135c4f0d82e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af722024-d9c0-41f5-ad97-5f21dcdeee10_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f1c6b083-67c6-4095-996c-4b10f21ce5b5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_8bad1f14-1a82-4422-97dd-e26bb4f5e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from insurance settlement, operating activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b0eccbbe-06bc-4b81-8330-cbf7a3e8ba82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5f7dc4d3-a3d5-4ca7-bd6f-dda9351f8652_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_37ad2e0b-fd70-4512-87e4-57d91d5a55db_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_22b47544-bb9c-45a6-a770-6ae98dae5e02_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a1143ed4-be39-46f1-944d-74f58a89343d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ad5b6ddf-06b9-4a38-a281-27528010077c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fbfcac7-2df7-469d-bc82-9da5da1dfcc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ef3eb287-fce4-4d07-b1c0-c4a3f57a5e0c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bd9f0766-1357-4be9-9eed-b50926bf14fb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7567e0c1-0ba4-42a4-b5de-66f288328a5f_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_abaddb88-3e6c-4866-96c3-183ba1820210_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2220bcd4-6093-4d98-909f-c751a8fc64c5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e130b827-261c-449b-8dee-3c430de970e2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f0987e2c-249b-4ebf-a590-8aaa1a97c202_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7bc9d236-a8de-4dd5-9ec7-36f4c17d01bc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bf4954ef-dfdd-4f44-8614-f62eb131e1bb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cc048455-cabd-4c82-93e0-7807718df80a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_002c24f2-01a2-460a-af7b-5583766fff0c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8521b80b-fd61-4ada-b0a8-b850d403caa6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net, (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_89916416-f41a-4a0a-a2dd-505b7b4820dd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7813cae7-45a2-4e29-bd04-c228ad504b45_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; September&#160;30, 2022 and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at September&#160;30, 2022 &#160;&#160; and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_05252a13-505d-46b1-a6db-5dd56a27f1a7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_bee7c0b8-9ebf-4aa4-9f38-a66df133bbc7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposals of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets for Financial Service Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:to="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_fc593822-3cd3-4271-804f-d885f21cf2f4_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20220930.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_556449ea-ff8a-4616-9b0b-9b47e833fa30_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9c95f87e-f8c1-4f5e-b010-3b372389e571_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_f6896e7d-92a5-427e-9cde-c1e2bd9cedaa_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_93fc9aeb-b507-4b32-950a-4008de0efd0c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_48b80ca5-d4d0-45f0-bb4f-79157f2fc98e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5b53a195-e423-4c1d-a438-ac2dc05ff2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_18201cbf-2ed4-42c2-8c40-77101df02235_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesTable" xlink:to="lab_krys_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_1a73fa83-40aa-4779-8fd3-5b97da38b7e9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1d9eeb3a-d7f6-41c3-b47e-5f77a48a7cb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4b045e74-9806-45ae-9261-9cc855d3e37b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8cd89d73-b778-4342-a65d-5a0ae4e85029_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_584095f8-c929-41b4-95a7-7387f682fc5c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f35a00a4-0ab8-42ae-96e8-71ce3ad773b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8882ea72-b0e9-4c94-bf7f-783442d88dca_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_81e965dd-fe3b-47db-af59-0075e7e38133_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a4ad95fa-f543-412f-ae7e-2b938fa5a8cd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_523ea991-4255-48be-be0f-446c631e2558_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_679333ef-af3a-4c9b-88df-7d912f0611e4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_f1b05848-c262-4d3e-9014-c6b3fd4bb705_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c5db49df-b1a6-4ba8-9062-a6abc25b1d76_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_283d0a51-5709-4395-b8d6-b9c73a0f2178_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b24a21e-4fb6-4460-ab1b-f03180711a75_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d42db4cf-fabe-4a50-8d1f-0c2730e21f1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_580c97cc-9da4-47ce-adf3-4bb2b1688aaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to settlement of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9c6ced48-e443-4f2c-b82c-c56a66d82955_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_60c268a8-9e8d-40b8-b1e0-99fc1d71366c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5dfcfca7-37b9-4449-b0b9-ec1562874e29_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_1bfce234-3b1b-4d04-9d56-0a7e1c92e729_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20220930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_79d99409-5410-4091-87c3-338f37c4d994_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesAxis_13f7664d-4a55-424d-be25-83b17af21745_terseLabel_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_label_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_documentation_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis" xlink:href="krys-20220930.xsd#krys_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesAxis" xlink:to="lab_krys_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_b7f623a8-3fd4-4095-862b-d0ea2056e9f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_74ae2906-d115-4d1b-aaa7-95e6608c2d94_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_73e0cf03-2b06-4924-851a-5e48b5eedf23_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b8a85880-c774-48ed-b3e9-3b59e9689c95_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_904fa288-ef59-42b3-8d35-0fd82bc6b5fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4cabb3a3-a509-4d02-a509-63c291d6359e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_969c4cd6-30c5-4244-a6e5-515c403ac02f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_77ad794a-123b-472a-b2c5-a3c4f5ba818e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_ddee879e-f834-40a1-bfed-1eac7c74c172_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20220930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76da46cb-3825-4e95-a9c5-9af4d733c7ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CostOfWorkPercentage_3ecd021a-f29e-41e3-b6a8-bee59017c02a_terseLabel_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of work, percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_label_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_documentation_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage" xlink:href="krys-20220930.xsd#krys_CostOfWorkPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CostOfWorkPercentage" xlink:to="lab_krys_CostOfWorkPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8632edad-03ca-40e4-b523-f27fb0023467_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_63e9d45a-db34-4a21-8cad-1df3d70d32d1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dcdcd0ca-c89f-40dc-9d0c-7c05cddf1d5e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff0e1e05-1c54-4789-a2b3-44d1a6be72fc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_96c9dae6-bde9-418c-89d5-90db049e5a17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b8e5b2f6-94f6-49f3-8d28-5b92c568f493_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76bbd4c0-3bc0-44c9-acfd-89df7639c9f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dc98dc1f-4c75-4141-b53e-31cd97d76f16_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e04f7d0a-fe68-4a76-a56e-d89cb59a1c02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_34096910-e4f6-4a9d-af59-7566995a0220_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, milestone payments, sales threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_label_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_documentation_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:href="krys-20220930.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:to="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneOneMember_8b46b552-fdfd-44ab-9a2f-39e590afb7e0_terseLabel_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_krys_MilestoneOneMember_label_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_krys_MilestoneOneMember_documentation_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember" xlink:href="krys-20220930.xsd#krys_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneOneMember" xlink:to="lab_krys_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6bc9e5a0-f964-4153-a847-bba6942bdb38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_6b370b7b-84a9-4ada-b590-825cd43ae607_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20220930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_441a13b3-76b0-436e-a0de-cee40eb6c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_c23dbf61-06e0-4714-9400-73e253253b31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cd9f3753-9025-4fc8-ba36-c367bb18c9e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_68a208e6-9559-4f19-b7e0-a19d361f4846_terseLabel_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:href="krys-20220930.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6443aed9-537c-4268-a7bd-534b4af6e799_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress, gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_81612c40-71fa-47e8-b614-f67427ba4601_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_098b805f-4391-47eb-9b0d-f66bc9ea5d57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c18b28e2-0d68-4c0d-89da-ced724014397_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_608c1d7b-7b45-4210-8f97-a5d251d45634_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d30e9e0-1d79-4dad-a9b3-cd48d1fc42c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7eb9e54e-009c-4dfc-88e0-93202e7569c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0d6998bd-bb83-41e9-9fc7-eb099c4a0c5f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_08b24c14-8234-4057-abcd-ba6b94409ba8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f174290a-b845-4220-b0d5-80488df73c38_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_ffd8d877-2f01-4821-8c9a-e79549beb74e_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_a9fd4ffa-111f-4794-a87c-b1cd1aa3b91d_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b59194ad-8c86-4675-a638-f358491d7e68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_1397a23c-fbc1-467e-8e3b-1f57d592ad2d_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20220930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ba696c2d-c1e2-47ed-9980-f65f7941aae9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_921cd934-3ca1-4085-9337-8e665f195185_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c34f40ae-2b02-4bd7-9b6b-381fb99857f7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4937d710-4a4b-47e7-a8af-6fc71fef7a61_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_183e0744-324c-4e3e-bc55-3ad92e79f549_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7fc30eca-3ce6-4688-8cfa-d8dcc94f2a83_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_352b04c2-e888-477a-a581-9f79564ffa44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21e0e460-a480-48ce-a3d7-b6ca9e467fec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_479e25a3-cf3e-4baa-9897-1ad0a9a13aa2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_70b79b6f-4714-495a-9368-3dfe04ab47be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_2f83178f-cc53-4635-abf5-a24ab2f72e5f_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20220930.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_16f49f88-9b0d-41c8-8539-1cf9ddcfc74b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_97973add-709e-407c-8905-1935ec70cf3a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_64f1e411-a399-4a98-abca-2726f5b17dcf_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7b00fdfc-61e0-4ebd-9560-ba6d34a14074_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_ae0e5e16-5fc2-4423-8ae2-59b5fc3ce3e0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3f26e9a6-b848-4d60-ada4-5bb4f3a4ce15_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ffbdef86-5594-4214-a40f-603b6682fcd1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_e2f171b6-b5ca-4b94-bb33-3c53bd4d7993_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3acf2454-0f02-4b31-a533-ebf2035782c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_00e89143-6dc4-4752-a2a6-996494835022_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_26a408e2-6889-4923-aa55-738726bf3e07_terseLabel_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_label_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area Of Real Estate Property Leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_documentation_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:href="krys-20220930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:to="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_dadb59b5-dcf2-417c-be6b-ba4061e44c57_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b857eca-e470-41b6-9225-ef120170b10b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4519a858-302e-4061-a081-a12287ae2c73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_07701351-99ea-4aa9-88b3-3846ad45cd0e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b0ecf4b5-855b-4a67-85ff-a967f477de30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_67e8cb64-3011-42e7-8372-b32f2361043d_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20220930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fe65ecfe-4494-433b-850e-c0bee994e853_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_ba76fa6e-a7c4-401e-a35c-fd3c011bcc69_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_46bea503-198b-47eb-aed0-f4a3c460ce69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e432e651-f130-4ba1-8606-aa3b508347d3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e355169d-8da8-486f-af57-8cac50c073fd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e3c0e9d3-ce39-4375-bcaa-4b530a683df5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5a0e2384-d78e-424c-9f1a-a295c2a743ed_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_1fda1006-6889-4d45-98e3-e04a825d0ec0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0024d6b7-99dc-4473-8309-3fc45a3df6e1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5cd33889-b51c-42cb-ad82-ce3f98baf6c3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9fd9b7d0-fdaa-4b7f-a93d-9a39c19fe067_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ebd47222-febf-48b5-b95d-5fa820070882_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_d323cecf-1de6-41e8-958e-01ca8ee4c16e_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress Current</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent" xlink:href="krys-20220930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressCurrent" xlink:to="lab_krys_AccruedConstructionInProgressCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_2b1fa402-c543-45ba-9723-3c3be01efcc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8cbdd7e8-436f-4d3a-b928-f56d0630e23d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d8e6abe-1f09-4519-9df0-dc58593fe8eb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_20102201-617a-4ad1-a628-97a0da2bcc21_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2fda1e6c-63d4-4088-98fd-3afd4e55bf07_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00469998-e34e-479e-a13b-10cbf8968c43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_87e686f6-f593-4347-bf30-f2eaf5219e65_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_68a91e23-a1af-41c8-8fa6-5bfbc61d9b89_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f997fc39-21d3-483c-9db2-55701764fd77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_076f8e6b-79a3-4e8f-a213-342c342bd9e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d929e5b-6e7a-4227-920e-6df585a72577_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OtherContractualObligationsMember_5dc9c388-900e-4e14-ad99-6ae83eb6c099_terseLabel_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_label_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations [Member]</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_documentation_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contractual obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember" xlink:href="krys-20220930.xsd#krys_OtherContractualObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OtherContractualObligationsMember" xlink:to="lab_krys_OtherContractualObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7521151c-08ce-4ed3-a6d6-2ea965b5155c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_23d5d439-03c4-4f25-a902-a5bf732deda6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d91da8c6-0478-48ab-8558-2322d9cdf094_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ca044676-82c1-4b45-820e-d6693906de9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bb408ac1-1b1b-4066-b679-a2a23185a15a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneTwoMember_1d60fb25-7846-4aab-935e-f2435b414712_terseLabel_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_label_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_documentation_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember" xlink:href="krys-20220930.xsd#krys_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneTwoMember" xlink:to="lab_krys_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca590e00-97ec-446c-a480-efbdee81adc5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_82db72cb-1db8-4bdb-8c87-b980034e5a72_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_dbd1d5de-5dfe-412b-93d0-6c4c6d1afa8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_af9a27aa-87b3-4615-9f63-2745b9498b08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2f3af4cb-0d57-4a4a-a53d-ef41f0ef5f40_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_dcf97295-3ecf-467e-ae96-a18b2bca01c1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_79d83c91-5387-48a5-80df-0beb68e79ac7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ba01dce-38ad-4276-a74a-e0c2638b5ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97eff0d9-53c3-4b85-a20b-fa93d94bc9ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78d0c323-bea5-4270-89c4-46e76346d540_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_f16706a9-a752-41f4-80fa-28394a7c1096_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20220930.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d5bd85f3-18ed-44e3-ad93-74566e031d99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_944dbf63-2e87-40f2-bd7e-31c83f928484_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_73b051f1-0523-4f52-9cc1-bc962ccfdf8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72db0286-c30c-44c1-9a28-358a3a02eabe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc2da83c-f818-4d5f-b2ee-5d2031a4d530_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2a032951-8a6e-41e9-a11c-b09de12be054_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_43edee1f-2f4d-4825-b41d-be26f807760c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8cd76f7-b4a6-45da-9d75-a137f09a199d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_72fd2623-d33d-4054-8313-c26e8859102b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4431330c-d7b9-4f21-9136-43a2cf57bf14_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_217ca57b-28fe-4e74-a793-bb172c5548bd_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20220930.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b362bb0e-52a3-4197-94b4-a5d7d5fc9a91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_21e964a8-b0f2-487a-a2a6-8d8df6b0324f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d3a7c8cf-8382-41fe-8f06-3f0599a2239b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9ae7e986-f93a-4755-b514-d24526e5f9d7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84f13bbf-76b1-4c37-93b8-61ccb845948f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92c402ca-32de-489d-9be0-9d6281495a1e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4df31cd0-c108-495a-a4fb-0e67067401a5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_210eedd2-56cc-4cb1-bf02-241d77f0705a_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d5f8e3e1-c4b5-4dc9-a3da-23250fce95e3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_b93cb1cb-af15-4161-a6b3-5346843582a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_08af5cd2-ee17-4de4-baf1-725a2a620ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_baa31080-b266-4947-bbb7-51a926afc18a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8fe910ab-99b1-4883-86fa-c5bab0f6989b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a455cdfa-e45a-4b7f-b19e-cbd9d4393ec2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6131901a-425f-40a8-9cf8-a9f8d3a0961b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8e8e135b-b3f9-43ce-ab9f-9225274c64c7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>krys-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b446ab86-d193-42ca-82b7-9672cb6c0bd4,g:791ca592-0004-40ca-a987-08a3bb89834e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_94c9573a-36ff-46b0-9370-9f59297a6477" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentType_94c9573a-36ff-46b0-9370-9f59297a6477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_cd55bb60-cdc3-498f-b035-5fb1fe62a3fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentQuarterlyReport_cd55bb60-cdc3-498f-b035-5fb1fe62a3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_80dd858b-58cc-4f5e-9d08-e68dd0203f3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentPeriodEndDate_80dd858b-58cc-4f5e-9d08-e68dd0203f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_36843222-c227-4cc8-9e82-86982c969260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentTransitionReport_36843222-c227-4cc8-9e82-86982c969260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_61588869-086f-4057-bba9-de3884032208" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityFileNumber_61588869-086f-4057-bba9-de3884032208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_219328ba-2d31-4767-bbef-c2c1d5350bcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityRegistrantName_219328ba-2d31-4767-bbef-c2c1d5350bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e0bfd33d-9da0-47ae-ac58-cad1f91366eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e0bfd33d-9da0-47ae-ac58-cad1f91366eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_80871f8a-51bb-4cd2-a54d-5cdd3d27fafa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityTaxIdentificationNumber_80871f8a-51bb-4cd2-a54d-5cdd3d27fafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a4b0f876-0ddc-4e41-9a69-81062591b2e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityAddressAddressLine1_a4b0f876-0ddc-4e41-9a69-81062591b2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_64f5989b-7331-4d08-9464-e19a9b005ec2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityAddressAddressLine2_64f5989b-7331-4d08-9464-e19a9b005ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8209ec62-6e46-4452-be50-0974aa55ff84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityAddressCityOrTown_8209ec62-6e46-4452-be50-0974aa55ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_585bc578-d074-434d-840f-44b4cbce52c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityAddressStateOrProvince_585bc578-d074-434d-840f-44b4cbce52c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ed5656fc-1392-4a3c-8afb-b4e0bcd882a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityAddressPostalZipCode_ed5656fc-1392-4a3c-8afb-b4e0bcd882a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d9b2ba0b-2317-4528-95e5-4e60cfe9d1d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_CityAreaCode_d9b2ba0b-2317-4528-95e5-4e60cfe9d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4b90e76e-7def-4dfa-8245-f3310874e497" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_LocalPhoneNumber_4b90e76e-7def-4dfa-8245-f3310874e497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_314cc72b-058c-429a-9e53-db7c5cb6ab27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_Security12bTitle_314cc72b-058c-429a-9e53-db7c5cb6ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1637beb2-9775-4cbb-b58c-fdf8dca56e84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_TradingSymbol_1637beb2-9775-4cbb-b58c-fdf8dca56e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_299874cc-e820-4351-b5fb-eefda1bc07fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_SecurityExchangeName_299874cc-e820-4351-b5fb-eefda1bc07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9efd9791-e1ec-4c4f-a7fc-4871e5228326" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityCurrentReportingStatus_9efd9791-e1ec-4c4f-a7fc-4871e5228326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6dea9270-cb9b-4129-9a7e-cb1d27fb6c44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityInteractiveDataCurrent_6dea9270-cb9b-4129-9a7e-cb1d27fb6c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d206d4ee-e562-4917-8fe6-1467139cd725" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityFilerCategory_d206d4ee-e562-4917-8fe6-1467139cd725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_78ca3412-dac8-41d9-9681-ad8eb61de0d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntitySmallBusiness_78ca3412-dac8-41d9-9681-ad8eb61de0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b2314bb1-fafd-46ed-848e-0d0012509258" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityEmergingGrowthCompany_b2314bb1-fafd-46ed-848e-0d0012509258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a0c22a1d-1c14-458a-8cee-0a0175fa787f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityShellCompany_a0c22a1d-1c14-458a-8cee-0a0175fa787f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10307680-6ac4-4a3c-801a-f0b346624a5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10307680-6ac4-4a3c-801a-f0b346624a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fff8ece5-c8ef-4f34-875d-aea9c9622c49" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_AmendmentFlag_fff8ece5-c8ef-4f34-875d-aea9c9622c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e9cc5a3e-6201-4aa8-9a0b-4bde80469d77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentFiscalYearFocus_e9cc5a3e-6201-4aa8-9a0b-4bde80469d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7b95ae4b-db55-46c7-9187-4df43bd6e3e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7b95ae4b-db55-46c7-9187-4df43bd6e3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3bc3beed-d213-427c-8e15-040e02269fef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_EntityCentralIndexKey_3bc3beed-d213-427c-8e15-040e02269fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_297c42b8-33fa-4f65-b8d2-a5df21b83bba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2bb9e9c-b532-4906-bf91-1fe9feb8587c" xlink:to="loc_dei_CurrentFiscalYearEndDate_297c42b8-33fa-4f65-b8d2-a5df21b83bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_02d9a6ca-aa71-48e9-922c-43f6435fe685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_02d9a6ca-aa71-48e9-922c-43f6435fe685" xlink:to="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11cb3966-ba4d-4217-87ab-1d917cf5adc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11cb3966-ba4d-4217-87ab-1d917cf5adc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4df0e948-0d84-498e-bbbf-7916468bf4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4df0e948-0d84-498e-bbbf-7916468bf4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16af31ad-4ae0-4c0f-b36b-9b2fc6ec2697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16af31ad-4ae0-4c0f-b36b-9b2fc6ec2697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9c33a9d6-3546-4711-8ba2-583d4472a808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f49b024c-1d96-4ebd-b6a4-29c9365a1773" xlink:to="loc_us-gaap_AssetsCurrent_9c33a9d6-3546-4711-8ba2-583d4472a808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8a6cba27-ccaa-4b55-ab1f-2951ed6544a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8a6cba27-ccaa-4b55-ab1f-2951ed6544a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_13cc97fe-5941-4414-b1e9-e56f0511a129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_LongTermInvestments_13cc97fe-5941-4414-b1e9-e56f0511a129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b27f6ea7-443c-4f18-85f8-0cb266a2181e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b27f6ea7-443c-4f18-85f8-0cb266a2181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c8c0e0a-a5a6-40fb-9ed7-9e6d3d04be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c8c0e0a-a5a6-40fb-9ed7-9e6d3d04be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d7ff28f1-d00e-4e3b-b73e-10d33268f61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_829e4ab6-a31e-4eba-b42d-f95d15186d1c" xlink:to="loc_us-gaap_Assets_d7ff28f1-d00e-4e3b-b73e-10d33268f61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_02d9a6ca-aa71-48e9-922c-43f6435fe685" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e48f33a6-c6ef-4e6d-ab46-935d3a67dae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:to="loc_us-gaap_AccountsPayableCurrent_e48f33a6-c6ef-4e6d-ab46-935d3a67dae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_51064677-0575-4c73-abae-737ed6105b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_51064677-0575-4c73-abae-737ed6105b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6f343f15-b03a-495a-91ed-17a7b6ccdfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6f343f15-b03a-495a-91ed-17a7b6ccdfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b17ec7a8-d100-41fb-9bfd-4f7dc2a77878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0966a77c-32f4-4929-9ca2-e8a35c25be7f" xlink:to="loc_us-gaap_LiabilitiesCurrent_b17ec7a8-d100-41fb-9bfd-4f7dc2a77878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_68fd2dbf-aac6-4e47-a449-b49ed710a20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_68fd2dbf-aac6-4e47-a449-b49ed710a20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_74954172-d468-416f-bfde-dda27dc52295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_Liabilities_74954172-d468-416f-bfde-dda27dc52295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2009fb51-e3f8-4f59-b004-ba3f3f1abcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2009fb51-e3f8-4f59-b004-ba3f3f1abcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f0b16f9a-acf3-4fb8-9e0c-a4f810b2a369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_PreferredStockValue_f0b16f9a-acf3-4fb8-9e0c-a4f810b2a369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f6b52fde-5e33-4d6f-972b-5a0e389c891e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_CommonStockValue_f6b52fde-5e33-4d6f-972b-5a0e389c891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a3e18fa0-34e3-4127-9c8e-9f1b7b3742da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a3e18fa0-34e3-4127-9c8e-9f1b7b3742da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21e8e891-1404-4d88-885f-7ef86cf0feb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21e8e891-1404-4d88-885f-7ef86cf0feb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68517cb3-a219-499f-8d85-4a7b9be9a192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68517cb3-a219-499f-8d85-4a7b9be9a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d12a3e58-ed8c-4790-ae67-397d14a16a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4099095d-9799-41dc-b34d-aceb228d803a" xlink:to="loc_us-gaap_StockholdersEquity_d12a3e58-ed8c-4790-ae67-397d14a16a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed5910f7-328c-410c-8152-1676a6d74453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_650ec1ff-01f0-4404-8097-3a7e8c3d78b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed5910f7-328c-410c-8152-1676a6d74453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c2f4fbe-a6cc-4686-8621-a9fd94c890c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c2f4fbe-a6cc-4686-8621-a9fd94c890c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_246a20d1-7a3c-4e86-bb5d-77b02437b462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_246a20d1-7a3c-4e86-bb5d-77b02437b462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_87e52137-7357-4c7e-8e19-847fa8be97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_87e52137-7357-4c7e-8e19-847fa8be97cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_764e3475-e244-401b-ae52-104fbcf0dbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_764e3475-e244-401b-ae52-104fbcf0dbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b8693f15-7834-40a1-8eb0-49b5f7f6c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b8693f15-7834-40a1-8eb0-49b5f7f6c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b3ce8781-5627-4635-a684-ed367eb04398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b3ce8781-5627-4635-a684-ed367eb04398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4fdb7d1b-90dc-403f-a76f-dbd7cdf22522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_CommonStockSharesIssued_4fdb7d1b-90dc-403f-a76f-dbd7cdf22522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d9dd0fb6-7285-4f91-9513-8668b9c95c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e83d375-a7a3-4dea-9787-1aae0fdb9a1f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d9dd0fb6-7285-4f91-9513-8668b9c95c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_962291e4-d765-49e6-ac7c-1a2bf4295f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_962291e4-d765-49e6-ac7c-1a2bf4295f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dc92aa70-0bb2-4b77-922d-fb83c3489110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dc92aa70-0bb2-4b77-922d-fb83c3489110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_e6a115dd-a52f-4fc0-bde3-3e0eacd69b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:to="loc_us-gaap_LitigationSettlementExpense_e6a115dd-a52f-4fc0-bde3-3e0eacd69b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a5e2176-1b3d-4efc-9bce-3a1119d43748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ab4ebc14-4771-4f59-a23f-10669457774d" xlink:to="loc_us-gaap_OperatingExpenses_8a5e2176-1b3d-4efc-9bce-3a1119d43748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_154f9d40-48f1-402b-b969-1006dadc9605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_OperatingIncomeLoss_154f9d40-48f1-402b-b969-1006dadc9605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11f39a6d-7bfc-4317-a2c2-b5b8146e2a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11f39a6d-7bfc-4317-a2c2-b5b8146e2a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_6aa4caea-2d16-4203-ad76-f64a6c3a3ede" xlink:href="krys-20220930.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11f39a6d-7bfc-4317-a2c2-b5b8146e2a63" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_6aa4caea-2d16-4203-ad76-f64a6c3a3ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f6377318-d671-4a5a-9382-203166561aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11f39a6d-7bfc-4317-a2c2-b5b8146e2a63" xlink:to="loc_us-gaap_InterestExpense_f6377318-d671-4a5a-9382-203166561aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b48a1e0-feea-4c1a-bbf1-1e3a42e4f788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_NetIncomeLoss_0b48a1e0-feea-4c1a-bbf1-1e3a42e4f788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f95a2df0-a472-4977-965f-7af8547687d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f95a2df0-a472-4977-965f-7af8547687d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1129963c-aaad-45b3-bc3a-c3c609a7a267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1129963c-aaad-45b3-bc3a-c3c609a7a267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d6b9da96-d8e5-44eb-a0be-f7cd79270eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_EarningsPerShareBasic_d6b9da96-d8e5-44eb-a0be-f7cd79270eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5a1e2bca-3669-448a-a5a6-77961e5a9774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5a1e2bca-3669-448a-a5a6-77961e5a9774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef030000-bb10-4411-b1da-9b8966cd4b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef030000-bb10-4411-b1da-9b8966cd4b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b68ad91-ae4d-46cd-abb2-aa4106264a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1bc5765-db57-4a85-bb2b-20119f0dbe19" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b68ad91-ae4d-46cd-abb2-aa4106264a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ba154231-43bf-4467-8439-d8093ab80d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ba154231-43bf-4467-8439-d8093ab80d87" xlink:to="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d8eb606-4872-45a1-b65a-e10a781380c8" xlink:to="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9326b77c-0706-49c7-a3bb-73ac89a388f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_CommonStockMember_9326b77c-0706-49c7-a3bb-73ac89a388f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_849f7569-c886-462a-aa8e-505266c87146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_849f7569-c886-462a-aa8e-505266c87146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72f87e1a-31df-40cf-9410-662ce5966bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72f87e1a-31df-40cf-9410-662ce5966bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_12f3f360-76b1-4cd6-80e0-56c7c00880d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933fcd5b-ae2c-4967-a569-50b75fa548e3" xlink:to="loc_us-gaap_RetainedEarningsMember_12f3f360-76b1-4cd6-80e0-56c7c00880d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4214572b-ab4c-4c10-9ce8-fa3eb2970c22" xlink:to="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32331c70-b0db-408d-a110-e7fdf959d3ee" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c8ac235c-b146-48ce-aeee-70d0eaa85b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_SharesOutstanding_c8ac235c-b146-48ce-aeee-70d0eaa85b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7afcf02-f9cb-406a-87d3-61e34f041bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockholdersEquity_c7afcf02-f9cb-406a-87d3-61e34f041bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a1821cc-fe16-4a07-9d31-de970af00e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a1821cc-fe16-4a07-9d31-de970af00e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8724c86d-5452-4dac-8b41-2b815fea7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8724c86d-5452-4dac-8b41-2b815fea7ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b6782b21-90a9-47d7-8f9c-b80f417411af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b6782b21-90a9-47d7-8f9c-b80f417411af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ada748cc-62f1-4923-9275-996d166de975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ada748cc-62f1-4923-9275-996d166de975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_182f414a-fcf2-4794-91a6-c9a4623676e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_182f414a-fcf2-4794-91a6-c9a4623676e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1f0a1091-bfe6-4145-ab10-6b7b51828d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1f0a1091-bfe6-4145-ab10-6b7b51828d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_041383c8-5dae-4209-b67e-dcd92b9662b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_NetIncomeLoss_041383c8-5dae-4209-b67e-dcd92b9662b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_744534d3-4704-427b-b0de-88cee8424cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_SharesOutstanding_744534d3-4704-427b-b0de-88cee8424cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_871b94e0-ad59-4c93-855f-448f62d3f114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_22f1ad51-04cb-434b-a065-a56bda94cb87" xlink:to="loc_us-gaap_StockholdersEquity_871b94e0-ad59-4c93-855f-448f62d3f114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2aac207c-121f-4773-a49e-e1342a29371b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:to="loc_us-gaap_NetIncomeLoss_2aac207c-121f-4773-a49e-e1342a29371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c704a3db-5dca-4552-babd-2c88f269c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:to="loc_us-gaap_DepreciationAndAmortization_c704a3db-5dca-4552-babd-2c88f269c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fe0857d9-4532-4d5e-9ddb-0af4dd386e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:to="loc_us-gaap_ShareBasedCompensation_fe0857d9-4532-4d5e-9ddb-0af4dd386e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_5c8ad54b-dff8-470d-b50b-dfb252e20ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_5c8ad54b-dff8-470d-b50b-dfb252e20ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_94c00994-4406-4134-abaf-ac2aa16ffcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:to="loc_us-gaap_OtherNoncashExpense_94c00994-4406-4134-abaf-ac2aa16ffcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2ffeed66-a1f6-46da-983f-72517033ea15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63175f23-1478-4c16-8614-1857ae7960d5" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2ffeed66-a1f6-46da-983f-72517033ea15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b71e09c3-37a1-4952-87e5-6ddc29c37584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b71e09c3-37a1-4952-87e5-6ddc29c37584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7a476ae6-3fc1-4d40-8af4-d0802494d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7a476ae6-3fc1-4d40-8af4-d0802494d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_a3fb519a-0738-4e68-83eb-66f1309342ed" xlink:href="krys-20220930.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_a3fb519a-0738-4e68-83eb-66f1309342ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_603b21c3-9b39-4802-aa2b-bbd1bb3aac0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_603b21c3-9b39-4802-aa2b-bbd1bb3aac0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b79d342f-1e43-4980-8dfd-88dae0bdd3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c044d-fbf5-4435-bafb-3500b9f07c43" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b79d342f-1e43-4980-8dfd-88dae0bdd3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9041eb71-3881-430b-86d9-0e203c3d1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67015882-43f0-4e2b-8998-fb178a459bc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9041eb71-3881-430b-86d9-0e203c3d1e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd1ecb09-d52b-4539-9c2c-e2a303755b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd1ecb09-d52b-4539-9c2c-e2a303755b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f42698d9-9734-4f57-86cb-8cd7ec250bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f42698d9-9734-4f57-86cb-8cd7ec250bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_bac05a7a-0b8c-4185-b310-d4239485b7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_bac05a7a-0b8c-4185-b310-d4239485b7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49602e7b-e982-4f9c-ba59-441e7c0e46aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6bff49fc-42fe-4b95-9727-db0a78be9b9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49602e7b-e982-4f9c-ba59-441e7c0e46aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ae79e157-efff-4710-b864-b1cca1b13c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ae79e157-efff-4710-b864-b1cca1b13c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07983708-9fd6-4d7d-b85a-f292b967f542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07983708-9fd6-4d7d-b85a-f292b967f542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_a3eaf7e7-a7ca-46a3-805e-c732317d5441" xlink:href="krys-20220930.xsd#krys_PaymentsForSuitLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:to="loc_krys_PaymentsForSuitLiability_a3eaf7e7-a7ca-46a3-805e-c732317d5441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_003d4280-2915-49fc-afbd-133d0e4451ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b76c3af-ee49-4a00-8df3-91b9741a11e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_003d4280-2915-49fc-afbd-133d0e4451ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7f1a48c-50e0-4255-86cc-0f12f2a6eba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7f1a48c-50e0-4255-86cc-0f12f2a6eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_127b2f38-14b6-439d-8d08-f34e4be54a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_127b2f38-14b6-439d-8d08-f34e4be54a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd1a4a7-9235-4bfa-9f8b-946403583fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd1a4a7-9235-4bfa-9f8b-946403583fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_225df263-58d7-4a87-af0b-692ead3a9666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_f39db82b-b9af-4c83-ad44-47d438e9fadc" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_225df263-58d7-4a87-af0b-692ead3a9666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38e3b1cd-41a6-4de7-89c4-b8350c5f5a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_225df263-58d7-4a87-af0b-692ead3a9666" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38e3b1cd-41a6-4de7-89c4-b8350c5f5a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_90f40d8b-d1de-4656-836f-817318c1b846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_225df263-58d7-4a87-af0b-692ead3a9666" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_90f40d8b-d1de-4656-836f-817318c1b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20220930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b41c397d-2916-4124-84b5-f7ef63b3091e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_71d9d446-b88a-464a-afc0-45a3114a357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b41c397d-2916-4124-84b5-f7ef63b3091e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_71d9d446-b88a-464a-afc0-45a3114a357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_738c3a2b-e866-4537-b67a-7ca97e4d8578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_db90a58e-9304-4790-9d4e-2ef319b84299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738c3a2b-e866-4537-b67a-7ca97e4d8578" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_db90a58e-9304-4790-9d4e-2ef319b84299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20220930.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1180ebaa-1616-40ca-ba97-b1b0c3a26472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e6e744b4-bf41-4bfe-a8bc-804d17438b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1180ebaa-1616-40ca-ba97-b1b0c3a26472" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e6e744b4-bf41-4bfe-a8bc-804d17438b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_08c72a57-54c4-4d83-b6b1-39d61fd565c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6aa2f24c-6ecd-4456-9abe-580db45445fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_08c72a57-54c4-4d83-b6b1-39d61fd565c0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6aa2f24c-6ecd-4456-9abe-580db45445fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_42b09bfe-66f6-4987-b9e9-fe4e52dae0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_88455a9a-21ae-43c5-aa6e-c412eb7dc130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_42b09bfe-66f6-4987-b9e9-fe4e52dae0a7" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_88455a9a-21ae-43c5-aa6e-c412eb7dc130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_785e5633-422a-41cd-bda4-a6fc5054b835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_001ee0f3-dfb9-42d4-8957-67b8698cda6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_785e5633-422a-41cd-bda4-a6fc5054b835" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_001ee0f3-dfb9-42d4-8957-67b8698cda6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20220930.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_71d1f28c-f345-49b9-a31b-c3e1568600aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_51bdaf6a-4a31-4341-93d9-026576edb9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_71d1f28c-f345-49b9-a31b-c3e1568600aa" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_51bdaf6a-4a31-4341-93d9-026576edb9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d96eb95-3f18-4936-81e7-f4d596b5eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f756b64b-4b22-4f94-816f-acbcaebea953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d96eb95-3f18-4936-81e7-f4d596b5eb3c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f756b64b-4b22-4f94-816f-acbcaebea953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_90dda293-caa6-4cdb-b6b2-952b48b3085c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d79b87bb-540b-417c-836d-05fc197a1c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_90dda293-caa6-4cdb-b6b2-952b48b3085c" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d79b87bb-540b-417c-836d-05fc197a1c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7bfd6654-3db5-429b-979f-ae33fcacbb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7bfd6654-3db5-429b-979f-ae33fcacbb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock_98c62c9e-84cc-4239-bfca-f068ffcb3216" xlink:href="krys-20220930.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_krys_RisksAndUncertaintiesPolicyTextBlock_98c62c9e-84cc-4239-bfca-f068ffcb3216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a24a0daa-1e5c-4cd2-a558-d064bc9e79e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_UseOfEstimates_a24a0daa-1e5c-4cd2-a558-d064bc9e79e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ca0ca3ab-64ba-426d-9762-c3e60b5d2ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ca0ca3ab-64ba-426d-9762-c3e60b5d2ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4714d1c0-a10c-4dc3-b856-7e165ec78890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4714d1c0-a10c-4dc3-b856-7e165ec78890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3b7fe46a-cb5b-4ccf-9c52-a6f0a080ca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3b7fe46a-cb5b-4ccf-9c52-a6f0a080ca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f0bc35fb-1f61-4cb7-b123-8ac798f2afe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f0bc35fb-1f61-4cb7-b123-8ac798f2afe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_748c9569-a601-4818-98a2-578c8f3a9086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_748c9569-a601-4818-98a2-578c8f3a9086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9d5f94b1-a0b4-4b9b-86b1-7eda361f62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9d5f94b1-a0b4-4b9b-86b1-7eda361f62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_73ab8ccd-61cf-47e3-93c2-8e31f448bee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_73ab8ccd-61cf-47e3-93c2-8e31f448bee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_49044575-1b62-4fbb-9b0b-ffadc5dc9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_49044575-1b62-4fbb-9b0b-ffadc5dc9aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_aec2a36d-b170-4390-b5f7-93a4c96acb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_aec2a36d-b170-4390-b5f7-93a4c96acb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4aba8182-68c4-421b-baf3-2437939966ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4aba8182-68c4-421b-baf3-2437939966ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f409ff20-f74c-48ae-a48d-7faf5f76fe48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66538f9c-1b03-4581-aac3-b2d930e0c4b1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f409ff20-f74c-48ae-a48d-7faf5f76fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c77d2973-6630-4461-9b26-50f40b0d98e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_46c6ec1e-b6f8-4633-9bde-75ee08896061" xlink:href="krys-20220930.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c77d2973-6630-4461-9b26-50f40b0d98e1" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_46c6ec1e-b6f8-4633-9bde-75ee08896061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20220930.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9c91abdf-8fad-47c4-959a-374a35e8e696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6432bb64-1922-4339-8f8c-7501886a15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9c91abdf-8fad-47c4-959a-374a35e8e696" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6432bb64-1922-4339-8f8c-7501886a15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ebc7e56c-0195-4f60-b62d-063445e454b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c5be945f-8a94-470c-bcd5-8f85fb6520e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ebc7e56c-0195-4f60-b62d-063445e454b9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c5be945f-8a94-470c-bcd5-8f85fb6520e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7b1fd736-900e-4e21-a84d-fb4c4cc09113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a168cd46-3955-4108-a1fb-affc5adcaeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7b1fd736-900e-4e21-a84d-fb4c4cc09113" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a168cd46-3955-4108-a1fb-affc5adcaeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b7c1d148-f573-48aa-83df-4c4a7ce9e257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7b1fd736-900e-4e21-a84d-fb4c4cc09113" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b7c1d148-f573-48aa-83df-4c4a7ce9e257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b232839-f1ca-419d-b10b-b37a6986eb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1a5e8793-1ae8-46bb-8619-617c42e405c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b232839-f1ca-419d-b10b-b37a6986eb94" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1a5e8793-1ae8-46bb-8619-617c42e405c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_8b79859e-cd47-4d7f-ae8d-e164df76beaf" xlink:href="krys-20220930.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b232839-f1ca-419d-b10b-b37a6986eb94" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_8b79859e-cd47-4d7f-ae8d-e164df76beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_04ac3ad2-8485-4b70-9c0d-4ea8b65aa5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b232839-f1ca-419d-b10b-b37a6986eb94" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_04ac3ad2-8485-4b70-9c0d-4ea8b65aa5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3f3a8bf-2929-46d6-963b-eef59dd2e8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f1b4b432-e329-45ca-a8ed-41e300d8dc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3f3a8bf-2929-46d6-963b-eef59dd2e8f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f1b4b432-e329-45ca-a8ed-41e300d8dc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51da2ad7-fa0a-4830-a5bc-25fec76e2937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3f3a8bf-2929-46d6-963b-eef59dd2e8f1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51da2ad7-fa0a-4830-a5bc-25fec76e2937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5c6a572b-fe57-4dce-89aa-4954de7958d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3f3a8bf-2929-46d6-963b-eef59dd2e8f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5c6a572b-fe57-4dce-89aa-4954de7958d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5e471780-fc99-43b0-aac8-1008c06611cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3f3a8bf-2929-46d6-963b-eef59dd2e8f1" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5e471780-fc99-43b0-aac8-1008c06611cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0331bf21-92c0-4205-845b-4acf9ea92ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a73577d-45c5-455f-8567-8e7f9a4034a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0331bf21-92c0-4205-845b-4acf9ea92ee9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a73577d-45c5-455f-8567-8e7f9a4034a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_733860a6-aa31-4314-8055-c9e6791c84f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0331bf21-92c0-4205-845b-4acf9ea92ee9" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_733860a6-aa31-4314-8055-c9e6791c84f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4aaec8cd-0f6f-46c9-abc7-8d1fa139fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4aaec8cd-0f6f-46c9-abc7-8d1fa139fac8" xlink:to="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b1502a-dbab-4292-8e56-7511d4b01037" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1f481870-ae8a-42a3-945e-90f1539a9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ec35551-8608-4eb6-ab05-ff527c64011f" xlink:to="loc_us-gaap_EquipmentMember_1f481870-ae8a-42a3-945e-90f1539a9cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:href="krys-20220930.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_030899de-f1cb-4a4a-bfc4-1cd00e556082" xlink:to="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_920ed22f-6252-430d-bb40-f16d3843e0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_920ed22f-6252-430d-bb40-f16d3843e0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d80a9609-2496-4ae9-9662-5ead33925ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d80a9609-2496-4ae9-9662-5ead33925ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bf22d4f3-57b8-4cbd-82a5-6bea9ab617c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6940645a-756d-4056-ab72-b37b23fafa20" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bf22d4f3-57b8-4cbd-82a5-6bea9ab617c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6cb3f62f-dbb0-4fd1-a8dd-b803eca31eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6cb3f62f-dbb0-4fd1-a8dd-b803eca31eb6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03a74a2f-9899-40b4-8ab0-012868a3fb00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_039c7be2-49ab-48a8-a47f-0d5ed91b7d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_ComputerEquipmentMember_039c7be2-49ab-48a8-a47f-0d5ed91b7d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_9ac51bd1-7218-4d2d-9308-f4c7b7a84490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_EquipmentMember_9ac51bd1-7218-4d2d-9308-f4c7b7a84490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a779784c-27b6-4008-b848-3186866ac256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_434ffe01-4c3b-463b-96fe-d870c67dcc12" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a779784c-27b6-4008-b848-3186866ac256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:to="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_026916ca-45f5-4e54-a2c8-81fc9833ee9e" xlink:to="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22883078-2614-465c-a2bf-a117c9326f9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:to="loc_srt_MinimumMember_22883078-2614-465c-a2bf-a117c9326f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e1df297b-01ff-4e7f-ba3c-ec0c690abe26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07835041-1d99-4337-a217-a1c4751ded19" xlink:to="loc_srt_MaximumMember_e1df297b-01ff-4e7f-ba3c-ec0c690abe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d59f0ab0-e657-4f4c-b18f-277676be9fed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b76b182-a7fd-4e0f-a87d-5bbfb9b9fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e84b1080-b795-4dc2-939c-b1403150e95a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b76b182-a7fd-4e0f-a87d-5bbfb9b9fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c9fa60d9-744f-406a-9afe-00d56e899a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4517176b-159b-49ee-876d-e71c0d0bf31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9fa60d9-744f-406a-9afe-00d56e899a9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4517176b-159b-49ee-876d-e71c0d0bf31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e3a2494a-75c8-430b-9c17-70454c437bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1003ed77-942d-492b-a782-c8d886362e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3a2494a-75c8-430b-9c17-70454c437bdd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1003ed77-942d-492b-a782-c8d886362e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15dfbad9-fe8c-4082-a8ac-0e2d89cf4982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1003ed77-942d-492b-a782-c8d886362e53" xlink:to="loc_us-gaap_NetIncomeLoss_15dfbad9-fe8c-4082-a8ac-0e2d89cf4982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_ce7058ae-be1f-43da-98a0-4bddd2bc4f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3a2494a-75c8-430b-9c17-70454c437bdd" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_ce7058ae-be1f-43da-98a0-4bddd2bc4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ae4cdef-5940-4095-9d01-6bb6f825f990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_ce7058ae-be1f-43da-98a0-4bddd2bc4f6a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ae4cdef-5940-4095-9d01-6bb6f825f990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a31c9d85-6bfd-452f-8bb3-e20b6eba2ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_ce7058ae-be1f-43da-98a0-4bddd2bc4f6a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a31c9d85-6bfd-452f-8bb3-e20b6eba2ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab7a5657-49a5-4f9c-b73c-68b454e3e07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3a2494a-75c8-430b-9c17-70454c437bdd" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab7a5657-49a5-4f9c-b73c-68b454e3e07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c225d064-80cb-4da8-972a-4f00fa0dfebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3a2494a-75c8-430b-9c17-70454c437bdd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c225d064-80cb-4da8-972a-4f00fa0dfebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6eede616-6859-4852-8500-c9fc5a60b933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6eede616-6859-4852-8500-c9fc5a60b933" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_311f9ebf-89cf-4147-9416-400d5a3de83c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1e2b5662-cba9-4f38-b3db-26acaf2eeebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_171b7bed-d5c3-459e-81fd-536ef0e17982" xlink:to="loc_us-gaap_CashMember_1e2b5662-cba9-4f38-b3db-26acaf2eeebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17d1c5f8-fbf5-4c4c-a228-55d7476b37eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_398bd513-79a1-49b3-b1c2-2ca9ef933154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_398bd513-79a1-49b3-b1c2-2ca9ef933154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_630f9988-91c9-4551-88b1-901a9b5e0851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76e7f09c-f16a-46f0-b56e-5289d96c571a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_630f9988-91c9-4551-88b1-901a9b5e0851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_add61d9a-a4d0-4c27-911e-f4711d6b1a52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6fd011d3-4419-4ee9-a279-83009bca30da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6fd011d3-4419-4ee9-a279-83009bca30da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_0f063dfd-dd9a-44ed-8aec-0df279bc22d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_0f063dfd-dd9a-44ed-8aec-0df279bc22d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_9627c429-5137-4cba-b6f6-c6bd96113cfd" xlink:href="krys-20220930.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b770b1d9-66e0-491c-abc0-06b982486428" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_9627c429-5137-4cba-b6f6-c6bd96113cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_57b70116-b90e-41a4-b6ef-b80186672665" xlink:to="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_254093af-57cd-40ae-9b23-188f315580c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:to="loc_srt_MinimumMember_254093af-57cd-40ae-9b23-188f315580c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c18a9fb0-88c9-414b-b38c-cd6e7d8a6739" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35c1f354-3b80-42ce-a259-f654894f424f" xlink:to="loc_srt_MaximumMember_c18a9fb0-88c9-414b-b38c-cd6e7d8a6739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a9c9f23a-12a0-4799-84bd-bc47083e3b30" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9fdbe7f2-7aa9-4888-88cb-3020e2c5b7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_CommercialPaperMember_9fdbe7f2-7aa9-4888-88cb-3020e2c5b7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_88a5e7c5-a5d2-4a3f-905d-e0041a8bba47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_88a5e7c5-a5d2-4a3f-905d-e0041a8bba47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a95a8dbc-76a0-452d-8084-4ec286ba5250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f934ce6a-761e-4154-aec9-84eab967b905" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a95a8dbc-76a0-452d-8084-4ec286ba5250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30f12d71-8a95-48e5-aa17-a33578af4a57" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bffa8c60-190a-450e-bb32-e6377ec56944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bffa8c60-190a-450e-bb32-e6377ec56944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_884f0fc1-d558-4d5d-bf11-14e8c7173a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_884f0fc1-d558-4d5d-bf11-14e8c7173a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2ac060ae-52a9-450c-8b01-9ca5e4581f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2ac060ae-52a9-450c-8b01-9ca5e4581f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08645950-9ca8-48fa-a716-b2f29fe6e589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08645950-9ca8-48fa-a716-b2f29fe6e589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_002c906b-27e8-439e-b524-42d9b24a35f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_002c906b-27e8-439e-b524-42d9b24a35f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fb1c039-6514-4dd8-bdca-19827adaa255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fb1c039-6514-4dd8-bdca-19827adaa255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c16cc48e-69b5-4a6d-8143-1bf3a162e9d6" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c16cc48e-69b5-4a6d-8143-1bf3a162e9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_659f79dc-1662-4765-a4c0-0c6462916de2" xlink:href="krys-20220930.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_659f79dc-1662-4765-a4c0-0c6462916de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_43c5902d-5f0e-454e-af20-b71b0fb439a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f2eecd9-3eb1-4d3e-b42a-1de5073c9cc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_43c5902d-5f0e-454e-af20-b71b0fb439a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220930.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2962d16b-57d4-47a8-a1db-e831edec2ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2962d16b-57d4-47a8-a1db-e831edec2ddd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94c41ea7-39bd-4690-b5cf-e7231ecb2aec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7dbf3c63-f03b-422f-817f-04fc7999641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_ConstructionInProgressMember_7dbf3c63-f03b-422f-817f-04fc7999641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_591cd124-24dc-406c-8f2c-b1f492fbbe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_591cd124-24dc-406c-8f2c-b1f492fbbe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_20605d7b-b613-4acb-9765-6a72ad7e355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_20605d7b-b613-4acb-9765-6a72ad7e355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_868f16be-289c-4092-9bfe-033a5819cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_us-gaap_ComputerEquipmentMember_868f16be-289c-4092-9bfe-033a5819cc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_f5db44cf-c7f3-4dce-862b-5cdd7eb61b6a" xlink:href="krys-20220930.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f18f70d1-8f60-4441-b47a-3a19abb24c15" xlink:to="loc_krys_LabEquipmentMember_f5db44cf-c7f3-4dce-862b-5cdd7eb61b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bd095f34-6892-4875-accf-a53ccad74f09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_192584af-8e3a-461a-8448-9b3065a7e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_192584af-8e3a-461a-8448-9b3065a7e5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f72a9cf-cfce-4efa-b0a1-0f0b151bcb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f72a9cf-cfce-4efa-b0a1-0f0b151bcb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0562dd8-35e9-4d5b-a2d8-96a2133b7b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f99deb0-d7dd-4c4a-b0a5-eedfbff584b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0562dd8-35e9-4d5b-a2d8-96a2133b7b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_123e9947-a84b-4894-98a8-cec5dc1d0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_028e6b29-dd7c-4e84-8241-a3a6b57b5976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_123e9947-a84b-4894-98a8-cec5dc1d0782" xlink:to="loc_us-gaap_Depreciation_028e6b29-dd7c-4e84-8241-a3a6b57b5976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_116891c7-baf9-4cde-bccc-d53798ea9b2a" xlink:href="krys-20220930.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_116891c7-baf9-4cde-bccc-d53798ea9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5e0440f4-0d9a-46ae-9665-0c3e74d199da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5e0440f4-0d9a-46ae-9665-0c3e74d199da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_144926f7-f5b0-49f0-87f9-e6e1ce0ef9ca" xlink:href="krys-20220930.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_krys_AccruedPayrollAndBenefits_144926f7-f5b0-49f0-87f9-e6e1ce0ef9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_0b61741a-0fdd-49e8-8d72-4e82a78c98ca" xlink:href="krys-20220930.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_0b61741a-0fdd-49e8-8d72-4e82a78c98ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_a558a94d-bb69-4871-883b-407f6314e287" xlink:href="krys-20220930.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_krys_AccruedFinancingFeesCurrent_a558a94d-bb69-4871-883b-407f6314e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_3e536a72-e7d3-47ce-98bb-f70ea2b4d3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_us-gaap_AccruedIncomeTaxes_3e536a72-e7d3-47ce-98bb-f70ea2b4d3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3d4cb96c-9f5c-4cb8-a7de-4bd663a7b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3d4cb96c-9f5c-4cb8-a7de-4bd663a7b580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_099b8218-b06b-4f39-ac34-8c57e2af1a67" xlink:href="krys-20220930.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35af1ea2-81c7-436d-8b82-44e9289026bf" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_099b8218-b06b-4f39-ac34-8c57e2af1a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5da56c3-37de-4003-890e-97b00803822a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5da56c3-37de-4003-890e-97b00803822a" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_caf38e0c-31d9-452f-a70f-faa2d2d74997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_1db170b2-ebc2-40f5-b045-3645e23c0aa2" xlink:href="krys-20220930.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_1db170b2-ebc2-40f5-b045-3645e23c0aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember_3ec7697b-2289-4f9b-a561-07ba48eeb40d" xlink:href="krys-20220930.xsd#krys_ShortTermAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_ShortTermAmendmentMember_3ec7697b-2289-4f9b-a561-07ba48eeb40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_03940f16-8a67-4a1d-ae67-4adcdcf6c4af" xlink:href="krys-20220930.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_BostonMassachusettsLeaseMember_03940f16-8a67-4a1d-ae67-4adcdcf6c4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_2c5f4ea5-e227-4238-a138-c3a23a077864" xlink:href="krys-20220930.xsd#krys_SwitzerlandLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e5c540-db21-40b4-9730-644684b9a620" xlink:to="loc_krys_SwitzerlandLeaseMember_2c5f4ea5-e227-4238-a138-c3a23a077864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_314df9f6-c1bd-4a97-b63a-6530a9829198" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_49d5e058-a2b7-4d0d-9e4a-3b293ede3987" xlink:href="krys-20220930.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_ClinicalSupplyAgreementMember_49d5e058-a2b7-4d0d-9e4a-3b293ede3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_8be51faa-1121-41e7-bcee-3092f4ed68f9" xlink:href="krys-20220930.xsd#krys_OtherContractualObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_OtherContractualObligationsMember_8be51faa-1121-41e7-bcee-3092f4ed68f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_b68d1937-adf2-46df-a477-60af177ca3fc" xlink:href="krys-20220930.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_882bcc3c-74fd-4ee9-a5ce-86f79eff3acb" xlink:to="loc_krys_ASTRAFacilityMember_b68d1937-adf2-46df-a477-60af177ca3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_458d68cf-a889-4180-bc27-541fb42b29cc" xlink:to="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_28051688-cf7d-4f9b-a9f9-c2575f204832" xlink:href="krys-20220930.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_46cc3bae-918d-4096-88a5-da3ce1ca159b" xlink:to="loc_krys_PeriphaGenMember_28051688-cf7d-4f9b-a9f9-c2575f204832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:href="krys-20220930.xsd#krys_MilestonesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:href="krys-20220930.xsd#krys_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesAxis_55f84bad-bb90-43c6-ac60-dadfc0f13864" xlink:to="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_d01622b8-db2e-45b2-b760-4cb0b59de8ae" xlink:href="krys-20220930.xsd#krys_MilestoneTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneTwoMember_d01622b8-db2e-45b2-b760-4cb0b59de8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_f7e44867-bc75-4455-94fb-1137282bc309" xlink:href="krys-20220930.xsd#krys_MilestoneThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneThreeMember_f7e44867-bc75-4455-94fb-1137282bc309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_30fc5f40-b340-46be-88b5-693f625c7309" xlink:href="krys-20220930.xsd#krys_MilestoneOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6012ba46-64ac-473f-9222-c3d1f4507096" xlink:to="loc_krys_MilestoneOneMember_30fc5f40-b340-46be-88b5-693f625c7309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_29c425ee-c351-49cb-a2c7-d785800a7923" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3aece7b4-7164-44a2-a555-8c2b3ce66dd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4e1b61f7-8100-44a4-9c89-977934fa959b" xlink:to="loc_srt_ScenarioForecastMember_3aece7b4-7164-44a2-a555-8c2b3ce66dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0bd1f172-49c5-4c0d-aaf0-1bc084ee06a2" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_c201aa79-c49f-4782-a723-e4b8bff362a5" xlink:href="krys-20220930.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_c201aa79-c49f-4782-a723-e4b8bff362a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_c00c2f86-4b7d-4d1c-a46b-4db2f77bd823" xlink:href="krys-20220930.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_c00c2f86-4b7d-4d1c-a46b-4db2f77bd823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_3afa80fd-8785-4d3f-83b9-7772d6c5504e" xlink:href="krys-20220930.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_3afa80fd-8785-4d3f-83b9-7772d6c5504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ea450e36-4163-4992-9370-1e7797037a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ConstructionInProgressGross_ea450e36-4163-4992-9370-1e7797037a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_4fa06f3a-1c86-4a9e-858a-87d04377da09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_FinanceLeaseLiability_4fa06f3a-1c86-4a9e-858a-87d04377da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2d2b167b-143e-4580-9ba5-fcfc2e5dd3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_EscrowDeposit_2d2b167b-143e-4580-9ba5-fcfc2e5dd3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fac1eca0-65e0-43e8-b046-db97c39134a5" xlink:href="krys-20220930.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fac1eca0-65e0-43e8-b046-db97c39134a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_6702dee3-6bbd-4a68-9a32-1958d6dd0c34" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CumulativeEscalationClausePercent_6702dee3-6bbd-4a68-9a32-1958d6dd0c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_63fb9eaa-5434-4278-8555-6c9d040838bf" xlink:href="krys-20220930.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CumulativeEscalationClauseTerm_63fb9eaa-5434-4278-8555-6c9d040838bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7f82856-68d8-41cb-81ab-c38f7ce63254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7f82856-68d8-41cb-81ab-c38f7ce63254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecc9538d-6941-4c90-bc20-3a8ece7f0546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecc9538d-6941-4c90-bc20-3a8ece7f0546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_a4a2f644-23cc-4285-b320-9aacf67c8d88" xlink:href="krys-20220930.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_RemainingCommitmentAmount_a4a2f644-23cc-4285-b320-9aacf67c8d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_27a7f65c-a7e0-4771-b486-1afac98a5bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ProfessionalFees_27a7f65c-a7e0-4771-b486-1afac98a5bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d6e5744c-620f-4525-a1ff-0b1c1b94e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ContractualObligation_d6e5744c-620f-4525-a1ff-0b1c1b94e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_8e542b18-7dff-4560-b407-f11231584d86" xlink:href="krys-20220930.xsd#krys_CostOfWorkPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_CostOfWorkPercentage_8e542b18-7dff-4560-b407-f11231584d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_23f561d0-5334-45d4-bf7f-4ca585a234d8" xlink:href="krys-20220930.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_23f561d0-5334-45d4-bf7f-4ca585a234d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_fd9a4617-3d63-4fe0-a8c3-1ac472fa362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LitigationSettlementExpense_fd9a4617-3d63-4fe0-a8c3-1ac472fa362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c0774018-c10e-4731-a3a9-22e88bf72dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c0774018-c10e-4731-a3a9-22e88bf72dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_35896730-3ef7-488c-a84d-d5ba7042ca3d" xlink:href="krys-20220930.xsd#krys_NumberOfMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_NumberOfMilestones_35896730-3ef7-488c-a84d-d5ba7042ca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2f6a0884-5fbc-4982-836c-8573707d6a2e" xlink:href="krys-20220930.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2f6a0884-5fbc-4982-836c-8573707d6a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_d4379931-cfdb-4aca-b829-7de3b51300c0" xlink:href="krys-20220930.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_krys_LitigationSettlementTotalConsideration_d4379931-cfdb-4aca-b829-7de3b51300c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83d42c9a-d024-4456-bb4d-9d38647df05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83d42c9a-d024-4456-bb4d-9d38647df05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b9ea1d48-e3cc-4450-933e-f243d927940a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_31aa27e2-96c9-4db7-8066-a8e91868ba60" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b9ea1d48-e3cc-4450-933e-f243d927940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2d368cd5-cf5f-46ed-83ad-e0939aeae6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2d368cd5-cf5f-46ed-83ad-e0939aeae6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c16c707c-1715-4f06-b0d0-ea61ef61e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c16c707c-1715-4f06-b0d0-ea61ef61e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e25d5e1a-37f8-4103-a048-f6a0fbde1e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e25d5e1a-37f8-4103-a048-f6a0fbde1e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2700ee7-7382-43a9-9c5f-91dbc0a5951b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2700ee7-7382-43a9-9c5f-91dbc0a5951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b76a527c-287a-4d8a-81b3-540845a80ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b76a527c-287a-4d8a-81b3-540845a80ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2e204f7f-43c6-4de3-920a-f66c9340f2a6" xlink:href="krys-20220930.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2e204f7f-43c6-4de3-920a-f66c9340f2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ccf60a0-e45f-4b51-b6ff-f4c52d58800f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9ccf60a0-e45f-4b51-b6ff-f4c52d58800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4333641e-0b6e-4e26-a9cd-3b85d1188ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4333641e-0b6e-4e26-a9cd-3b85d1188ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_91ea24b4-52bd-4f1f-afe5-d40942a848bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2357df04-7941-4fc3-804a-caefe961c22f" xlink:to="loc_us-gaap_OperatingLeaseLiability_91ea24b4-52bd-4f1f-afe5-d40942a848bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e359e8ce-5067-4135-ae2a-539413f3a9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e359e8ce-5067-4135-ae2a-539413f3a9cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_29ca6b64-ae55-44c9-a706-7cbeb5d5786f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_29ca6b64-ae55-44c9-a706-7cbeb5d5786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ec400e2-a888-40c6-bb11-b332bd3debcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ec400e2-a888-40c6-bb11-b332bd3debcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f44f1943-301d-425f-9379-765b3a5150c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f44f1943-301d-425f-9379-765b3a5150c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9be0a04-59c3-4635-a1d1-f94b1ac324cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseLiability_f9be0a04-59c3-4635-a1d1-f94b1ac324cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2817f717-200c-4a46-813b-f4d7671303c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2817f717-200c-4a46-813b-f4d7671303c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f431ae1-3f12-42dc-87a9-c7a997bbfa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4886879d-b911-4641-a662-8628edadfa13" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f431ae1-3f12-42dc-87a9-c7a997bbfa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="krys-20220930.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2e0934b-e110-4d37-a8cc-e174c496cfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ef28b314-4873-4ee3-9aaa-d92974a8058f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2e0934b-e110-4d37-a8cc-e174c496cfee" xlink:to="loc_us-gaap_OperatingLeaseCost_ef28b314-4873-4ee3-9aaa-d92974a8058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_500e7e54-2b69-4abc-9a4e-18839ab7cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2e0934b-e110-4d37-a8cc-e174c496cfee" xlink:to="loc_us-gaap_VariableLeaseCost_500e7e54-2b69-4abc-9a4e-18839ab7cb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b2cc526b-98ca-4d76-b7df-f406defbe2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2e0934b-e110-4d37-a8cc-e174c496cfee" xlink:to="loc_us-gaap_LeaseCost_b2cc526b-98ca-4d76-b7df-f406defbe2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_63cdf0ac-a21b-4a97-a646-160ce23b8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_63cdf0ac-a21b-4a97-a646-160ce23b8dab" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59d488d6-e95f-465f-8b1b-9ffdb78e9a89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_132e724c-f88a-4e0b-84f2-3873c6d89042" xlink:href="krys-20220930.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_PlacementSharesMember_132e724c-f88a-4e0b-84f2-3873c6d89042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_0456d499-5a17-44e7-b91a-87156d452873" xlink:href="krys-20220930.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_PublicOfferingMember_0456d499-5a17-44e7-b91a-87156d452873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_4499dcf1-feb2-429f-aa0f-a53acd1da285" xlink:href="krys-20220930.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_krys_ATMProgramMember_4499dcf1-feb2-429f-aa0f-a53acd1da285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_eff4cb1f-6453-41ad-be51-ea9b969f3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aea80eff-d235-495f-975f-7a872bf6eec8" xlink:to="loc_us-gaap_OverAllotmentOptionMember_eff4cb1f-6453-41ad-be51-ea9b969f3ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_14e92bd7-9ab3-4046-9cc8-0864c189f442" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_7a26cd00-625f-41a8-ae1f-89689cfee801" xlink:href="krys-20220930.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_7a26cd00-625f-41a8-ae1f-89689cfee801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a682206-eb90-42fd-a5de-dafe9078d8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2a682206-eb90-42fd-a5de-dafe9078d8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f80d5bf2-31f5-49e2-be7b-5daf002a6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f80d5bf2-31f5-49e2-be7b-5daf002a6f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a260eb86-ffaa-4fa0-9441-a7d643e9e316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a260eb86-ffaa-4fa0-9441-a7d643e9e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_612fbd85-c689-4417-90ae-c30941234f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_612fbd85-c689-4417-90ae-c30941234f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_091fd860-a74a-493c-b0b2-2df1b068ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_091fd860-a74a-493c-b0b2-2df1b068ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_7e5ea09a-cc10-4d47-9b95-22cbadc86e42" xlink:href="krys-20220930.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_7e5ea09a-cc10-4d47-9b95-22cbadc86e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f8c1b791-cdb1-4d3c-a98b-a7feb1ab3731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_f8b37276-91f2-40c4-a6ad-dbcbe965f566" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f8c1b791-cdb1-4d3c-a98b-a7feb1ab3731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13b52a58-068b-40c6-b0c2-8a3497f61bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13b52a58-068b-40c6-b0c2-8a3497f61bd6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9189d3c-2fee-4c93-a1f3-0b63dd54026a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a529d750-6649-4b43-ab8b-ebfd921b9ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a529d750-6649-4b43-ab8b-ebfd921b9ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_cca818af-077b-4719-b4cd-f44667ee4de1" xlink:href="krys-20220930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_krys_NonEmployeeStockOptionMember_cca818af-077b-4719-b4cd-f44667ee4de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e1ed89b3-42fd-461d-8cce-b3591f3f4fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_us-gaap_RestrictedStockMember_e1ed89b3-42fd-461d-8cce-b3591f3f4fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_ecfe0a4d-9adb-4c44-a519-bc2c24d078c8" xlink:href="krys-20220930.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_633132b4-42d4-46ee-a203-79ffd62dbf25" xlink:to="loc_krys_IncentiveStockOptionsMember_ecfe0a4d-9adb-4c44-a519-bc2c24d078c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df9666bb-8f7b-4864-a0ac-0a5218854bb2" xlink:to="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02a048c2-250f-4e9c-b06e-c299096b07a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:to="loc_srt_MinimumMember_02a048c2-250f-4e9c-b06e-c299096b07a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_333809db-82dc-4904-907c-07b4e9f9dec6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f4d307e9-c3ff-480c-8f5c-55bcf3f414f2" xlink:to="loc_srt_MaximumMember_333809db-82dc-4904-907c-07b4e9f9dec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0f1a83f1-cb21-4283-8573-c1fc25351bfa" xlink:to="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_18cfd9ea-3979-4d3e-bbf4-3af03e6d8829" xlink:href="krys-20220930.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_663094c2-6e62-4e96-98ac-55fef66c8d32" xlink:to="loc_krys_StockIncentivePlanMember_18cfd9ea-3979-4d3e-bbf4-3af03e6d8829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1aa468a6-6875-4948-8097-9ce0e42da896" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_bf71cb66-d2ef-431a-9e3c-c6aa69eee6b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:to="loc_srt_DirectorMember_bf71cb66-d2ef-431a-9e3c-c6aa69eee6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_8b215b5b-81c1-4b0c-ac3c-97b8fdad6fd8" xlink:href="krys-20220930.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bfbe8f6b-ae7e-432e-ab7f-9561885a393c" xlink:to="loc_krys_NonEmployeeStockOptionMember_8b215b5b-81c1-4b0c-ac3c-97b8fdad6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbafa024-bf9c-42c5-8845-50bc2370f039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24d83c13-9c65-405a-b2c2-aef9d7eacac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24d83c13-9c65-405a-b2c2-aef9d7eacac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540ad6be-4c15-4114-88fc-91dd27f544aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_540ad6be-4c15-4114-88fc-91dd27f544aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e664f-12d9-4b2a-81d0-bc4aad34d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e664f-12d9-4b2a-81d0-bc4aad34d62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c79b351-5de5-4f3b-8f5c-7d78ae08c568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c79b351-5de5-4f3b-8f5c-7d78ae08c568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e036333b-56ca-4d5b-b95c-c2366f2df7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e036333b-56ca-4d5b-b95c-c2366f2df7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f11f36-fc57-4761-8b9b-6561b460a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f11f36-fc57-4761-8b9b-6561b460a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc8f45d5-281e-4fcc-8c3a-bf7da9549ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc8f45d5-281e-4fcc-8c3a-bf7da9549ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_34e2a182-9bdd-4d0f-8ea4-04fe6b26e8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_34e2a182-9bdd-4d0f-8ea4-04fe6b26e8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5793940d-877d-4482-a85e-56c3ebf4aa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5793940d-877d-4482-a85e-56c3ebf4aa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b18e3783-f69b-4b1c-939d-2f48d98fe2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b18e3783-f69b-4b1c-939d-2f48d98fe2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1736726b-a17f-4809-a113-691cae15de0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1736726b-a17f-4809-a113-691cae15de0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82fb5f72-7847-493f-a818-eb5e72554f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eafa5a68-286e-4d9e-9d8d-7436b6a48f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_596079dc-fb24-46e6-b5ad-d49e5f9be056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eafa5a68-286e-4d9e-9d8d-7436b6a48f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13145331-094b-4215-b240-22242551f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13145331-094b-4215-b240-22242551f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2084d964-d499-4ee9-a921-fe8d4cea180d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2084d964-d499-4ee9-a921-fe8d4cea180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b1d85260-eee2-4488-88ee-fdd552b020bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b1d85260-eee2-4488-88ee-fdd552b020bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a1603fbe-b7a1-4470-a273-31a226d03971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a1603fbe-b7a1-4470-a273-31a226d03971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_75f697ba-35b1-4e55-878a-6930fe119665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_75f697ba-35b1-4e55-878a-6930fe119665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5177a332-60de-4675-85f3-78b68eb2982e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_13ce69db-cc4f-4a82-be09-0cea0e76281e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5177a332-60de-4675-85f3-78b68eb2982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_79a25355-22d0-424f-9354-cd3f60509e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_79a25355-22d0-424f-9354-cd3f60509e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8660d89-39bf-4f18-8c2a-babcaceba730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8660d89-39bf-4f18-8c2a-babcaceba730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c67657c-c1aa-4345-8fa6-4c258829c2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c67657c-c1aa-4345-8fa6-4c258829c2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eaedc34c-572b-4458-b99e-cf1ca1f9d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eaedc34c-572b-4458-b99e-cf1ca1f9d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_770c3782-b524-4bab-8c44-ff978818e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_770c3782-b524-4bab-8c44-ff978818e2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5bd2a6af-6a39-443a-9424-214c9d9f908e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5bd2a6af-6a39-443a-9424-214c9d9f908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ccea389e-9d17-485e-8162-ff4033473532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_028349cb-8f7a-4fa2-a3d1-7f2300ea5156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ccea389e-9d17-485e-8162-ff4033473532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_92dfe5c6-3a0b-40a6-bc4e-198331a417b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_92dfe5c6-3a0b-40a6-bc4e-198331a417b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f35eeba7-d2c5-4da8-acb3-b4ff11b283b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f35eeba7-d2c5-4da8-acb3-b4ff11b283b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ad95101-c4db-4309-8f20-34ec686fb3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f35eeba7-d2c5-4da8-acb3-b4ff11b283b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ad95101-c4db-4309-8f20-34ec686fb3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_34f0bf2f-acde-4b15-b3e4-b632d35786c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_34f0bf2f-acde-4b15-b3e4-b632d35786c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_e9e88d80-eef6-4f2c-ac2c-8492240849ef" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_e9e88d80-eef6-4f2c-ac2c-8492240849ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e6a6c5b9-cebc-4600-9f59-c71fef309c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_e9e88d80-eef6-4f2c-ac2c-8492240849ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e6a6c5b9-cebc-4600-9f59-c71fef309c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02414eaf-c0ec-43e3-8e7e-cf9e79e26606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a3e1937-f7f4-44f7-811f-3f34daac5cc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02414eaf-c0ec-43e3-8e7e-cf9e79e26606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_904a12d6-9771-41c3-bde2-4441f0870152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_904a12d6-9771-41c3-bde2-4441f0870152" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_957b6887-3fbb-40d4-8eeb-33e45997af85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d29a3da-68d1-4dd0-9335-629d9dad122f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d29a3da-68d1-4dd0-9335-629d9dad122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4123add-7c49-4dd0-ba8b-d7dbf4147bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d8310f27-88f8-43fd-b0bd-861395fffbbf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c4123add-7c49-4dd0-ba8b-d7dbf4147bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:to="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac4f0748-8041-4fdb-b323-2315e9e0946f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bee9d83-be07-4852-a479-06261d0300fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bee9d83-be07-4852-a479-06261d0300fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d97e2e69-85ad-47c0-935f-36bf56fc0564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eabc51f8-d2f3-42ef-93aa-d594ff2a11c4" xlink:to="loc_us-gaap_RestrictedStockMember_d97e2e69-85ad-47c0-935f-36bf56fc0564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ef92b24-a087-4189-ab83-f4f2d50c12d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5c52a6e1-d255-4649-9b14-6d28a548a199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d52a191-3006-4a4f-a4ef-f2eb01cfd4e3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5c52a6e1-d255-4649-9b14-6d28a548a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d2e0aa6-e77d-4338-a165-3338612140e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d2e0aa6-e77d-4338-a165-3338612140e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:to="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9445c167-45eb-4474-9f3b-9786863c1fb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35c64bb3-8080-4123-806f-c0de5d02db17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1e636c0-17b5-4958-8efa-54c35958e260" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35c64bb3-8080-4123-806f-c0de5d02db17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa54efd6-2c9d-4824-8b58-e6fe45d96afc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd77b320-cf72-497b-be0c-716263415766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd77b320-cf72-497b-be0c-716263415766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99ca0c29-f51c-4ca3-adcb-b42346ea40a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99ca0c29-f51c-4ca3-adcb-b42346ea40a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_676028e1-275e-4fee-ab7c-a6c995fd45ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_676028e1-275e-4fee-ab7c-a6c995fd45ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_52451773-37fe-499e-8e5f-7deddcf543df" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_52451773-37fe-499e-8e5f-7deddcf543df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_da1bc160-f83b-4b71-a2bd-597fa82d6b71" xlink:href="krys-20220930.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bf2e4f8-48b5-4a28-a9cd-8641f4ea0baa" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_da1bc160-f83b-4b71-a2bd-597fa82d6b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220930.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e896c28f-3135-4293-ac2a-e4aa3c1efee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e896c28f-3135-4293-ac2a-e4aa3c1efee6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:to="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_17267af9-c622-4119-9bcf-554c387e2629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9ea04e55-138f-4c10-ac47-ecb0fdc83bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_810060b6-2d50-4027-8d5c-74078b447c72" xlink:to="loc_us-gaap_RestrictedStockMember_9ea04e55-138f-4c10-ac47-ecb0fdc83bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52bacf7a-5e60-4580-bef2-ab7286d6d3f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a216a361-1859-48c2-a2b5-5b49a790d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a216a361-1859-48c2-a2b5-5b49a790d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_44e49895-0d71-40d6-9217-612bd4d0a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_44e49895-0d71-40d6-9217-612bd4d0a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b97acb0a-2158-47ac-b10a-b354f1b9c122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b97acb0a-2158-47ac-b10a-b354f1b9c122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f15c4f6-212b-4931-8bb6-cb545ba844dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f15c4f6-212b-4931-8bb6-cb545ba844dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3b5082f5-cb33-4d5c-bc87-ad2584a0635c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_967e6688-2585-46f8-8c61-bae03275c155" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3b5082f5-cb33-4d5c-bc87-ad2584a0635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dee8c6fa-ce9e-4bf4-b9f7-1568056ad081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_151a6e5f-e90e-4fca-b08e-ca44433537a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_151a6e5f-e90e-4fca-b08e-ca44433537a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_376c5ac3-ff83-4b2d-8aa8-47b94b9fcd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_376c5ac3-ff83-4b2d-8aa8-47b94b9fcd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be955ccb-677b-4a09-8e71-5c8cdeed93e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be955ccb-677b-4a09-8e71-5c8cdeed93e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46928743-4b39-4eae-8276-8e88c3c16e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46928743-4b39-4eae-8276-8e88c3c16e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4150c7e-4987-45a0-b93a-df1d7f60b535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e47e60e9-a2b1-47c5-9b1f-f8f0b8a02d4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4150c7e-4987-45a0-b93a-df1d7f60b535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>krys-20220930_g1.jpg
<TEXT>
begin 644 krys-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :&!2T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!KCP3\>+SQ)I=G:ZWX0\2^'%675O#OC"Q_L^_M(F&1*\99ALQ@DAOEW+N
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MB'E7![=P002"">ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
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MTG^_=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !%
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M5@_\)QI/]^[_ / "X_\ B*/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P
MN/\ XBC_ (3C2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_
M=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16
M#_PG&D_W[O\ \ +C_P"(H_X3C2?[]W_X 7'_ ,10!O45@_\ "<:3_?N__ "X
M_P#B*KWWQ&T'3+5[F[N;BWMTQNDDL9P!D@#^#U(H Z:BL'_A.-)_OW?_ ( 7
M'_Q%'_"<:3_?N_\ P N/_B* -ZBL'_A.-)_OW?\ X 7'_P 11_PG&D_W[O\
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MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
M$4 ;U%8/_"<:3_?N_P#P N/_ (BC_A.-)_OW?_@!<?\ Q% &]16#_P )QI/]
M^[_\ +C_ .(H_P"$XTG^_=_^ %Q_\10!O45S,OQ&T&"[@M9+FX2XG#&*,V,^
MY]HR<?)V%6/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P N/\ XBC_ (3C
M2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_=_\ @!<?_$4
M;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16#_PG&D_W[O\
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MI/\ ?N__   N/_B* -ZBL'_A.-)_OW?_ ( 7'_Q%'_"<:3_?N_\ P N/_B*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\?O$/P9\%_%*Q\&+\.]%L?[=\82>&K>\NM;U"6)2S"VD/E0QL23A#\I7JP(
M\[F_;[^*<?[-NHZ<XTE/C)#X]_X5Y%K,< -F9CD_:_**[0PPRXP5R VW'R4
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MG_X3/Q#;QE;S7?[/CL?M;%B0WD1DI'A2%P#_  Y[UTE !1110 4444 %%%%
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MO(-/M)[JZGCMK6!&EEFF<(D:*,LS,>   22:_/+P+^TWXF^#/[+?[,D/PW\
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MJG[57["'[1!UNVT4ZGX;A2T.I>'%N8]/OXI&5DDBCN0)DY1N' .,<#D5]V_
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MU[Q9KLS0:/HME+?74B+N;RXU+$*.['& .Y(KD?#O[1G@;5/A5X8^(&N:Q:^
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M%?#7P?\ \*\^'?A?PM]K_M#^Q-,MM-^U^5Y?G>3$L>_9D[<[<XR<9ZFNDHH
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MAN/_  &@_P#B*-VN?]##<?\ @-!_\10!W=%<)NUS_H8;C_P&@_\ B*-VN?\
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MHW:Y_P!##<?^ T'_ ,10!W=%<)NUS_H8;C_P&@_^(HW:Y_T,-Q_X#0?_ !%
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M^ T'_P 10!W=%<)NUS_H8;C_ ,!H/_B*-VN?]##<?^ T'_Q% '=T5PF[7/\
MH8;C_P !H/\ XBC=KG_0PW'_ (#0?_$4 =9=:[8V.K6.F33[+V^$AMXMC'>$
M&6Y P,#U(J_7D>L:3X@N_&'A^_74YIH[1;@-=&* &'>@  7;\V[IT./:NAW:
MY_T,-Q_X#0?_ !% '=T5PF[7/^AAN/\ P&@_^(HW:Y_T,-Q_X#0?_$4 =W17
M";M<_P"AAN/_  &@_P#B*-VN?]##<?\ @-!_\10!W=%<)NUS_H8;C_P&@_\
MB*-VN?\ 0PW'_@-!_P#$4 =W17";M<_Z&&X_\!H/_B*-VN?]##<?^ T'_P 1
M0!W=%<)NUS_H8;C_ ,!H/_B*-VN?]##<?^ T'_Q% '=U5U/4K;1]/N+Z\D\F
MUMT,DLFTMM4#). "3^%<=NUS_H8;C_P&@_\ B*RO%5CKVJ>&]2M$UB:[>:!T
M$#0P()"1]W.T8S]10!Z59W<5_:07,#;X)D62-L$94C(.#[&IJ\XT6WUVST>P
MMVUR>!HH(T,0@@8(0H&W.TYQ]:N;M<_Z&&X_\!H/_B* .[HKA-VN?]##<?\
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M ,10!W=%<)NUS_H8;C_P&@_^(HW:Y_T,-Q_X#0?_ !% '=T5PF[7/^AAN/\
MP&@_^(HW:Y_T,-Q_X#0?_$4 =W17";M<_P"AAN/_  &@_P#B*-VN?]##<?\
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M_P >:?\ 70?R-8-06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG;\>7L4'ICG.?45L5CZAX?\ M_B/2-5^T>7_ &>LR^3LSYF]0.N>,8]#6Q0
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MCV[XTF9"00 O'RC'7G-7/^%A:')Y'D3W5X9E+JMG87%P0H8IN81H2JDJV"V
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MX(_Z G_DW/\ _%T?7J?9_P!?,/JL^Z/DVBOK+_A1O@C_ * G_DW/_P#%T?\
M"C?!'_0$_P#)N?\ ^+H^O4^S_KYA]5GW1\FT5]9?\*-\$?\ 0$_\FY__ (NC
M_A1O@C_H"?\ DW/_ /%T?7J?9_U\P^JS[H^3:*^LO^%&^"/^@)_Y-S__ !='
M_"C?!'_0$_\ )N?_ .+H^O4^S_KYA]5GW1\FT5]9?\*-\$?] 3_R;G_^+JGI
MOPD^'NL+<-::5YPMYFMY/])N%VR+]X<OSUZCBCZ]3[/^OF'U6?='RS17UE_P
MHWP1_P! 3_R;G_\ BZ/^%&^"/^@)_P"3<_\ \71]>I]G_7S#ZK/NCY-HKZR_
MX4;X(_Z G_DW/_\ %T?\*-\$?] 3_P FY_\ XNCZ]3[/^OF'U6?='R;17UE_
MPHWP1_T!/_)N?_XNC_A1O@C_ * G_DW/_P#%T?7J?9_U\P^JS[H^3:*^LO\
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M1K!K V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%'V.W_P">$?\
MWP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?
M_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%'V.W
M_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1
M]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_
M +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\
M\\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'['
M;_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ*
M (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_?
MJ:B@"'[';_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'
M_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_
M .>$?_? J:B@"'[';_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4
M?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\
M[X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%4=:\,Z7XATV;3[^S2:TFV[XU
M)0G#!ARI!'('0UJ5P?QT_P"26:W_ -L/_1\= ';?8[?_ )X1_P#? H^QV_\
MSPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_YX1_]\"C[
M';_\\(_^^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#?
M H^QV_\ SPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_Y
MX1_]\"J.E^&=+T5;E;.S2(7,[W,N26W2-C<?F)QTZ#BM2N#^$?\ QZ^*/^Q@
MO/YK0!VWV.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#? H^QV_\
MSPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_YX1_]\"C[
M';_\\(_^^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#?
M H^QV_\ SPC_ .^!4U% &7=>&=+O-4LM1FLT:\LPX@DR0%WC#?*#@Y'J#CM5
M[[';_P#/"/\ [X%<3XJ_Y*QX&_ZYWW_HH5WE $/V.W_YX1_]\"C[';_\\(_^
M^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#? H^QV_\
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M=EF]QNV[L^5B3'4==F,]LYYZ545=I";LKE__ (65X0_Z&K1/_!C#_P#%4?\
M"RO"'_0U:)_X,8?_ (JO@6BO6^HQ_F/.^M2['WU_PLKPA_T-6B?^#&'_ .*H
M_P"%E>$/^AJT3_P8P_\ Q5? M%'U&/\ ,'UJ78^^O^%E>$/^AJT3_P &,/\
M\51_PLKPA_T-6B?^#&'_ .*KX%HH^HQ_F#ZU+L??7_"RO"'_ $-6B?\ @QA_
M^*H_X65X0_Z&K1/_  8P_P#Q5? M%'U&/\P?6I=C[Z_X65X0_P"AJT3_ ,&,
M/_Q5'_"RO"'_ $-6B?\ @QA_^*KX%HH^HQ_F#ZU+L??7_"RO"'_0U:)_X,8?
M_BJ/^%E>$/\ H:M$_P#!C#_\57P+11]1C_,'UJ78^^O^%E>$/^AJT3_P8P__
M !59/AWXR>&M:COVNM8TK3#;WDEM&LVHQ?OD7&)1DCAL\=1QU-?#=%'U&/\
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M,Z8DV;-N/QSG\*WJP7\+[O'$?B+[5C9IYL?LWE]<R;]^[/X8Q^-;U !1110
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MBCJ7BSP'X;N4N=.\-G3(K4 IG8LLRLS2* 2N"!P2!MS7U+11[20<J/(OB/\
M"7Q_XA\076H^#?B]J7@JWO$1;C3I=)M]2@4JNW,/F;6AR.3@\G)J[\!?V?\
M0O@%X?OK+3+J[U;5-3G^UZGJ]^P:>[EYY..BC+8'/WB223FO4**GF=K!RJ]P
MHHHJ2@HHHH **** "BBB@ HHHH *Y+Q=J4Q\4^$M&@GD@6\N9;F<Q2%&:*&,
MMMR.<%VCR.XR#P376UR7B[39O^$J\):S!!).MG<RVTXBC+LL4T97=@<X#K'D
M]ADG@&@##:QU[_A8RZ*/&FLBR;36O_\ CWL-V\3!-N?LWW<'Z^]0GQ--K46I
M:SJ'C1?!NAPW\NG67EFT02M$S(SR27"."S,CX5=N%'.3T[0^&\^-%U_[1]W3
MS8_9]GK('W[L^V,8_&L"?X?ZKI\FL1^']<MK#3=5>2::RU#3VNEBED!\QH66
M:,J&)W%6W#.2,9Q0!S_B3QUK6A^./#&S5K>]\/FPBFU'[/ @CN/-E6%9T;+%
M5#.C8#$8SSWJ]?>,=8N/BYI>GV=WY7AY)GL+B'R5/GW MWF8[R,@(/*'RD<E
MLUI'X4VDD*6LUVTUDOA\Z T31C<R9'[S=GKQTQ^-+X?^&/\ 8=OX75]5DO;G
M1Y[BZN+F:+Y[V69'5V/S?+RY/?@ >] #/!NL>([CQ_XHTS7;JTD@@MK6XM;6
MRC(2!9'G7!<@,[%8T))P,YP!WT/AO?3S:3J%A=3R75QI6HW%B9II&=W17W1E
MF;DGRW0$GKC-5]'\(:_I_C:^U^YUO3;B&]ABMYK6+2Y(V\N(R%-KFX;#9E.2
M5(.!@"IOAII]Q;Z1J-_=Q307&K:E<7_DSQF-XT9]L092 0?+1#@\C.* .NHH
MHH **** "BBB@ HHHH **** "BBB@"CJFBV>M"U%Y#YPM;A+J'YF7;*ARK<$
M9QZ'BJGB#PAI7BA[62_MW-Q:EFM[JVGDMYXLC#!98V5U!'4 X/&:V:* .>L_
M .AV-G#;1VLCQQ7JZB'GNI99&N!TD:1V+.1@#YB1@ =!1)X \/R0Z[$=-0)K
MCB34-KNIG8  $D'(X';'4GJ370T4 <UKWP[T;Q)J4%_??VB;JW.Z%K?5;N!8
MFVE=R+'*JJ2I() R03FMZYL8+VREL[F);BUEC,4D4PWJZ$8(;/4$>M3T4 <O
MI/PS\.:-=&Y@L'FN#;/9&2]NIKIC;MMS$3*[?)\@PO0<X W'-C1? NE: S_8
MVU#RFA,'D7&J74\*H<<+')(RK@  ;0,#@8%=!10!D6_A32K7^QO+M=O]CQF*
MQ_>.?*4IL(Z_-\HQ\V:H6/PX\/Z:]P;>SE5)XY8C UW,\,2RG,@BC9RD6[_I
MF%KIJ* .<O?A]HE\MB#!<VKV5N+2&:QOI[640C&(VDB=691@'#$\\]:OV_AK
M3[:?SUBD><VBV+2S3R2.T*DD!F9B2<L?F/S'/)K4HH YVW\ :':3:-+;VLUM
M)I%N+2T:"[FC*PC;B-]KCS%^4</N'%:C:+92:U'JS0[M0CMVM4F+-\L;,&90
M,XY*KSC/ J]10!AW?@O1K[4)KZ:S+W,TUO<2,)I &D@.8FVAL9'TY  .0!5B
M3POI<UYJ5U+9QS2:E"EO>+*2\<\:A@H9"=IX8C.,D<'@"M2B@#F+'X;Z#IZL
MJ074T?DM;I'=ZA<7"0QLNUA$LDC"/Y?ER@!QQTK?T^Q@TNQMK.V3RK:WC6&)
M,D[54  9/)X ZU8HH *XWXP:I<:/\.-9NK4H)0D<?[V)95*O(B,I5@5(*L1@
MCO7950UW0K'Q+I4^FZE!]ILIMOF1;V7.&##E2#U [T 97_"M?"'_ $*NB?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW)'/3O0!FS>-H[,6UK:V]UXGO/L:W<DFE+%M\H\+)EY%7#$'"J6)P>,4L/Q
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M MLY ]3FN_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*V*YN35[M?B)%I@E_P!!;3#<&+:/]9YNW.<9Z=LXKI* "BBB@ HHHH ****
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M%% !6]H/_'F__70_R%8-;V@_\>;_ /70_P A0!I4444 %%%% !1110 4444
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MBM4'EA3%&A8D;L\Y9B>W0#M5]-)L8UM52RMU6T):W"Q*!"2"I*<?+P2..Q-
M'D^GZC?:MJ?PWU6^US[;+J5Q/=?8&CB58,VLQQ'M4-M7=M.XMDXY'0W-&\0:
M_<>&O"5Q=Z_*+CQ%,D$ES]G@5+4".1QY0V8WOL"Y<L,DD*.!7H=KX7T6QO)+
MNVTBPM[N23SGGBMD61I,,-Y8#);#N,]?F/J:EFT'3+C2?[+ETZTDTS:%^QO
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M!B_^)H^O1_E#ZK+N?%]%?:'_  @/AC_H7-)_\ 8O_B:/^$!\,?\ 0N:3_P"
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M **** "M[0?^/-_^NA_D*P:WM!_X\W_ZZ'^0H TJ*** "BBB@ HHHH ****
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M;]F[<ZKUP<?>ST[5L5C^+O#_ /PE7AV[TO[1]E\_9^]V;]NUU;ID9^[CKWH
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MWK(W?G[_ $?;MVX_'.:V*QV\/[O%R:W]HQMLC:>1L]7W;MV?PQBMB@ HHHH
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M!#14WV.X_P">$G_?!H^QW'_/"3_O@T 0T5-]CN/^>$G_ 'P:/L=Q_P \)/\
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M4*UE"\D61$6^>W99" Q3JF>"HP6! SG0:7)X7T7QGJBZ0N@:1-9?Z/HH,?\
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M*F^QW'_/"3_O@T?8[C_GA)_WP: (:*F^QW'_ #PD_P"^#1]CN/\ GA)_WP:
M(:*F^QW'_/"3_O@T?8[C_GA)_P!\&@"&BIOL=Q_SPD_[X-'V.X_YX2?]\&@"
M&BIOL=Q_SPD_[X-'V.X_YX2?]\&@"&M[0?\ CS?_ *Z'^0K'^QW'_/"3_O@U
MM:+&\5JX=&0[R<,,=A0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,^+/^0]X+_["\G_ *07==-7,^+/^0]X+_["\G_I
M!=UO1^)^C_)F-;X5ZK\T=-1116!L%%%% !1110 4444 %%%% !1110 4444
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M]ESOT\WWVGS.F)-FS;C\<Y_"MZ@ HHHH **** "BBB@ HHHH **** "BBB@
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MQGNOAWI-UH/@'PYIM]%Y-[9Z=;P31[@VUUC4,,@D'D'I70T4 %%%% !1110
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MDOAWKM]KUOKS7T_GM:ZQ<VL/R*NV-"NU> ,XR>3S4E'6T444 %%%% !1110
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MK"T@MH$V00HL<:Y)PH& ,GV%35D>$?\ D4]%_P"O*#_T6M:] !1110 4444
M%%%% !1110 4444 %%%% %!M"L6UQ=8,'_$Q6W^RB;>W^JW;MNW..O.<9J_7
M!S?\ERM_^Q?;_P!**[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KF?%G_(>\%_]A>3_P!(+NNFKF?%G_(>
M\%_]A>3_ -(+NMZ/Q/T?Y,QK?"O5?FCIJ***P-@HHHH **** "BBB@ HHHH
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M_CI_PH_M>T_YZ_\ CI_PKFZ* .D_M>T_YZ_^.G_"C^U[3_GK_P".G_"N;HH
MZ3^U[3_GK_XZ?\*/[7M/^>O_ (Z?\*YNB@#I/[7M/^>O_CI_PH_M>T_YZ_\
MCI_PKFZ* .D_M>T_YZ_^.G_"C^U[3_GK_P".G_"N;HH Z3^U[3_GK_XZ?\*/
M[7M/^>O_ (Z?\*YNB@#I/[7M/^>O_CI_PK$\:>.K?PEX9O-6CB^W/;[,6^XQ
M[MSJOWMIQC=GIVJM6/XN\/\ _"5>';O2_M'V7S]G[W9OV[75NF1G[N.O>@#O
M/[7M/^>O_CI_PH_M>T_YZ_\ CI_PKFZ* .D_M>T_YZ_^.G_"C^U[3_GK_P".
MG_"N;HH Z3^U[3_GK_XZ?\*/[7M/^>O_ (Z?\*YNB@#I/[7M/^>O_CI_PH_M
M>T_YZ_\ CI_PKFZ* .D_M>T_YZ_^.G_"C^U[3_GK_P".G_"N;HH Z3^U[3_G
MK_XZ?\*/[7M/^>O_ (Z?\*YNB@#I/[7M/^>O_CI_PK$\+>.K?Q)'J3O%]D^Q
MWTMF!N+^8$Q\_P!T8SGIV]:K5C^&_#__  CT>H)]H^T?:[V6[SLV[=^/EZG.
M,=: .\_M>T_YZ_\ CI_PH_M>T_YZ_P#CI_PKFZ* .D_M>T_YZ_\ CI_PH_M>
MT_YZ_P#CI_PKFZ* .D_M>T_YZ_\ CI_PH_M>T_YZ_P#CI_PKFZ* .D_M>T_Y
MZ_\ CI_PH_M>T_YZ_P#CI_PKFZ* .D_M>T_YZ_\ CI_PH_M>T_YZ_P#CI_PK
MFZ* .D_M>T_YZ_\ CI_PH_M>T_YZ_P#CI_PKFZ* +.I^.K?3_%&BZ0(O-345
MF9KC<1Y7EJ&^[M^;.<=1BMO^U[3_ )Z_^.G_  K@]0\/_;_$>D:K]H\O^SUF
M7R=F?,WJ!USQC'H:V* .D_M>T_YZ_P#CI_PH_M>T_P">O_CI_P *YNB@#I/[
M7M/^>O\ XZ?\*/[7M/\ GK_XZ?\ "N;HH Z3^U[3_GK_ ..G_"C^U[3_ )Z_
M^.G_  KFZ* .D_M>T_YZ_P#CI_PH_M>T_P">O_CI_P *YNB@#I/[7M/^>O\
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M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\
MA7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_
M:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I
M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\
MA7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_
M:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I
M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A4]O<1W2%HFW*#C
M."*Y2M[0?^/-_P#KH?Y"@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(M-'6X6TB\H7$S7$GS%MTC?>/)XZ=!Q0!<HHHH **** "BBB@ HHHH ****
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MQ R2'.Z4%4!7(S@ @ HH[U<\)_$C6?B;\9KR#P]J07P+HUNHN98H8W6\F8'
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M9;%I(H^?E&XA2^!C)PN?05Q.H^!]8\1:E<ZC?6^DZ=??V9<:>)K&:1S=F10
M928UVHI&0OSD%NO'(!IZEXXCM_#]TUI>VIU2SMX)KAKJ*5H(BY7AS&O#$$D*
M.>0<8YJ]J?Q!T'1]0GLKJ\=+BW*"?9;2NL&_&UI&52J*<CYF('7G@XYC_A6N
MJ:?X7U7P[87%J^EW<:2P_:)',D-QO#2@MM)=&(+!B=P)(Y&,:OB#P7?:MI?C
M6VAEMU?6X@EN79@$(A"?/A>.1VSQ0!VE+38U*1JIZ@ 4Z@ HHHH **** "BB
MB@ KC_BY_P D]U;_ +9?^CDKL*IZOJ]IH.GRWU]+Y%K%C?)M+8R0HX )ZD4
M7**\NUCXW?V3JU]8_P!B^;]FG>'S/M6-VUB,XV<9Q53_ (7[_P!0+_R<_P#M
M=>FLMQ4E=0_%?YG(\713LY?F>N45Y'_POW_J!?\ DY_]KH_X7[_U O\ R<_^
MUT_[,Q?\GXK_ #%]<H?S?@SURBO(_P#A?O\ U O_ "<_^UT?\+]_Z@7_ ).?
M_:Z/[,Q?\GXK_,/KE#^;\&>N45Y'_P +]_Z@7_DY_P#:Z/\ A?O_ % O_)S_
M .UT?V9B_P"3\5_F'URA_-^#/7**\C_X7[_U O\ R<_^UT?\+]_Z@7_DY_\
M:Z/[,Q?\GXK_ ##ZY0_F_!GKE%>1_P#"_?\ J!?^3G_VNC_A?O\ U O_ "<_
M^UT?V9B_Y/Q7^8?7*'\WX,]<KC_AK_Q[^(/^PS<_S6N3_P"%^_\ 4"_\G/\
M[71_POW_ *@7_DY_]KH_LS%_R?BO\P^N4/YOP9ZY17D?_"_?^H%_Y.?_ &NC
M_A?O_4"_\G/_ +71_9F+_D_%?YA]<H?S?@SURBO(_P#A?O\ U O_ "<_^UT?
M\+]_Z@7_ ).?_:Z/[,Q?\GXK_,/KE#^;\&>N45Y'_P +]_Z@7_DY_P#:Z/\
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M^5?&VD^#O!VE^#-6^&>H0CQN]S"C6VEW[73R;H_G#IO;;\V%V\ [B,'M[/\
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M^61XOW\H\MD9SL! Y7 W=3F@#VFBO'6UR6:XD<:Q>+XV36O)71UNW"_9Q/M
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MG%>*45%:>O\ F><\#3;O=_U\CYU_X5/XK_Z!7_DQ%_\ %T?\*G\5_P#0*_\
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M9U>[M?&GAVPBEV6EVER9H]H.[:@*\XR,'TKI* "BBB@ HHHH **** "BBB@
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M'%;W]@W']^/\S_A7%?"_29KBV\1E60;=<ND.2>H*^U '1T5I?V#<?WX_S/\
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M% &;16E_8-Q_?C_,_P"%']@W']^/\S_A0!FT5I?V#<?WX_S/^%']@W']^/\
M,_X4 9M%:7]@W']^/\S_ (4?V#<?WX_S/^% &;16E_8-Q_?C_,_X4?V#<?WX
M_P S_A0!FT5I?V#<?WX_S/\ A1_8-Q_?C_,_X4 9M;V@_P#'F_\ UT/\A5/^
MP;C^_'^9_P *TM,M'L[=D<J26W?+]!0!<HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *K:AJ5II-E+>7UU#96D(W27%Q((XT'
MJ6)P!]:LUPGC3R?^%B>"1J10:9NN3")2!&;[:GDYSQNV^=M]\XYQ0!UFC:]I
MGB*S^UZ3J-IJ=KN*>?9SK,FX=1N4D9Y''O5^N(\<:XGA6ZMM7M+JU@M[:[A&
MNQJD9<V\@,:22'&Y0C%6!_NANPKG_P"V/&.N:'9:W9SWS:3>7%S<"/1ULQ>)
M;=+8K]H7RV0JI=L_/EUP< B@#U>J]CJ%KJEJEU9W,-W;29V30.'1L$@X(X/(
M(_"O+M%;_A(/BKHVJ67B+4)K*X\.+<Q[XK=?/C\Y 0P,((#?>.,$$\%1Q5?P
MEKFIZIIW@_1+?4!H,5_'J$\EW86L".QAGVK#&K1F-<ARQ^0DA#ZDT >L:AJ5
MII-E+>7UU#96D(W27%Q((XT'J6)P!]:S--\<>'-80/8>(-+OD,JP!K:]CD'F
M-G:G#'YC@X'4X-<O\4)))/@SJC?;8=5E^SQC[7& B3L)%&[Y<@9/7''7 [4_
MQ7J.M+:^'GU73M,LYVUZTB5;>?[:NPD@L#) FQNN"HR.Q% ':Z;JUIK$<[VD
MOFK!/);R':5Q(AVLO(['OTJY7B=KK.H^'[76=6LM>W+#XI:S;14AB:.02W2H
MRN<&02$2;E*LHP%^4\DVY?%GB&U\/ZWK<NNLJKKLFCP1O;0BWM(3>"$3N=NY
MF12<98+@#()R2 >PU7N]0M;#R?M5S#;>=(L,7G2!?,D/1%SU8XX YKSBXOO%
MEKJ7B7P]I>KOKEW;6=M>07=U% EQ$7=EDARB+%O*1[DWI@%ANRO2K/XADN-/
MTB"6XO[K4;7Q+:VMU'KUK:-/;E@&"@PIY7W6#!T)8;OO \  ]9HKSRQU;6]+
M\<+;^(;S4X;>]NY8=/6W2T;3IUV%HTX0W"R!%8G<0NY3@X(%>AT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-=
MUVQ\-:5/J6I3_9K*';YDNQFQE@HX4$]2.U7ZY+XK:%?>)? .J:;IL'VF]F\K
MRXMZKG$J,>6('0'O0!UM%%% !1110 4444 %%%% !1110 4444 %4-(UVQUY
M;IK&?SUM;A[6;Y&7;*F-R\@9QD<CBK]<E\.]"OM!M]>6^@\AKK6+FZA^=6W1
MN5VMP3C.#P>: .MHHHH **** "BBB@ HHHH **** "BBB@"A=:[8V.K6.F33
M[+V^$AMXMC'>$&6Y P,#U(J_7)>(-"OK[XA>%-3A@WV5BEV+B7>HV%XP%X)R
M<GT!KK: "BBB@ HHHH **** "BBB@ HHHH *JZGJ5MH^GW%]>2>3:VZ&263:
M6VJ!DG !)_"K587CG3;G6/!VLV-G'YUU<6LD<4>X+N8C &20!^- &O9W<5_:
M07,#;X)D62-L$94C(.#[&IJSO#EK+8>'M+MITV3PVL4<BY!PP0 C(]Q6C0 4
M444 %%%% !1110 4444 %%%% !1110!0;7;%=<71S/\ \3%K?[4(=C?ZK=MW
M;L8Z\8SFK]<E)H5\WQ5AU@0?\2Y=':U,V]?]9YV[;MSGISG&*ZV@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K-U76AI=]HUL8C(=2NVM0V['EX@EFW>_P#JL8_VO:M*N9\6?\A[P7_V%Y/_
M $@NZUIQ4I6?9_DS*I)QC==U^:.FHHHK(U"BBB@ HHHH **** "BBB@ HJII
M.KV.O:;;ZAIE[;ZC87"[X;JTE66*1?574D$>X-)JNL6&A637FI7MOI]HK(C7
M%U*L489V"("S$#+,RJ!W) [T 7**** "BBB@ HHHH **** "JNI:99ZS8RV>
MH6D%]9RC$EO<QK)&XSG!4@@\BK5<)\7)-6TGPO?:SI7B"^TJ:TC7;;P16SQ.
M2X&6\R)VS@]F X% &GK/P_TV[\%ZEX;TJVL]"LKY&CD6SM$5 &P'.Q=HW%<C
M/;@\XJYJ7@;PYK5O9PZCH.F:C%9Q^5;K>6D<PB3 &U=P.!P.GH*R+7Q(_A_Q
M /##'7/%&IF*.\>ZDBM46&%W9,LRB)<*4)Q@N=W ;!Q;M/'D4^N6FFW&CZII
MJWOF?8[N\CC2.X*#<0%#F1#MRP$B+P#WXH U[KP[I-]<V-Q<Z79W%Q8G-I++
M;HSVYXYC)&4Z#ICH*AOO".A:EI<>FWFBZ==Z=&_F):3VD;PJW/S!", _,W..
MY]:P-"^*MCKMUI<8TK5;&UU3S!97MW#&L4SHI9D #EP<*Q!*A6VG!/&9+'XF
M6]_X=OM?71=3BT.VM)+V.^<VY6YC0$_(JS%P2 2 ZKZ'!XH Z>72;*?3AI\M
MG;R6 18Q:M$IBVC&%VXQ@8&![5)=6-M?>4+FWBN!%(LT?FH&V.OW6&>A'8]:
MX?\ X6] UP]NGACQ!)<_8QJ$,(@A#36QSF4$R@+C RCE7^884\XOS_$RRD6T
M_LC3=1\0R7%BFI>7IRQ QV[_ ''8RR(,M@X4$L=IXH V?^$1T+^UH]4_L73O
M[3C+%+W[)'YREB2Q#XW#)9B>>=Q]:MC1[ 6=S:"QMA:71D:>#R5V2E\[RRXP
MV[)SGKDYKD=2^+VF6I/V'3-4UM1I::P7T^&/:+9BXW9D=/F&P_)]XYX!PV*F
MK?$NWUGP_K4%I;:EIEQ)HL^HZ?=7"+$+F$+CS8]K%U(+(<.$;Y@<4 =5'X'\
M.1:/)I">']+32I'\Q[%;*,0,_'S&/;M)X'..PJQ9>%]&TVQ@LK32+&UL[>43
MPV\-LB1QR Y#JH& V><CFN2T[XJ6EGI&[4]-U:Q>'2GU*)[N- ;V*)09&C^<
MD-RIVR!&^8<=<:\/CB:ZTV"[M_#&N3FX.;> 1P(\D>T'S26E"Q@Y'RR,K]?E
MX- &AI_@SP_I.J2ZE8Z%IMEJ,N[S+RWLXXYGW'+9<#)R>3SS6S7&?\+1L9K/
M19;+2]4U&XU99C!9VT4?F(T1 D20LZHA4DC);;\IP3E<K#\4+"]T_2IK#3M1
MU&]U$S"+3(4B6X3R6VS;R\BQKL;Y3\_)(QF@#LJ*S?#NO6_B72H[ZV26)69H
MY(9U"R0R(Q5XW )&Y6!!P2.."1S6E0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6#XZ\4_P#"%^%;[6?LOVS[-L_<^9Y>
M[<ZI][!QC=GIVK>K!\=>%_\ A-/"M]HWVK[']IV?O_+W[=KJ_P!W(SG;CKWH
M WJ*** "BBB@ HHHH **** "BBB@ HHHH *P?"/BG_A*HM4?[+]E^PZA-8X\
MS?O\O'S]!C.>G/UK>K!\(^%_^$5BU1/M7VK[=J$U]GR]FSS,?)U.<8Z\?2@#
M>HHHH **** "BBB@ HHHH **** "BBB@#!U7Q3_9GBS0M%^R^9_:BSMY_F8\
MORU#?=QSG/J,5O5YE\;XK[0])@\9:=>+;WFA(WEPR0B19?->-#DD\#!/8]>W
M6N<\!?M1:-KGEVOB*'^Q;P\?:$R]LQ_]"3\<CWK:-&<X\\5<SE4C&7*V>X45
M#:7D&H6T=Q:S1W-O(-R2PN&1AZ@C@BIJQ- HHHH **** "BBB@ HHHH *S/$
MVM?\([X?U'5/)^T?9(&F\K=MW[1G&<''Y5IUF>)M%_X2+P_J.E^=]G^UP-#Y
MNW=LW#&<9&?SH L:1J']JZ397OE^5]I@2;R\YV[E!QGOUJW532+#^RM)LK+S
M/-^S0)#YF,;MJ@9QVZ5;H **** "BBB@ HHHH **** "BBB@ HHHH P7\4[?
M'$?AW[+G?IYOOM/F=,2;-FW'XYS^%;U8+^%]WCB/Q%]JQLT\V/V;R^N9-^_=
MG\,8_&MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KF?%G_ "'O!?\ V%Y/_2"[KIJYGQ9_R'O!?_87D_\
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MCX%_!SP/\9X?B?XGUW6[V:TGUC1-6N_-TN2.X0R>7'!M C X7CGDE=F!7!?
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MZ8#='SD ?.%ZG'KQ51M=7$]M#Q/_ (;"_P"I2_\ *E_]IH_X;"_ZE+_RI?\
MVFO./^&=OB%_T+__ ).V_P#\<H_X9V^(7_0O_P#D[;__ !RO9]EA>Z^__@GF
M>TQ'G]QZ/_PV%_U*7_E2_P#M-'_#87_4I?\ E2_^TUYQ_P ,[?$+_H7_ /R=
MM_\ XY1_PSM\0O\ H7__ "=M_P#XY1[+"]U]_P#P0]IB//[CT?\ X;"_ZE+_
M ,J7_P!IH_X;"_ZE+_RI?_::\X_X9V^(7_0O_P#D[;__ !RC_AG;XA?]"_\
M^3MO_P#'*/987NOO_P""'M,1Y_<>C_\ #87_ %*7_E2_^TT?\-A?]2E_Y4O_
M +37G'_#.WQ"_P"A?_\ )VW_ /CE'_#.WQ"_Z%__ ,G;?_XY1[+"]U]__!#V
MF(\_N/1_^&PO^I2_\J7_ -IH_P"&PO\ J4O_ "I?_::\X_X9V^(7_0O_ /D[
M;_\ QRC_ (9V^(7_ $+_ /Y.V_\ \<H]EA>Z^_\ X(>TQ'G]QZ/_ ,-A?]2E
M_P"5+_[31_PV%_U*7_E2_P#M-><?\,[?$+_H7_\ R=M__CE'_#.WQ"_Z%_\
M\G;?_P".4>RPO=??_P $/:8CS^X]'_X;"_ZE+_RI?_::H:1^UM?6:W0OM"_M
M%I+AY(6^V+%Y49QMCXB^;;S\QY.:X?\ X9V^(7_0O_\ D[;_ /QRC_AG;XA?
M]"__ .3MO_\ '*/987NOO_X(>TQ'G]QZ/_PV%_U*7_E2_P#M-'_#87_4I?\
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M $'AR[EO_#VEW,[;YYK6*21L 98H"3@>YK1J&SM8K"T@MH$V00HL<:Y)PH&
M,GV%34 %%%% !1110 4444 %%%% !1110 4444 <E)KM\OQ5AT<3_P#$N;1V
MNC#L7_6>=MW;L9Z<8SBNMJ@VA6+:XNL&#_B8K;_91-O;_5;MVW;G'7G.,U?H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *YGQ9_R'O!?_87D_P#2"[KIJYGQ9_R'O!?_ &%Y/_2"[K>C\3]'
M^3,:WPKU7YHZ:BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *XKQE#<Z7XL\/>(TL[G4+*RBN+2ZCLXC-+$LWED2K&OS. 8P"%!;#
M9 .#7:T4 >9>-M4_X2NUTB8:+J]YX9M]14ZI;3:=*K7,1C<+_HS*)9$24Q%A
MLP1T# '&#;^#?[2CCMX=&NK;PG<>)(Y[339()(!%;_9F64F$@&*)Y=QV,%!#
M'*X;GVNB@#Q"\\+/IRWUA+H5Q)X.MO%(FETNWLGDC:T-JA!2%5.^(7#!BJ*1
MD'C@TW0]'DT>"^U&UT#4K#2(/%<5_%:"RD,HM3:1QAXX0"^T,WW%&5 (VKM*
MCW&B@#P^?3[S47U>_O-$U*3P[<>*$N[RPDLI&ENK3['$B.8 "SH)0C%-I.%(
M905(%S6O"_AV75/!>IQ>#9O[#M[FZB>&31GE>)61C&?(V,\<?F9(!50I.<+F
MO9** /!=5L]3O?'=K>P^'_L>HPZ_'OF31+F2Y%J)-AD.HL^PQLA_U2J=JMMP
M I(TKKP.889-:@T:;^WU\6+)'>"%VG2U:\ ?8>JQ&-G) PI!8GJ37M%% 'E7
MA;2[2W\27G]JZ#?3>+SJ=S)'K'V*39Y#%C$1=8V>4(BB>5O/((V9KG?AKX9O
MK+7M#DU _P!GZ_;O)_:$L?AB[2:\)5]ZS:AYC12J3APW0E4P >*]WHH ****
M "BBB@ HHHH **** "H+FQMKTPFXMXIS#()8C(@;8XSAEST(R>1ZU/10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_'3_DEFM_]L/\ T?'7
M>50UW7;'PUI4^I:E/]FLH=OF2[&;&6"CA03U([4 7Z*** "BBB@ HHHH ***
M* "BBB@ HHHH *X/X1_\>OBC_L8+S^:UWE4-(UVQUY;IK&?SUM;A[6;Y&7;*
MF-R\@9QD<CB@"_1110 4444 %%%% !1110 4444 %%%% '@G[45M->?V)!;Q
M//-)#<*D<:EF8[HN !U-</X"_9@US7_+NM?E_L.R//DX#7+#_=Z)^//M7U)=
M:[8V.K6.F33[+V^$AMXMC'>$&6Y P,#U(J_733Q$J<.6)A.C&<N:1R_@OX:>
M'? -N$TC3TBF(P]U)\\S_5SV]A@>U=1116$I.3NS9)15D%%%%2,**** "BBB
M@ HHHH *YGXF?\D^\0_]>4O_ *":Z:JNIZE;:/I]Q?7DGDVMNADEDVEMJ@9)
MP 2?PH I>$?^13T7_KR@_P#1:UKU#9W<5_:07,#;X)D62-L$94C(.#[&IJ "
MBBB@ HHHH **** "BBB@ HHHH **** .#F_Y+E;_ /8OM_Z45WE4&UVQ77%T
M<S_\3%K?[4(=C?ZK=MW;L8Z\8SFK] !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7,^+/^0]X+_["\G_I!=UT
MU<SXL_Y#W@O_ +"\G_I!=UO1^)^C_)F-;X5ZK\T=-1116!L%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %><_%B^CMM8\(075QJT6G7%W.
MMQ'H[W0FD @=E&+;]X0& /'IS7HU9>I^'K;5M6TC4)GE6;3)))850@*Q>-HS
MNR.1ACT(YH \XT?XC#PGX%@U"YNUOK34-5DMM'GU;4%C46Y)*&XG;<5VA'^^
M&DX56&[(&A8_&:/5--B%A::??ZO)JBZ2L=KJ8DL3(T9E#BY$>2NP'_EGNW#;
MCO6[-\-=.:&Y2"[O+.1]2.JV\UNR!K.X888Q H1ALN2KA@=[>O'._$3P'J>J
MZ/I5I+)?^+;>&^-Q<&:&P:Y1?*95\M)$CMV 8\^8K$!CCG! !J:'\1KZ^L[.
M6_T>WM)+C69-("6U\9U4IY@:3<8ES\T9 &.AY(.165XN\3?V_>6MK]F\C^RO
M%UE9;M^[S?W:2;L8&W_68QSTSGFKOACP7J.H>$DT[5FNM'%G?"?2'A6UCN[2
M-  N]84-OG/F#:JE=C 'G-:=G\+].M4;??:A=32:K%K,D]Q*C/)<(BKSA  I
MV E0 !G"[1@  SM5^+46C^,+?1KB/2U6:]CLO)&KHVH*S\+(;54/R$E3DON"
MG)7M6?HOQ&U^QL_$MWK=A:W,=MK#:=8QVMV3(TSO&D4/,* )EQ^\))Y/'%;/
M_"IK'[8'75]52Q74O[6335>(0+<>9YA;/E^8P+9^5G(^;@ A2)[KX7Z?>#6X
MWU#45M-4N!>FV22-5MKD%")X6";U<-&K8+%<_P ..* ,S5OBI?\ AR'5H=5\
M/H-6L1:2I:V-]YT5Q#/,(599'C0A@V[*LH' ^;!)%OXA:UJNF_"_5;F[B@TW
M4YD%JHL[AITB:618E8.40Y&\'[O!]>M6)?A?8WUO>C4=3U'5+V\>W:34+AHA
M,$@E$L<:A(U14W DX7)W')S@C3\>>'Y/%/@_5=+@8)<SPGR';HLJ_,A/MN"T
M <]<6)U;QI%X52YN=-T'2M*AN/LVGSO:O.SN\:#S(R'5$$1X5ADMSD#%9/CJ
MW@\.:KX/TRXU+Q%/I,T]V9$L[J\EN6 BW(A:W/G.JMW8L1W.*[#4/"O_  D;
M:;JQN+_P[KD4&PSV4D1D16 +PN&5XW&[U4X(RI%/MO!,$=]I-]<:CJ&H7NG2
M32K/=2J3*TJ;&W*%"J ,85 H'7')R <7XR\/V2:?X8NM/O\ Q':QWFJ6EJZR
MZSJ,+M"[$,K(\H92?4@-5?QM)IGAWQAI>GZC?^)(]#AT>YG(L+W499 XE3]Y
M(\+%R I;YI#@=/2O2]>\/6WB); 7+RH+*\BO8_*(&7C.5!R#QSSW]Z27P[:S
M>)(M;9I#=1VCV0CR/+*,ZN21C.<J.^,9XH \]AFU"S\.?#K6]3G%QJ<=]':R
M7&Y)&D@N T8!=#M8G,+$KD$IGGK7J]<%-X!-C_PB6BV(N)-$TW4'U"2661/W
M00.880!@D!Y%QP<+'@GIGO: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Y+XK:%?>)? .J:;IL'VF]F\KRXMZKG$J,>6(
M'0'O76U@^.O%/_"%^%;[6?LOVS[-L_<^9Y>[<ZI][!QC=GIVH WJ*** "BBB
M@ HHHH **** "BBB@ HHHH *Y+X=Z%?:#;Z\M]!Y#76L7-U#\ZMNC<KM;@G&
M<'@\UUM8/A'Q3_PE46J/]E^R_8=0FL<>9OW^7CY^@QG/3GZT ;U%%% !1110
M 4444 %%%% !1110 4444 <EX@T*^OOB%X4U.&#?96*78N)=ZC87C 7@G)R?
M0&NMK!U7Q3_9GBS0M%^R^9_:BSMY_F8\ORU#?=QSG/J,5O4 %%%% !1110 4
M444 %%%% !1110 5A>.=-N=8\':S8V<?G75Q:R1Q1[@NYB, 9) 'XUNUF>)M
M:_X1WP_J.J>3]H^R0--Y6[;OVC.,X./RH =X<M9;#P]I=M.FR>&UBCD7(.&"
M $9'N*T:J:1J']JZ397OE^5]I@2;R\YV[E!QGOUJW0 4444 %%%% !1110 4
M444 %%%% !1110!R4FA7S?%6'6!!_P 2Y=':U,V]?]9YV[;MSGISG&*ZVL%_
M%.WQQ'X=^RYWZ>;[[3YG3$FS9MQ^.<_A6]0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !61XA\6:7X4C@EU6X:SMYG
MV"X:&1H4)( \R0*5C!+#ER!6O7+>+KC5[C4M/TC2-9M=%FO(IG,\MDUS-\AC
M_P!6,B->&.2^>V%/.-:45*:4MOZ\G^1C5DX0;CO_ %YK\SH=/U&TU:SBN[&Y
MAO+249CGMY!(CC.,A@<'FL'Q9_R'O!?_ &%Y/_2"[K'T/X+Z%X?U"74[2YU-
M-7GN1<W%_'=F)ISOWE'CC"Q%#R"-G0GOS6QXL_Y#W@O_ +"\G_I!=UO%4U-^
MS=U9]+='_7Z&+E4E37M(V=UL[]5_77U-V_O/L,(DV;\MMQG'8U0_X2#_ *=_
M_'__ *U3:]_QYI_UT'\C6#7&=AL?\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M6/
M10!L?\)!_P!._P#X_P#_ %J/^$@_Z=__ !__ .M6/10!L?\ "0?]._\ X_\
M_6H_X2#_ *=__'__ *U8]% &Q_PD'_3O_P"/_P#UJ/\ A(/^G?\ \?\ _K5C
MT4 ;'_"0?].__C__ -:C_A(/^G?_ ,?_ /K5CT4 ;'_"0?\ 3O\ ^/\ _P!:
MC_A(/^G?_P ?_P#K5CT4 ;'_  D'_3O_ ./_ /UJ/^$@_P"G?_Q__P"M6/10
M!L?\)!_T[_\ C_\ ]:C_ (2#_IW_ /'_ /ZU8]% &Q_PD'_3O_X__P#6H_X2
M#_IW_P#'_P#ZU8]% &Q_PD'_ $[_ /C_ /\ 6H_X2#_IW_\ '_\ ZU8]% &Q
M_P )!_T[_P#C_P#]:C_A(/\ IW_\?_\ K5CT4 ;'_"0?].__ (__ /6H_P"$
M@_Z=_P#Q_P#^M6/10!L?\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M6/10!L?\)!
M_P!._P#X_P#_ %J/^$@_Z=__ !__ .M6/10!L?\ "0?]._\ X_\ _6H_X2#_
M *=__'__ *U8]% &Q_PD'_3O_P"/_P#UJ/\ A(/^G?\ \?\ _K5CT4 ;'_"0
M?].__C__ -:C_A(/^G?_ ,?_ /K5CT4 ;'_"0?\ 3O\ ^/\ _P!:C_A(/^G?
M_P ?_P#K5CT4 ;'_  D'_3O_ ./_ /UJ/^$@_P"G?_Q__P"M6/10!L?\)!_T
M[_\ C_\ ]:C_ (2#_IW_ /'_ /ZU8]% &Q_PD'_3O_X__P#6H_X2#_IW_P#'
M_P#ZU8]% &Q_PD'_ $[_ /C_ /\ 6H_X2#_IW_\ '_\ ZU8]% &Q_P )!_T[
M_P#C_P#]:C_A(/\ IW_\?_\ K5CT4 ;'_"0?].__ (__ /6H_P"$@_Z=_P#Q
M_P#^M6/10!L?\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M6/10!L?\)!_P!._P#X
M_P#_ %J/^$@_Z=__ !__ .M6/10!L?\ "0?]._\ X_\ _6H_X2#_ *=__'__
M *U8]% &Q_PD'_3O_P"/_P#UJ/\ A(/^G?\ \?\ _K5CT4 ;'_"0?].__C__
M -:L/QM;KXS\,7NC/NM5N=F9E.XKM=7Z<?W<?C4E<S\2-4NM%\%ZC>V4Q@N8
M_+V2* 2,R*#U]B: .^_X2#_IW_\ '_\ ZU'_  D'_3O_ ./_ /UJQZ* -C_A
M(/\ IW_\?_\ K4?\)!_T[_\ C_\ ]:L>B@#8_P"$@_Z=_P#Q_P#^M1_PD'_3
MO_X__P#6K'HH V/^$@_Z=_\ Q_\ ^M1_PD'_ $[_ /C_ /\ 6K'HH V/^$@_
MZ=__ !__ .M1_P )!_T[_P#C_P#]:L>B@#8_X2#_ *=__'__ *U'_"0?].__
M (__ /6K'HH V/\ A(/^G?\ \?\ _K5A^%+=?"\6IHNZX^W7\U\2QV[#)CY?
M?&.M25S/@75+K5(=9:ZF,Q@U2>"/( VHI&%X],T =]_PD'_3O_X__P#6H_X2
M#_IW_P#'_P#ZU8]% &Q_PD'_ $[_ /C_ /\ 6H_X2#_IW_\ '_\ ZU8]% &Q
M_P )!_T[_P#C_P#]:C_A(/\ IW_\?_\ K5CT4 ;'_"0?].__ (__ /6H_P"$
M@_Z=_P#Q_P#^M6/10!L?\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M6/10!L?\)!
M_P!._P#X_P#_ %J/^$@_Z=__ !__ .M6/10!'JENNI>*=$UH[HVTQ9U$(.1)
MYBA>3VQBMS_A(/\ IW_\?_\ K5P.M:I=6OC;PW913%+6Z2Y,T>!A]J K^1KI
MJ -C_A(/^G?_ ,?_ /K4?\)!_P!._P#X_P#_ %JQZ* -C_A(/^G?_P ?_P#K
M4?\ "0?]._\ X_\ _6K'HH V/^$@_P"G?_Q__P"M1_PD'_3O_P"/_P#UJQZ*
M -C_ (2#_IW_ /'_ /ZU'_"0?].__C__ -:L>B@#8_X2#_IW_P#'_P#ZU'_"
M0?\ 3O\ ^/\ _P!:L>B@#8_X2#_IW_\ '_\ ZU9OB2X7Q%H.H:8R&!;N%H3(
M&R5R,9QCFH:Q_&%[-IWA?5;JVD,4\-N[HX .U@.#S0!TNDZD-+TNSLA%Y@MH
M4A#EL;MJ@9QCVJW_ ,)!_P!._P#X_P#_ %JYG0;B2ZT/3IY6WRR6\;NWJQ4$
MFKU &Q_PD'_3O_X__P#6H_X2#_IW_P#'_P#ZU8]% &Q_PD'_ $[_ /C_ /\
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M_P )!_T[_P#C_P#]:L>B@#8_X2#_ *=__'__ *U'_"0?].__ (__ /6K'HH
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M[_\ C_\ ]:L>B@#8_P"$@_Z=_P#Q_P#^M5^PO/MT)DV;,-MQG/85S%;V@_\
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M-=?; 9=QE$0=(MG*;F7.6!'. < FUHOCB;6O%%YI0M["U%M))&\,VH%;_:O
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MC^SM"K1,!;;F,;-TCC)VN.2>G-6%\%ZOXRGUB^UFZOO#_P!NMTL18VYM90T
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M *Z#^1K!K>U[_CS3_KH/Y&L&N [PHHHH **** "BBB@ HHHH **** "BBB@
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M_A7.=!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;_P!^3\Q_A1_8-O\
MWY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_8-O_ 'Y/S'^%']@V
M_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%;W]@V_\ ?D_,?X4?
MV#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;_P!^3\Q_
MA1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_8-O_ 'Y/
MS'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%;W]@V_\
M?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;
M_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_
M8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%
M;W]@V_\ ?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!
M@T5O?V#;_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^
M% &#16]_8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_
M,?X4 8-%;W]@V_\ ?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]
M^3\Q_A0!@T5O?V#;_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#
M;_WY/S'^% &#16]_8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-<A\6D:3X?ZJJ*68
M^5@*,G_6I7IO]@V_]^3\Q_A6=X@.E>%]'N-3U">:*S@V[W4;B-S!1P!GJ10!
M2HK>_L&W_OR?F/\ "C^P;?\ OR?F/\* ,&BM[^P;?^_)^8_PH_L&W_OR?F/\
M* ,&BM[^P;?^_)^8_P */[!M_P"_)^8_PH P:*WO[!M_[\GYC_"C^P;?^_)^
M8_PH P:*WO[!M_[\GYC_  H_L&W_ +\GYC_"@#!HK>_L&W_OR?F/\*/[!M_[
M\GYC_"@#!KD/APC);Z_N4KG6+DC(QD97FO3?[!M_[\GYC_"L[13I7B!+MK*>
M:06MR]I+N&W$B8W#D<]>M %*BM[^P;?^_)^8_P */[!M_P"_)^8_PH P:*WO
M[!M_[\GYC_"C^P;?^_)^8_PH P:*WO[!M_[\GYC_  H_L&W_ +\GYC_"@#!H
MK>_L&W_OR?F/\*/[!M_[\GYC_"@#!HK>_L&W_OR?F/\ "C^P;?\ OR?F/\*
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M9C6^%>J_-'34445@;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,_45H53T>_.J:/8WI3RS<P1S% <[=R@XS^-7* "BBB@ HHHH **** "BBB@
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M%I5_B  !Z]* /8**\LD^(WB.;1K*9;2"T,5W=V.I:A!IMQJ44<L#E 5@B=9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "LG6M'DU/4M!N4D5%TZ]:Z=6SE@;::+
M]\R@_0&M:BJC)Q=T3**DK,****DH**** "BBB@ HHHH **** "BBB@ HHHH
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MDW#/F&;=C'7IWKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXB^T,'2P-C]GV<8,F_=G/X8Q6Y0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 4M4TB#5XT2>2ZC"'(^R
MW<MN?Q,;*3^-9W_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM-D\$6#J0+O6$/\ >76;O(_.6N@HH P?^$*T
M_P#Y^-6_\'-Y_P#':/\ A"M/_P"?C5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P
M<WG_ ,=H_P"$*T__ )^-6_\ !S>?_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_
M (0K3_\ GXU;_P '-Y_\=K>HH P?^$*T_P#Y^-6_\'-Y_P#':/\ A"M/_P"?
MC5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P<WG_ ,=H_P"$*T__ )^-6_\ !S>?
M_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_ (0K3_\ GXU;_P '-Y_\=K>HH P?
M^$*T_P#Y^-6_\'-Y_P#'::G@BP7.;O6'R<_-K-WQ[<2UT%% &#_PA6G_ //Q
MJW_@YO/_ ([1_P (5I__ #\:M_X.;S_X[6]10!@_\(5I_P#S\:M_X.;S_P".
MT?\ "%:?_P _&K?^#F\_^.UO44 8/_"%:?\ \_&K?^#F\_\ CM'_  A6G_\
M/QJW_@YO/_CM;U% &#_PA6G_ //QJW_@YO/_ ([1_P (5I__ #\:M_X.;S_X
M[6]10!@_\(5I_P#S\:M_X.;S_P".T?\ "%:?_P _&K?^#F\_^.UO44 8/_"%
M:?\ \_&K?^#F\_\ CM'_  A6G_\ /QJW_@YO/_CM;U% '/MX(L"ZG[7K  ZJ
M-9N\'_R+3O\ A"M/_P"?C5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P<WG_ ,=H
M_P"$*T__ )^-6_\ !S>?_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_ (0K3_\
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MI_\ S\:M_P"#F\_^.T?\(5I__/QJW_@YO/\ X[6]10!@_P#"%:?_ ,_&K?\
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MQ&4 LQ; DP">..*SK?X3:1;V4%JMS>F.&ULK1273.RUF,T9/R=2QPWJ.F.M
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MPB$A;YL\.!QTQD4 ;_B+5O[!T6ZO]L!\E=V;JX6WB7D#<\C<(HSDG!. < G
M/$Z?\7GU?1XYM/T^QU&_;5O[(VV6J"6T,AB\Q76<1_,F"N?DR/FX)&#V?B;P
M[!XHTHV,\T]MB6*>.>V91)')&ZNC#<"IPR@X8$'N*Q].^&]E8R":34-0OKDZ
MDNJO<7+QEI)A"(N0J !=H^ZH&#TP.* ,#4_C5:Z3XD?2KA-+C-M<6]G=1OJR
MK=^;*$R8+<QYEC7S%RQ*$X;"G'.UXX\92>$M0C<1RW$<>DW]^UNLB(DA@$1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB$I*Q")MRA&'5@2<\ #=0!W=%<?XRFU*X\2>'-+L=8NM&BO#<M-+9QP/(VQ
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M%J&@SQW-G:0ZA%;:=+]KDGAE+JHQM7$@,;949'3#-0!VE%(#D ]*6@ HHHH
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M*C(Y92/TJ9<L4Y-#CS2=DS"_X3CQ'_T']4_\#9/_ (JC_A./$?\ T']4_P#
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MF1QGGFNYHH \XTGX2S:%H=Y:V&HV%E=S:K%JL1MM+$5I"Z)&IC$"R#Y#L/\
M&#\W4D9-^^^'=W)JUSJ]GJ\5MJSWZ7T,DEF9(DQ;+;O&R>8"RLH)X92#CKCG
MN** .-T/X>MI.J:?J,NH_:KN%;UKEO(V">6Y>-V8#<=BKY>T+\QQC))&3)X0
M\.ZMX8DTS2OM@FT/3=+2VW&-5-S<;OO@9+*%5>F<'?[5UU% !1110 4444 %
M4]7TN+6M/ELYI+B*.3&6M;F2WD&#D8>-E8?@1GI5RL/QMK\OA?PKJ6IV\2SW
M,$6887_Y:2$A44 <L2Q "CEB0!R: ,WPSX$G\(^%=+TC3M9N$DM7@,]S<%[@
M3(F Z*DKMY2L!C"G"YX%6?%'AK4]4UC2=4TK4K73[JP2:/%Y9-<HZR!,\++&
M01L]3UJ#0/&UG)H4%UJ&L6MY,]XMBSVME+;;)W8!8GA=G>-^1D.1U!.!4_BC
MQ+J>EZQI.EZ5IMKJ%U?I-)F\O6MD18PF>5BD))W^@Z4 4=9^'\WB#^T);W4H
MQ=WFEQV!EM[8HL<J.TBSH"[$89@0I)QM^\:I3?"EO[*@M(-8>WD72+C3);D0
M R2/.Z/+/][AB5<X[%\]L&Y=?$&?3/&ND>'K_3(XOMMLDDMY#<F2.&=M^V(
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M ,53/^%\>#?^@A-_X#2?X4?\+X\&_P#00F_\!I/\*/8XS^67XASX?NOP'_\
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MN45(W>W,:HC+@_.K%B  >.G>T4 <KH'A>XDTK1#K8>VU+38EB":7JMR+=]H
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MRG%7:??;IW]"E0DW96^\\BHKTJQ\ ^&['P-8^(->O=2@>2YDMI+>S5&+,&8
M+D?+@*222>G%7&^#5I_PGSZ8-0F&AI9#47N& \T1=-O3&<CKCIVI/&4DW?I?
MIVW#ZO/2W]7/,H]+O);"2^2TG>RC8(]RL;&-6., MC /(X]Z+_2[S2I$CO;2
M>SD=!(J7$;(64]& (Y'O7K=U#H47P5UX^'[B\FLVOXBRWR*)48,@QE>"",$?
M6NE&AZ==?%C3K/6Y;K7)FTI7MQ>Q0/'_ ,M-P<!!G Y!QG/4USO'<MVXZ*_K
MHE_F;?5KV2>]OQN?/]II=YJ$4\EK:3W,=NN^9X8V<1K_ 'F(' XZFJU>O^&[
M/39++QX?#U]JME8PV!,L-P(,ROB7*G"G"8Z8(/)YK-A^'_AC0=/T+_A)K_4D
MU#6%62..P5/+@1L8+E@2>HZ>_'>MEC(\S4EZ+KM<S]@[)K^M;'F5%>L67P=T
MZWUCQ59ZMJ-Q#!I,,=Q%=0*#F-@S99<$D@#& 1SFL_5/AUHE[I7A[5-!U"[C
ML=3O18R?VD$WQ,21N^7 QP>,^G-4L91;LG\[::J_Y$_5YI7_ *['F]%>@?$S
MP/HW@U1!9G5TO$E"%K^)?(N%VDEXG4=C@$'GFO/ZZ*56-:"G'8RG!TY<K-WP
M'_R//AW_ +"-O_Z-6OLNOC3P'_R//AW_ +"-O_Z-6OLNOF,Z_B0]#V,O^&04
M445\X>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[27_ "(U
MC_V$8_\ T5+7J]<!\:/"6I^,O"UK9:5"L]Q'>K,RLX0;0D@)R3ZL*[<%*,,1
M"4G97.?$)RI22/E:BO0?^%#^,O\ H'P_^!,?^-'_  H?QE_T#X?_  )C_P :
M^X^N8?\ Y^+[T?/>PJ_RO[C6N/C!8+X^T76[:WN_L5M8"RNHI$4.XRV=HW$$
M9*GDCI19_%ZP7XB:KKMQ!=_V?-8FRM8(T0O&ORXR-P &0QX)ZUD_\*'\9?\
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M$[Z/_A']2U/SM)T_9=2C=:V^T>4S;<L=QR2?6N5NO#?Q'^#/_!/WX?\ QO\
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MJ[]G\?M/?!'6?AZ==/AO^T9;>7^T1:?:O+\J99,>7O3.=N/O#&:[KX:^#_\
MA7GP[\+^%OM?]H?V)IEMIOVORO+\[R8ECW[,G;G;G&3C/4T ?(T?C;Q/I_\
MP5)TCP.GB;5SX1A\$"3^Q/ML@LFE5&_>F -L+\?>QGWKR3]E[PK\4OVJIOC;
MIFJ?'3QSX9T;P[XGO8=+71=3=+H7#LP027#[G^S1K&N((V0$NQR*^OI_V61-
M^V);_'<>)BIBT(Z*= -AG=PP\WS_ #./O?=\OMUKX;_8U^ WCKXH:Q^T%>>!
M_BYK7PKOF\77>F7HM].BO[6ZA+RL?W3E#',I;B5'#*"1WS0!!HG[?7Q1T/\
MX)^:EJLFKMJ'Q"M?%O\ PA]KX@DC2>8PF#SO.Z;7E"AD#'.<JQW')K;^%OCK
MXP>#/CE\,Y?"&G_M(^(- U+4(K'Q?;_%K1I9-/6&5T0W%NR[_LX3<[\XQL7+
M%=P/U%;?\$ZOAK'^RS_PI.:?4)[)KO\ M5]?!1;TZCT^T\#;PO[L*0?W?RY)
M^:M3X5_LS_%CPCKWA]_%_P"T;KWC+PUH;H]KHEMH=MIK3[%*HEU<HSR7"8(R
MK'YB,DT >!? FZFL?V[_ -L"YMY&AN(=)62.1#AD81J00?4$5Y+9_&WXB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\
MP*_^M1_PB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_
M ,"O_K5O44 >?>"?#NJW4.LG5M3UJ%H]5NH[;S+@C=;A_P!VPR.A'<<5T?\
MPB?_ %&=6_\  K_ZU5? 7B2[\20ZZ]V(P;+6+NQB\M2/W<;[5SSUQU-=16U9
M-5&FK&=/6*L8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]16)H8/_")
M_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^M1_P
MB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O
M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\
MP*_^M7./X=U7_A8D5N-3UK^PSI3R--]H.S[1YR@+G&,[-QQUKT&N7D\27:_$
MZ'0 (_L+Z/)?$[3O\P3H@YSTPQXQ6U)-WLKZ,SGTOW+7_")_]1G5O_ K_P"M
M1_PB?_49U;_P*_\ K5O45B:&#_PB?_49U;_P*_\ K4?\(G_U&=6_\"O_ *U;
MU% &#_PB?_49U;_P*_\ K4?\(G_U&=6_\"O_ *U;U% &#_PB?_49U;_P*_\
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M_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^M1_PB?\ U&=6_P#
MK_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O44 8/_")_P#4
M9U;_ ,"O_K5SGP[\.ZK>>"]*FUS4]:M]5>,FXCDN"K*VX]01GIBO0:Y?X8^)
M+OQ=X#T?6+X1B[NHB\@A4JN0S#@9/I6R3]E)VTNOU,W;G2\G^A:_X1/_ *C.
MK?\ @5_]:C_A$_\ J,ZM_P"!7_UJWJ*Q-#!_X1/_ *C.K?\ @5_]:C_A$_\
MJ,ZM_P"!7_UJWJ* ,'_A$_\ J,ZM_P"!7_UJ/^$3_P"HSJW_ (%?_6K>HH P
M?^$3_P"HSJW_ (%?_6H_X1/_ *C.K?\ @5_]:MZB@#!_X1/_ *C.K?\ @5_]
M:C_A$_\ J,ZM_P"!7_UJWJ* ,'_A$_\ J,ZM_P"!7_UJYSPOX=U6XUKQ4FH:
MGK45I#J*)8,]P0)(?LT)++D<CS#(..,@UZ#7+^$?$EWKFO>,+.X$8ATG4TM+
M?8I!*&U@E.[GD[I6_#%;4TW&;2Z?JC.6\?ZZ%K_A$_\ J,ZM_P"!7_UJ/^$3
M_P"HSJW_ (%?_6K>HK$T,'_A$_\ J,ZM_P"!7_UJ/^$3_P"HSJW_ (%?_6K>
MHH P?^$3_P"HSJW_ (%?_6H_X1/_ *C.K?\ @5_]:MZB@#!_X1/_ *C.K?\
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M;P6GBA_+\/:QXKT3[%I^L$XV?9IA(VX-N3:2 #O4=2!6)^T-^WMX*\*M\3/
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MI]C;Q+N2#4)GG?R[SJ"BC&2!Q0!]C4444 %%%% !1110 4444 %%%?#'Q/\
MB!\:OB!^W'XE^$W@CXNQ_#'P[I/A2+71*_ARRU-6?=&KAC, RY\W.[?@!/N\
MYH ^YZ*^#/@'_P %%)-*_9[UOQG\9%_M,:%XO_X1-]>\+6JO!>Y0,MSL+*"H
M&XL8^JE"J9.*]>OOV^/ 6C_#.V\::OX<\;:+%J6J?V5H6B:AH;1ZIK\A1'26
MR@W_ +R)Q(H5V*@G@X) (!]*T5\S^%_V\/"/C71/'2:=X2\;:=XW\)V']H77
M@;5]#,.MR1':%>.V$AWKET)PP(# G&1GD_V1?V]I/C%\'=2\6_$GPQJ7@^+1
M;&XU'4?%$>D2P>'98HYB@CM9FED>64# * $E@P&3@4 ?8E%?,_PS_;\\ _$C
MQIX>\.OX:\;^$5\2DCP]K'BC0C9Z?K)QN46TV]MVY>5W!0<@=2 ?//AW^T/I
M'PI\6?M4^+]?\8^.O&FC>$]9MQ<:'?6D/EZ4&DE3RM/S=LKH21G*P\(N0QR:
M /MNBOF'P#_P4,^&?Q"^('A/PO::3XOTN'Q8K#0?$&L:(UIIFI2J!NBAE9MS
ML&.PD)MW<;N1GZ>H **** "BBB@ HHHH **** "BOEK]O#XU>,_@S8_".3P=
MK/\ 8[Z]XVL=(U$_989_/M9 ^^/]ZC;<X'S+AAV-:GQ-_;P\"_"_XLZW\-;C
MPYXS\0^,=-M(;R/3?#FC?;WOD=!(1 $DSE$.YC($  .": /I&BOGJ+]NSX52
M?LWM\:VOM0B\++,;0V3VP_M#[8&V_9?*#;3+W^_MQ\V[;S7A/A;]J:^^,W[?
MWPUTO2!XX\&:-_PC-^=4\'^)K>;3F\X+,\4TMMO,;Y38RN"W&.01B@#[[HKX
MD_9<_:3\*_#/]F;QU\0/&?Q(\6^+M$L/%=W:_P!H>*[,"^60B():01QW$^Y,
MG*X91\S'8BBO5O!G[;7@[Q-X/\5^(=7\+^./ D7ARVM[RXL?%7A^2VN[B"=B
MD,EO'&9/-5W!08/7T'- 'T+17S;\/?V[?!WC[QQ=>#)_!WC[P?XL&FS:I8Z-
MXHT V=SJD,:LQ^RIYC%V(1MH;;G! Z5X]\$_V]?$7QX\._%G2/$'@GQ=X4_L
MW^V([+Q-H6@O'#I%O!;,Z)=R2W!"7ZX/[OY5W;1QG- 'WG17QM\%_P!JWPA\
M%_V.?AMXF\5>+/%WQ O-=EGL]*:_L/-U_6KC[3*!$L GERPX0%IB,; 6!8+7
MH?PV_;A\"?$>+QK;'1_%'A3Q-X1TV35]3\*^*-,%CJHM43>9$B+E6!&WJPQO
M3. P- 'T-17R#X?_ ."H7PF\0+X6NTT3QO9^']>O(]-'B2\T+R],LKQ\XMIY
M_,(\P#DB+S  <YP#CZ^H **** "BBB@ HHHH P/"/BK_ (2J+5G^R_9?L&I7
M&GX\S?O\IMN_H,9].<>IK?K \(ZCI.HQ:L=)M?LJPZE<07(\L)ON%;$C\'G)
M[]ZWZUJI*;25B(7<5=W"BOSR^!NN?M/_ +1FG_$OQ'X;^.UEHA\.>*M1T33_
M  YJ/A*QFM[@0[6C62Z51(BD2!<A6(VYR<UM7'[8_C7XD?LDCQ1;>)=%^$'Q
M%T;Q=%X8U^;4=/FO;1;A'Q)%'&D,[#S RXRORD,N\?>K(L^\Z*\9^(G[8?P<
M^$?CRS\$>+O'VGZ5XIN#&OV%HII/*+A2GG/&C)!N#*1YC+P0>G-2_&#]K[X/
M? 7Q!8Z%X[\<V.A:Q>*LD5GY,UQ(J,<*\@A1_*4\X9]H.#SQ0![#17BWQ8_;
M,^"_P0_L@>,O'MAILFK6RWEE%;PSWLDL##*2[+>-V5&'W68 -@X)P:O1_M8_
M"6?2?!FJ0>-;*YTSQA?_ -E:+>6\4TL-Q=Y \AW5"(7RP^64I0!ZW17GMY^T
M!\/M.\=>)/!]YXFMK+7O#FEC6=7BNHY(H;*S.W$LD[*(@,,IQOS@]*Y?X0_M
MG?!?X\>*9_#?@?QW9ZUKD*-)]A:VN+5Y%7.XQ>=&@EP 2=F[ YZ<T >U45\Y
MO_P4._9[5G1?B)#/-'%<SRP6^EWTLL*0$B9I$6 LFW:3\P&5&X9'->CZE^T-
M\/-)M? -Q<>)(C#X\FB@\-M#;S2_V@\BJR;0B$H,,N6?:!D D&@#T6L!O%6W
MQY%X;^RYWZ:^H?:O,Z;95CV;<?[6<Y[=*WZP&U'21X\BL#:YUTZ:\ZW/ECBW
M$JJ4W9S]\J<>U:TTG>ZOHR)7TLS?HK&\9ZA<:3X/UV^M9/*NK:PGFBDP#M=8
MV*G!X."!UK\PM+_::_:,\%?LG^%_VB]5^,ND^);*^U VC^!=6\,V5J+@"ZD@
M*QW, 21WQ&7PH7"[CSMYR+/U6HKPKQE^VW\&_AKK$NA^,?&,7ASQ%;PV<MQI
M%Q9W+SQ_:4#1JH2(^9P?FV9V\;MN:D^)G[;GP/\ @_XV3PCXM^(5AI7B$[!)
M9K!/<>07QM$SQ1LD)P0<2%< @G@YH ]QHKRCXN?M5?"?X%:/H^J>-O&VGZ19
MZQ&)M/,2R7;W49 (DCC@5V:/!'S@;>1SS7BNK?&9_&W[<7P,/A'Q?=ZAX!\0
M>$]4OOLUC>2"QO642!)'BR%9E*X^894C'&* /L&BOE/X"_M-6WAGX+Z[XQ^+
MWQ5T7Q#8)XPN-$MM<T_2KBUM[4%D6*VE!MHCE3NS(4V $9D;!:O2_A+^U[\'
M_CIXNU'PQX%\<66OZ[81M++:1P3Q;D5MK/&TB*LJ@XYC+#!!Z$&@#V&BOE[]
MGC]H9=)^!OC#QS\6/BMX?\0:9I?B2]LUURSL9;&&VB0HJ6I1X(6DE4DCY4;=
MN #.1FNLTO\ ;D^!FM?#74_']I\0K%_"NFW,=G=W<EM<1R13/G8GD-&)26"L
M1A#D*Q' - 'NM%?'7QV_; \"_&#]D?XNZW\'OB!)<ZQH>EK(USIOVG3[VS+2
M*%=0ZQR*#AAN48ZC-?27P5U"ZU7X-^ [V]N9KR\N= L)I[BX<O)+(UO&6=F/
M+,2223R2: -'5?%W]F>-_#_A[[)YG]K6UY<?:?,QY7D>3QMQ\V[SNN1C;WSQ
MT5<[JNI:/;^-_#]E=6OF:U<VUX]C<>6#Y4:>3YPW9RN[='P.NWVKHJVFDHPL
MK:??J]?T^1$6[RUZ_H@HKX;\*_$#XK?$3P_^TAXCC^+^I^&Y? /B?5['1[-=
M)TE].6UM4$J)/YEH9F&,J6$RG&#G(YP-8_:_NY/B1^R=XZ\4:OJ/A;P]XJ\/
MZE<:OHNE?:Y[>[NWCBC@46L0=YR97'EC:[#>/<UB6?H'17FO@_\ :/\ AOXY
M\,^)M?TSQ3;Q:9X9FDM]<;5(9=.ETR1,[EN(;E(Y(L8/WE&2I R0:J>!/VG_
M (<?$;Q98>&='UB^AU[4-/\ [5L;'6-$O]+>]M?^>T'VJ",3+CGY"W )Z F@
M#U6BO(+?]K7X577BJ+0(?$TDMU+K'_"/1WR:5>G37U+&1:"_\G[,9>VSS<YX
MZ\5!XD_;!^$OA36?$&FWWB>>1_#T\=MK-Y8:-?7MCIDKMM5+F[A@>"%MW!#N
M-I!!P0: /9J*H'4CJ.@_VAHCVFJ&>V\^Q?[3MM[C<NZ,^:BOA&R/G56X.0#T
MKY>_9Z^)'Q=O/VK_ (C> _B5XDTG5;?3M L-5M],T*P6&RL)9FPT<4KKY\P
M'WI&Y))"J,  'UA6!X#\5?\ ";>$=-UO[+]B^V1E_(\SS-F&(QNP,]/2M^L#
MP'J.DZMX1TV[T*U^QZ3+&3;P>6(]B[B"-H.!SFM4E[-NVMUK]_Y_H0[\R5^_
MZ&_117Q'\5O&GQJ\??MO:O\ "?P'\7%^&N@V/A"+7P[>'++5 TGG+&RGSE#
M'S <[R!M^[S619]N45^6'CW]KSXD^._V*?$^KW_B;^SO$GA7X@V_AUO%OA2Y
MDL8=4MU(+2J\; 88')VD*5*' K[M^$?[7?PA^./BO4/"W@CQQ9:_K^GQM)/:
MQQ31[D5MK/$\B*LR@X^:,L,$'."#0![%17S]IW[??P U;X@1^"K7XDZ?)XAD
MN_L"0FUN5@>?=L""X,0A.6X!#X/8UN?$;]L3X-?"7Q_:>"?%OCW3](\3W+1J
M+!HYI?*+X*><\:,D.0RD>8R\$'IS0![+17CWQI_:]^$'[/.J66F>/_&]IH6I
M7D?G1626\]W/Y>2 [1P1NR*2#AF !P<9P:])\(^+]%\?>&=/\0^'-4M=9T74
M(O.M;ZSD#Q2KR,@CT(((Z@@@\B@#8HK\^/VH/B]^T;^ROKW@'Q;JWQ(\/>*-
M.\1Z\FF3> ]/\/1P01(V6Q%<LQN)./EW$KAF7@@XK]!ATZ8H 6L'PYXI_P"$
M@U?Q+8_9?(_L:_6R\SS-WG9MX9MV,#;_ *W;CG[N<\X&]6#X<U'2;W5_$L.G
M6OD7=K?K%J$GEA?.F-O"P;(/S?NVC7)_NX[5K!)QE=7T^[5?\,1*]UJ;U%%%
M9%A17Y]:E\1/CS\2/CQ^T1IWAOXXV?P]\-?#:2WGMK+4?#=A=6TD<D#R%9+A
MU#Q(#$<N2YP_;%<=KW[9'BOQQ\*_V4OB-X@UV7P-!J?C&:V\1R:?>2V5C>6T
M$H1WE7?AHB%)*L2N=V/2@#]-J*\D^$G[67PE^.FEZ]J/@GQK9ZM::#'YVIM+
M#-:-:Q[2WF,LZ(VS"M\X&W@\UA?#/]NGX%?&#QM!X1\)?$&TU/Q#<%E@LWL[
MJV\\J"2L;RQ*CG )PK$G'% 'O%%>-2?MB_!J/XO1_"\^/=/;QP]S]C&FI',R
MBXR1Y)G">4)-P*["^[/&,\54^)O[;?P0^#OCA?"'B[X@V&E>(LH)+-8)[C[.
M6QM$SQ1LD)P0<2,N 03P<T >X45D:AJ%SJWA*YOO"]SI]W>7-DT^EW-PY>SD
M=H]T+LT?)B)*DE>2IXKX3^'OQZ^+.F_M5?#_ ,'V7QL\-_M ^'?$"7$NOVGA
MG1K2*'P]&@X<SVS.0 QP/-?)VX*Y930!^@=%%% '.ZOXN_LKQIX=T#[)YO\
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MTWIVKZYJ6J:?I'B>VM].M+V[DFBLHS%(2D*,2(U) X4 <4 ?4]%%% !1110
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M44 ?E]J'PD^(?AG]E_\ 9'\4P?#_ ,1ZQ>_#O6VOM<\,V>GO_:T<+71;*VS
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M+P#K6IW7AGXOW/BF]\*7-F\-UJ>GJ>L4,B_O0V> %.X$X!Z5[#^T1\3OB?\
M%SX-WOB#X:?![QYX";^W=-36+F?2(;;Q/>6*+-YKVMO\S[HF\M4?=N_>' "A
MC7WM10!^/FF_!SX@:I'^T7J-IX+^,%]8^(/ D-OI%S\1K>2\UN_D6[@!C8QI
M]\"-]L/+!%#="*_5#X*V%UI7P;\!V5[;36=Y;:!80SV]PA22*1;>,,C*>58$
M$$'D$5V=% '.ZK9Z++XW\/W-W/LUV&VO%L(=Y&^-O)\\X[XVQ?3-=%7.ZKX1
M_M/QOX?\0_:_+_LFVO+?[-Y>?-\_R>=V?EV^3TP<[NV.>BK:;3C"SOI]VKT_
M7YD1O>5U_5D?$7[//[+.E>.O$7Q[;XE^&?$8TW4/B/?WMGIM_J.I6.FZE;"2
M.2*9K194@NHRZ@AW1PVT#) Q7;_%KX=W\W[:G[.>HZ5X8N'\+:!I>MPRW5GI
M[&RTW-LB0(SJNR+.-J D=,"OJ:BL2SX>GM?BI\-?BS^V)XO\#>#+[4-7NK70
M[GPZMW8RBVU&2.U9;AH.@N'123L0DE@J]2!7'^'(?&GCC]K[]GC7+M/BIXOB
MT33M1EUK6_%O@A=$LK"XGL'4PQLEG!@F1<$.TBY:,)(Q+&OT1HH ^#]*O/$7
MP^\4Z)_PHGPU\3/#DNN>+F?Q%\._%_AJ0:%;0L9%N[M=0:-D@!*B9/L]W(C%
MD C.2M<K\.?A]KOPF^&_Q)^'7CG4OC+9F74M4DDT[P5X.M=6L/$-M=%R)(+O
M^S;@B22-@K">="A(!V@<?HU10!P7PC\+V'PE^"GAC0[:VUJ#3="T>*)+75%2
M[U*.-(\^7(+8,LDJ@;<0[@2,+GBOFSX;^,PO[=/Q \8R^%O'-MX9\0:!I>E:
M=J5SX'UF&*2Y1\.K[[0&)5R,O(%0#G=@5]H44 %8'@.TT>Q\(Z;!H$WVC1TC
M(MI=Y;<NXYY/7G-;]8'@/PM_PA/A'3=$^U?;?L<93S_+\O?EB<[<G'7UK5->
MS:OK=:??^7ZD._,G;O\ H;]?!GQ,_91T?]H#_@HAK,_Q$\":GKGP_C\$0FVU
M%A=VMD;Y+A $%S"R!G"/)\FX\9.../O.BLBSXK_;T^ -OI?['^F^ OA=X$FF
ML+37]/DCT/P_I\EPWEAV,DC(@9FZY9VR3G+&M'XF?#C7+?\ ;_\ @GXA\/\
MA6Z70M/\+:C97.J6FGNMC;MY4PAAFF1=J#) 52>_ K[#HH _%KQU\/?CC\0/
M#T%EXL\)?&_5/'%CXFCN]1T];<#P=!;BYPKV<$2$32#?]Z/Y54LV2H-?0G[7
M'AKQGI?QX\6ZG\*OAY\2K;Q_K@L;22[L=-M]4\'>)+8)&O\ IXF^2!D7S(^<
M@;-WR^86K](:* /RZ^/7P9\>>'/VJ/%WC3Q/I/QHF\-^*])L8X;OX&W(>6*6
M.WC2:TN(]I/DAU?;N(&"#\Q8[?M/]C;X;6GP>_9S\/Z%9:%XBT"VC:ZNDTKQ
M+<PW.I1+)/(ZB4PHB!F4JVQ1\N[:22"3[E10!^6^@_%CQ5X\_:3G^+'QE^ O
MQHU:/P_(T/@GPOHG@V::QTM,Y^U2M(\?F7!P#G;@$ Y^5 GZ@:?=_;[&VN?)
MFM_.C63R;A=LB9 .UAV89P1ZU8HH *P/#EIH]OJ_B6339O-O)[]9-17<3Y<_
MV>%0N.W[L1''O6_6#X<\+?\ "/ZOXEOOM7G_ -LWZWOE^7M\G%O##MSD[O\
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MP@_9[\3_  (E\,ZK]K\1^(]6T&+0;>6U#*7@5(FV7.\*ZYY)W@'Y22/TPHH
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MDEXT_9\\4>%/B_\ &32?'.@_M ZOHOC#7+F^L)OA/<Q2Z3JEM,S%4OU9"JL
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M;?\ 0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *]
M'3T5S'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,
MU3_P%_\ KT?\)];?] S5/_ 7_P"O0!T]%<Q_PGUM_P! S5/_  %_^O1_PGUM
M_P! S5/_  %_^O0!T]%<Q_PGUM_T#-4_\!?_ *]'_"?6W_0,U3_P%_\ KT =
M/17,?\)];?\ 0,U3_P !?_KT?\)];?\ 0,U3_P !?_KT =/17,?\)];?] S5
M/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5S'_"?6W_ $#-4_\  7_Z]'_"?6W_
M $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P%_\ KT?\)];?] S5/_ 7_P"O0!T]
M%<Q_PGUM_P! S5/_  %_^O1_PGUM_P! S5/_  %_^O0!T]%<Q_PGUM_T#-4_
M\!?_ *]'_"?6W_0,U3_P%_\ KT =/17,?\)];?\ 0,U3_P !?_KT?\)];?\
M0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5
MS'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P
M%_\ KT?\)];?] S5/_ 7_P"O0!T]%<Q_PGUM_P! S5/_  %_^O1_PGUM_P!
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MK;_H&:I_X"__ %ZQ-#IZ*YC_ (3ZV_Z!FJ?^ O\ ]>C_ (3ZV_Z!FJ?^ O\
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M,?\ "?6W_0,U3_P%_P#KT?\ "?6W_0,U3_P%_P#KT =/17,?\)];?] S5/\
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M\!?_ *]'_"?6W_0,U3_P%_\ KT =/17,?\)];?\ 0,U3_P !?_KT?\)];?\
M0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5
MS'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P
M%_\ KT?\)];?] S5/_ 7_P"O0!%KWA>\U+XB>$];A,0L]+@OHYPS$.3,L03:
M,<_<.>?2NLKS+6O&-_-XZ\-7-I9ZNFC0PW@OX1 0KLRQ^22,X."'Z],UTW_"
M?6W_ $#-4_\  7_Z];U&W&%WT_5[F<4KRTZ_HCIZ*YC_ (3ZV_Z!FJ?^ O\
M]>C_ (3ZV_Z!FJ?^ O\ ]>L#0Z>BN8_X3ZV_Z!FJ?^ O_P!>C_A/K;_H&:I_
MX"__ %Z .GHKF/\ A/K;_H&:I_X"_P#UZ/\ A/K;_H&:I_X"_P#UZ .GHKF/
M^$^MO^@9JG_@+_\ 7H_X3ZV_Z!FJ?^ O_P!>@#IZ*YC_ (3ZV_Z!FJ?^ O\
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MFO/^/R?_ *Z-_.H: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQMQSG?ZC&.];M;U/AA[MM/OU>OZ?(SCO+6^OW:+_ (<****P- HHHH ****
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MB5=>$+Y_^)!K4GVG3;I_X9#QL8^O 4^X4\;JY]=#\'ZY\;/'$?C"6TBMD*&
MW=Z;8;\+G!#+DX[<U]92PU"G.?)33IJDG"7)&;E>4;R:EHY7NFF_=6B\_,E4
MG)*\O><M5=I+1Z:=/S/0_A1XZ\2?$#P%J4Y^PKK5K<-:PWCHWV>4@*=Y"_4]
M, \=*PM?\5>-/AWXZ\,Z?>>)+?Q1#JTXBEL5L(X'B4LHR-I+?Q'!)_A/%5?@
MIX@M]$T7QE'?7TC^!K&\\BQO)]Q4([LI (&<'=&3V&[/&37->.+'POX.U[PW
M=_#&^C?7IKGRC:Z?=FZ21#V?);&3@8STR<<9JJ6#I?VE7H>R7([V7(G'6%]9
MO6'+=-J*T>FP2JR]A"?-JM]==^VSOYGI7B+Q9XB\3_$R?P=X:U*'0H["U%S>
M:B]LMPY8X(148XQ\Z^_7TY3X<_$'Q'J,?BS1-2MH=7\1Z Y6(PE;<7OW@N<_
M*I)7K@###CCG#T_4K;P-^T1XAFURYATZTU:Q62WN;AQ'$2 F1N) '*,/PJ7X
M.W5O>>-OB'XM\](=#EN/+CO)6V1L%)+-DX& -IR?[U<5;#4H8.5J2<53IRB[
M:N;:NN9:N^JM?2VEK&L:DG57O.[E)-7V2VTV[:ECX=^-O&6H?%[5O#_B6XMD
MC@L/M L;.-?+B8^45 ?&XD!SG)(R3[5[+7@&@>+M"A_:/\1ZG)K6GIITVFI'
M'>-=1B%VVP?*'S@G@\ ]C7OP.1D<BO%SRBJ=6E)4U#FA!V2LKVU_X/7N=>#E
MS1DG*]FQ:***^;.\**** "BBB@ HHHH *XG7?%WB72?$FGZ5!H.E7*ZB\RVL
MTFKRQG$:;R746S;21V!;GO7;5S'B#1[R^\9>%+Z"'?:V+W1N)-RC9OAVKP3D
MY/IF@9JV>O6<^EVMY+>V*K.RQ;X;E9(3,3M,:/@;CNRHX!)'0'BF6/BO1-3U
M V%GK&GW=\(Q,;6"Z1Y0A (;:#G&".>G(KSS2]"N?^%J7FBK&O\ PCVF2G7X
MRK?=N)U9!$5QT#>?(/=EK/\  NC:EK6A^"((=#_LRTTV>2^DU198O+E#12IA
M I\S>S2 MN4#Y6^9N,H#U2S\4:-J.JSZ9::O8W6I6X)FLX;E'FCP0#N0'(P2
M!R.]0ZMXB_LOQ%H6E_9_-_M1IE\W?CR_+CW],<YZ=1BO.O ?@;6-(N/#MCJR
M:^XT:1VCG1]-^P;MCJ6!4"Y*N&/##.6^;.,UW'B#1[R^\9>%+Z"'?:V+W1N)
M-RC9OAVKP3DY/IFF!3T3XC?VQ_PC/_$O\G^VGND_UV[R?)W<_=&[=M]L9[UT
MNL:[IOAVT^U:KJ%KIEKN">=>3K$FX]!N8@9X-<!X6\':QIO_  @WVBT\O^S9
M=0:[_>H?+$N_R^AYSN'3.,\XK<\6:?J-OXNT'7K33)=;@LX;BVDL[>2))8VD
M"$3)YKHIQL*GY@</QGFD!M:IXNT+1+6UN=1UK3K"WNANMYKJ[CC288!RA8@-
MP0>/6L?7O%]WI?B*]L(8X'@AT.;4T9E)8R*^T D'[N/Q]ZQ&TO5M'\03ZK'X
M3&HVVH:1%9C3[2XMQ]B=7D9HV\QD4QOYBY*9Y0_*>":FE?#W6-&M[:T9%NQ;
M^%'TKSHY %:X+ A &(.,="0!@=NE,#L+7QSI=GX:T74M>U33M(DU"UCF'VJX
M2!&9D5F";VYQGU-7]:\6:'X;\G^U]9T_2O.R8OMMU'#YF,9V[B,XR.GK7F^K
M^'/%D>GZ=8VEE=1Q_P!A16+R:8;$2>>%*M'</<!CY0XQY0)Y<\\5SM]I.MPW
M3Z=';RSF+PM9:;K$,%M#/)"F)2V'EN(D5L;L%?-'&6 XRAV/9[[QIX>TNRM+
MR]UW3+2TO!NMKB>\C2.88!RC%L,,$=/6I-7\6:)X?Q_:FL:?IN0I'VRZ2+AL
M[?O$==K8^A]*\XU+2-0U;6+#Q-H3ZQ=Z+J.BPV\8TK[#YX7)?]XMXN-K*X^Z
M0<KR#P1KZ%X$>POHF^P3/;0^'(]-@DU!H7N%;<Y:)BAQG!0';\IQU.*8CT16
M#J&4AE89!'(-+7/_  _TV[T7P+X>T^_C,5]:Z?!#/&6#;76-0PR"0>0>0:Z"
M@04444 <IXH\&R>+/$6E2WD\D>CV$4LJQVEU+;SM<MA5;?&5(54,@X;G?R*Y
M34OA#>H;B+3KDM8PZG'JMG#/J=TDS2-$T<\;W"YD0'.\.&8Y)!&.OHNN>(+#
MP[:+<ZA/Y*.XBC54:225ST1$4%G8X/RJ">#Q3-#\26/B*.9K-Y@T+!)8;JVE
MMY4)&1NCD56 (Z$C![4#U.*3P%=QZ#/#_P (]8RWUQ>K<OYWB>^D<,J!5E2Z
M:$RJX VX4#Y?XN2*EB\'^)K6/PK>&YM-3U'2I[AI8KRZD \F5654$_ELSM&"
MHW,H+X).#7HE% 7."O/ 6H7&AR6:S6PE;Q"FK EFV^4+I9BOW?O;01CIGOWK
M(M_A7=V>KW"26J:KI4VIM?B23Q#?6OE[I1+C[*BM$Q1LD<@-@9P<FNQC\>Z3
M]LNK:9Y;:2#4TTD&2,D27#QI(H7;G@AQRV.0:O:EXITG2=,O-0N;Z(6=G)Y-
MQ)'F3RGR!M8+D@Y9>,<9H#4XO4? 6N76D^,=(0Z?]EU:\-[:W33R!U9C&2CQ
M^60 -C?,&.>.!6O;Z#K^A^)]7N-+73;C3M6N8KJ66\FD6:V8(L;A45") 5C4
MC+I@D]:[*B@#*\0#5OLR?V5;Z?>DDK-:ZA(\22(01PZJ^TYQP4;(R..M>;K\
M#GNM-TFTGN(+&.UFO+Q8[%F$=G-+(DD2Q*1AXXV7.' !Z[1G ]=HH \^O/!F
MOZU)<7>HR:<E]<>'YM*D^SR/Y9G9\AQE,A".2.2,XYQDZ]OX5NX?%FAZH9(3
M;V.DS6$BACO,CO"P*C&-N(FZD'D<5U5% !1110(**** "BBB@#$\+>&_^$:C
MU-/M'VG[;J$]_G9MV>8V[9U.<>O?TK;KG/!/A^Z\/PZRMT8R;O5;J]C\ML_N
MY'RN>.N*Z.MJSO-N]_,BG\*TL%%%%8EA7%?$CXA2> _[.\NR6\^U>9G=(4V[
M=OL?[WZ5VM><?&#P9JOB[^R/[,@6;[/YWF;I%3&[9CJ?]DUZF61H3Q<(XJW)
MK>[LMG;7U.?$.<:3=/<YW_AH2X_Z L7_ ($'_P")H_X:$N/^@+%_X$'_ .)K
MFO\ A3/BK_GQC_\  A/\:/\ A3/BK_GQC_\  A/\:^Z^JY#WC_X$_P#,\;VF
M-\_N_P" =+_PT)<?] 6+_P "#_\ $T?\-"7'_0%B_P# @_\ Q-<U_P *9\5?
M\^,?_@0G^-'_  IGQ5_SXQ_^!"?XT?5<A[Q_\"?^8>TQOG]W_ .E_P"&A+C_
M * L7_@0?_B:/^&A+C_H"Q?^!!_^)KFO^%,^*O\ GQC_ / A/\:/^%,^*O\
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M^!!_^)H_X:$N/^@+%_X$'_XFN:_X4SXJ_P"?&/\ \"$_QH_X4SXJ_P"?&/\
M\"$_QH^JY#WC_P"!/_,/:8WS^[_@'2_\-"7'_0%B_P# @_\ Q-'_  T)<?\
M0%B_\"#_ /$US7_"F?%7_/C'_P"!"?XT?\*9\5?\^,?_ ($)_C1]5R'O'_P)
M_P"8>TQOG]W_  "SJ7Q<GU#Q=HNNG38T;3;>Z@$'FDB3SO*YSCC'E>G.?:MS
M_AH2X_Z L7_@0?\ XFN.N/@?XNDU2TN!8P^7$DBM_I"9^;;CO[&KG_"F?%7_
M #XQ_P#@0G^-:2P^1R44Y1T7\WF_,B,\8FVD]?+_ (!TO_#0EQ_T!8O_  (/
M_P 31_PT)<?] 6+_ ,"#_P#$US7_  IGQ5_SXQ_^!"?XT?\ "F?%7_/C'_X$
M)_C6?U7(>\?_  )_YE^TQOG]W_ .E_X:$N/^@+%_X$'_ .)H_P"&A+C_ * L
M7_@0?_B:YK_A3/BK_GQC_P# A/\ &C_A3/BK_GQC_P# A/\ &CZKD/>/_@3_
M ,P]IC?/[O\ @'2_\-"7'_0%B_\  @__ !-'_#0EQ_T!8O\ P(/_ ,37-?\
M"F?%7_/C'_X$)_C1_P *9\5?\^,?_@0G^-'U7(>\?_ G_F'M,;Y_=_P#D=5O
MCJFJ7EZ4\LW$SS% <[=S$XS^-1VMW/8W"3VTTD$R'*R1L58?0BB\M)=/O)[6
M9=LT,C1NH.<,IP1GZBH:^LC&/(DMOT/,;=[O<]2\*_'.^L-D&M0_;X!Q]HC
M64?4=&_3ZUZ'\*YM*M_!^GZ9INJ1ZE]CC*LVSRWY8GE"21UQ7B_A7X8ZWXJV
M2QP?9+-N?M-P"JD?[(ZM^''O7JGPM^$MGX)TFREOHUN-:C4[Y=Y9$))^X,#M
MCDC-?G^=4<LIPDJ4K3NM(ZJ^N_;Y=]CVL)+$2DG)77=_(]%HHHKX4]H****
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M;>$?^A6T7_P70_\ Q-=$!@8 P*6BJJ5JE6WM)-V[NX1C&/PJP4445B4%%%%
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MA*R"-G.,YQYF,D'&<<5[S10%SQCQEKFW4O%\=]KM]I?B.T9/^$>T^WO)(?M
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M+TI=:\XZH(SY_P!H.9-VX]3],5T=<U\-]>N_$W@C2=4OBK75S&6D*+M&=Q'
M_"O)C?V4G;2Z_)_U]QT.W.O1_H=+1116!H%%%% !1110 4444 %%%% !7.>%
MTU1=:\5&_P#.^RMJ*&P\TY7R?LT.=GH/,\S\<UT=<UX5UZ[U;7/%EK<%3%IN
MHI;6^U<$(;:"0Y]3ND:MZ=^2=ET_5;&<K<T;_P!:,Z6BBBL#0**** "BBB@
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M110 4444 %%%% !1110 4444 %%%% !72:1_R#XOQ_F:YNNDTC_D'Q?C_,T
M7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKRKPY_R=-\0_^Q,\,_\ I=KU>JUY5X<_Y.F^(?\ V)GAG_TNUZ@#NKC19Y;B
M1P\8#,6&2>Y^E,_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB
M@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_  K>
MHH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^_'^9_P *
MWJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\
M"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_
M  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^_'^9
M_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_
MF?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\
M?YG_  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^
M_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X
M_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!
MN/[\?YG_  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^
MP;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH
M_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#A?"GAJP@CU0:
M1<Q3JVHW#W7SLVVX+?O%Z<8/:MS^P;C^_'^9_P *3PCX6_X16+5D^U?:OM^I
M7&H9\O9L\UMVSJ<X]>,^@K?K6JTYMIW(A=15U8P?[!N/[\?YG_"C^P;C^_'^
M9_PK>HK(LP?[!N/[\?YG_"C^P;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_O
MQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/
M[\?YG_"MZB@#!_L&X_OQ_F?\*PV\-6'_  F\<QN8O[=_LYD6'>W_ ![^:I+8
MQ_?VC/O7=5@-X6W>/(O$GVK&S37T_P"R^7UW2K)OW9_V<8QWZUK3:5[NVC(E
M?2R%_L&X_OQ_F?\ "C^P;C^_'^9_PK>HK(LP?[!N/[\?YG_"C^P;C^_'^9_P
MK>HH P?[!N/[\?YG_"C^P;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?
M\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?Y
MG_"MZB@#@M4\,Z<_C+0IKJZB36X[>[%C#YC#?&?*\XXQSC$7TS6__8-Q_?C_
M #/^%1ZKX1_M/QOX?\0_:_+_ +)MKRW^S>7GS?/\GG=GY=OD],'.[MCGHJVF
MTXPL[Z?=J]/U^9$;WE=?U9&#_8-Q_?C_ #/^%']@W']^/\S_ (5O45B68/\
M8-Q_?C_,_P"%']@W']^/\S_A6]10!@_V#<?WX_S/^%']@W']^/\ ,_X5O44
M8/\ 8-Q_?C_,_P"%']@W']^/\S_A6]10!@_V#<?WX_S/^%8?@GPU86WA73HM
M"N8KC2%0BWEWLVY=QSSCGG-=U6!X#\+?\(3X1TW1/M7VW['&4\_R_+WY8G.W
M)QU]:U37LVKZW6GW_E^I#OS)V[_H+_8-Q_?C_,_X4?V#<?WX_P S_A6]1619
M@_V#<?WX_P S_A1_8-Q_?C_,_P"%;U% &#_8-Q_?C_,_X4?V#<?WX_S/^%;U
M% &#_8-Q_?C_ #/^%']@W']^/\S_ (5O44 8/]@W']^/\S_A1_8-Q_?C_,_X
M5O44 8/]@W']^/\ ,_X5A^'_  U8PZMXB;3KF*6[DO5;4%WD^7/Y$0"XQQ^[
M$9Q[UW58/ASPM_PC^K^);[[5Y_\ ;-^M[Y?E[?)Q;PP[<Y.[_5;L\?>QCC)U
M@URRN[:??JO^'(E>ZT#^P;C^_'^9_P */[!N/[\?YG_"MZBLBS!_L&X_OQ_F
M?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_  K>HH P?[!N/[\?
MYG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^_'^9_P *WJ* ,'^P;C^_
M'^9_PH_L&X_OQ_F?\*WJ* ."U7PSITGC#0);NZB368XKH6$/F,-ZD1^<<8YP
M GYUO_V#<?WX_P S_A4>K^$O[5\:>'=?^U^5_9$5W%]G\O/F^<(QG=GY=OE^
MASGMBNBK:;3C"SOI]VKT_7YD1O>5UU_1&#_8-Q_?C_,_X4?V#<?WX_S/^%;U
M%8EF#_8-Q_?C_,_X4?V#<?WX_P S_A6]10!@_P!@W']^/\S_ (4?V#<?WX_S
M/^%;U% &#_8-Q_?C_,_X4?V#<?WX_P S_A6]10!@_P!@W']^/\S_ (4?V#<?
MWX_S/^%;U% &#_8-Q_?C_,_X4?V#<?WX_P S_A6]10!@_P!@W']^/\S_ (4?
MV#<?WX_S/^%;U% &#_8-Q_?C_,_X4?V#<?WX_P S_A6]10!@_P!@W']^/\S_
M (4?V#<?WX_S/^%;U% &#_8-Q_?C_,_X4?V#<?WX_P S_A6]10!@_P!@W']^
M/\S_ (4?V#<?WX_S/^%;U% &#_8-Q_?C_,_X5K6-NUK:I$Y!9<YV].I-6**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\J\.?\G3?$/_ +$SPS_Z7:]7JM>5>'/^3IOB'_V)GAG_ -+M>H ]5HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#E_ 7AN[\-PZZEV8R;W6+N^B\MB?W<C[ESQP<=1745R_
M@*/5XX==_M?SRQUB[-KY[9_T;?\ N]O^SCI745O6;=1W=S.G;E5@HHHK T"B
MBB@ HHHH **** "BBB@ KEY/#=VWQ.AU\&/["FCR6)&X[_,,Z..,=,*><UU%
M<O)'J_\ PLZ%QY_]@_V/(&^;]U]I\],<?WMF[\,UO2;]ZSMHS.=M+]SJ****
MP- HHHH **** "BBB@ HHHH **** .3USPO>:A\2/"NNQ&+[%IEG?P3AF(?=
M-Y&S:,<C]TV>?2NLKD]<CUEOB1X5>U-Q_8:V=^+[8W[KS#]G\G>.Y_UN/QKK
M*WJ-\L+OI^KW_K8RA:\K+K^B"BBBL#4**** "BBB@ HHHH *Y?X8^&[OPCX#
MT?1[XQF[M(BDAA8LN2S'@X'K745R_P ,8]7C\!Z.NO>>=7$1^T?:6S)NW-C<
M?IBMTW[*2OI=?D_Z^XS=N=>C_0ZBBBBL#0**** "BBB@ HHHH **** "N7\(
M^&[O0]>\87EP8S#JVII=V^QB2$%K!$=W'!W1-^&*ZBN7\(QZNNO>,#J1G^QM
MJ:'3O.;*^1]E@SL]%\SS?QS6]-OEG9]/U1G*UX_UT.HHHHK T"BBB@ HHHH
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M5_:0M/(T_F(R[_);^\!C&[WK2'#F-5[J+T[_ / (ECZ+MJSZBKPSXI_$K7/
M_P 1"NGW(>T-M&SVDXW1,><G'4'W!%<S_P -$^*O^>>G_P#?AO\ XJN*\7>+
M;[QIJW]HZ@(A<>6L?[E2JX&<<$GUKT\KR*M0KN6*BG%IKN88C&1G"U-M,^A/
M!OQVT+Q'L@OS_8UZW&V=LQ,?9^W_  +'XUZ2K!U#*0RL,@CD&OABNK\(?$[7
M_!;*EE=F6T!YL[C+Q?@.J_@15X[AF,KSPDK>3V^3_P Q4<P:TJKYGU[17FO@
MWX[:%XCV07Y_L:];C;.V8F/L_;_@6/QKTE6#*"#D'D$5\-B,+6PD^2M%Q?\
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\J\.?\G3?$/_ +$SPS_Z7:]7JM>5>'/^3IOB'_V)GAG_ -+M>H ]5KQ7]J+P
M_JGB#P_X:CTO3;O4I(=7CED2S@>4H@1LL0H.!SU->U45W8'%RP.(AB(J[CT,
M:U-5H.#ZG@5UX;UCX-?&9=6\/Z3?:EX1\1'&HVEA;O-]DESS)M4' !.X>S.!
MT%9^FZIJ?P[^.7CS5KOP?XEU?3]2\N.";2=,:=&P%).XD CMP37T;17K1SER
M35:FI-PY).[3:333?FK6OU1S/"V?N2M9W7D>"_!_PSXE\#6?C?Q1_P (U-'_
M &M>)<67AM9DCF6+S&+'GY5(63A>"=F.,BL3XHQ:U\=M6\.V&C^"=;T"XLKG
MS9]9UJS%MY*?W4;)W#/S8!ZJ.*^E:*<<ZE'%/&^R7M.CN]/=Y5I?6R[]=[@\
M(G35+F?+\N]SP;6M-UGX6?''4?%T&@:IXCT/6[(0S#2(//GAE4(.4!''R#D\
M?,>>,5#X%L?$OA&Q^(7Q$N?#=XVK:Q,'L-#5"\^S<0N]%&>KC(ZX1CBO?Z*S
M_MB4J2ISIINT8R>OO1BTTO+9)M=A_54I<REW:\FSY7^$VK77A;6=1\4^*O W
MCC6?&-_(Q:ZBT1FB@C/&V/<P/(XS@8&%' .?J6.3S(T?:R;@#M88(]C[T^BN
M7,L>LPJJKR<KVWNK=$ET2\C3#T?81Y;W"BBBO(.H**** "BBB@ HHHH *YK7
MO#=UJGC#PMJT4D*V^EM<M,KDAV\R+8NT 8//7)'%=+10!Y%HWAJ:?XW:TB2Q
MR>'M,"ZLEO@YBU&XC,;<],>6K/CL9LU2^'?A?7_%'AGP-]N_LV'0M+=KZ.>W
MED-S.3%)&D;1%-J;?-8EP[;MH^5<\>U44#N>1> _A'?>%;W1+:^LX]0L](<F
MWU%O$NH,1A&5'%BRF%6VMM*A\#+$>E=QKWANZU3QAX6U:*2%;?2VN6F5R0[>
M9%L7: ,'GKDCBNEHH"YQ_BSP[K$GBC1?$6AI8W=Y8P7%G+9ZA</!')%+L8LL
MBQR%65HD_@.03R*RYO#?B_3?$EQKVG+HE]>ZGIL-G?074\UO'!+$TC(\16.0
MR+^^8%6"D[0=PR0/1** /+]-^$=WH<,-K;7D-Q;0>%Y-#627*.\S-NWE0" G
M7N2/?K5+7OAGXJO=/TK3X+Z&:Q@T6+3C"NL7>GK;W"KM>?%NH-RI&WY)"H&W
M@C<:]=HH"Y\Q^*[1_"6KQZ5>ZY9:4;?PO9:;>PW>L1:;#J$:^;O6)GMIGE_B
M4E!$R[@ 26^7O]2\"ZAXFU'3/%>F6,T*WVD6]M+I%UK=[HTMKM+.H9[8,7($
MC*4=>" 0>HKUVB@+G">'_A_-HMX'MX;:QLAH,.EQV<=S)/Y,BM(Q D=0SH-X
M 8\G'05N> -!N/"O@;P_HMV\<EUI]A!:RO"24+)&%)4D XR.X%;]% @HHHH
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M_P#(G_Q-'_#-6N?]!33_ /R)_P#$U]%44?ZQ8_\ F7W(/J-#L?.O_#-6N?\
M04T__P B?_$UCM\";Y?%T>BG4++^TVL6O!)M?;Y0D5",XZ[F'&*^HJP&M-'_
M .$\BNC-_P 3\::\:P[S_P >WFJ6;;_OA1FM8<0XYWO+IV1$L#1TLOQ/%/\
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M ,?_ /K4?\)!_P!._P#X_P#_ %J -BBL?_A(/^G?_P ?_P#K4?\ "0?]._\
MX_\ _6H V**Q_P#A(/\ IW_\?_\ K4?\)!_T[_\ C_\ ]:@#8HK'_P"$@_Z=
M_P#Q_P#^M1_PD'_3O_X__P#6H V**Q_^$@_Z=_\ Q_\ ^M1_PD'_ $[_ /C_
M /\ 6H V**Q_^$@_Z=__ !__ .M1_P )!_T[_P#C_P#]:@#8HK'_ .$@_P"G
M?_Q__P"M1_PD'_3O_P"/_P#UJ -BBL?_ (2#_IW_ /'_ /ZU'_"0?].__C__
M -:@#8HK'_X2#_IW_P#'_P#ZU'_"0?\ 3O\ ^/\ _P!:@#8HK'_X2#_IW_\
M'_\ ZU'_  D'_3O_ ./_ /UJ -BBL?\ X2#_ *=__'__ *U'_"0?].__ (__
M /6H V**Q_\ A(/^G?\ \?\ _K4?\)!_T[_^/_\ UJ -BBL?_A(/^G?_ ,?_
M /K4?\)!_P!._P#X_P#_ %J -BBL?_A(/^G?_P ?_P#K4?\ "0?]._\ X_\
M_6H V**Q_P#A(/\ IW_\?_\ K4?\)!_T[_\ C_\ ]:@#8HK'_P"$@_Z=_P#Q
M_P#^M1_PD'_3O_X__P#6H V**Q_^$@_Z=_\ Q_\ ^M1_PD'_ $[_ /C_ /\
M6H V**Q_^$@_Z=__ !__ .M1_P )!_T[_P#C_P#]:@#8HK'_ .$@_P"G?_Q_
M_P"M1_PD'_3O_P"/_P#UJ -BBL?_ (2#_IW_ /'_ /ZU'_"0?].__C__ -:@
M#8HK'_X2#_IW_P#'_P#ZU'_"0?\ 3O\ ^/\ _P!:@#8HK'_X2#_IW_\ '_\
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M_P#C_P#]:@#8KEY(]7_X6="X\_\ L'^QY WS?NOM/GICC^]LW?AFM#_A(/\
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M -:@#8KE_",>KKKWC ZD9_L;:FAT[SFROD?98,[/1?,\W\<UH?\ "0?]._\
MX_\ _6KF?"?CV\U;7?%UK<Q(T.G:DEM;!3@K&;6"0@G')W2-S[BMZ=^2=ET_
M5;&<K<T;_P!:,[ZBL?\ X2#_ *=__'__ *U'_"0?].__ (__ /6K T-BBL?_
M (2#_IW_ /'_ /ZU'_"0?].__C__ -:@#8HK'_X2#_IW_P#'_P#ZU'_"0?\
M3O\ ^/\ _P!:@#8HK'_X2#_IW_\ '_\ ZU'_  D'_3O_ ./_ /UJ -BBL?\
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MRH#*S'SW.%W$5N^'/^3IOB'_ -B9X9_]+M>H ZN\_P"/R?\ ZZ-_.H:FO/\
MC\G_ .NC?SJ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,3PMXD_X26/4W^S?9OL6H3V.-^[?
MY;;=_08SZ=O6MNL3PM?:9?QZF=+M_LZQ:A/#<#8%WSJV)'XZY/?O6W6M5)3:
M2L1"[BKNX4445D6%%%% !1110 4444 %%%% !6(WB3;XTC\/_9OOZ>U]]HW]
M,2*FS;C_ &LYSVZ5MUB-?:8/&D=D;?\ XG)T]IEN-@X@$B@INZ_>(./:M::3
MO=7T9$KZ69MT445D6%%%% !1110 4444 %%%% !1110!A:EXH_L_QAH>A?9O
M,_M.WNI_M'F8\OR?*XVXYW>;ZC&WOGC=K"U+4-*A\8:'9W-MYFKW%O=/9W'E
M@^7&GE>:-W4;MT?3KM]JW:VFDHPLK:??J]?T^1$6[RUZ_H@HHHK$L**** "B
MBB@ HHHH *Q/!?B3_A+_  OI^L?9OLGVM"_D[]^W#$8W8&>GI6W6)X+OM,U/
MPOI]UHUO]DTR1"8(=@3:NXC&!TYS6J2]FW;6ZU^_\_T(=^9*_?\ 0VZ***R+
M"BBB@ HHHH **** "BBB@ K$T#Q)_;FJ>(+/[/Y']DWJV>_?N\W,$4N[&!M_
MUN,<_=SWQ6W6)H-_IEYJGB"*PM_)NK:]6*^?8%\V8P1,&R/O?NVC&3_=QVK6
M"3C*ZOI]VJ_X8B5[K4VZ***R+"BBB@ HHHH **** "BBB@ HHHH PM4\4?V;
MXMT+1/LWF?VI%<R>?YF/*\D(<;<<YW^HQCO6[6%JFH:5;^+="M+JV\S5KB*Y
M:RG\L'RU4)YHW=1D%.G7%;M;324865M/OU>OZ?(B+=Y:]?T04445B6%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !72:1_P @^+\?
MYFN;KI-(_P"0?%^/\S0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *^:_V@]2\&^ _%VE6ESIWC..\\8:W;3ZS=^&(_$>Z2..SG
MCC\N?32 ) (4!@5CE07:,X#CZ4KQS]J34KO2_ >F2/K&L>'?"S:M"/$VLZ 9
M$O;+31'(S2))&"\2>:L"R2J,I$TC97&Y0#EO@W-82?&@P^$=*^(Q\+QZ%,]_
MJGCJY\2+&+IIX1##!%JLNUVV+,S,D65&P!QN93V_AS_DZ;XA_P#8F>&?_2[7
MJ\D_93^++?%+Q!X,30/$VH>*M)T7P6;3Q+>M=S75J-2>2V>V1IG)66Y$?VDN
M0S. 5#G.!7K?AS_DZ;XA_P#8F>&?_2[7J .KO/\ C\G_ .NC?SJ&IKS_ (_)
M_P#KHW\ZS-4UO3M#CBDU&_M=/25_+C:ZF6,.W]T%B,GVJHQE-\L5=B;25V7:
M*HZEKFFZ.]NE_J%K8O<-LA6YF6,RMQ\JY(R>1P/6J-_XZ\-Z5>26E[X@TJSN
MHSAX+B]B1UXSRI;(X(K6%"K4MR0;]$R7.,=V;E%0P7EO=6JW,,\<ULR[UFC<
M,A7U!'&*SM/\7:%J]X;2QUK3KVZ&<P6]U'(_'7Y0<U"IU))M1>F^FWJ/F6FN
MYKT51U;7--T&!9M3U"UTZ%CM62[F6)2?0%B.:EL]2M-0LDO+6ZAN;1UW+<0R
M!XV'J&!P11[.?+SV=N_0?,KVOJ6:*R-/\7:%J]X;2QUK3KVZ&<P6]U'(_'7Y
M0<UKT3ISINTTT_,%)2U3"BBBLQA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !17"?%?5+9;'3-$N$N)H=6N@ES%:6T
MES(;5/GE_=QJS%6PL9(''F5R^D?$B;0? ^FZ=:0S_;H-3.AH]WI]S+)'&B-)
M'*ULJB9R853Y>"2<D@"@=CV.BO-$\=^)IO#TTT6FR&XM]06VDU!M$NT4V[*&
M\]+)B)GP2(RJL<'+<@8JM>:[KNL:_P"!I-+\1Z?)#=-=K.4TZ9(Y'1"2KPF<
M,I7&W8QRK D_W0!8].M[R"\5VMYHYQ&[1N8W#;74X93CH0>HJ:O(])\0:WX:
M^V7B?V>^BR^)Y+)[=HW-PWG7/E^8)-P5=K./EVMD*?F&<">#XJ:O?:S*UK8R
M3V$6J-IYL8=%O)9&19?*:;[6O[D8.7V[3\JXW9Z 6/5:*\4O+O6'\%^/Y=:N
M[/6[*VU1XH[22":/#*\)&&$Y(09X08P><D'%=U!KVO:YXEU>WTLZ=;V&D7,5
MK-'>12-+<L421RKJX$8"N ,H^2#TH"QV-0R7D$5Q%;O-&EQ,&:.)G 9PN-Q
MZG&1G'3(KE_B5X8O?%&D64=G!:7XM;Q+J;3-0<K;WT:A@8G(5NY##*D;E7([
MCSR^\>Z=H'_",ZC8Z)<:<EF-0LFTN3Y4LY@\2L'==RQPJ3G>/E5,8'1: L>X
MT5YGJ6KW>B^)+F]N(=/N=9M_"TMT]Y LJQLR29"*ID(V9Y_O'U'2M/PWXHUZ
M3Q-8:9K0TZ1=2TQ]1A^P12(;<H\:M&S,Y\SB5<, GW3\O- '<T444""BBB@
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M6[6TVG&%G?3[M7I^OS(C>\KKK^B"BBBL2PHHHH **** "BBB@ HHHH ****
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M)8^&_L?B[5=<^T;_ +=:V]MY&S&SRFE.[=GG/F],#&WOFMNF2%%%% !1110
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MNRV[+_,B67U5;5?C_D>%45]*?\*@\(_] G_R9F_^+H_X5!X1_P"@3_Y,S?\
MQ=9_ZSX/^27W+_Y(O^SJO=?C_D?-=%?2G_"H/"/_ $"?_)F;_P"+H_X5!X1_
MZ!/_ ),S?_%T?ZSX/^27W+_Y(/[.J]U^/^1\UT5]*?\ "H/"/_0)_P#)F;_X
MNC_A4'A'_H$_^3,W_P 71_K/@_Y)?<O_ )(/[.J]U^/^1\UT5]*?\*@\(_\
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M!1116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"/'_&C^R+3_GE_X\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44
M4_[(M/\ GE_X\?\ &C^R+3_GE_X\?\:N44 4_P"R+3_GE_X\?\:/[(M/^>7_
M (\?\:N44 4_[(M/^>7_ (\?\:/[(M/^>7_CQ_QJY10!3_LBT_YY?^/'_&C^
MR+3_ )Y?^/'_ !JY10!3_LBT_P">7_CQ_P :/[(M/^>7_CQ_QJY10!3_ +(M
M/^>7_CQ_QH_LBT_YY?\ CQ_QJY10!3_LBT_YY?\ CQ_QH_LBT_YY?^/'_&KE
M% %/^R+3_GE_X\?\:/[(M/\ GE_X\?\ &KE% %/^R+3_ )Y?^/'_ !H_LBT_
MYY?^/'_&KE% %/\ LBT_YY?^/'_&C^R+3_GE_P"/'_&KE% %/^R+3_GE_P"/
M'_&C^R+3_GE_X\?\:N44 <MX3\!VWAF/54:7[7]NU&XOP=I3RQ*V[9]XYQZ\
M9]!6[_9%I_SR_P#'C_C6'X"\-W?AN'74NS&3>ZQ=WT7EL3^[D?<N>.#CJ*ZB
MMJSO-N]_,BG\*TL4_P"R+3_GE_X\?\:/[(M/^>7_ (\?\:N45B64_P"R+3_G
ME_X\?\:/[(M/^>7_ (\?\:N44 4_[(M/^>7_ (\?\:/[(M/^>7_CQ_QJY10!
M3_LBT_YY?^/'_&C^R+3_ )Y?^/'_ !JY10!3_LBT_P">7_CQ_P :/[(M/^>7
M_CQ_QJY10!3_ +(M/^>7_CQ_QK";P';-XXC\0^;A4TYK#[+M/):57W[MW^SC
M&._6NIKEY/#=VWQ.AU\&/["FCR6)&X[_ ##.CCC'3"GG-;4W:^MM'_PQ$^FE
MS<_LBT_YY?\ CQ_QH_LBT_YY?^/'_&KE%8EE/^R+3_GE_P"/'_&C^R+3_GE_
MX\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44 4_[(M/\ GE_X\?\
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MX\?\:/[(M/\ GE_X\?\ &KE% %/^R+3_ )Y?^/'_ !H_LBT_YY?^/'_&KE%
M%/\ LBT_YY?^/'_&C^R+3_GE_P"/'_&KE% %/^R+3_GE_P"/'_&C^R+3_GE_
MX\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44 4_[(M/\ GE_X\?\
M&C^R+3_GE_X\?\:N44 4_P"R+3_GE_X\?\:/[(M/^>7_ (\?\:N44 4_[(M/
M^>7_ (\?\:/[(M/^>7_CQ_QJY10!3_LBT_YY?^/'_&C^R+3_ )Y?^/'_ !JY
M10!3_LBT_P">7_CQ_P :/[(M/^>7_CQ_QJY10!3_ +(M/^>7_CQ_QJS#"EO&
M(XQM0=!FGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,IX>HVE+MOL<V(J.C2E..Z/6/$WQ!\/^#]1TNPU;4%M;W4Y!%:0+$\CRL2%
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MC1="3ES)W?2\9.+MY76FYMAJTZSESJUOU5]0HHHKY\[0HHHH **** "BBB@
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M\26)LM7TVTU6S+!S;WL"S1[AT.U@1D4MKH>FV*V:VVGVMNME&8;58H540(0
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M]^X__B:/]5\7_/'\?\@_M&EV9];45\D_\+B\9?\ 0<F_[]Q__$T?\+B\9?\
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M'S;O.ZY&-O?/'15SNJZEH]OXW\/V5U:^9K5S;7CV-QY8/E1IY/G#=G*[MT?
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MQYOV@KPS]?+Y [=: ,OX>^+;^#X<Z-<26&K>)=1N)+D;;8H\FU9Y!EY9G1
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MHB %9MQ"!0#ECQ5SQ9X3EUZZTS4M/U#^RM:TUW:VNFA$T95P!)%)'E2R, .
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MI,$=E+"\%S;:2R:G&B$-Y2W?GG"L=P8"/!5V&.<UW] !1110(**** "BBB@
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M ,!1_P#%5[;16?\ ;F8_\_?P7^1?U.A_+^9XE_PS+:_]!^;_ ,!1_P#%4?\
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MBL2PHHHH **** "BBB@ K \!VFCV/A'38- F^T:.D9%M+O+;EW'/)Z\YK?K
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M!1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW;FQN/TQ6Z;]E)7TNOR?]?<9NW.O1_H=11116!H%%%% !1110 4444 %%%%
M!7+^$?#=WH>O>,+RX,9AU;4TN[?8Q)""U@B.[C@[HF_#%=17+^$8]777O&!U
M(S_8VU-#IWG-E?(^RP9V>B^9YOXYK>FWRSL^GZHSE:\?ZZ'44445@:!1110
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M[9<?\]Y/^^S0!U5%<K]LN/\ GO)_WV:/MEQ_SWD_[[- '545ROVRX_Y[R?\
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M[- '545ROVRX_P">\G_?9H^V7'_/>3_OLT =517*_;+C_GO)_P!]FC[9<?\
M/>3_ +[- '545ROVRX_Y[R?]]FC[9<?\]Y/^^S0!U5%<K]LN/^>\G_?9H^V7
M'_/>3_OLT =517*_;+C_ )[R?]]FM_2W:2QB9V+,<Y+')ZF@"W1110 4444
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M7]@NRJDN0V7$@W'[@. 0,#J#U]1\/_"2W\.Z'JUM;ZSJ"ZOJDJSW6LHX6=I
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M4EXG_P">5M_W_%'_  I+Q/\ \\K;_O\ BON_89#WC_X%_P $\;GQOG]QL?\
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MCK?^&@=1_P"@5:_]_&KS[Q/KTGB?7+K4Y8EADN"I,:$D#"A?Z5U/_"DO$_\
MSRMO^_XKD-<T6Y\/:I/I]X%6YA(#A&R.0".?H17;@*>6PJ-X.W-;H[Z??Z&5
M:6(<?WM[%)':-E9&*LIR&4X(->@>%?C1K&A[(;__ (FMH./WC8E4>S]_QS]:
M\]KI?"_P]UKQ8RM:6ICM2>;J?Y8_P/?\,UVXZEA*E)_6TN7S_1_Y&5&56,OW
M6Y[_ .%_'VB^+% LKH+<XR;6;Y9!^'?\,UT5<#X2^#ND>'6CN;O.IWR$,'D&
M(T/LO^.?PKOJ_(<;'"QJM823<?/]/^"D?4474<?WJU"BBBN V"BBB@ HHHH
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MGK>I?EA==/U>_P#6UC*%KRMW_1!1116!J%%%% !1110 4444 %%%% !1110
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M)8?D#(5*E%P0X;[Q]L=;10!Q]E\,=.LXV#7VH74KZI%K$DUQ*K/)<(BKS\N
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M;@; N^=6Q(_'7)[]ZVZUJI*;25B(?"KNX4445D6%%%% !1110 4444 %%%%
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M!<,1UP/2MVL3P7?:9J?A?3[K1K?[)IDB$P0[ FU=Q&,#ISFM4E[-NW5:_?\
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M(_Y!\7X_S-<W72:1_P @^+\?YF@"Y1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>5>'/^3IOB'_ -B9X9_]+M>KU6L.S\'Z
M?9>-M5\51"3^U=3T^STRX)?*>3;27,D6%['=>39/?Y?2@"C>?\?D_P#UT;^=
M0T7UY MY< S1@^8W\8]:A^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\
MSWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[
M9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?
M8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y
M[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_
M )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-
M14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $
MU%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC
M_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#S
MWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^
MV6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8
MH^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[
MQ_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_
M .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-1
M4/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!E>%[72K6/4QI4OG+)J$\ES\Q;;<%O
MWB^V#VK;KGO"^EV?AV/4UCU".Y^V:A/>L<@;#(V2G7M6W]LM_P#GO'_WV*UJ
MM.;:=R(7Y5=6)J*A^V6__/>/_OL4?;+?_GO'_P!]BLBR:BH?MEO_ ,]X_P#O
ML4?;+?\ Y[Q_]]B@":BH?MEO_P ]X_\ OL4?;+?_ )[Q_P#?8H FHJ'[9;_\
M]X_^^Q1]LM_^>\?_ 'V* )J*A^V6_P#SWC_[[%'VRW_Y[Q_]]B@":L1K72O^
M$TCN3+_Q/!I[1K#N/_'OYBDMC_>VC-:OVRW_ .>\?_?8K$;2[-O&D>N_VA'Y
MJZ>UE]GR.09%??G/^SCIWK6FTKW=M&1*^ED=#14/VRW_ .>\?_?8H^V6_P#S
MWC_[[%9%DU%0_;+?_GO'_P!]BC[9;_\ />/_ +[% $U%0_;+?_GO'_WV*/ME
MO_SWC_[[% $U%0_;+?\ Y[Q_]]BC[9;_ //>/_OL4 345#]LM_\ GO'_ -]B
MC[9;_P#/>/\ [[% $U%0_;+?_GO'_P!]BC[9;_\ />/_ +[% &/J5KI$GC#0
M[BZFV:S%;W2V46XC?&WE><<=\8C^F:WJYS4M'L[_ ,8:)K3:C''+IUO=0+;Y
M4^8)O*R<YXV^6.W\5;OVRW_Y[Q_]]BM9M.,+.^GW:O\ X?YD1O>6G]61-14/
MVRW_ .>\?_?8H^V6_P#SWC_[[%9%DU%0_;+?_GO'_P!]BC[9;_\ />/_ +[%
M $U%0_;+?_GO'_WV*/MEO_SWC_[[% $U%0_;+?\ Y[Q_]]BC[9;_ //>/_OL
M4 35B>"[72K+POI\&B2^?I2(1;R;BVY=Q[]^<UJ_;+?_ )[Q_P#?8K$\%Z79
M^%/"^GZ3%J$=W':H4$V0N[+$YQD^M:IKV;5];K3[_P OU(=^9.W?]#H:*A^V
M6_\ SWC_ .^Q1]LM_P#GO'_WV*R+)J*A^V6__/>/_OL4?;+?_GO'_P!]B@":
MBH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8
MH FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )JQ- M=*M]4\0/I\WF7<UZKW
MZ[B=DWD1 #';]V(SCWK5^V6__/>/_OL5BZ#I=GHNJ>(+M-0CG;5+U;ITR!Y1
M$$46WKSQ&#_P*M8-<LKNVGWZHB5[K0Z"BH?MEO\ \]X_^^Q1]LM_^>\?_?8K
M(LFHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'
M_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_
M .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* ,C5+72)?%NA3W<VS
M6(8KD6,6XC>K!/-..^ $_.MVN<U31[/4/%FA:RVH1QR:;%<QI!E3YOFA 3G/
M&-@[=ZW?MEO_ ,]X_P#OL5K-IQA9WT^[5_\ #_,B-[RT_JR)J*A^V6__ #WC
M_P"^Q1]LM_\ GO'_ -]BLBR:BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;
M_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV*
M)J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H
M FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">
M\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_
M^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FKI-(_Y!\7X_S-<K]L
MM_\ GO'_ -]BNHT5EDTV%E(93G!!R.IH O4444 %%%% !1110 4444 %%%%
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M=_X"1_X5KT4 9'_"(Z%_T!=._P# 2/\ PH_X1'0O^@+IW_@)'_A6O10!D?\
M"(Z%_P! 73O_  $C_P */^$1T+_H"Z=_X"1_X5KT4 9'_"(Z%_T!=._\!(_\
M*/\ A$="_P"@+IW_ ("1_P"%:]% &1_PB.A?] 73O_ 2/_"C_A$="_Z NG?^
M D?^%:]% &1_PB.A?] 73O\ P$C_ ,*;_P (;X?\S?\ V%IN_&W=]DCSCTSB
MMFB@#(_X1'0O^@+IW_@)'_A1_P (CH7_ $!=._\  2/_  K7HH R/^$1T+_H
M"Z=_X"1_X4?\(CH7_0%T[_P$C_PK7HH R/\ A$="_P"@+IW_ ("1_P"%'_"(
MZ%_T!=._\!(_\*UZ* ,C_A$="_Z NG?^ D?^%'_"(Z%_T!=._P# 2/\ PK7H
MH R/^$1T+_H"Z=_X"1_X4?\ "(Z%_P! 73O_  $C_P *UZ* ,C_A$="_Z NG
M?^ D?^%'_"(Z%_T!=._\!(_\*UZ* ,9O!OA]I%<Z%II=00K&SCR,]<<>U._X
M1'0O^@+IW_@)'_A6O10!D?\ "(Z%_P! 73O_  $C_P */^$1T+_H"Z=_X"1_
MX5KT4 9'_"(Z%_T!=._\!(_\*/\ A$="_P"@+IW_ ("1_P"%:]% &1_PB.A?
M] 73O_ 2/_"C_A$="_Z NG?^ D?^%:]% &1_PB.A?] 73O\ P$C_ ,*/^$1T
M+_H"Z=_X"1_X5KT4 9'_  B.A?\ 0%T[_P !(_\ "FQ^#?#\2!$T+344=%6T
MC 'Z5LT4 9'_  B.A?\ 0%T[_P !(_\ "C_A$="_Z NG?^ D?^%:]% &1_PB
M.A?] 73O_ 2/_"C_ (1'0O\ H"Z=_P" D?\ A6O10!D?\(CH7_0%T[_P$C_P
MH_X1'0O^@+IW_@)'_A6O10!D?\(CH7_0%T[_ ,!(_P#"C_A$="_Z NG?^ D?
M^%:]% &1_P (CH7_ $!=._\  2/_  H_X1'0O^@+IW_@)'_A6O10!D?\(CH7
M_0%T[_P$C_PIJ^#?#Z,Q70M-4L<L1:1C)QC)XK9HH R/^$1T+_H"Z=_X"1_X
M4?\ "(Z%_P! 73O_  $C_P *UZ* ,C_A$="_Z NG?^ D?^%'_"(Z%_T!=._\
M!(_\*UZ* ,C_ (1'0O\ H"Z=_P" D?\ A1_PB.A?] 73O_ 2/_"M>B@#(_X1
M'0O^@+IW_@)'_A1_PB.A?] 73O\ P$C_ ,*UZ* ,C_A$="_Z NG?^ D?^%'_
M  B.A?\ 0%T[_P !(_\ "M>B@#(_X1'0O^@+IW_@)'_A1_PB.A?] 73O_ 2/
M_"M>B@#&;P9X?:17.A::77.UC9QY&>N.*=_PB.A?] 73O_ 2/_"M>B@#(_X1
M'0O^@+IW_@)'_A1_PB.A?] 73O\ P$C_ ,*UZ* ,C_A$="_Z NG?^ D?^%'_
M  B.A?\ 0%T[_P !(_\ "M>B@#(_X1'0O^@+IW_@)'_A1_PB.A?] 73O_ 2/
M_"M>B@#(_P"$1T+_ * NG?\ @)'_ (4?\(CH7_0%T[_P$C_PK7HH R/^$1T+
M_H"Z=_X"1_X4?\(CH7_0%T[_ ,!(_P#"M>B@#(_X1'0O^@+IW_@)'_A1_P (
MCH7_ $!=._\  2/_  K7HH R/^$1T+_H"Z=_X"1_X4?\(CH7_0%T[_P$C_PK
M7HH R/\ A$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._\!(_\*UZ* ,C_A$="_Z
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M;][G=Y'7C&[H<<@%JS^(EG>:Q%9K87R6<UU)90:JZQBVFG0-NC7Y_,ZHX#%
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MXXYJ:?\ !T6?C*UUY[ZREDM[VXO%F&F*M[,)5D7RY;G>2ZKY@"@*H 0 @\$
M&SX5\7.OPKT[Q)K,S3.NFK>74JHH+83<Q & /T%0W?CS5(]6\.V\?A;44BU)
MI1*LDEH7C"KD'*W!7_:.,\=.>*U=#\,S^'_ ]GH-M=P33VMHMJES=6Q>)B%Q
MEH@X)!_N[A]:PM%^&MYH-GHZV6J6<%Q87L]T4CT]EM?+ER&ABA$N8@ 1CYV
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MVMD]\5=M? 6J6NM:UJT.L6-A?Z@L<8DT_2_*7"2%BTJM*XED*G9O^7 SQTP
M=L[K&C.Q"JHR6/  KRZ'XF:GJ7A3QC='[/:75MICZMI,MNN=UJZ2>2[!B0S9
MB)/&.5X]>_\ %&CR>(O#NHZ7%=M8->0- ;A%W,BL,,0,CG!.#V/-<9J'P5L
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M75FV0^:=C@HI#%F&<Y4@X !L_#C6+K7_  %H&I7TOGWEU9132R% FYBH).
M!] *Z.N:\'>%;WPGI^F:>=6^V6%CI\=F(#;*F^13S-NR2,C V]!C-=+0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077826304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,747,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075901632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 186,409<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">208,011<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,158<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">397,578<span></span>
</td>
<td class="nump">442,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">157,786<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,253<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">576,379<span></span>
</td>
<td class="nump">626,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,761<span></span>
</td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">20,724<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,032<span></span>
</td>
<td class="nump">25,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,575<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">35,607<span></span>
</td>
<td class="nump">32,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; September&#160;30, 2022 and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at September&#160;30, 2022 &#160;&#160; and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized a September&#160;30, 2022 and December&#160;31, 2021; 25,709,664 shares issued and outstanding at September&#160;30, 2022; and 25,207,985 shares issued and outstanding at December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">790,954<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,475)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(248,707)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">540,772<span></span>
</td>
<td class="nump">593,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 576,379<span></span>
</td>
<td class="nump">$ 626,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077841472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">2,061,773<span></span>
</td>
<td class="nump">2,061,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,709,664<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,709,664<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077635600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 11,516<span></span>
</td>
<td class="nump">$ 6,080<span></span>
</td>
<td class="nump">$ 31,720<span></span>
</td>
<td class="nump">$ 18,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,935<span></span>
</td>
<td class="nump">9,572<span></span>
</td>
<td class="nump">53,705<span></span>
</td>
<td class="nump">27,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,451<span></span>
</td>
<td class="nump">15,652<span></span>
</td>
<td class="nump">110,425<span></span>
</td>
<td class="nump">46,399<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,451)<span></span>
</td>
<td class="num">(15,652)<span></span>
</td>
<td class="num">(110,425)<span></span>
</td>
<td class="num">(46,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,850)<span></span>
</td>
<td class="num">(15,589)<span></span>
</td>
<td class="num">(107,923)<span></span>
</td>
<td class="num">(47,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (29,780)<span></span>
</td>
<td class="num">$ (15,582)<span></span>
</td>
<td class="num">$ (109,235)<span></span>
</td>
<td class="num">$ (47,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,619,125<span></span>
</td>
<td class="nump">22,212,266<span></span>
</td>
<td class="nump">25,428,097<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,619,125<span></span>
</td>
<td class="nump">22,212,266<span></span>
</td>
<td class="nump">25,428,097<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216072036992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 363,292<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,812)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,237,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">408,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">527,229<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(118,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,205,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">418,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">521,950<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(103,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,589)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,237,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">408,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">527,229<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(118,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures</a></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740,500<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(190,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(107,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,709,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">540,772<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">790,954<span></span>
</td>
<td class="num">(1,475)<span></span>
</td>
<td class="num">(248,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740,500<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(190,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 30,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,664,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">559,181<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">779,583<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
<td class="num">(218,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,850)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,709,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 540,772<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 790,954<span></span>
</td>
<td class="num">$ (1,475)<span></span>
</td>
<td class="num">$ (248,707)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075442976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,923)<span></span>
</td>
<td class="num">$ (47,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">23,678<span></span>
</td>
<td class="nump">10,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposals of fixed assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(459)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">6,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(78,240)<span></span>
</td>
<td class="num">(27,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(47,762)<span></span>
</td>
<td class="num">(27,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(214,712)<span></span>
</td>
<td class="num">(83,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">153,599<span></span>
</td>
<td class="nump">11,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(108,875)<span></span>
</td>
<td class="num">(100,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">32,927<span></span>
</td>
<td class="nump">153,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to settlement of restricted stock awards</a></td>
<td class="num">(649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PaymentsForSuitLiability', window );">Repayment of ASTRA build to suit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,960)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">32,278<span></span>
</td>
<td class="nump">145,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(154,837)<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">341,246<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">286,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">15,305<span></span>
</td>
<td class="nump">23,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentsForSuitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Suit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentsForSuitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077940880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 23, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022 and August 25, 2022, the Company incorporated Krystal Biotech Switzerland GmbH and Krystal Biotech Netherlands, B.V., respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had an accumulated deficit of $248.7 million. With the net proceeds raised from its public offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $394.4 million as of September&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216078266336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216080451168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,565,110 and 1,900,638 common share equivalents outstanding as of September&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:53.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,923)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,619,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,212,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,428,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.24)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216078134304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value Instruments<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(886)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,319&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,016&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,568&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,011&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.100%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216078057120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,968&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,587&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,801)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,786&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $669 thousand and $1.6 million for the three and nine months ended September&#160;30, 2022 and $474 thousand and $1.4 million for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,905&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,724&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216078047248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. On September 30, 2022, the Company amended the 2016 Lease ("Short-Term Amendment") to add a short-term lease for additional office space that commenced on October 1, 2022 and expires on September 30, 2023. The amendment increased the area leased by approximately 7,000 square feet through September 30, 2023, resulting in a total area leased of approximately 54,000 square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $2.4&#160;million.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed in 1H 2023.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office that commenced on September 1, 2022 and expires December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:85.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.760%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Short-Term Amendment not exceeding twelve months, the Company has not recorded a right-of-use asset or corresponding lease liability for the amendment as of September 30, 2022. Future minimum remaining operating lease payments under this amendment are $40&#160;thousand and $121&#160;thousand for the years ending December 31, 2022 and 2023, respectively. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2022 under these agreements is approximately $2.4 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $2.1 million and $5.1 million for each of the three and nine months ended September&#160;30, 2022 and $744 thousand and $3.3 million for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $6.2 million. The Company has incurred expenses under these activities of $3.2 million and $9.5 million for the three and nine months ended September&#160;30, 2022 and $1.8 million and $4.1 million for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $10.3 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the interior construction of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $84.1&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of September&#160;30, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $0 and $768&#160;thousand of insurance proceeds during the three and nine months ended September&#160;30, 2022  and Company recorded an additional $372&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216080450816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the nine months ended September&#160;30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216181347952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjAw_1d212468-e6cb-466c-91ca-14c8b3f2974b">one</span>-year to four-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 189,000 and 1,913,000 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted zero and 45,000 stock options to non-employees during the three and nine months ended September&#160;30, 2022, respectively, and 50,000 stock options to non-employees during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,892)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498,510&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,213&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2022 was $1.3&#160;million and $2.1&#160;million, respectively, and during the three and nine months ended September&#160;30, 2021 was $64&#160;thousand and $872&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and nine months ended September&#160;30, 2022 was $49.59 and $43.66, respectively, and during the three and nine months ended September&#160;30, 2021 was $34.85 and $43.31, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $105.5 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of 3.1 years as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,338&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $137&#160;thousand and $423&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2022, respectively, and $79&#160;thousand and $182&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.935%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.91</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.03</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and nine months ended September&#160;30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $4.2 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.4 years as of September&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Shares remaining available for grant under the Company&#8217;s stock incentive plan were 607,366, with a sublimit for incentive stock options of 7,223, at September&#160;30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216078491584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075442224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div>As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense.</span></div>Construction in progress ("CIP") is not depreciated until the asset is placed in service.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was </span></div>obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216081526848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077815472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:53.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,589)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,923)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,764)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,619,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,212,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,428,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.24)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.18)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075461888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(886)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,319&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,016&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,568&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,011&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.100%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077940880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,503&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,968&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,587&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,801)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,786&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,905&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,724&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075739696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:85.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.760%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental condensed consolidated balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075427008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,892)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498,510&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,213&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,338&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.935%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.91</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.03</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.15</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077712912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 248,707<span></span>
</td>
<td class="nump">$ 140,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 394,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075913648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216070156432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077873712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</a></td>
<td class="nump">3,565,110<span></span>
</td>
<td class="nump">1,900,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216077564880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,850)<span></span>
</td>
<td class="num">$ (28,108)<span></span>
</td>
<td class="num">$ (49,965)<span></span>
</td>
<td class="num">$ (15,589)<span></span>
</td>
<td class="num">$ (16,363)<span></span>
</td>
<td class="num">$ (15,812)<span></span>
</td>
<td class="num">$ (107,923)<span></span>
</td>
<td class="num">$ (47,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,619,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,212,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,428,097<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,619,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,212,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,428,097<span></span>
</td>
<td class="nump">21,893,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216072524912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 186,409<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">408,425<span></span>
</td>
<td class="nump">502,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">406,977<span></span>
</td>
<td class="nump">502,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">52,777<span></span>
</td>
<td class="nump">40,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">52,738<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">94,415<span></span>
</td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(886)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">93,529<span></span>
</td>
<td class="nump">83,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">74,824<span></span>
</td>
<td class="nump">37,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">74,301<span></span>
</td>
<td class="nump">37,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">208,011<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">52,738<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">87,291<span></span>
</td>
<td class="nump">35,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">67,982<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">6,238<span></span>
</td>
<td class="nump">47,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">6,319<span></span>
</td>
<td class="nump">16,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">222,016<span></span>
</td>
<td class="nump">161,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">220,568<span></span>
</td>
<td class="nump">161,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 208,011<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 12,557<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 186,409<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075777088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 163,587<span></span>
</td>
<td class="nump">$ 116,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,801)<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">157,786<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">130,071<span></span>
</td>
<td class="nump">104,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">21,503<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 10,968<span></span>
</td>
<td class="nump">$ 5,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216080370272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075838544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">$ 10,905<span></span>
</td>
<td class="nump">$ 9,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedFinancingFeesCurrent', window );">Accrued financing costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 20,724<span></span>
</td>
<td class="nump">$ 16,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedFinancingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedFinancingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216069745328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
<th class="th">
<div>Sep. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2016 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PaymentToEscrowForReducingLeaseRentals', window );">Cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments', window );">Lessor, operating lease, liability, annual lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CumulativeEscalationClausePercent', window );">Cumulative escalation clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CumulativeEscalationClauseTerm', window );">Cumulative escalation clause, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid', window );">Loss contingency, guaranteed maximum price to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from insurance settlement, operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_NumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementTotalConsideration', window );">Litigation settlement, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember', window );">Other Contractual Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">ASTRA Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CostOfWorkPercentage', window );">Cost of work, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember', window );">2016 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember', window );">Short-Term Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember', window );">Boston, Massachusetts Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember', window );">Switzerland Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdditionalAreaOfRealEstatePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area of real estate property leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdditionalAreaOfRealEstatePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CostOfWorkPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Work, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CostOfWorkPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClausePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClausePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClauseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClauseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Liability, Annual Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LessorOperatingLeaseLiabilityAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payments, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementMilestonePaymentsSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Guaranteed Maximum Price to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyGuaranteedMaximumPriceToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentToEscrowForReducingLeaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to escrow for reducing lease rentals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentToEscrowForReducingLeaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075842608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining three months)</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">18,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">9,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216069861504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,253<span></span>
</td>
<td class="nump">$ 7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,575<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">12 years 7 months 6 days<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216071972560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216069694016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember', window );">Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">434,782<span></span>
</td>
<td class="nump">2,866,667<span></span>
</td>
<td class="nump">2,211,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.00<span></span>
</td>
<td class="nump">$ 65.00<span></span>
</td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="nump">$ 66.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="nump">$ 201,900<span></span>
</td>
<td class="nump">$ 134,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Sale of stock, remaining available issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">288,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216076950512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="nump">297,500<span></span>
</td>
<td class="nump">1,913,000<span></span>
</td>
<td class="nump">799,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">607,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 49.59<span></span>
</td>
<td class="nump">$ 34.85<span></span>
</td>
<td class="nump">$ 43.66<span></span>
</td>
<td class="nump">$ 43.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,617<span></span>
</td>
<td class="nump">$ 3,175<span></span>
</td>
<td class="nump">$ 22,338<span></span>
</td>
<td class="nump">$ 9,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock award outstanding (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 1,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">7,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216076112544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,043,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(84,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares) | shares</a></td>
<td class="num">(412,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(5,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">3,498,510<span></span>
</td>
<td class="nump">2,043,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable end of period (in shares) | shares</a></td>
<td class="nump">637,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">63.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">46.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">58.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">78.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">60.38<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 48.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (Years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (Years), exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding | $</a></td>
<td class="nump">$ 37,213<span></span>
</td>
<td class="nump">$ 31,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at September 30, 2022 | $</a></td>
<td class="nump">$ 14,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216075864768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 8,617<span></span>
</td>
<td class="nump">$ 3,175<span></span>
</td>
<td class="nump">$ 22,338<span></span>
</td>
<td class="nump">$ 9,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">5,547<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">6,433<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">16,791<span></span>
</td>
<td class="nump">6,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 1,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216069732672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 70.91<span></span>
</td>
<td class="nump">$ 53.69<span></span>
</td>
<td class="nump">$ 63.03<span></span>
</td>
<td class="nump">$ 67.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140216072358448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Surrendered or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Surrendered or forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>krys-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20220930"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20220930.xsd" xlink:type="simple"/>
    <context id="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9d41541995b4fe2ab20091cba0c85c2_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i4a9c29f2cd0b44559649153e923cfb6e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06dfdd468a0b4f669b11ecad09c55f82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i775193c878c44f59b88bf9723aa001a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dd74b71c5964f71aee86633bf510cf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2775a9a719c3456a9237c8c0bfe82b9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i152425a33b7e4cbcb9970cc97b2cace5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3634606c684047bba8c4d34eaa98022c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i840b1bacbbf34eb686c537dd492045ce_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8eec4dac16a4daab1a85db49aaf6f9f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea2f3d8999c54a118d9796dcfca0feaf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie10b23711a0741f5a1c060825f98ba98_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7f996c6f367a493784f701839cfebdee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i60635a52ed064f588cfe46ee6683334f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3cf27db60a1c497cbf41c87a9b613266_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3185b9d4440145839e7322dfeaf5e54a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i895df53b1ba54daab24b6813c0528941_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i49fd3e7bf09145a0ba746d34252ffa18_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0fa7c0396011440f81f7befcb8eedf7d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7f9c70f6616c4a18acab21995ed3bd27_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i41ca242fc83249a2920e7e8a2eeda3fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib5edf79ca55d4b1c92d3dde303374d72_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf0c84181c984977949009a857d8fa3c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib57a417ebdc84df6a8e2b1cade9e5951_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c2883f5567f477db55ba6210ef2d8ef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i72689f291e4242d5be528af1c05de8d9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6a4ab7f7eb574fbebd360c4189819573_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1651b324e8e341258e711103298899a6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia512091aa9cc474e8677a732ef039459_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b263a75424b4a47848e30c65da9385e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib20636276ad04e9d896807348404d0a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1ad0ed0f0ad43ed8c2ee76bcadd6adc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8627db24c8ef4f7e8eb028920efbc320_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i97649db97aba4548addc129f6b210a44_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i48b37f8044404214ab59a210c61d1bf8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id2cb27f4b2244b9482d9a7a4799cb32e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i890467fedbdd4ba3aa14064c4d4782fb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07652d3bbafc4de89373f4382ad0adeb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie2bd578d48664208ba4ed1ca9a668b4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4ecc2576a4cf40d2a8e639f2124feb66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id3dd1fba9fd4476eacb885999e7f77e7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6ea41483449459b936d6bca734640e9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i48b6c2cb1c8a494fa13868c00724fde9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic6cdd346df1c4094b1949ffe62f42958_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i219a217858014087b2e593831b4b4195_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i39e8f6cac3a6489e8ba7ec64fc5e26ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifdbe031717624bf18894ff53096917ee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09fb66d89a964f519eef9b01dd2a64dd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i804e7ae90e0c4170b9443943d0900e79_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i59b3698ee4784a65906fc83187b5d36a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30cb962689ff4c3aa3dbddb683a95c6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9eca0e9d35b487a8f129507b42cea8c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i58b010cf48b94020be75c64bcf4ef43e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i90cb5ac5c4eb41499523aaf1cda7629c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i60ce97a3eb9f46338729167ca12679df_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6597ad2d405542ce9626662507030a7e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id2aebf72749342469c8fe09700344c6b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i120f39a8c06046dc8927af6d7756608e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib54b929ec80d44839ff7152507ca4c1c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86399381f2054cfb96cf8e0c08c527fa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibcf8290ed1234e40ae5260bc12184c04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05ce38678ccd4f96b65c96b347657521_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e2711458b1a41d6b98bc1413bdbc152_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6b2986e81f44720abbc09b89ba3a446_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic57420e235a64a5fb3a723c554ea7d5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icdca84ad76694a69aee10fc9cfd0e0f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d8f94d206814d259cc04e6134260599_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0521592fe8214fdcbf9363ed85d04e75_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibd8fa447f8214bfe917bfea3629882f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if7e1c1e1be2f4fca992ef8ae2c01448e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2564b238dda24ae892c179c7d56fe33c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieed83ef245114b17b4ec315c5b79e99a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if128286fde8e48bda27846143219a6a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i70b0d7eff19849baad70f4c1ccf194fb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6efb41c0e52f44a8bf5e1dc4ac1647b2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia6ecfa420d4d405385cf50e5cbda74b6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i76a570d866504e0a94f3b9b2a20a2f8d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idc9e5b5c9da54691afa3f377ff8c028f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i030326b8c06846669784eeba5596ca2f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3954f8ffb03540639aa7f22b7c875a2a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i375366091dbe420e8154d3503d92c83c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b32c1a4a1954edc8663be651ea566e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if0b3fa0dd16b46198ffe62a62527cae5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic6644b768bf541ba8408590ac2dd5956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51fb68a8e9dd42179b7f44937fd02d2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d41d0a58bfe460d9793cfbb8d115862_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id55754357bb34466811d0d9b089fbfb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77eb6667d87d4a48a23a1c05f70f0054_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8814b6e4d26342739fbd6b838acaa863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae6166c735944a67af8bad5424f2374d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26c0695b52704d2aab04ad37cd4579dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a7c1ee294504734a051a54cc80afd33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i132a91679b794ea4b461110cc358acba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida1c894de1ca4c588bcceda18014bc3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6bc2ff934854878b2f463664d5a6acc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c13850920c64e95897ca644335b133d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i169676a81ad4497aa2d1347caf2c7e5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae71768f86a84ff38722ac63232d8be0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0eecdcc8e5048a587e31bc5751ed3fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie39c0b6bc40a420b862bc4cf852d00bb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idff5589cd93c46cb87913f248b6eb315_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff436f8b9563446293b5781dc7e26b82_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i574448c6d24c4a17ad6bf5c2ba879888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ce49bed180d47aaa7a25633ed9e0d0a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2103bb237f91481a841947ba35171c0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1647014b96864f48aa14287e6d16e887_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i687bee7c6c9147be9f354df54817d16e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3928d17425554a3a99f3ba2ebcf67515_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d7df56418f54686af3bd73d39453c69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib688aa903552456cb0df8bb52f2a6c35_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i753b83af693442cdaf1ec67d12b5d9a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i389d7854847544d0bf805ab6494af671_I20160526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-26</instant>
        </period>
    </context>
    <context id="i51995febb28d40aca39ea569c56e2121_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ShortTermAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i84c7af875bb2430591fb076cbadd84fd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i9b7872ff13c54442a94e52d5702cac2a_I20201005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="icd7d043bf3db47c0ad21c9a2482c6d41_I20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="i1c15e03628914d43970aaad1d2908cff_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="i42838452e79140c2a17a6b085770b63a_I20220516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="i84afbfefdee44283aad3240ba9ff5307_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee48ed1af849452cb48d2605517b57ce_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i91a5f95e9ca04dbeaedc4b0678713b09_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i02d346d3ba744ec1b1737860d62e3b84_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b281ab636c94ea6bd90e055d3589ac1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc55688aaad54360ab017dae30869a94_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i185716a2727648acad1bd93183ea6948_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01c7ee9b693a458cb42ad232c2bffc54_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3429310d21c54f51b8a52e3cdd70ecaf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e01a31d978c42ffbd78aa936eef3109_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia61a04c79d69473eb9ccc0fb8188c965_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf130c14e7754e39a5e8a947488cdf56_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2c6103d6d6474ab09e162650723b7b42_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="ibb1e5a79af6a486eb62a8e55c89d9956_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic785c649e5754160bc5a5ec1d8456f79_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22c03d6d59cb46e1980e5371e1219705_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d5333910ddc449b91395b95aedb3b6e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic437ced0a09847f29ac47c72470b481a_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i880fa33842f74d9c9c0071788d237821_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="ic6402aea5802416894421190b1b7c2aa_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="ia911f16a65084debb3a3812c943cd418_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i2afdf84dc726448aad231c9d735efdf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9468c5dcd0a64aaaad772669a3b8abe9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9295b53dfb2645f78dbe60fefa07587f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="i66fb2504463a49eda96d3323c25ec8da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i1559256d15ff46e2b6b221d76549e677_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="id0041f489e334ddba2da2707d6d6515d_I20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i7ce1955630ff46e58df59ed150227ca5_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i543a231c136d4fbea8192a671046f7d2_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="iae6a49f61bf04d37ad841675aa460161_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i486816b282c448beb5dfc59d3dd09a4b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac5d78fd59e541a99ea4c0f4e1de1d37_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9bafc7ab51364dee96000779f13a8763_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b84e5d94eed444397515564515f6e25_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i554b9366933442a2aa09ffe226b09237_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4944831e440c4e57954464b8eac273a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id88546130308412087cf656552ac4dad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife4673f017ae43eaa5817b3e918cb7df_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib38e44d1e815453f9fa009b512d8c70b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41f08e8bf17b425f835e3620c83e2398_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2103c585e344ff197ab0e7bb4cc2ae9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22bd4f06054f4551a0c04a0a482190a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i977428fb79094a95b2d8d909cdd22eaf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id108621ccf904c55942c6ee24593df70_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba0e76d9070c4128b90730ceba7e6793_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d9ff3681fe9437586096cd7401ca9ce_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a7d2608b4e8487e85fca38da9b0a67c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8420fcd5952417fa51cddbbcf6d44b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i312172e49cc6483fb8ba4c537f5a773e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic09e88a222d54915b2b03b547c38c599_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c42738289064a8ea522bd02105cc6c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf80894786944bc1920dbabf15657881_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i327eb87761364089af22aa767f369073_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i124dbd40c51a45a2bf0196c7305130a2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba3ffb69ea7a49f2a999c26d33b7fd55_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4fe3e9d3d544384841d12bece5bca42_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2e6fb6eea9d48e1a6a317593df48bf6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia304daa15c32499381cbc07b635d095c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1ec14cf55416487cb3ce5a09f7e544f7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>krys:milestone</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl8zLTEtMS0xLTMyMzA5_9e2bc651-42d9-4835-9417-b6cee774c5a8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl81LTEtMS0xLTMyMzA5_d2a6a1d1-78de-422a-a600-d48fe7262915">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl82LTEtMS0xLTMyMzA5_29396079-5fce-463c-978a-b0315ec22d28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl85LTEtMS0xLTMyMzA5_3aca8c7a-1f97-4b35-ae80-4a709ec0cfec">0001711279</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180L2ZyYWc6YjQzNDNmMmY5ZTBmNDE5Mzk2NmZlNTNhMzRlNzMyNjIvdGFibGU6NWFlMjBhYmI2ZjRmNDkxN2E5MTY2M2FiZTVjMDMzYzIvdGFibGVyYW5nZTo1YWUyMGFiYjZmNGY0OTE3YTkxNjYzYWJlNWMwMzNjMl8xMC0xLTEtMS0zMjMwOQ_662ff818-0ed0-4e09-b8ea-e131278b999d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i486816b282c448beb5dfc59d3dd09a4b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjAw_1d212468-e6cb-466c-91ca-14c8b3f2974b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYx_4387d276-1b65-4f66-9808-d4328e11d48c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6OGRhZTIwM2MxNDA1NDkwMzhkOWVjNzk4ZWJlZjZmZjUvdGFibGVyYW5nZTo4ZGFlMjAzYzE0MDU0OTAzOGQ5ZWM3OThlYmVmNmZmNV8wLTAtMS0xLTMyMzA5_35de4c8b-9067-4895-8457-acb1ad1904e7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDI_f0ca4eeb-dfa6-48b4-b035-24b232edd8cf">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6OWI4ODJiM2ZlMjY5NDg5NTkxMjdjZTE3MzFiZDJhMTQvdGFibGVyYW5nZTo5Yjg4MmIzZmUyNjk0ODk1OTEyN2NlMTczMWJkMmExNF8wLTAtMS0xLTMyMzA5_939c5a24-4f90-46d1-b4ca-10b8ca4ca6c3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY4_405e9160-4ed9-4979-8fc1-969cde95b3d7">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcw_a15fdc6b-bd6e-416a-8d19-038571a6d208">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ZTU1MjQ4MzY0ZDQxNDc4OWI4YzE2N2VjOTFhMjUwODgvdGFibGVyYW5nZTplNTUyNDgzNjRkNDE0Nzg5YjhjMTY3ZWM5MWEyNTA4OF8wLTAtMS0xLTMyMzA5_8f90a640-f724-4faa-a32c-85b54268f25a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ZTU1MjQ4MzY0ZDQxNDc4OWI4YzE2N2VjOTFhMjUwODgvdGFibGVyYW5nZTplNTUyNDgzNjRkNDE0Nzg5YjhjMTY3ZWM5MWEyNTA4OF8wLTItMS0xLTMyMzA5_3d048021-fbca-4707-9331-ea0264ab55a4">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU3_f207589b-e058-4f08-861e-c16185df9c4b">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY0_a57b5655-861f-4ea3-8fc0-b08606af9dc6">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcz_6122b57b-f6bc-4424-9b15-ded1c3955c86">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYz_307c4c40-b298-49b0-8f00-a9680fb6492a">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF81OTk_7ecdc0b0-01e1-4df7-9e85-f12156459c31">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU4_dc414435-5c05-45de-a638-b6d380072715">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY1_867072c3-73f0-400e-a94d-5ea344734534">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTAtMS0xLTMyMzA5_ebc3d989-abe6-4bee-a54d-bcc1a8a42042">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTEtMS0xLTMyMzA5_fdd512ec-3436-4124-87db-e957ea945032">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6YTg2NjEwNzM3ZGZhNDcyYjk3MGZmNjQ5N2Q3NmE4YmMvdGFibGVyYW5nZTphODY2MTA3MzdkZmE0NzJiOTcwZmY2NDk3ZDc2YThiY18xLTItMS0xLTMyMzA5L3RleHRyZWdpb246NTc3MmE3MTUyMmMxNDI0OThiN2FkOWRjNDIxNTJhYmFfNA_b56a20e1-677a-4fea-b807-0962a3034a15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDU5_36f5f773-474e-4d42-9d8c-f6fa4e910396">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDY2_0c31382a-f634-4403-8dcf-06f4c59fffc9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ODgxODZkYWM5MWY3NDI4MWFmN2YyN2Q5NjA1Nzc3ZTMvdGFibGVyYW5nZTo4ODE4NmRhYzkxZjc0MjgxYWY3ZjI3ZDk2MDU3NzdlM18wLTAtMS0xLTMyMzA5_21f6ed6a-a763-45e3-bb6e-8824d3e71afa">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGFibGU6ODgxODZkYWM5MWY3NDI4MWFmN2YyN2Q5NjA1Nzc3ZTMvdGFibGVyYW5nZTo4ODE4NmRhYzkxZjc0MjgxYWY3ZjI3ZDk2MDU3NzdlM18xLTYtMS0xLTMyMzA5_2be27b02-cafc-4edd-8bdb-6c4118b255ef">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDYw_08a72298-8a8d-4d62-a80e-27b2b8e16f7a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF8yNDcx_73bdb9e1-e09e-449a-ab30-825b1711032b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if9d41541995b4fe2ab20091cba0c85c2_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xL2ZyYWc6MTY4NDkxZWI5ZTg4NDFmYmE1ZjQ1NmViNDc0OTI0ZjQvdGV4dHJlZ2lvbjoxNjg0OTFlYjllODg0MWZiYTVmNDU2ZWI0NzQ5MjRmNF81NDk3NTU4MTY0MzM_2570e3d7-a887-4281-8e27-d7e538cc9289"
      unitRef="shares">25747647</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNC0xLTEtMS0zMjMwOQ_be1601b4-bd8d-4990-9513-7126cdd368e5"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNC0zLTEtMS0zMjMwOQ_e63d77b7-2151-419d-ad3d-6862ed88b152"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNS0xLTEtMS0zMjMwOQ_a2e570d2-b604-48bd-8646-1521de805e36"
      unitRef="usd">208011000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNS0zLTEtMS0zMjMwOQ_aac274b3-35bd-4def-bf41-77724364f177"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNi0xLTEtMS0zMjMwOQ_ea33eec0-e766-4888-b392-52eb81d121d5"
      unitRef="usd">3158000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNi0zLTEtMS0zMjMwOQ_1c359b13-f5be-4509-b37b-2ae59c4c11c4"
      unitRef="usd">4171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNy0xLTEtMS0zMjMwOQ_3fa69c20-fe92-496c-8c07-90d65502f5be"
      unitRef="usd">397578000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfNy0zLTEtMS0zMjMwOQ_aae909ce-b890-4a9e-80de-007e0fbbbce0"
      unitRef="usd">442267000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOC0xLTEtMS0zMjMwOQ_29e9b2af-a61b-4c7e-b4f9-67bf937a6b25"
      unitRef="usd">157786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOC0zLTEtMS0zMjMwOQ_4864a833-7e4a-4220-9d8f-d08b937f7cb5"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOS0xLTEtMS0zMjMwOQ_a4fb1b9d-6949-43ae-97b4-fef69acfce65"
      unitRef="usd">12557000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfOS0zLTEtMS0zMjMwOQ_69017f24-c9e2-4375-a6b0-197a7c9c7087"
      unitRef="usd">64371000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTAtMS0xLTEtMzIzMDk_6c71d2c7-7383-4f63-ab17-624f0fc86be4"
      unitRef="usd">8253000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTAtMy0xLTEtMzIzMDk_0c3e7594-0462-4ad1-9819-37feafd56786"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTEtMS0xLTEtMzIzMDk_cd8e9edb-24ed-40cf-8275-626ae8eb6893"
      unitRef="usd">205000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTEtMy0xLTEtMzIzMDk_8794b393-e7a6-436b-bcbf-12f83d545f34"
      unitRef="usd">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTItMS0xLTEtMzIzMDk_6d54c019-a6c4-4370-ae74-6f9cac8e95e4"
      unitRef="usd">576379000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTItMy0xLTEtMzIzMDk_fbc62f8e-e082-4ee5-9030-1063d6838d1d"
      unitRef="usd">626295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTUtMS0xLTEtMzIzMDk_f164211c-faa1-4695-8035-41dbd0e3d45e"
      unitRef="usd">5761000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTUtMy0xLTEtMzIzMDk_04fd0183-e658-4f56-bee0-711781205bdd"
      unitRef="usd">8398000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTYtMS0xLTEtMzIzMDk_e1ded526-dc64-4e8d-a1c3-e45e3c19414f"
      unitRef="usd">1547000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTYtMy0xLTEtMzIzMDk_2ccba2a2-356e-4af7-b999-0eb4fcf72881"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTctMS0xLTEtMzIzMDk_0aff9081-56b5-49ef-9f21-3e12c4e453ea"
      unitRef="usd">20724000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTctMy0xLTEtMzIzMDk_6fa9f1c1-0f6b-4e99-9a83-931b4f3ecd92"
      unitRef="usd">16297000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTktMS0xLTEtMzIzMDk_221597f5-4985-40f2-997a-8abce13b0487"
      unitRef="usd">28032000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMTktMy0xLTEtMzIzMDk_a6a19c95-8d12-4b37-9f23-36d30dd115b1"
      unitRef="usd">25736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjAtMS0xLTEtMzIzMDk_443f9f77-9519-4fb7-81d6-d84a1fa52cfb"
      unitRef="usd">7575000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjAtMy0xLTEtMzIzMDk_fed7f12f-2ba0-440f-9b9f-a991d1331160"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjEtMS0xLTEtMzIzMDk_dfb06761-6750-4417-98c0-7943e1d523ee"
      unitRef="usd">35607000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjEtMy0xLTEtMzIzMDk_422c9734-548d-4fc2-be8a-5d0f6bc8dbe5"
      unitRef="usd">32719000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjItMS0xLTEtMzIzMDk_6920e9bf-df3d-4162-81cd-f84bd2d4f523"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjItMy0xLTEtMzIzMDk_a3d27136-e57b-465d-9ebc-a29a85eb9e6c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18yMQ_74ad305a-9f1b-410f-ad9b-1a60dccc51f4"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18yMQ_79a47d81-eda6-431e-b19d-1b56e33016d5"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18zNQ_43263da8-6dae-4a94-8eff-963a9f4defde"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18zNQ_d4636e66-b4bc-4c9f-81c0-a6b6062bb9bb"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N184NQ_45cb5986-a277-46b0-99d4-65d9cbc67cf0"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N184NQ_c96703f8-d0ad-499f-bd50-ffc61006cb73"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18xMTA_1ed14507-88b0-404a-a370-735cbff1958d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjoyMmUzNzlmYmRjYjY0NTIzYWM3ZDlhNDMwZjBiZGI5N18xMTA_7cd93131-b99a-4d73-b1d3-549263b6e77c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMS0xLTEtMzIzMDk_0159f434-8799-4a6c-9df1-dbac47aa3641"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjQtMy0xLTEtMzIzMDk_48fafd8b-40ce-4507-adee-9e5eb3325228"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xOA_222ba38b-0a72-471e-b447-4310e928ae86"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xOA_3fb8305b-45f7-4aa3-a6f2-3c12e3fa7641"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18zMg_aaf8b6fc-398f-43ef-bc78-d204dc504bd5"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18zMg_e7f55288-5968-441a-a032-b11a3b6b1828"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y184Mg_0ae5042a-52f8-442a-bd35-c4e84ceffb4f"
      unitRef="shares">25709664</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y184Mg_3c983527-c1aa-460d-b6c5-5c7138befe57"
      unitRef="shares">25709664</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xNDQ_3aa9e5f4-32dc-4ccb-a7bf-bbf2a4f1cefd"
      unitRef="shares">25207985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMC0xLTEtMzIzMDkvdGV4dHJlZ2lvbjozOGNhMjM0ZWM3OTI0MDZjYmFjZmMwNWUwNDdiMWI5Y18xNDQ_a6fad967-2ce3-4db9-99c3-07e954cf8b43"
      unitRef="shares">25207985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMS0xLTEtMzIzMDk_884c2db8-33f0-4a4f-af3a-55d5ca5a1fb9"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjUtMy0xLTEtMzIzMDk_3eb44ec4-a74a-48c8-ac03-63108ef6207e"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjYtMS0xLTEtMzIzMDk_0f00d53d-8acc-463c-9f7b-df2fa22f85e1"
      unitRef="usd">790954000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjYtMy0xLTEtMzIzMDk_712bbe3f-35dc-4800-bcf3-0cbdac2cc4ec"
      unitRef="usd">734523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjctMS0xLTEtMzIzMDk_63606665-5d0d-4231-baab-5ff4c6a7bee7"
      unitRef="usd">-1475000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjctMy0xLTEtMzIzMDk_0a34d048-121e-4e1f-ab24-2515d3c8670d"
      unitRef="usd">-163000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjgtMS0xLTEtMzIzMDk_01d5176f-4a9c-4e9d-9cbc-2f0d3d70b933"
      unitRef="usd">-248707000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjgtMy0xLTEtMzIzMDk_cff64c0f-ede2-44f9-a8f1-5b5cac4629d0"
      unitRef="usd">-140784000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjktMS0xLTEtMzIzMDk_1911299c-210a-41d6-8919-7930d91afb66"
      unitRef="usd">540772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMjktMy0xLTEtMzIzMDk_3e3ba1e8-14d1-490a-bcf3-e934888028a1"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMzAtMS0xLTEtMzIzMDk_60dc698b-b854-4bf0-80e6-c565e16dcec1"
      unitRef="usd">576379000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xNi9mcmFnOmFkZmJlMzk0YzA2YzQ2YmRhYjEzNjVmOTJmNmY5NDU1L3RhYmxlOmFhMjcyZjliY2E5MjQ5ZmE5OWRkZjU2MTFmNGZlM2RjL3RhYmxlcmFuZ2U6YWEyNzJmOWJjYTkyNDlmYTk5ZGRmNTYxMWY0ZmUzZGNfMzAtMy0xLTEtMzIzMDk_006e34ce-b6bb-401a-b1bc-53990fdb47b4"
      unitRef="usd">626295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy0xLTEtMS0zMjMwOQ_5482876b-8624-409c-a92b-beb6fda01cc6"
      unitRef="usd">11516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy0zLTEtMS0zMjMwOQ_3616e6f9-965f-4069-8100-6041b68c2b6f"
      unitRef="usd">6080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy01LTEtMS0zMjMwOQ_9fbda636-067b-4705-b72d-3adbc9f28d74"
      unitRef="usd">31720000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMy03LTEtMS0zMjMwOQ_bbb4bc54-3d13-4619-a6a4-626929ebd5b8"
      unitRef="usd">18875000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC0xLTEtMS0zMjMwOQ_8d77b4aa-ea07-45cf-b296-7a2a949f806f"
      unitRef="usd">19935000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC0zLTEtMS0zMjMwOQ_7e1242cb-cc68-4bff-9188-0cedfb098b3e"
      unitRef="usd">9572000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC01LTEtMS0zMjMwOQ_d3d35b9f-fe35-408d-a033-c75c130ffd5d"
      unitRef="usd">53705000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNC03LTEtMS0zMjMwOQ_f2f856d4-54ea-40fb-8ceb-1497dcb2d868"
      unitRef="usd">27524000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS0xLTEtMS0zMjMwOQ_5795b03d-12c5-4e3b-8b32-f9531a0822cd"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS0zLTEtMS0zMjMwOQ_1e7b240d-1e03-4a23-bda0-5f85bb8f65c6"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS01LTEtMS0zMjMwOQ_b54454f9-1f54-4ce3-a961-bbd2388aa49a"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNS03LTEtMS0zMjMwOQ_aa5cc2fc-8b34-4173-803f-d4677ac590e8"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi0xLTEtMS0zMjMwOQ_b43cb4ac-e55f-4038-ae57-1e70d77df1ec"
      unitRef="usd">31451000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi0zLTEtMS0zMjMwOQ_edcbd204-7cfc-4738-a5c1-5560c2ae5adc"
      unitRef="usd">15652000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi01LTEtMS0zMjMwOQ_9693abaa-3b9d-4b30-aba3-79e900061383"
      unitRef="usd">110425000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNi03LTEtMS0zMjMwOQ_93d0b8da-8d95-42b0-899e-2bed8cd67127"
      unitRef="usd">46399000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy0xLTEtMS0zMjMwOQ_4c045473-614d-41e3-9169-9f3626f941b7"
      unitRef="usd">-31451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy0zLTEtMS0zMjMwOQ_982681cd-be9a-4a5f-aa59-1205c17abd87"
      unitRef="usd">-15652000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy01LTEtMS0zMjMwOQ_4056f963-6057-4b0c-ade9-0514a5e5e266"
      unitRef="usd">-110425000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfNy03LTEtMS0zMjMwOQ_6fc94f5b-a70b-48cc-a804-044c28a60f3f"
      unitRef="usd">-46399000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS0xLTEtMS0zMjMwOQ_6bdad474-0413-4bf7-87f3-fdccd7dc1390"
      unitRef="usd">1601000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS0zLTEtMS0zMjMwOQ_26e3a281-90dd-452f-b7a3-7602715c327b"
      unitRef="usd">63000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS01LTEtMS0zMjMwOQ_95114045-ad8e-4b96-80fb-08164203f70e"
      unitRef="usd">2502000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfOS03LTEtMS0zMjMwOQ_a3ef526b-ed03-4dfe-bb80-339b7420ffca"
      unitRef="usd">127000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtMS0xLTEtMzIzMDk_8d96324b-ff0d-4d5d-9f4d-9969b9ce1dab"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtMy0xLTEtMzIzMDk_d16e5eb0-5bbc-43df-885a-073f967b5e18"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtNS0xLTEtMzIzMDk_2df8a70e-6051-4ffa-83a6-6b967980ff31"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTAtNy0xLTEtMzIzMDk_f5539d6a-cb0f-49b4-8a1f-e619d0088131"
      unitRef="usd">1492000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtMS0xLTEtMzIzMDk_74dae3ac-7eff-473a-9861-70b8663af050"
      unitRef="usd">-29850000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtMy0xLTEtMzIzMDk_c106287e-1330-40ea-8e2b-f6bff7b8f6f8"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtNS0xLTEtMzIzMDk_d9f264dd-3810-4673-b9ea-1d3c7aa2682d"
      unitRef="usd">-107923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTEtNy0xLTEtMzIzMDk_5778562b-a077-4ab9-8261-27e90db9a6aa"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItMS0xLTEtMzIzMDk_5230b510-eb4f-4260-8a0b-56bef4bfc039"
      unitRef="usd">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItMy0xLTEtMzIzMDk_7c2c06c3-c76f-4d34-994a-9834b6531663"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItNS0xLTEtMzIzMDk_6fadbd6c-f609-403f-9639-fa583916409f"
      unitRef="usd">-1312000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTItNy0xLTEtMzIzMDk_51a9c904-5590-4755-8540-5443f460b3cc"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtMS0xLTEtMzIzMDk_52bf958d-5f1f-480d-9cbe-915c8b853c5d"
      unitRef="usd">-29780000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtMy0xLTEtMzIzMDk_cad20700-80a1-49e6-b6c6-d884ae651789"
      unitRef="usd">-15582000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtNS0xLTEtMzIzMDk_5e8f6933-596c-4809-b8db-594bc850cfb6"
      unitRef="usd">-109235000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTMtNy0xLTEtMzIzMDk_76da43f6-ebdc-464a-93a4-1d62544d9acd"
      unitRef="usd">-47784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMS0xLTEtMzIzMDk_3bdafda1-5f71-4d77-96e3-64fc88c63f29"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMS0xLTEtMzIzMDk_501b7ace-92fd-4f86-9e30-09658267ebd6"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMy0xLTEtMzIzMDk_92d29c3e-e0bc-4e33-9a31-5f2580bdfd09"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtMy0xLTEtMzIzMDk_d818ee47-0fb2-4ddd-9ee5-6084bbf2ad32"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNS0xLTEtMzIzMDk_418b413e-03f4-499c-8729-877d941625da"
      unitRef="usdPerShare">-4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNS0xLTEtMzIzMDk_b041ae85-01fc-4d53-b5d7-c6be253c4b80"
      unitRef="usdPerShare">-4.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNy0xLTEtMzIzMDk_2636aa88-4066-4211-87d9-5c6d57cb8f5b"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTUtNy0xLTEtMzIzMDk_a40b114d-59f0-4b88-9622-2b7473304576"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMS0xLTEtMzIzMDk_402b2894-cc13-4489-b2c2-e65d84c5f2a9"
      unitRef="shares">25619125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMS0xLTEtMzIzMDk_b3d8d660-281d-4c90-ba08-9a9350df584e"
      unitRef="shares">25619125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMy0xLTEtMzIzMDk_1d16f6f4-2db2-45b7-8a29-87abec89b4b5"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctMy0xLTEtMzIzMDk_27b379fc-073b-4b8c-9766-b83fa7ff0851"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNS0xLTEtMzIzMDk_ab13f971-dbb6-4468-afed-6d5359e5eb7f"
      unitRef="shares">25428097</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNS0xLTEtMzIzMDk_fb666474-4aa4-4bf4-ab61-e3f6ec261ffa"
      unitRef="shares">25428097</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNy0xLTEtMzIzMDk_d1062314-81c1-4e3b-8123-ce1fa4b54ddd"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18xOS9mcmFnOmY2Yzg0MDIyZmUxZTRkNzY4ODc0NjU1Nzk2ODhhMjJlL3RhYmxlOmIyZmZjN2VmYjg5MjQzZmY5NTY2NmFhZWE4ODg4ZDUzL3RhYmxlcmFuZ2U6YjJmZmM3ZWZiODkyNDNmZjk1NjY2YWFlYTg4ODhkNTNfMTctNy0xLTEtMzIzMDk_d37b974b-bee1-42f9-865e-7d07187b02e7"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i775193c878c44f59b88bf9723aa001a7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0xLTEtMS0zMjMwOQ_a5b7de49-9798-4342-95fc-ce5def0be4c9"
      unitRef="shares">25207985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i775193c878c44f59b88bf9723aa001a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0zLTEtMS0zMjMwOQ_b4e04624-d652-4bb0-9b06-3833db95532a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dd74b71c5964f71aee86633bf510cf2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy01LTEtMS0zMjMwOQ_a6672d90-e08c-4ac4-b6b7-945370ef8069"
      unitRef="usd">734523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2775a9a719c3456a9237c8c0bfe82b9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy03LTEtMS0zMjMwOQ_d1e07850-8d89-4a2f-bb52-f075b262c53a"
      unitRef="usd">-163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i152425a33b7e4cbcb9970cc97b2cace5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy05LTEtMS0zMjMwOQ_c533aabf-affd-4e24-bd59-5344ce2e8cef"
      unitRef="usd">-140784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMy0xMS0xLTEtMzIzMDk_bd2bb63c-bc2c-42d1-913a-6ceaf992555d"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC0xLTEtMS0zMjMwOQ_5737c8f5-fc26-4bd0-b908-8757a46b103c"
      unitRef="shares">1475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC01LTEtMS0zMjMwOQ_1697b4f8-0bec-4af5-929c-8e253e7ed1d7"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNC0xMS0xLTEtMzIzMDk_d3d85730-2a50-4738-9a03-31b5615045f9"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i3cd97133022341ac99feb4cb37145ff9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS0xLTEtMS0zMjMwOQ_373cd35f-f01a-4833-9260-ff0a0bc93d00"
      unitRef="shares">10379</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS01LTEtMS0zMjMwOQ_2141eead-9c28-474d-882e-5e03a28bd990"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNS0xMS0xLTEtMzIzMDk_249e59b0-c0f3-435e-a76f-d76cb8a162e4"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i631bcf9410fb482a830e52b7e5a1c08a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNi01LTEtMS0zMjMwOQ_3e4fa06e-8e60-41cb-a707-9c4b8f99e996"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNi0xMS0xLTEtMzIzMDk_cbced6ab-a480-4327-bbbc-83bd33a4506d"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3634606c684047bba8c4d34eaa98022c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNy03LTEtMS0zMjMwOQ_b7f693ec-111a-466e-a18a-9319b3646aec"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfNy0xMS0xLTEtMzIzMDk_d7303f78-ee5c-415d-8562-ea3b3a895811"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i840b1bacbbf34eb686c537dd492045ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOC05LTEtMS0zMjMwOQ_edacbd0c-d2b9-4154-8aeb-45d67254ec71"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id16efeb51edf4329b4075b7b5efe0705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOC0xMS0xLTEtMzIzMDk_65d264a5-61e8-4288-ae93-93fabbca8ecb"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0xLTEtMS0zMjMwOQ_ee06bb32-87ab-4d59-9010-d43e0d5aa3c6"
      unitRef="shares">25199081</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1e2e5217f9e142bfaaaecfbd88fb3e1d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0zLTEtMS0zMjMwOQ_1e1331aa-549f-4ad9-9e89-46c05ccc6cc2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8eec4dac16a4daab1a85db49aaf6f9f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS01LTEtMS0zMjMwOQ_f1ebc9e3-9bee-4b50-9224-bcf597e4010c"
      unitRef="usd">740500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea2f3d8999c54a118d9796dcfca0feaf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS03LTEtMS0zMjMwOQ_d223106b-844d-491b-a548-56ed686bb070"
      unitRef="usd">-1197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie10b23711a0741f5a1c060825f98ba98_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS05LTEtMS0zMjMwOQ_fb641333-1ce2-4e47-950c-bad675b1f93c"
      unitRef="usd">-190749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f996c6f367a493784f701839cfebdee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfOS0xMS0xLTEtMzIzMDk_293fbaf6-6f06-434f-98ff-95cc520c8cef"
      unitRef="usd">548554000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i60635a52ed064f588cfe46ee6683334f_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtMS0xLTEtMzIzMDk_da57cb18-3bdc-4f9b-9816-b8051f9d1319"
      unitRef="shares">472706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtNS0xLTEtMzIzMDk_ce8686b5-2b68-41b6-8fd9-e8e74384c6fb"
      unitRef="usd">30748000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTAtMTEtMS0xLTMyMzA5_b25b35a0-9d73-454c-8ddb-68ddb3d46c8e"
      unitRef="usd">30748000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTEtMS0xLTEtMzIzMDk_88b0a64e-b80b-436e-8728-6ac45e0ff8eb"
      unitRef="shares">7500</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib140724ee5fb4c1dbadbaf0eb3697f3d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTItNS0xLTEtMzIzMDk_7a1f0e14-f90d-42ec-a5b6-98fadbda2158"
      unitRef="usd">8335000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTItMTEtMS0xLTMyMzA5_353cc4e4-0b97-4cb1-b2a5-cd2e01dd7b8d"
      unitRef="usd">8335000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3cf27db60a1c497cbf41c87a9b613266_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTMtNy0xLTEtMzIzMDk_05c82cd1-14b2-43b9-b9b0-30809a5f6967"
      unitRef="usd">-348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTMtMTEtMS0xLTMyMzA5_74760308-e0ad-4c75-96d0-96d32f5c0370"
      unitRef="usd">-348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3185b9d4440145839e7322dfeaf5e54a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTQtOS0xLTEtMzIzMDk_bb7fdb83-89ef-4195-905a-5b8b390153b3"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i75404540ff294f7d9fd800e583cabc70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTQtMTEtMS0xLTMyMzA5_e74076cc-9b58-49ef-b9ee-91321c2a10a1"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i895df53b1ba54daab24b6813c0528941_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMS0xLTEtMzIzMDk_2975ebac-6c32-4a94-9ef1-ff0d0c24fe21"
      unitRef="shares">25664287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i895df53b1ba54daab24b6813c0528941_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMy0xLTEtMzIzMDk_098e6c82-838b-4354-8e4d-c4f2e904ee35"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49fd3e7bf09145a0ba746d34252ffa18_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtNS0xLTEtMzIzMDk_6e5e4b76-3890-4189-8c9a-2eb1ba3129ed"
      unitRef="usd">779583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fa7c0396011440f81f7befcb8eedf7d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtNy0xLTEtMzIzMDk_dc77fb0a-ef2c-40b6-b929-c03903584031"
      unitRef="usd">-1545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f9c70f6616c4a18acab21995ed3bd27_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtOS0xLTEtMzIzMDk_d8fa805d-d646-4d09-bbda-add2be114611"
      unitRef="usd">-218857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41ca242fc83249a2920e7e8a2eeda3fc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTUtMTEtMS0xLTMyMzA5_3084a7e3-babe-4688-b983-18129bcd8d79"
      unitRef="usd">559181000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib5edf79ca55d4b1c92d3dde303374d72_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtMS0xLTEtMzIzMDk_4515b419-c088-402f-a855-fda56a8e54e3"
      unitRef="shares">45377</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtNS0xLTEtMzIzMDk_44801026-7621-45ad-98dd-e3d8367ee1be"
      unitRef="usd">2176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTYtMTEtMS0xLTMyMzA5_6e084f40-3468-4d79-ac41-bfeaa19e76dc"
      unitRef="usd">2176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i35671b7a6e2f4d16a478cc041bf1949a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTctNS0xLTEtMzIzMDk_e8730c00-8afb-46f0-9799-db6ebdb31f6b"
      unitRef="usd">9195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTctMTEtMS0xLTMyMzA5_a7db328f-2487-4458-a6ec-5e4fcdefb2d3"
      unitRef="usd">9195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibf0c84181c984977949009a857d8fa3c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTgtNy0xLTEtMzIzMDk_28d6282f-40a7-4577-8648-a45f2439e8b6"
      unitRef="usd">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTgtMTEtMS0xLTMyMzA5_6d79ab1b-5eca-4c6b-b986-586f67d7ec41"
      unitRef="usd">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib57a417ebdc84df6a8e2b1cade9e5951_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTktOS0xLTEtMzIzMDk_9e1a5b64-03f8-46f5-9ffe-2a593fed94ea"
      unitRef="usd">-29850000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMTktMTEtMS0xLTMyMzA5_80676a72-0bc2-4fab-a4f5-66c77a05d92f"
      unitRef="usd">-29850000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3c2883f5567f477db55ba6210ef2d8ef_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMS0xLTEtMzIzMDk_c10f4fe0-1006-423f-9772-5ed8efe82e01"
      unitRef="shares">25709664</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3c2883f5567f477db55ba6210ef2d8ef_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMy0xLTEtMzIzMDk_50d4da83-506b-412c-9d07-65eaf6a417a7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72689f291e4242d5be528af1c05de8d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtNS0xLTEtMzIzMDk_0f25833b-0438-47a1-a682-44cef4be8584"
      unitRef="usd">790954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a4ab7f7eb574fbebd360c4189819573_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtNy0xLTEtMzIzMDk_d0db8166-7eff-4e6a-9dcc-7a08ecbf9d29"
      unitRef="usd">-1475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1651b324e8e341258e711103298899a6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtOS0xLTEtMzIzMDk_c3059603-3561-4347-9964-912aa6ec574e"
      unitRef="usd">-248707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOjcwYjgwMWRkNDFkMTQ1OTE4YTk1NWJlYTYwYmQ1YTVlL3RhYmxlcmFuZ2U6NzBiODAxZGQ0MWQxNDU5MThhOTU1YmVhNjBiZDVhNWVfMjAtMTEtMS0xLTMyMzA5_bb3c93e0-8217-4e8c-9d12-b8be2907213e"
      unitRef="usd">540772000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia512091aa9cc474e8677a732ef039459_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0xLTEtMS0zMjMwOQ_ce5239bb-0678-41c5-9d21-2b225c53c21c"
      unitRef="shares">19714220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia512091aa9cc474e8677a732ef039459_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0zLTEtMS0zMjMwOQ_93491fd4-e461-45c4-b130-1e320dc337e0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b263a75424b4a47848e30c65da9385e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy01LTEtMS0zMjMwOQ_80d43b50-7ab7-4eab-bdfa-c3572bea3992"
      unitRef="usd">363292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20636276ad04e9d896807348404d0a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy03LTEtMS0zMjMwOQ_b8ab6127-300e-4db8-b05f-943fe7b26173"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1ad0ed0f0ad43ed8c2ee76bcadd6adc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy05LTEtMS0zMjMwOQ_f7a17f31-b8d4-4b54-bb4d-2c5dc7ab8121"
      unitRef="usd">-71214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMy0xMS0xLTEtMzIzMDk_df2c5041-65c7-462a-ae74-644423b3b7cb"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8627db24c8ef4f7e8eb028920efbc320_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC0xLTEtMS0zMjMwOQ_d0e2876a-edba-4f3d-b2ae-670e1d50ad1f"
      unitRef="shares">2489837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i97649db97aba4548addc129f6b210a44_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC01LTEtMS0zMjMwOQ_abf2d031-90de-4fda-8fd8-75134e724859"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNC0xMS0xLTEtMzIzMDk_f83c423f-60c1-4b58-9425-37cddc37f4b1"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97649db97aba4548addc129f6b210a44_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNS01LTEtMS0zMjMwOQ_ebcb3d3d-dc46-4292-9583-0310b04cec23"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNS0xMS0xLTEtMzIzMDk_95028779-38cf-469c-a5e1-c531d594a62f"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48b37f8044404214ab59a210c61d1bf8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNi03LTEtMS0zMjMwOQ_237e6212-e239-4cb8-8ff5-d937bc1915bc"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNi0xMS0xLTEtMzIzMDk_935035c2-213c-4cb8-8650-e92c9080e0f7"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id2cb27f4b2244b9482d9a7a4799cb32e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNy05LTEtMS0zMjMwOQ_c9e6d898-bc7f-4e79-ac71-61c294392960"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i033ca87e759847ae9d9bedb9e068b205_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfNy0xMS0xLTEtMzIzMDk_f2d9f195-eb02-4be0-8a88-cfebfe92e5fc"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0xLTEtMS0zMjMwOQ_a683fa73-a5d9-428c-b687-c61cf347ec62"
      unitRef="shares">22204057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ide79ee6fdc854ab4afbb96cdf2b0cca1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0zLTEtMS0zMjMwOQ_4403b45b-2622-40c2-9b5c-ac42c609b0aa"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i890467fedbdd4ba3aa14064c4d4782fb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC01LTEtMS0zMjMwOQ_b388236b-354c-4973-8f72-dc13cf900b64"
      unitRef="usd">517675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07652d3bbafc4de89373f4382ad0adeb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC03LTEtMS0zMjMwOQ_2291ad48-0ef3-49c0-bc56-e6d1833c9530"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2bd578d48664208ba4ed1ca9a668b4a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC05LTEtMS0zMjMwOQ_76b605c7-ee3b-45e8-99b9-81fa27f21a2c"
      unitRef="usd">-87026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ecc2576a4cf40d2a8e639f2124feb66_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOC0xMS0xLTEtMzIzMDk_6f85ccf2-62e6-4a76-a4e8-ab4e62ab1788"
      unitRef="usd">430652000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id3dd1fba9fd4476eacb885999e7f77e7_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS0xLTEtMS0zMjMwOQ_854f423a-85de-48ff-a340-8bd549a9469c"
      unitRef="shares">975</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS01LTEtMS0zMjMwOQ_7368e51f-9bcb-4757-aa9f-056c240c0483"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfOS0xMS0xLTEtMzIzMDk_30dc60e9-fdbd-4a5c-84ab-431aed621aa5"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a5b917a143547dc8e2b50bae13056ff_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTAtNS0xLTEtMzIzMDk_0855ab30-f02b-40da-9392-bef8ba3ab72d"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTAtMTEtMS0xLTMyMzA5_97616d89-8c45-4e78-84fe-25cc8f3044bd"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48b6c2cb1c8a494fa13868c00724fde9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTEtNy0xLTEtMzIzMDk_dd9b6616-30b1-47c6-9e65-16a75d1d9afc"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTEtMTEtMS0xLTMyMzA5_463dd646-be9c-43e1-bb74-0700423dcdfc"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic6cdd346df1c4094b1949ffe62f42958_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTItOS0xLTEtMzIzMDk_86ee2f67-3de8-45ad-ae05-ca7c9b8bc4c9"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if6ea41483449459b936d6bca734640e9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTItMTEtMS0xLTMyMzA5_8fa288ce-914a-4779-af01-2d803a788e60"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i219a217858014087b2e593831b4b4195_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMS0xLTEtMzIzMDk_7e7783e2-1783-482f-b724-539718ab9685"
      unitRef="shares">22205032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i219a217858014087b2e593831b4b4195_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMy0xLTEtMzIzMDk_d398ef09-915e-427b-ade9-ad8e653bef26"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39e8f6cac3a6489e8ba7ec64fc5e26ad_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtNS0xLTEtMzIzMDk_0f941240-2eeb-45e2-a626-104d107f99d2"
      unitRef="usd">521950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifdbe031717624bf18894ff53096917ee_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtNy0xLTEtMzIzMDk_6646d728-a28a-4a90-99ec-b51feb662882"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09fb66d89a964f519eef9b01dd2a64dd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtOS0xLTEtMzIzMDk_6f1b39b1-cbc8-4882-97cb-96c3e73bf74a"
      unitRef="usd">-103389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i804e7ae90e0c4170b9443943d0900e79_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTMtMTEtMS0xLTMyMzA5_111e6ba9-ff0f-478e-b380-99e6343a5234"
      unitRef="usd">418540000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i59b3698ee4784a65906fc83187b5d36a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtMS0xLTEtMzIzMDk_47713a87-ff88-44f7-b10d-8fa3a3c2feab"
      unitRef="shares">32952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtNS0xLTEtMzIzMDk_a62916da-107f-41ce-b444-9c4a32634d8f"
      unitRef="usd">1534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTQtMTEtMS0xLTMyMzA5_5c2df853-6895-481d-9a0c-1bb578fddf7c"
      unitRef="usd">1534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8dd5995d1c044d7082ef1b1851733ae9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTUtNS0xLTEtMzIzMDk_d524679e-863f-4360-bdf3-47e7e44200ae"
      unitRef="usd">3745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTUtMTEtMS0xLTMyMzA5_883b11bc-4dfd-47a8-86e3-c84b26789854"
      unitRef="usd">3745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i30cb962689ff4c3aa3dbddb683a95c6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTYtNy0xLTEtMzIzMDk_68c5aaa7-5a58-44b7-b04f-79f7e564bf82"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTYtMTEtMS0xLTMyMzA5_7a79aa27-2383-4d84-8138-b32c42e18809"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia9eca0e9d35b487a8f129507b42cea8c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTctOS0xLTEtMzIzMDk_c174441f-bf6f-41a8-b727-61a0767d42b1"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTctMTEtMS0xLTMyMzA5_9ebc6cf1-8534-4682-bda3-574a92b1178f"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMS0xLTEtMzIzMDk_104c61a6-ca76-4a0e-8559-49b396d8be0a"
      unitRef="shares">22237984</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic3c9ece298804e9dbc31eb6f1b144fda_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMy0xLTEtMzIzMDk_28b68cff-c0fe-465d-ba9d-cf69fe6cc25a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58b010cf48b94020be75c64bcf4ef43e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtNS0xLTEtMzIzMDk_22991c1c-ae43-46e7-bab2-3711b9132545"
      unitRef="usd">527229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90cb5ac5c4eb41499523aaf1cda7629c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtNy0xLTEtMzIzMDk_44ee6467-7db4-44c6-a0a9-4e461e52b458"
      unitRef="usd">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60ce97a3eb9f46338729167ca12679df_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtOS0xLTEtMzIzMDk_a99e9f70-1836-4d92-a06b-684810e3679f"
      unitRef="usd">-118978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6597ad2d405542ce9626662507030a7e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yMi9mcmFnOmU3YmRhNTM3MWFhYjRiYmI5OGY5NzVmMzU4MjQ3YWY4L3RhYmxlOmYwOTc1ZDFjYTM5MDRlZmQ4NmRmYWEyZDUwOGIyZmNjL3RhYmxlcmFuZ2U6ZjA5NzVkMWNhMzkwNGVmZDg2ZGZhYTJkNTA4YjJmY2NfMTgtMTEtMS0xLTMyMzA5_8268b2ca-928d-4de2-b73b-272105d4cff1"
      unitRef="usd">408237000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMy0xLTEtMS0zMjMwOQ_7934f721-a8cc-48ea-8bae-2abacd24cec3"
      unitRef="usd">-107923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMy0zLTEtMS0zMjMwOQ_f573bb13-c3bd-4f87-9296-3a04715e79f2"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNS0xLTEtMS0zMjMwOQ_508e0117-6aa4-4ed7-9b24-317ff112de44"
      unitRef="usd">2966000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNS0zLTEtMS0zMjMwOQ_2110b8d8-dc0e-4a48-b7e3-663a1cb05eb7"
      unitRef="usd">1985000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNi0xLTEtMS0zMjMwOQ_d16c31a2-8e0e-4f3c-be20-ae2adad72e23"
      unitRef="usd">23678000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNi0zLTEtMS0zMjMwOQ_04b28d67-fcd5-4501-88f2-f483a83cbe6e"
      unitRef="usd">10174000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNy0xLTEtMS00MjU2Nw_2ef5535b-165d-4b2a-8d6e-1350c7787c00"
      unitRef="usd">-22000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNy0zLTEtMS0zMjMwOQ_88d46287-065c-4e9d-ba55-3536889ed1a8"
      unitRef="usd">0</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfOC0xLTEtMS0zMjMwOQ_c95f7815-3312-41d0-a8aa-a931947cfd76"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfOC0zLTEtMS0zMjMwOQ_e66c0614-6b32-4adc-b69a-b7277b063f10"
      unitRef="usd">1492000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTAtMS0xLTEtMzIzMDk_bb914e1a-b7b1-4fd8-bd31-f3c79c5fa5bc"
      unitRef="usd">-224000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTAtMy0xLTEtMzIzMDk_057fee9d-923a-48d5-b6fc-1053bab2bcce"
      unitRef="usd">-224000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTItMS0xLTEtMzIzMDk_c0b080b7-9fc7-43a2-b752-a35dcfee82c5"
      unitRef="usd">-1031000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTItMy0xLTEtMzIzMDk_3474db78-94a7-464a-8bb8-fa41e2c9ccfe"
      unitRef="usd">-1038000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTQtMS0xLTEtMzIzMDk_923a5ca7-81b5-4023-98f7-070973085b94"
      unitRef="usd">31000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTQtMy0xLTEtMzIzMDk_9c9d6b33-fa29-4692-b120-8b91f1ee3c81"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTUtMS0xLTEtMzIzMDk_91a34a12-4d09-4996-851a-68d0ce55074e"
      unitRef="usd">-459000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTUtMy0xLTEtMzIzMDk_d9b61652-67f0-4f9f-8755-10c2e84de9e9"
      unitRef="usd">-240000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTYtMS0xLTEtMzIzMDk_823a583d-5ff3-4217-867a-79c113e25fc8"
      unitRef="usd">-316000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTYtMy0xLTEtMzIzMDk_4d3f7b34-0ba4-4886-b67a-a138395592c0"
      unitRef="usd">-225000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTctMS0xLTEtMzIzMDk_8a834e57-201a-4020-8750-8c7e20b1942a"
      unitRef="usd">3016000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTctMy0xLTEtMzIzMDk_fb5bbd6b-ca26-4b1b-9cec-eed3e082a48c"
      unitRef="usd">6726000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMS0xLTEtMzIzMDk_6b0af62c-24fa-4d51-93a8-334c907e00e0"
      unitRef="usd">-78240000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMy0xLTEtMzIzMDk_8bf34fd1-1f41-46e9-ae34-4b41ec212a26"
      unitRef="usd">-27038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMTktMy0xLTEtMzIzMDk_9df6e537-0fbb-4eea-83eb-5357bdaf6b0e"
      unitRef="usd">-27038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjItMS0xLTEtMzIzMDk_40c3014e-d5ed-421d-9e8a-1b39430f4173"
      unitRef="usd">47762000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjItMy0xLTEtMzIzMDk_bb63658a-a72e-4fce-ac8d-86166ab9735f"
      unitRef="usd">27453000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjMtMS0xLTEtMzIzMDk_b6fe30da-ebb6-4492-94ca-4214f29cc3da"
      unitRef="usd">214712000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjMtMy0xLTEtMzIzMDk_5d8f3217-5fd5-420e-8322-733e72decf16"
      unitRef="usd">83810000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjQtMS0xLTEtMzIzMDk_154757f1-46d8-452b-9ea2-bc6df3a4c9ae"
      unitRef="usd">153599000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjQtMy0xLTEtMzIzMDk_e0ea3e86-84a6-49ee-9293-7759367199a0"
      unitRef="usd">11033000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjYtMS0xLTEtMzIzMDk_22e90e6c-96fa-42ac-9674-c0e7010bb98b"
      unitRef="usd">-108875000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjYtMy0xLTEtMzIzMDk_bc75969f-21c0-4675-8654-31dbc9b26837"
      unitRef="usd">-100230000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjktMS0xLTEtMzIzMDk_db24319d-3903-4b99-9499-e4a7f314e236"
      unitRef="usd">32927000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMjktMy0xLTEtMzIzMDk_4fb71095-511f-4116-b300-9630fc2fb381"
      unitRef="usd">153573000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzAtMS0xLTEtMzIzMDk_001bdce8-e17d-4bcb-b4f1-d6668c79fde7"
      unitRef="usd">649000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzAtMy0xLTEtMzIzMDk_dfad460f-b98f-47dc-9bcf-1997b97eef96"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <krys:PaymentsForSuitLiability
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzEtMS0xLTEtMzIzMDk_3e32abad-b43c-47d8-98bb-90f71df09cf1"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzEtMy0xLTEtMzIzMDk_85c747a5-dc86-4643-a2c6-47a3f130455f"
      unitRef="usd">7960000</krys:PaymentsForSuitLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzItMS0xLTEtMzIzMDk_59aad973-9006-490a-85c6-e13c5c1a2947"
      unitRef="usd">32278000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzItMy0xLTEtMzIzMDk_2dd6edb3-cfa8-44be-bae9-9fef2d9e83bb"
      unitRef="usd">145613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzQtMS0xLTEtMzIzMDk_31534241-3170-4f66-a18c-d24b2f473eda"
      unitRef="usd">-154837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzQtMy0xLTEtMzIzMDk_f2835d24-94b1-466e-8952-f8ffddefa54d"
      unitRef="usd">18345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzYtMS0xLTEtMzIzMDk_a0a88ded-d0d5-4540-b82d-220f1883167d"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iddffec90cbf44b4fbbb0b6f362ea2323_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzYtMy0xLTEtMzIzMDk_fae957fa-165d-4b90-b870-182a4d7d8f7d"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzctMS0xLTEtMzIzMDk_c7d3afdd-9c3f-47d7-b6ca-902a55e96d38"
      unitRef="usd">186409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6597ad2d405542ce9626662507030a7e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfMzctMy0xLTEtMzIzMDk_ca32d3de-1f8a-411a-a30e-aa657fc63b43"
      unitRef="usd">286614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDAtMS0xLTEtMzIzMDk_023bebc9-ca96-47fb-8c64-f75e73c9a587"
      unitRef="usd">15305000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDAtMy0xLTEtMzIzMDk_3cd38222-958f-437b-8e08-00bc91a2f7f5"
      unitRef="usd">23213000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDEtMS0xLTEtMzIzMDk_5f2bc107-5a5d-4ac1-96fc-da037328ef13"
      unitRef="usd">1556000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18yNS9mcmFnOjg3MTczN2ZlM2MzNTRmOGQ5NWY0YjVhNTE4YmU1ZWEyL3RhYmxlOjgyMmM4YzY1NzU4YjRkYmE4NmFhYzE2NjU3ZjA2ZDQ5L3RhYmxlcmFuZ2U6ODIyYzhjNjU3NThiNGRiYTg2YWFjMTY2NTdmMDZkNDlfNDEtMy0xLTEtMzIzMDk_2fb6f8c3-1899-4343-95c0-18d5e0bdfba3"
      unitRef="usd">4396000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMzQ2OA_0bb5bd6b-9ecc-45e7-96e7-e60af875c89e">Organization&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 23, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022 and August 25, 2022, the Company incorporated Krystal Biotech Switzerland GmbH and Krystal Biotech Netherlands, B.V., respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had an accumulated deficit of $248.7 million. With the net proceeds raised from its public offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $394.4 million as of September&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercialize product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMTkzMA_79c428a4-7330-4e73-b268-80bdd17b3b70"
      unitRef="usd">-248700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zMS9mcmFnOjY2Yzg2MmFjZmNjZjQxZGM5YTA4ZDJlZjkxNTdmNjEzL3RleHRyZWdpb246NjZjODYyYWNmY2NmNDFkYzlhMDhkMmVmOTE1N2Y2MTNfMjExMA_cd5b89f3-aef8-46e7-8420-2d67f4f2f2c2"
      unitRef="usd">394400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDA_96d5ee78-3878-401e-9db3-76463ef149fb">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s condensed consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDE_0cc912b7-812d-409c-ad82-acdb2f607e76">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <krys:RisksAndUncertaintiesPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDI_937ab71f-aae2-4fba-8cf3-9e7cf7cbc6d3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;</krys:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzU_b342c623-48a5-41c3-96a8-b95632f73beb">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDQ_ca410790-90ef-412c-acdb-e79050db081d">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfNDE5NQ_713975f2-a8f2-4c85-a89a-cf7d7f7c01f2"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzQ_532d132a-e9b1-4b57-94c6-6eb8cf30f0e6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3MzY_5bcd3852-912a-4973-9491-8ec584ffdd17">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzc_08405c21-7f98-415d-af35-ca795a32fe9c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s condensed consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDk_7d62e5ac-f7ee-4806-bffa-a0da616e5165">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense.&lt;/span&gt;&lt;/div&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzg_f5a6cd98-3e40-441d-9ee1-d852d83a8451">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id2aebf72749342469c8fe09700344c6b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMC0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjAwNzkzZGFhMDBmYTRkZmFiOTkwYzZkNDgwNGQwNWI2XzQ_b230b809-8b5c-46b8-aca8-ce07a1e27bee">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i120f39a8c06046dc8927af6d7756608e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMC0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjAwNzkzZGFhMDBmYTRkZmFiOTkwYzZkNDgwNGQwNWI2Xzk_4888b859-70e5-4ccb-8fed-2156a8241d1d">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib54b929ec80d44839ff7152507ca4c1c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMS0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOmZmNjMwNjc1MzdiYzQ4OThiNzMyMzNlYjRhMjBlM2NmXzQ_a49ca620-f498-4eec-a59d-0c0113f68165">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i86399381f2054cfb96cf8e0c08c527fa_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMS0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOmZmNjMwNjc1MzdiYzQ4OThiNzMyMzNlYjRhMjBlM2NmXzk_75fd958e-b9ee-4aea-939c-5f6e547e96ec">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibcf8290ed1234e40ae5260bc12184c04_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMi0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjNiYzYxMjU4YTc1OTQyNTI4NTFhNTdlMmY1M2RjNzkzXzQ_486a264e-4c91-4538-ba4d-960d65f08fe5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i05ce38678ccd4f96b65c96b347657521_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RhYmxlOjA4ODk0YjUyM2YyYzRjYzJiYTc1YzhiYjBhODIyZTFkL3RhYmxlcmFuZ2U6MDg4OTRiNTIzZjJjNGNjMmJhNzVjOGJiMGE4MjJlMWRfMi0xLTEtMS0zMjMwOS90ZXh0cmVnaW9uOjNiYzYxMjU4YTc1OTQyNTI4NTFhNTdlMmY1M2RjNzkzXzk_2258a2dc-5d64-4b02-bdc1-e2f8bccf14d1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8e2711458b1a41d6b98bc1413bdbc152_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY0OTI2NzQ3MDI1Nw_96f28f6a-87f2-4696-8881-faeed8048238">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY0OTI2NzQ3MDI2NA_ca78295d-6108-4898-8e1c-6d9333dc0c0f">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDU_67b8d913-7e0e-451f-ac42-51e907b274f8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i91ef2bf841e14f4ea07d03c1ca860c24_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_37ad0c03-fe12-40ed-a5c7-e7e5d57f2293"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia6b2986e81f44720abbc09b89ba3a446_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_864304c0-7b9b-45cd-863b-f3f9236a5d30"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ic57420e235a64a5fb3a723c554ea7d5a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_87b17ece-6594-4d24-984f-c9f4da86e859"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="icdca84ad76694a69aee10fc9cfd0e0f8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTAyNzM_f988792e-f414-42e7-b173-010a2a4ec891"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3Mzk_b8042016-120e-4901-bc6c-0480addf714c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDc_0eedf3c6-f3f7-4b2d-a912-9b9a9a67e199">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDY_e0b39fbd-61d9-430c-9426-4fdea0526359">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was &lt;/span&gt;&lt;/div&gt;obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDg_846f9803-ba32-4d7d-9d76-56cf1ec71e3b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNC9mcmFnOjk5NjhmMjQ5OTBiYTQzNGNiZGZhMTg4MjkzYmMxYjdjL3RleHRyZWdpb246OTk2OGYyNDk5MGJhNDM0Y2JkZmExODgyOTNiYzFiN2NfMTY3NDM_a2288690-408b-49c9-9037-ec9e16129f51">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfOTU4_042cb5df-4ae1-40ed-9741-3a6e85c28315">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,565,110 and 1,900,638 common share equivalents outstanding as of September&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,619,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,212,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,428,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,893,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfNjYz_507b9ffd-5617-4993-b985-8d94463123ba"
      unitRef="shares">3565110</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfNjcw_5cf77683-bf1f-4755-a424-b34b2857fddf"
      unitRef="shares">1900638</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RleHRyZWdpb246MzNkYzVhMmQ3MzBkNDJhNTk1MTRlMTc4N2E4NzFkODJfOTU5_386e2d5e-6840-462c-8a96-05cc1c027f0c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,619,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,212,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,428,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,893,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC0xLTEtMS0zMjMwOQ_1d703960-3073-4ad8-831c-d71696c428c2"
      unitRef="usd">-29850000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC0zLTEtMS0zMjMwOQ_aec034b8-37db-4b16-9875-a2d74f2797c1"
      unitRef="usd">-15589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC01LTEtMS0zMjMwOQ_d9f264dd-3810-4673-b9ea-1d3c7aa2682d"
      unitRef="usd">-107923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNC03LTEtMS0zMjMwOQ_5778562b-a077-4ab9-8261-27e90db9a6aa"
      unitRef="usd">-47764000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0xLTEtMS0zMjMwOQ_52dea3c7-a5a1-41f5-88d9-545fceb17f3e"
      unitRef="shares">25619125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0xLTEtMS0zMjMwOQ_62acd11e-994a-44ea-814d-dfd8da28ba34"
      unitRef="shares">25619125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0zLTEtMS0zMjMwOQ_0101e373-9abf-4e95-a83f-4bc14fe8b488"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi0zLTEtMS0zMjMwOQ_404c1125-9ba2-4d6a-9847-7e5748149d80"
      unitRef="shares">22212266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi01LTEtMS0zMjMwOQ_ab13f971-dbb6-4468-afed-6d5359e5eb7f"
      unitRef="shares">25428097</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi01LTEtMS0zMjMwOQ_fb666474-4aa4-4bf4-ab61-e3f6ec261ffa"
      unitRef="shares">25428097</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi03LTEtMS0zMjMwOQ_d1062314-81c1-4e3b-8123-ce1fa4b54ddd"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNi03LTEtMS0zMjMwOQ_d37b974b-bee1-42f9-865e-7d07187b02e7"
      unitRef="shares">21893656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0xLTEtMS0zMjMwOQ_561d2099-208f-422f-996e-757ced4e6c87"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0xLTEtMS0zMjMwOQ_f060c097-72fa-46bf-abd3-bd14d7d928dc"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0zLTEtMS0zMjMwOQ_2053b537-525b-4bd2-968e-6158c6781cfa"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy0zLTEtMS0zMjMwOQ_c0ae468e-bf0b-49d2-8d97-3fb935511392"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy01LTEtMS0zMjMwOQ_418b413e-03f4-499c-8729-877d941625da"
      unitRef="usdPerShare">-4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy01LTEtMS0zMjMwOQ_b041ae85-01fc-4d53-b5d7-c6be253c4b80"
      unitRef="usdPerShare">-4.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy03LTEtMS0zMjMwOQ_2636aa88-4066-4211-87d9-5c6d57cb8f5b"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M18zNy9mcmFnOjMzZGM1YTJkNzMwZDQyYTU5NTE0ZTE3ODdhODcxZDgyL3RhYmxlOjIyYzkwZGQ4NDBmODRlNTg4OGQzMzcxMmE3NmI3MWE3L3RhYmxlcmFuZ2U6MjJjOTBkZDg0MGY4NGU1ODg4ZDMzNzEyYTc2YjcxYTdfNy03LTEtMS0zMjMwOQ_a40b114d-59f0-4b88-9622-2b7473304576"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfNTAz_1ef593aa-b7d4-4f27-a943-5d4f477d6885">Fair Value Instruments&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfNTA0_de36dd1c-2027-467e-80a0-5021f212b723">&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of September&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5d8f94d206814d259cc04e6134260599_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC0xLTEtMS0zMjMwOQ_f6003d6c-863f-441d-93a2-dff678e75050"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d8f94d206814d259cc04e6134260599_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC03LTEtMS0zMjMwOQ_6ffcc009-9c61-4d3b-8537-ebd0706ae0d6"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0521592fe8214fdcbf9363ed85d04e75_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNC05LTEtMS0zMjMwOQ_3858d694-1fcf-46e4-aff5-7c37cfa6e6cd"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd8fa447f8214bfe917bfea3629882f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS0xLTEtMS0zMjMwOQ_44296eb7-2b1d-4ba5-9a20-a51d385dbc9b"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibd8fa447f8214bfe917bfea3629882f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS03LTEtMS0zMjMwOQ_c079868b-b294-4156-a712-8c3db788091b"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if7e1c1e1be2f4fca992ef8ae2c01448e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfNS05LTEtMS0zMjMwOQ_2508bdd4-9019-4000-8cf1-5adb7e64e19c"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xLTEtMS0zMjMwOQ_39953141-9a3f-4cc0-812c-a50d8d4d190a"
      unitRef="usd">52777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0zLTEtMS0zMjMwOQ_bdcc488c-a5fe-4761-bb3d-54f43620a97f"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC01LTEtMS0zMjMwOQ_b8596556-c42a-4030-b173-004d39511fa0"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2564b238dda24ae892c179c7d56fe33c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC03LTEtMS0zMjMwOQ_a789ffe7-c959-4430-9a95-e1e66636fe3d"
      unitRef="usd">52738000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieed83ef245114b17b4ec315c5b79e99a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xMS0xLTEtMzIzMDk_62acea09-18be-4ab8-9b3c-78b6045cf843"
      unitRef="usd">52738000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if128286fde8e48bda27846143219a6a1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOC0xMy0xLTEtMzIzMDk_ceec016c-9fab-4af8-998b-fd14618a96a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xLTEtMS0zMjMwOQ_2d6cb470-defd-4f12-ba67-4a34b9ce5225"
      unitRef="usd">94415000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0zLTEtMS0zMjMwOQ_e29ea89a-a832-4572-818b-0a8a55aca5e9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS01LTEtMS0zMjMwOQ_3ba24749-5e21-46fc-94ef-528918523c49"
      unitRef="usd">886000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70b0d7eff19849baad70f4c1ccf194fb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS03LTEtMS0zMjMwOQ_541aa614-fb0e-414b-b190-2b74a58b557c"
      unitRef="usd">93529000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6efb41c0e52f44a8bf5e1dc4ac1647b2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xMS0xLTEtMzIzMDk_2bef598c-0365-446d-bea7-8c268edffac8"
      unitRef="usd">87291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6ecfa420d4d405385cf50e5cbda74b6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfOS0xMy0xLTEtMzIzMDk_5733b99f-11df-4b5e-803d-27b67cce227e"
      unitRef="usd">6238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMS0xLTEtMzIzMDk_1530d664-7ad6-47bd-bf8d-9169d00c7f67"
      unitRef="usd">74824000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMy0xLTEtMzIzMDk_00861ad7-f071-4ca3-8bb1-f1e17a381fbc"
      unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtNS0xLTEtMzIzMDk_f67bb216-d23e-46cf-b745-2460bac9d5b2"
      unitRef="usd">559000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib045a5c752ac4bf6b3c03edf9b80aa74_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtNy0xLTEtMzIzMDk_9e1bef0a-588a-494f-ba33-0752dd98fb35"
      unitRef="usd">74301000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76a570d866504e0a94f3b9b2a20a2f8d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMTEtMS0xLTMyMzA5_d0a0ac1b-10cf-40d8-a673-aec8330f521e"
      unitRef="usd">67982000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc9e5b5c9da54691afa3f377ff8c028f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTAtMTMtMS0xLTMyMzA5_7a5572c9-b501-4dc7-9f56-8d4577831e43"
      unitRef="usd">6319000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i030326b8c06846669784eeba5596ca2f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMS0xLTEtMzIzMDk_7c1921f4-9a0e-4e6e-89c7-b4f31d93a71c"
      unitRef="usd">222016000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i030326b8c06846669784eeba5596ca2f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMy0xLTEtMzIzMDk_271e384e-3ce3-4cca-9457-a914e7555971"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i030326b8c06846669784eeba5596ca2f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtNS0xLTEtMzIzMDk_606f7658-58aa-4cc3-93b1-f751c1c16b11"
      unitRef="usd">1486000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i030326b8c06846669784eeba5596ca2f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtNy0xLTEtMzIzMDk_4fbad7bd-001b-4f68-9206-16f7af45617e"
      unitRef="usd">220568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMTEtMS0xLTMyMzA5_f9dc5c61-f2b7-46df-9aa8-23956375fb2e"
      unitRef="usd">208011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3954f8ffb03540639aa7f22b7c875a2a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTEtMTMtMS0xLTMyMzA5_a4a9da1c-6633-4a3f-8574-1a27ba179a3a"
      unitRef="usd">12557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMS0xLTEtMzIzMDk_20dd6fe3-fa1f-4b92-a1f0-74d83b6bba1b"
      unitRef="usd">408425000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMy0xLTEtMzIzMDk_d23bb6f0-46ce-46bd-889a-0f3bef5967a7"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItNS0xLTEtMzIzMDk_b624fca5-7fbe-4605-9afc-41d8c8fff8d1"
      unitRef="usd">1486000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItNy0xLTEtMzIzMDk_f30777aa-1856-4792-a27c-577e77b89d6f"
      unitRef="usd">406977000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i375366091dbe420e8154d3503d92c83c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItOS0xLTEtMzIzMDk_fae7d934-ccae-4f80-9208-35410ea27bab"
      unitRef="usd">186409000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i2b32c1a4a1954edc8663be651ea566e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMTEtMS0xLTMyMzA5_069c13ac-3e47-4160-ba21-94a04c8d4598"
      unitRef="usd">208011000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="if0b3fa0dd16b46198ffe62a62527cae5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjYxZGJkMWNlYmNmOTQ1NWZhYmYwYzU0NGQ0MDE5NjQ4L3RhYmxlcmFuZ2U6NjFkYmQxY2ViY2Y5NDU1ZmFiZjBjNTQ0ZDQwMTk2NDhfMTItMTMtMS0xLTMyMzA5_bc9c31d4-a177-4318-a8c2-b072062ae25e"
      unitRef="usd">12557000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic6644b768bf541ba8408590ac2dd5956_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy0xLTEtMS0zMjMwOQ_7f7733e1-1981-4e08-92a9-916aa88a6486"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6644b768bf541ba8408590ac2dd5956_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy03LTEtMS0zMjMwOQ_137431b4-b3b6-4d9b-92ca-936eeec4841c"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i51fb68a8e9dd42179b7f44937fd02d2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMy05LTEtMS0zMjMwOQ_e42e5b20-aed3-42d5-8700-fddaa706fc53"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS0xLTEtMS0zMjMwOQ_d6bfcbc3-3f99-4413-8be9-53bbc1c87423"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f5ce2ee92cd45b8a7dc3569d9600ed5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS03LTEtMS0zMjMwOQ_bf1dfa82-56b7-434b-a7ef-65f2746f2f84"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d41d0a58bfe460d9793cfbb8d115862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNS05LTEtMS0zMjMwOQ_c6af172e-a5fb-4fe2-8495-df8a130ffad2"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xLTEtMS0zMjMwOQ_651f3432-c46e-49c4-ad2f-a0861c81e22a"
      unitRef="usd">40469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0zLTEtMS0zMjMwOQ_78ce6479-2dce-4c6e-bd3d-cbe1b15d81da"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy01LTEtMS0zMjMwOQ_0cbdc0d6-958f-4eb4-8e7f-5a62a79de95f"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id55754357bb34466811d0d9b089fbfb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy03LTEtMS0zMjMwOQ_4d26b013-12cd-4042-8958-ead8956168f3"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77eb6667d87d4a48a23a1c05f70f0054_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xMS0xLTEtMzIzMDk_997f8b6b-6255-49ec-a1d5-ca70f81b3029"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8814b6e4d26342739fbd6b838acaa863_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfNy0xMy0xLTEtMzIzMDk_4ab38b61-a131-4625-a509-a41368ba64d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xLTEtMS0zMjMwOQ_fde0c520-4929-40c8-bfc5-61bf65a12011"
      unitRef="usd">83300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0zLTEtMS0zMjMwOQ_88c103ac-ee6e-4dd4-b774-39fc46020695"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC01LTEtMS0zMjMwOQ_171975db-a213-4513-9dd4-fe119d9d7b59"
      unitRef="usd">114000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f864bb8a0ca4ccda79d6b13964e535d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC03LTEtMS0zMjMwOQ_23a87595-a68d-4e9e-9c24-573d3c76cf16"
      unitRef="usd">83196000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae6166c735944a67af8bad5424f2374d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xMS0xLTEtMzIzMDk_8e7d5da5-efb2-4793-b3b0-1847fa60753e"
      unitRef="usd">35768000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26c0695b52704d2aab04ad37cd4579dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOC0xMy0xLTEtMzIzMDk_3232b653-0c68-4d74-bd93-78e50927af7f"
      unitRef="usd">47428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xLTEtMS0zMjMwOQ_dc3f4523-2706-421a-b5bb-adb277c34f7d"
      unitRef="usd">37621000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0zLTEtMS0zMjMwOQ_db4bc97b-7cfb-4f98-b0d2-7d5eefd916ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS01LTEtMS0zMjMwOQ_885fcacf-c4eb-4e4b-8d89-fbefc99b1056"
      unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a7c1ee294504734a051a54cc80afd33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS03LTEtMS0zMjMwOQ_48cbc2a0-368b-482f-9248-72a6199c3cd2"
      unitRef="usd">37559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i132a91679b794ea4b461110cc358acba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xMS0xLTEtMzIzMDk_d0d4e4dc-7eea-428d-9332-37f657d94cc9"
      unitRef="usd">20616000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida1c894de1ca4c588bcceda18014bc3d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfOS0xMy0xLTEtMzIzMDk_41b2b41b-1195-44a2-a733-d546aec583e3"
      unitRef="usd">16943000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMS0xLTEtMzIzMDk_38b47082-7423-40bf-b9d2-e36f2302a35a"
      unitRef="usd">161390000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMy0xLTEtMzIzMDk_2dd7fded-88db-4421-9418-0a9f214ddc70"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtNS0xLTEtMzIzMDk_7aa4dc67-ffef-43ff-a731-ffaafab235e6"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id153b0bb8c28418b9401f74b6ba0f3a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtNy0xLTEtMzIzMDk_822171ec-9876-4637-ab2c-517caf984ffe"
      unitRef="usd">161221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6bc2ff934854878b2f463664d5a6acc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMTEtMS0xLTMyMzA5_568638dc-2a93-425d-bc33-4f86d8a9a4bd"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c13850920c64e95897ca644335b133d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTMtMTMtMS0xLTMyMzA5_064cdab6-d233-417d-9db8-ae4f1d178e5b"
      unitRef="usd">64371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMS0xLTEtMzIzMDk_3a1e3ead-f94e-4321-a8dd-ffa6ac9e383e"
      unitRef="usd">502636000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMy0xLTEtMzIzMDk_1e03fbf8-4345-4116-9094-f727aeb9077d"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtNS0xLTEtMzIzMDk_9127c0c7-670e-4783-b930-918d5ea47e27"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtNy0xLTEtMzIzMDk_249b7f4a-7f8d-4630-a532-04d3c791938d"
      unitRef="usd">502467000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i169676a81ad4497aa2d1347caf2c7e5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtOS0xLTEtMzIzMDk_3579be58-b57d-440a-93ca-56fef0a6859c"
      unitRef="usd">341246000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="iae71768f86a84ff38722ac63232d8be0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMTEtMS0xLTMyMzA5_bf50aeb9-4a17-430f-9a2b-a9e04839734e"
      unitRef="usd">96850000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="id0eecdcc8e5048a587e31bc5751ed3fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RhYmxlOjA1NDdhZTJiOWNjOTQ0NGY5ODM0N2M0MWM3N2Y0ZDJmL3RhYmxlcmFuZ2U6MDU0N2FlMmI5Y2M5NDQ0Zjk4MzQ3YzQxYzc3ZjRkMmZfMTQtMTMtMS0xLTMyMzA5_9fcee2a0-5985-44e9-8b0c-0e49b0a666c0"
      unitRef="usd">64371000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i95e7592bc21a4dddb6b2f42c92e1dbb3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMjcy_14c657fb-a1f9-4660-9cba-4e80749fd7c4">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ie39c0b6bc40a420b862bc4cf852d00bb_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMzQ1_61969a78-9774-47c8-b9f3-cb96540a764e">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="idff5589cd93c46cb87913f248b6eb315_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180MC9mcmFnOmY1OGExZTA4MzIwNzRkMTdiMGRkMDllODA3MjI3M2VkL3RleHRyZWdpb246ZjU4YTFlMDgzMjA3NGQxN2IwZGQwOWU4MDcyMjczZWRfMzUy_9201be19-95cb-4f64-80c7-47e00b6e1f0f">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzg4_2962c23b-aa2a-4554-a1c1-bc9de6c187e5">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $669 thousand and $1.6 million for the three and nine months ended September&#160;30, 2022 and $474 thousand and $1.4 million for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzg5_49d12821-33c3-404a-b275-fe6746128ac6">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff436f8b9563446293b5781dc7e26b82_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMi0xLTEtMS0zMjMwOQ_9885203a-1dcb-4e7a-910d-98cc65a1d312"
      unitRef="usd">130071000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i574448c6d24c4a17ad6bf5c2ba879888_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMi0zLTEtMS0zMjMwOQ_f3c2f698-32b6-4f70-836a-d4acb246cd4a"
      unitRef="usd">104340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0ce49bed180d47aaa7a25633ed9e0d0a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMy0xLTEtMS0zMjMwOQ_5e4a8ec2-fe75-4c8f-934c-5a2e96fd9aa2"
      unitRef="usd">21503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2103bb237f91481a841947ba35171c0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfMy0zLTEtMS0zMjMwOQ_557fe7e4-aa3b-4247-a9f3-9154790e8482"
      unitRef="usd">5723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1647014b96864f48aa14287e6d16e887_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNC0xLTEtMS0zMjMwOQ_ee817eb5-e36a-47c7-8749-3f74a181867b"
      unitRef="usd">949000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i687bee7c6c9147be9f354df54817d16e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNC0zLTEtMS0zMjMwOQ_4718516e-8faa-493b-8cd1-c3b66a774065"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3928d17425554a3a99f3ba2ebcf67515_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNS0xLTEtMS0zMjMwOQ_e1e77131-4b91-4152-9329-90310b7d46dc"
      unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2d7df56418f54686af3bd73d39453c69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNS0zLTEtMS0zMjMwOQ_96fc969b-57af-4311-85e3-67affe5fdaf0"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib688aa903552456cb0df8bb52f2a6c35_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNi0xLTEtMS0zMjMwOQ_5b03dda9-8c1a-4a4d-98f8-765b9c26624b"
      unitRef="usd">10968000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i753b83af693442cdaf1ec67d12b5d9a3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNi0zLTEtMS0zMjMwOQ_6a08d154-5c8d-4ec0-afd6-fa45d2ae7b87"
      unitRef="usd">5530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNy0xLTEtMS0zMjMwOQ_09e7619d-2446-49b3-b3f5-7fd95de660ad"
      unitRef="usd">163587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfNy0zLTEtMS0zMjMwOQ_8cacb562-28c4-45e6-8573-b0dab284d62f"
      unitRef="usd">116569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOC0xLTEtMS0zMjMwOQ_b67a6b7d-dfec-4e16-acd3-98b34a7f38bc"
      unitRef="usd">5801000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOC0zLTEtMS0zMjMwOQ_4856252a-810e-4ff5-ba6d-959a9ff666ef"
      unitRef="usd">4214000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOS0xLTEtMS0zMjMwOQ_b67a2443-54d4-47bd-bfff-8c514161c1a7"
      unitRef="usd">157786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjlhMTA3M2E1M2U3NzRhZjNhMTk3YmE2MzIyNzdmZWY1L3RhYmxlcmFuZ2U6OWExMDczYTUzZTc3NGFmM2ExOTdiYTYzMjI3N2ZlZjVfOS0zLTEtMS0zMjMwOQ_487a83c4-1799-43ef-81e2-88eadd10379d"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTU3_ce380f64-94dd-4f29-858d-4813dcdaf611"
      unitRef="usd">669000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTY0_f6db0d16-f7f2-4ae2-9e89-a9eecbf6f1c5"
      unitRef="usd">1600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMTk4_0fa48764-6fb4-4461-8573-55162e557f48"
      unitRef="usd">474000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMjA1_9e9f36a5-c0e9-4d6f-84c9-e5a641dfa3f3"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RleHRyZWdpb246YjhmYTVmNDhjNTc0NDgxN2ExOTkwYmRlZTU5ZjQ3ZjNfMzkw_c3676749-9a25-48a6-89cf-7a7d222555b4">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMi0xLTEtMS0zMjMwOQ_41c80a80-454e-465e-b1ad-5cf2fb3778e4"
      unitRef="usd">10905000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMi0zLTEtMS0zMjMwOQ_e71e8f38-e246-4fac-ae58-cbff552f8c25"
      unitRef="usd">9606000</krys:AccruedConstructionInProgressCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMy0xLTEtMS0zMjMwOQ_a8a06a56-d0d4-4951-8a78-bb1ce1e8e718"
      unitRef="usd">2960000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMy0zLTEtMS0zMjMwOQ_53f09a3c-7f21-41ba-b67d-70a0d38cfe43"
      unitRef="usd">2011000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNC0xLTEtMS0zMjMwOQ_abe4dba7-8881-430d-b5dc-800dc34c8312"
      unitRef="usd">3934000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNC0zLTEtMS0zMjMwOQ_6a594adc-d95a-4221-8249-4d655b0dd710"
      unitRef="usd">2882000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNS0xLTEtMS0zMjMwOQ_15fe12ab-51c6-4ed4-9fe3-e35bb154661f"
      unitRef="usd">2325000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNS0zLTEtMS0zMjMwOQ_647ff41e-442b-4a3b-b90d-e0efdd674d57"
      unitRef="usd">1602000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNi0xLTEtMS0zMjMwOQ_343740d0-8cdb-4f37-a6a4-40aa56ab19e0"
      unitRef="usd">10000</krys:AccruedFinancingFeesCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNi0zLTEtMS0zMjMwOQ_20458e50-27f1-432c-865d-3d8320a279a7"
      unitRef="usd">26000</krys:AccruedFinancingFeesCurrent>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNy0xLTEtMS0zMjMwOQ_3ea37770-5618-4bef-8315-e9ea78b580b3"
      unitRef="usd">122000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfNy0zLTEtMS0zMjMwOQ_89b50c50-4904-403b-ab53-7fd4cbd85e1d"
      unitRef="usd">83000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfOS0xLTEtMS0zMjMwOQ_e5274027-1271-4059-a3f9-3393508b04f0"
      unitRef="usd">468000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfOS0zLTEtMS0zMjMwOQ_be4b65c1-6555-43f6-946f-b323ee5b6cfc"
      unitRef="usd">87000</us-gaap:OtherLiabilitiesCurrent>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMTAtMS0xLTEtMzIzMDk_ba8ae902-8ff6-42a7-885e-19b0ed759a31"
      unitRef="usd">20724000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180My9mcmFnOmI4ZmE1ZjQ4YzU3NDQ4MTdhMTk5MGJkZWU1OWY0N2YzL3RhYmxlOjQxMDk2Zjg0MWU5MDQ0MDViYTA1NWRmNjg2NDY3NGU1L3RhYmxlcmFuZ2U6NDEwOTZmODQxZTkwNDQwNWJhMDU1ZGY2ODY0Njc0ZTVfMTAtMy0xLTEtMzIzMDk_908ed7fb-f5b3-48bf-8499-d35ee999f1c8"
      unitRef="usd">16297000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzQ_311f26dd-bd72-4def-8219-63c3e7c4791a">Commitments and Contingencies&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Contracts and Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#x201c;2016 Lease&#x201d;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. On September 30, 2022, the Company amended the 2016 Lease ("Short-Term Amendment") to add a short-term lease for additional office space that commenced on October 1, 2022 and expires on September 30, 2023. The amendment increased the area leased by approximately 7,000 square feet through September 30, 2023, resulting in a total area leased of approximately 54,000 square feet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $2.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of September&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed in 1H 2023.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office that commenced on September 1, 2022 and expires December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, future minimum commitments under the Company&#x2019;s operating leases with lease terms in excess of 12 months were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Short-Term Amendment not exceeding twelve months, the Company has not recorded a right-of-use asset or corresponding lease liability for the amendment as of September 30, 2022. Future minimum remaining operating lease payments under this amendment are $40&#160;thousand and $121&#160;thousand for the years ending December 31, 2022 and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Manufacturing Organizations and Contract Research Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of September&#160;30, 2022 under these agreements is approximately $2.4 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $2.1 million and $5.1 million for each of the three and nine months ended September&#160;30, 2022 and $744 thousand and $3.3 million for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Preparedness Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $6.2 million. The Company has incurred expenses under these activities of $3.2 million and $9.5 million for the three and nine months ended September&#160;30, 2022 and $1.8 million and $4.1 million for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to complete the interior build-out of our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of September&#160;30, 2022 is $10.3 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#x201c;Agreement&#x201d;) with The Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), pursuant to which Whiting-Turner is constructing and managing the interior construction of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $84.1&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the nine months ended September&#160;30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of September&#160;30, 2022, and therefore no additional accrual has been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received $0 and $768&#160;thousand of insurance proceeds during the three and nine months ended September&#160;30, 2022  and Company recorded an additional $372&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="i389d7854847544d0bf805ab6494af671_I20160526"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMzc4_0d17ca30-cb03-4d39-ae88-d0dfd37c6438"
      unitRef="sqft">47000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="i51995febb28d40aca39ea569c56e2121_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODI0NjMzNzIyNDg5Nw_e2e69085-83eb-413e-8e05-a65c6b9de518"
      unitRef="sqft">7000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="i84c7af875bb2430591fb076cbadd84fd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODI0NjMzNzIyNDkwNA_60e82c67-ddf3-4014-8ece-f8701e653628"
      unitRef="sqft">54000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTc0NA_beb76c81-d386-4fc8-a9ac-33c8c04f56fd"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:FinanceLeaseLiability
      contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjAzOA_9df19561-d728-4c70-8ee3-7adf872f0626"
      unitRef="usd">10000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:ConstructionInProgressGross
      contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjAzOA_df173c30-a9c8-4c70-92f4-192c53709122"
      unitRef="usd">10000000</us-gaap:ConstructionInProgressGross>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i9b7872ff13c54442a94e52d5702cac2a_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjE5Mg_ec949c50-a6a8-4de8-91e5-5515bbecd416"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i0c1b445f109f4c4cbf1d51d630451cf5_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjQwOQ_97170f0e-88b5-47e8-8ee3-fd46e850b409"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:EscrowDeposit
      contextRef="icd7d043bf3db47c0ad21c9a2482c6d41_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMjQ0NA_724e8338-bcb2-48d5-9839-dc1feffb89c2"
      unitRef="usd">1500000</us-gaap:EscrowDeposit>
    <krys:LessorOperatingLeaseLiabilityAnnualLeasePayments
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDMwMA_645dfb25-f023-44a1-b626-01ed8a0c9a2e"
      unitRef="usd">82000</krys:LessorOperatingLeaseLiabilityAnnualLeasePayments>
    <krys:CumulativeEscalationClausePercent
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDMzNg_10d48fed-7f28-462d-8de5-fe932b5c4de6"
      unitRef="number">0.10</krys:CumulativeEscalationClausePercent>
    <krys:CumulativeEscalationClauseTerm
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDM2Mw_9248c05b-4059-445a-9b94-b5c3eba28fab">P5Y</krys:CumulativeEscalationClauseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1c15e03628914d43970aaad1d2908cff_I20211215"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNDQzMA_a3d4670b-0aa2-49d6-9a20-24913b6b8d0f">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i42838452e79140c2a17a6b085770b63a_I20220516"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI3MTcy_81a0d963-cb14-47a8-bd1c-0bd6fb542042">P16M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzU_b97a88a2-edf5-47b5-a4a4-95e83ff72112">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, future minimum commitments under the Company&#x2019;s operating leases with lease terms in excess of 12 months were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMS0xLTEtMS0zMjMwOQ_00b1865f-9a9a-4b7d-a6c4-69fe3e8e8606"
      unitRef="usd">404000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMi0xLTEtMS0zMjMwOQ_c670dc8d-a77b-4717-a8af-2bd45c53280c"
      unitRef="usd">1640000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfMy0xLTEtMS0zMjMwOQ_63e3bc84-5939-4dca-9597-17208f4d8967"
      unitRef="usd">1539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNC0xLTEtMS0zMjMwOQ_29135f8d-b9df-48a9-9fc4-8e4338b245db"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNS0xLTEtMS0zMjMwOQ_8952ac97-4f37-47d6-a4f0-d3276022c99c"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNi0xLTEtMS0zMjMwOQ_4443ffd6-661c-403a-9f80-45216fe7693a"
      unitRef="usd">12062000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfNy0xLTEtMS0zMjMwOQ_25a9449b-a54e-4a4f-b542-e8c8212837ec"
      unitRef="usd">18199000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfOC0xLTEtMS0zMjMwOQ_b3f2f67e-a956-4e31-9347-20696226502e"
      unitRef="usd">9077000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjIyYjlkNDYwMDk3ZjRhZGY5NDVjODEyM2E0YThhY2I3L3RhYmxlcmFuZ2U6MjJiOWQ0NjAwOTdmNGFkZjk0NWM4MTIzYTRhOGFjYjdfOS0xLTEtMS0zMjMwOQ_8378a6de-47b5-424e-a154-cb32f5aa9e7b"
      unitRef="usd">9122000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i84afbfefdee44283aad3240ba9ff5307_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI5MDk0_2f1025b9-6ad5-421e-811e-dbda103d6ff7"
      unitRef="usd">40000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iee48ed1af849452cb48d2605517b57ce_I20231231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNTQ5NzU1ODI5MDc5_d0ab9448-f427-4ee7-850d-bad559373099"
      unitRef="usd">121000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTI3MzY_2368d432-4ba2-4bc6-acfa-a2690a37abaa">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfMy0xLTEtMS0zMjMwOQ_a9cf8d76-6a2e-41ca-b936-fc4cce44dfc1"
      unitRef="usd">8253000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfMy0zLTEtMS0zMjMwOQ_02b16c7c-f04f-4b73-836f-62f964cd16c9"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNC0xLTEtMS0zMjMwOQ_0896e064-1b00-433a-a973-046bc3349a9d"
      unitRef="usd">1547000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNC0zLTEtMS0zMjMwOQ_b3c4de5c-1234-4696-829b-5f4c3663e64b"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNS0xLTEtMS0zMjMwOQ_02d891e1-43f7-4f97-ade8-6aa67120dc73"
      unitRef="usd">7575000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNS0zLTEtMS0zMjMwOQ_993e54ac-4d13-46d1-b3ce-fdef8a65db1d"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNi0xLTEtMS0zMjMwOQ_2a99f8df-8f44-42ac-9e65-b91b61a5012f"
      unitRef="usd">9122000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNi0zLTEtMS0zMjMwOQ_9dece3e8-771c-4896-a9a7-b9f12f4d6d6d"
      unitRef="usd">8024000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNy0xLTEtMS0zMjMwOQ_e9694614-90f6-4069-b4a5-070a2cc33191">P12Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfNy0zLTEtMS0zMjMwOQ_b24783a9-135b-4325-a40e-90d4c9cb19c7">P14Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfOC0xLTEtMS0zMjMwOQ_2eead473-4c31-4238-a5c7-be5211061342"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjkyMDhmMmM2ODJjODRiNjNhNGEyOTRhNzA2Y2RkMThiL3RhYmxlcmFuZ2U6OTIwOGYyYzY4MmM4NGI2M2E0YTI5NGE3MDZjZGQxOGJfOC0zLTEtMS0zMjMwOQ_e9b08bd4-2fa8-4f29-b516-2880e8b74e14"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTY0OTI2NzQ1NTY1Mw_a0b2e3bf-3940-485c-af04-10714ea3293f">&lt;div style="margin-top:2pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC0xLTEtMS0zMzQxOQ_16c8af71-c7c7-4602-bbf8-6e34caeaad53"
      unitRef="usd">399000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC0zLTEtMS0zMzQwMA_e66120b8-c07a-466f-bd10-20edfe9233fd"
      unitRef="usd">339000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC01LTEtMS0zMzQyMQ_fa38a7b1-fc8a-47f3-aed8-576b82e9315d"
      unitRef="usd">1200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNC03LTEtMS0zMzQwMw_ef8b4e8c-a210-48b4-a1da-a38f17dd5809"
      unitRef="usd">836000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS0xLTEtMS0zMzQyMw_4d59234a-91bf-4d9c-90e7-cf73d4bf1aef"
      unitRef="usd">48000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS0zLTEtMS0zMzQwNg_33974e68-54b0-4f93-971e-1b0d88a8b0a6"
      unitRef="usd">65000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS01LTEtMS0zMzQyNQ_8055539a-f301-40a5-bb33-bc648f33754c"
      unitRef="usd">168000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNS03LTEtMS0zMzQwOQ_200f5d9b-59df-4aea-a56b-7dd742da22e1"
      unitRef="usd">183000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi0xLTEtMS0zNDkzNw_0aec91c6-6218-42e6-b3dd-4e0042191c52"
      unitRef="usd">447000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi0zLTEtMS0zNDk0MQ_14b27905-cc32-43e9-ba69-917af22e4a66"
      unitRef="usd">404000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi01LTEtMS0zNDk0Mw_c4cd17cc-0971-4b08-a03a-fda9e15410bd"
      unitRef="usd">1368000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RhYmxlOjY2ZTlhNzAyMGVhMDQzNDU5ZTE0NTQ1MTk5Nzg4OWE3L3RhYmxlcmFuZ2U6NjZlOWE3MDIwZWEwNDM0NTllMTQ1NDUxOTk3ODg5YTdfNi03LTEtMS0zNDk0NQ_98f1dc1c-9c13-41a3-bc0f-6500638e65c6"
      unitRef="usd">1019000</us-gaap:LeaseCost>
    <krys:RemainingCommitmentAmount
      contextRef="i91a5f95e9ca04dbeaedc4b0678713b09_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjQyOA_93d4d964-8d3a-4eb1-bac4-f788d1ab53bf"
      unitRef="usd">2400000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i02d346d3ba744ec1b1737860d62e3b84_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjYzNw_fbd8e312-7cfe-4385-94f7-15db2ab930e7"
      unitRef="usd">2100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i6b281ab636c94ea6bd90e055d3589ac1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY0NA_2078ac48-1ee3-48db-91c9-446866feffa8"
      unitRef="usd">5100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="idc55688aaad54360ab017dae30869a94_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY4Ng_218b5612-61f7-48ed-8fde-e1333e60209c"
      unitRef="usd">744000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i185716a2727648acad1bd93183ea6948_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNjY5Mw_9fdce779-19db-4462-8f7c-54a0a73d15e6"
      unitRef="usd">3300000</us-gaap:ProfessionalFees>
    <krys:RemainingCommitmentAmount
      contextRef="i01c7ee9b693a458cb42ad232c2bffc54_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzExNw_0e6db719-1f25-45af-af62-412740ecec4d"
      unitRef="usd">6200000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i3429310d21c54f51b8a52e3cdd70ecaf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzE4MQ_63db0664-3e89-4957-9ea4-00472d833b66"
      unitRef="usd">3200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i2e01a31d978c42ffbd78aa936eef3109_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzE4OA_4d718002-1b3f-4808-aace-c47cd12c1a8f"
      unitRef="usd">9500000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ia61a04c79d69473eb9ccc0fb8188c965_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzIyMg_55971c8b-c5e9-4942-ab7a-23ce986a5ba4"
      unitRef="usd">1800000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="iaf130c14e7754e39a5e8a947488cdf56_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzIyOQ_fbe7599f-08d9-4b6a-adb7-382dbca18033"
      unitRef="usd">4100000</us-gaap:ProfessionalFees>
    <us-gaap:ContractualObligation
      contextRef="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfNzc0MQ_f5e7d62f-f14f-4f81-9661-90f688b3150d"
      unitRef="usd">10300000</us-gaap:ContractualObligation>
    <krys:CostOfWorkPercentage
      contextRef="i13d58cc37aff4a7bb53bcc5bf99d5fe9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODM1Nw_38d6233c-9bc3-4703-99fb-0afffa735d38"
      unitRef="number">0.0175</krys:CostOfWorkPercentage>
    <krys:LossContingencyGuaranteedMaximumPriceToBePaid
      contextRef="i2c6103d6d6474ab09e162650723b7b42_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfODc0NA_67ba7d9c-db84-4ee3-82a6-b4db6ccd8f2c"
      unitRef="usd">84100000</krys:LossContingencyGuaranteedMaximumPriceToBePaid>
    <us-gaap:LitigationSettlementExpense
      contextRef="ibb1e5a79af6a486eb62a8e55c89d9956_D20220428-20220428"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTA4MjA_7ce9892e-37f4-4e29-97a2-5bdfbda26fcf"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTExODE_b01c5216-7b21-4212-875f-8be5574818d7"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:NumberOfMilestones
      contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTExOTc_3172b1a5-a9b1-421c-85c9-73f287402ec7"
      unitRef="milestone">3</krys:NumberOfMilestones>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic785c649e5754160bc5a5ec1d8456f79_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_0ee125a6-7a63-4699-8385-93086e45b15f"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i22c03d6d59cb46e1980e5371e1219705_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_2cae2ded-b2dc-4546-9ae6-96469a717b1f"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i5d5333910ddc449b91395b95aedb3b6e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyMTE_506e62c9-d825-4e25-b478-a25daafb4293"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="ic437ced0a09847f29ac47c72470b481a_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyNTg_808fa8e7-d25e-4e0b-b185-b4b2fe7ac169"
      unitRef="usd">100000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i880fa33842f74d9c9c0071788d237821_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEyODg_56cd3743-715f-4024-9665-d1bad389c60f"
      unitRef="usd">200000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="ic6402aea5802416894421190b1b7c2aa_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTEzMjE_7258f6bd-4175-4aa5-94de-9da6c49f0c74"
      unitRef="usd">300000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementTotalConsideration
      contextRef="ia911f16a65084debb3a3812c943cd418_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTE3MjQ_08e7d493-40da-4dc5-b038-442325d93709"
      unitRef="usd">75000000</krys:LitigationSettlementTotalConsideration>
    <us-gaap:LitigationSettlementExpense
      contextRef="if9d0e0a7deec4a29b33e0e493535cd0f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTE3NTM_0da9ae89-8998-4628-9815-7220fdde05bd"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTY0OTI2NzQ2Mjg0OQ_2e632f87-f0e2-4cdd-abf4-d0b984ecb887"
      unitRef="usd">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTIxMTc_64710123-f5d8-4ed4-807e-74443f16615e"
      unitRef="usd">768000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180Ni9mcmFnOmI5ODVmYzcxYTcwYTRkOTliODg5YzYxNjc3ODQwYjNmL3RleHRyZWdpb246Yjk4NWZjNzFhNzBhNGQ5OWI4ODljNjE2Nzc4NDBiM2ZfMTIyMDg_b1dba55f-35dc-4b60-97e2-c2f28da7abb4"
      unitRef="usd">372000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMjA1OQ_cd056650-ad2f-489f-8679-ff15f9052116">Capitalization&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the nine months ended September&#160;30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="i2afdf84dc726448aad231c9d735efdf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfNTMx_3c6c0127-b3d0-4fe8-a1d9-b95b189b902a"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9468c5dcd0a64aaaad772669a3b8abe9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfNzc0_267c3e91-91bc-4e82-a1a1-907274196da4"
      unitRef="shares">262500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9295b53dfb2645f78dbe60fefa07587f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfODMx_5a081d78-f2d2-451c-a9b5-9a341d6277f4"
      unitRef="usdPerShare">66.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfODY0_92a1b434-fcf2-4e00-bdca-180ff6863572"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i2b4e263286204c8caca652e5cc6047a6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfOTIw_910a52c4-c59c-4ffc-a349-ce5593d286ec"
      unitRef="usd">524000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfOTk1_fa335cc3-9a64-4b1a-b6d4-54e3de42f057"
      unitRef="shares">434782</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i66fb2504463a49eda96d3323c25ec8da_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTA1Mg_1b09ab6d-c92d-475d-a844-7398ea41276a"
      unitRef="usdPerShare">69.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i0cfc4e11ab0e4a9ab21e66bd31950eac_D20220405-20220405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTA4NQ_9232e550-fd0e-4d9e-b7b6-b7853d6d599b"
      unitRef="usd">29100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTE0MQ_56ad5566-fed0-4f06-a163-49cf31dab8f0"
      unitRef="usd">900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="i4ced2e26211d402ea4397a252ad03307_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTE3MA_1a847894-88e3-4f38-b329-6725a6a9c763"
      unitRef="usd">102500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTI5Nw_fd730e1f-22d2-41c8-90f9-34e75550e0ec"
      unitRef="shares">2866667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1559256d15ff46e2b6b221d76549e677_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTMzOA_71b177d8-52ae-4f2f-90bc-80fce3a92a09"
      unitRef="shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id0041f489e334ddba2da2707d6d6515d_I20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTQzNw_bf841359-07d2-4cca-aa6e-8e3e8ff29fe4"
      unitRef="usdPerShare">75.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTUwMw_89d08d41-591f-422d-9971-a2505eb5dc20"
      unitRef="usd">201900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i56058e68286d4f3faf9dfcb49f89f4ef_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTU3OA_8941a8e6-d812-4f35-93f4-3e52e9c3b77b"
      unitRef="usd">12900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTYzNg_cc54d1e7-127d-421f-9717-8f3d399d05ec"
      unitRef="usd">227000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTcxOA_07451b56-3216-453e-96a1-4a32479a549e"
      unitRef="shares">2211538</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7ce1955630ff46e58df59ed150227ca5_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTc1OQ_db36f542-e989-4c84-a90e-b884a4dd7a5c"
      unitRef="shares">288461</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i543a231c136d4fbea8192a671046f7d2_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTg1OA_07116f60-ccb0-4762-8317-9ac62e820aa2"
      unitRef="usdPerShare">65.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTkyNA_411b517c-56b0-49a5-b23a-a78125276cd4"
      unitRef="usd">134900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i332bf47da37b4f5e8fde8d72fc81fea3_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMTk5OQ_c2e164cd-83ef-4711-88f7-521e4db0c2db"
      unitRef="usd">8600000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iae6a49f61bf04d37ad841675aa460161_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M180OS9mcmFnOjU0ZWRhYWQ0ZThmYzRiNmY5NjdhNGY2MmU4NTA5MzFhL3RleHRyZWdpb246NTRlZGFhZDRlOGZjNGI2Zjk2N2E0ZjYyZTg1MDkzMWFfMjA1Nw_c04c811b-b8a9-4248-b35c-db20e174d686"
      unitRef="usd">198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5NQ_03cab727-7f0b-4799-952c-99ddd635ae2e">Stock-Based Compensation&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjAw_1d212468-e6cb-466c-91ca-14c8b3f2974b"&gt;one&lt;/span&gt;-year to four-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 189,000 and 1,913,000 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted zero and 45,000 stock options to non-employees during the three and nine months ended September&#160;30, 2022, respectively, and 50,000 stock options to non-employees during the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and nine months ended September&#160;30, 2022 was $1.3&#160;million and $2.1&#160;million, respectively, and during the three and nine months ended September&#160;30, 2021 was $64&#160;thousand and $872&#160;thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and nine months ended September&#160;30, 2022 was $49.59 and $43.66, respectively, and during the three and nine months ended September&#160;30, 2021 was $34.85 and $43.31, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $105.5 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#x2019; option awards that is expected to be recognized over a weighted-average period of 3.1 years as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $137&#160;thousand and $423&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2022, respectively, and $79&#160;thousand and $182&#160;thousand of stock-based compensation that was capitalized in the three and nine months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and nine months ended September&#160;30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $4.2 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.4 years as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Shares remaining available for grant under the Company&#x2019;s stock incentive plan were 607,366, with a sublimit for incentive stock options of 7,223, at September&#160;30, 2022.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMA_e37a14a5-7410-4d36-ad10-d1b7c631c538">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iac5d78fd59e541a99ea4c0f4e1de1d37_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5Ng_78967b9d-39d0-4e3b-9f16-b1425dcbc8da">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjU3_77534f8c-e534-455c-aac4-5b700057a71e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9bafc7ab51364dee96000779f13a8763_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjgy_ca0f7ec6-2cb9-40c6-868b-915e75083688"
      unitRef="shares">189000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0b84e5d94eed444397515564515f6e25_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjg5_33d76108-f494-44f5-9ed4-5f2c6f706f69"
      unitRef="shares">1913000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i554b9366933442a2aa09ffe226b09237_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzk3_9384b1c8-9e39-4f2d-9c8c-f833d84a857e"
      unitRef="shares">297500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4944831e440c4e57954464b8eac273a8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNDA0_8db48e52-e724-49e4-bf20-de41656688f9"
      unitRef="shares">799950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id88546130308412087cf656552ac4dad_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTI4_b67778a5-59d7-4846-b8db-61499bbac79e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ife4673f017ae43eaa5817b3e918cb7df_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MTg4_49ddd8c6-988f-494c-9f05-a4ee873054d6"
      unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib38e44d1e815453f9fa009b512d8c70b_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNjEx_50c1579b-fce6-4027-ae80-f42476c952de"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i41f08e8bf17b425f835e3620c83e2398_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNjEx_e00f8bb7-2466-4f1d-a529-27b4d57a61d2"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMQ_569f184d-edaa-4d73-8417-0d70ba0e78f8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on September&#160;30, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS0xLTEtMS0zMjMwOQ_97d34e75-3437-4088-9f28-4c8ffd13eacc"
      unitRef="shares">2043179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS0zLTEtMS0zMjMwOQ_219b929d-4b48-47c6-af0a-5f65aa232459"
      unitRef="usdPerShare">57.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id2103c585e344ff197ab0e7bb4cc2ae9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS01LTEtMS0zMjMwOQ_df280fdc-216c-473d-b270-89e71f9e9018">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i06dfdd468a0b4f669b11ecad09c55f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMS03LTEtMS0zMjMwOQ_5016839f-f052-4ea6-80dd-eb2102f2996f"
      unitRef="usd">31331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMi0xLTEtMS0zMjMwOQ_bb546585-7824-495e-91fa-16ca99cb07d2"
      unitRef="shares">1958000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMi0zLTEtMS0zMjMwOQ_b741e891-3f30-447d-b755-f7945e3e0abe"
      unitRef="usdPerShare">63.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMy0xLTEtMS0zMjMwOQ_fb7bdc31-5ad5-450b-9594-ae2dd36adc3c"
      unitRef="shares">84776</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfMy0zLTEtMS0zMjMwOQ_eedf8371-dfdc-48a4-81bf-c87a097bce75"
      unitRef="usdPerShare">46.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNC0xLTEtMS0zMjMwOQ_c145460e-842a-4087-b004-5ecd05692e4b"
      unitRef="shares">412892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNC0zLTEtMS0zMjMwOQ_c72e5a2d-e9e9-40cb-b432-f95ebe22ad04"
      unitRef="usdPerShare">58.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNS0xLTEtMS0zMjMwOQ_a0959137-c178-42be-8a7c-c44692d5092f"
      unitRef="shares">5001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNS0zLTEtMS0zMjMwOQ_6c5a8998-e354-4a84-9b7e-03ec5c9dcc32"
      unitRef="usdPerShare">78.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi0xLTEtMS0zMjMwOQ_26f634cd-37c4-4a72-a9aa-d62076ba18a2"
      unitRef="shares">3498510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi0zLTEtMS0zMjMwOQ_8559e15c-3336-477d-a918-f0263c69a96a"
      unitRef="usdPerShare">60.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi01LTEtMS0zMjMwOQ_01f30d76-40bc-49e3-a033-9d6d35b2ffdf">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNi03LTEtMS0zMjMwOQ_fb497463-577c-44e0-b664-428faaf06e6e"
      unitRef="usd">37213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy0xLTEtMS0zMjMwOQ_bec94b6b-b525-461d-a00e-0db26579aacb"
      unitRef="shares">637315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy0zLTEtMS0zMjMwOQ_dbdd4ccf-1d4c-4441-8e1e-81cbb64f8a12"
      unitRef="usdPerShare">48.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy01LTEtMS0zMjMwOQ_25f4a38c-30bb-49da-808a-fd56a413b230">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i4a9c29f2cd0b44559649153e923cfb6e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmE2Yjg0Nzg5N2Y2YjQwOWRiNGM1MzM0ZGFjMTAyM2M3L3RhYmxlcmFuZ2U6YTZiODQ3ODk3ZjZiNDA5ZGI0YzUzMzRkYWMxMDIzYzdfNy03LTEtMS0zMjMwOQ_32a676d9-d2bd-4c0a-b8ef-618f652b9190"
      unitRef="usd">14225000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTA4OQ_0c37207e-0b39-4776-98e3-9160e9ea0d7d"
      unitRef="usd">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTA5Ng_26cf2e1b-5c3f-489f-8731-cb85b302f60e"
      unitRef="usd">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTE1Mg_590cf20f-809e-4aaa-b5da-6ef69772fc3b"
      unitRef="usd">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTE1OQ_3fbb1449-eb5e-4e4f-9bfe-add0aad7c52d"
      unitRef="usd">872000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTMyNg_bda613d6-6ec5-4323-9ac5-4d25286b195a"
      unitRef="usdPerShare">49.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTMzMw_606985f1-f25d-46b0-91de-04b8266a0c73"
      unitRef="usdPerShare">43.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTM4OQ_92e73f4a-0af3-4e6d-b2fa-9b80a0a8e7a7"
      unitRef="usdPerShare">34.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTM5Ng_6c46ce20-de00-4ef9-850e-84fcb960ae8f"
      unitRef="usdPerShare">43.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i22bd4f06054f4551a0c04a0a482190a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTQyNA_af9d2762-b0a7-4ce9-bf37-c46722ea1da7"
      unitRef="usd">105500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i977428fb79094a95b2d8d909cdd22eaf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MzIy_08831858-e43d-48af-b81d-a764dc39f84d">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5Nw_48d3ad03-54a4-44e4-ab0b-89e130cced00">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2022 and 2021 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id108621ccf904c55942c6ee24593df70_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy0xLTEtMS0zMjMwOQ_dc17d115-3604-45d0-9b5d-d6390c373e2a"
      unitRef="usd">2184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba0e76d9070c4128b90730ceba7e6793_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy0zLTEtMS0zMjMwOQ_11e9669e-9cc6-44b8-8168-792093b2caea"
      unitRef="usd">673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d9ff3681fe9437586096cd7401ca9ce_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy01LTEtMS0zMjMwOQ_a2dbff45-9aa0-47b3-b7ca-7d3d9de59cad"
      unitRef="usd">5547000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a7d2608b4e8487e85fca38da9b0a67c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfMy03LTEtMS0zMjMwOQ_333a0fb3-aac8-4de7-a4a4-27794f728633"
      unitRef="usd">2273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8420fcd5952417fa51cddbbcf6d44b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC0xLTEtMS0zMjMwOQ_67de97e1-1795-4aa9-85dc-cd84ace325b1"
      unitRef="usd">6433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i312172e49cc6483fb8ba4c537f5a773e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC0zLTEtMS0zMjMwOQ_740ea7cd-e3bf-4353-81af-77267502f885"
      unitRef="usd">2502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic09e88a222d54915b2b03b547c38c599_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC01LTEtMS0zMjMwOQ_b52b7545-b5a3-4847-a5d2-7e0ab1b31b54"
      unitRef="usd">16791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c42738289064a8ea522bd02105cc6c5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNC03LTEtMS0zMjMwOQ_b299b86d-c1e2-49cc-8efc-c3abb31ca9f6"
      unitRef="usd">6742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS0xLTEtMS0zMjMwOQ_6f4d2ef7-3fa6-4cfe-b7fc-67c60677c0b9"
      unitRef="usd">8617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS0zLTEtMS0zMjMwOQ_370a1def-b2db-48d0-9942-2b4c35fef988"
      unitRef="usd">3175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS01LTEtMS0zMjMwOQ_d88af8bc-6985-4484-b20a-196f096abc4a"
      unitRef="usd">22338000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ3YzAyYTgxMjU2YTQxNTA4OWQxMzZjODBkYzMzZmY0L3RhYmxlcmFuZ2U6NDdjMDJhODEyNTZhNDE1MDg5ZDEzNmM4MGRjMzNmZjRfNS03LTEtMS0zMjMwOQ_a5ffd906-a335-4fbe-b41a-585b18253587"
      unitRef="usd">9015000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTk5MQ_c51e02a8-2d78-478d-abe3-42f52133cab6"
      unitRef="usd">137000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMTk5OA_8d2af610-8189-43fe-986d-69986db72f8e"
      unitRef="usd">423000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i02863c29f27445b6a5ad09a1499135ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjA5NQ_442e5e0b-c25e-4b91-8940-ac1c3bf2238e"
      unitRef="usd">79000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="icdb2c33768724064aa1c122000bf1f59_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjEwMg_b6b3ddef-ca3e-4bc5-9c7c-f8efd43fd75d"
      unitRef="usd">182000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5OA_bb41fbfa-bae4-4bb7-a293-a467f9ec199b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi0xLTEtMS0zMjMwOQ_3c702666-8467-4387-9706-4101ccba26e6"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi0zLTEtMS0zMjMwOQ_622c74a3-3f48-4331-a07e-b5365f6c8493"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi01LTEtMS0zMjMwOQ_a86829e5-582a-4e91-b5f0-f75f556e0c7a"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMi03LTEtMS0zMjMwOQ_dfc08568-0886-4033-b561-694b8a526e38"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy0xLTEtMS0zMjMwOQ_cf93fb60-baad-47b0-9e96-a0257507d1b7">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy0zLTEtMS0zMjMwOQ_ca3bc21e-22b7-4c94-9c98-7077817e8ce9">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy01LTEtMS0zMjMwOQ_70778106-984d-4087-abf3-df28ffd80c0b">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfMy03LTEtMS0zMjMwOQ_bd7f2a5e-b84c-4ac4-8b2d-70a37a4cd4c5">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC0xLTEtMS0zMjMwOQ_850773dc-b3fb-41f2-ba5a-b6d811a715d4"
      unitRef="number">0.0320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC0zLTEtMS0zMjMwOQ_00f0f804-dcee-4c92-84d5-fc81eb5166b2"
      unitRef="number">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC01LTEtMS0zMjMwOQ_dee1cf7b-d048-4122-8f26-e1a38fd3afa4"
      unitRef="number">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNC03LTEtMS0zMjMwOQ_a00c0436-146a-4205-aef0-2be8349a6acc"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS0xLTEtMS0zMjMwOQ_cbfef293-f43b-4ed6-98ff-97c3355c43fd"
      unitRef="usdPerShare">70.91</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS0zLTEtMS0zMjMwOQ_51b7dbbe-fe59-490a-bb5a-73ce978df141"
      unitRef="usdPerShare">53.69</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS01LTEtMS0zMjMwOQ_6a3ba2cb-62ac-47e8-b3ab-4eeaa0e406e1"
      unitRef="usdPerShare">63.03</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNS03LTEtMS0zMjMwOQ_0e229d5a-bfbe-48ab-88dd-4c3614255b28"
      unitRef="usdPerShare">67.15</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi0xLTEtMS0zMjMwOQ_a298db2d-7228-4be1-ba80-cecd279907d9"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ib2eda5e9cada49a690fb783340fe5e7a_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi0zLTEtMS0zMjMwOQ_04cc98df-2499-4782-80e6-4a35f2b8d7c9"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i20a2b0f28eeb434da5b1c63168bec71e_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi01LTEtMS0zMjMwOQ_f66182d2-8b4f-4a5b-9a2d-8f72dca0ba45"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ib74bd5e9e49c4b23836eba36010c6eac_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjYwZWYyOGM0MmE4YjRhNTBiOGU4NGM3ODU2OGYwNjQzL3RhYmxlcmFuZ2U6NjBlZjI4YzQyYThiNGE1MGI4ZTg0Yzc4NTY4ZjA2NDNfNi03LTEtMS0zMjMwOQ_99632cba-9387-4a8f-b6d9-eb78de9a4d44"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibf80894786944bc1920dbabf15657881_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE5NA_d4554253-347d-4893-9b1b-3cb694cc8d0c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjUxNg_edb6a3af-dc6b-4767-b9b6-5bae9452006a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjUxNg_f676f4d9-1469-4582-bba4-afd50d37e003"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i327eb87761364089af22aa767f369073_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjYwMQ_44e529ae-2b39-49a8-9783-81df831298fe"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjYwOA_4f5fa0c7-6e59-4547-ae75-2bc028796dda"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzIwMg_98819bdf-aec2-45f5-8b89-eec8986a037d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMS0xLTEtMS0zMjMwOQ_2252d26e-a204-432a-a901-3471951151f4"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0046fa99d7c941b0bbb5d5b667ccac30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMS0zLTEtMS0zMjMwOQ_f15bc920-36b6-49e5-a08c-5138cec29b3f"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMi0xLTEtMS0zMjMwOQ_04ab2b63-e7fe-4c1c-8064-e2feae886122"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMi0zLTEtMS0zMjMwOQ_eacdeac8-ac83-4a31-9f6f-596b86f288cf"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMy0xLTEtMS0zMjMwOQ_f1015323-742c-4bad-8653-2397cf56fd2c"
      unitRef="shares">14321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfMy0zLTEtMS0zMjMwOQ_79e649f0-cec5-4c75-bd07-e40368754759"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNC0xLTEtMS0zMjMwOQ_7efc2747-9cb2-42b5-91e5-b83a83c36b35"
      unitRef="shares">17879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNC0zLTEtMS0zMjMwOQ_4067f7d1-8bb9-42b0-91a5-66397f0d180c"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNS0xLTEtMS0zMjMwOQ_9479a4bb-8d41-4fe5-9fbf-f4b94e548e15"
      unitRef="shares">66600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOmRjOGIwNjRjN2E1NDQzM2I4OGViZjQ0MjQ0ZmRkNWFjL3RhYmxlcmFuZ2U6ZGM4YjA2NGM3YTU0NDMzYjg4ZWJmNDQyNDRmZGQ1YWNfNS0zLTEtMS0zMjMwOQ_eba85b0c-b928-4c5d-9e92-dc41455c5cd4"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5b0630f368c64e4bafaa3f6775be6b5b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMjcwMQ_4b3f582d-fe50-4b34-b7b0-930106ea0f8a"
      unitRef="usd">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfNTQ5NzU1ODE3MzE0_c96ca4b8-47ce-4227-bc90-f12a56e3f23c">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i124dbd40c51a45a2bf0196c7305130a2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy0xLTEtMS0zMjMwOQ_24d9b885-8541-4c0d-be2f-481932680d01"
      unitRef="usd">441000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba3ffb69ea7a49f2a999c26d33b7fd55_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy0zLTEtMS0zMjMwOQ_29705c05-273d-4c86-b398-1aab8c55991e"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4fe3e9d3d544384841d12bece5bca42_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy01LTEtMS0zMjMwOQ_c55ee2ab-1a67-4ddc-96ac-3be16a5e2afa"
      unitRef="usd">1340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2e6fb6eea9d48e1a6a317593df48bf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfMy03LTEtMS0zMjMwOQ_8c41a670-9575-4acf-ba26-5131c3f7a48b"
      unitRef="usd">1159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a6c60466a984d57adb2a94eec715367_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC0xLTEtMS0zMjMwOQ_468ac5b6-bcc6-4159-9d10-a27378d5ca46"
      unitRef="usd">441000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i327eb87761364089af22aa767f369073_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC0zLTEtMS0zMjMwOQ_c54b9d64-87ca-414a-8a0c-ad9ec3177707"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC01LTEtMS0zMjMwOQ_d4520611-da53-4a8c-8253-2231689cb17d"
      unitRef="usd">1340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2137541a93e48849d5da0a7f65c3d5d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RhYmxlOjQ2OTlmNjllMTNjZTQ0YzBiYjRkYzEwM2U1ZmUyNDM5L3RhYmxlcmFuZ2U6NDY5OWY2OWUxM2NlNDRjMGJiNGRjMTAzZTVmZTI0MzlfNC03LTEtMS0zMjMwOQ_62bee555-dcb7-4256-95d0-34a903dabc79"
      unitRef="usd">1159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia304daa15c32499381cbc07b635d095c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzEzNA_83644775-2c5b-467a-85c8-da107039a5f1"
      unitRef="shares">607366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1ec14cf55416487cb3ce5a09f7e544f7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181Mi9mcmFnOjNiNzdlYTQyNjNjYTRiM2JiZWQwYzJmNDg0YzIzYWI4L3RleHRyZWdpb246M2I3N2VhNDI2M2NhNGIzYmJlZDBjMmY0ODRjMjNhYjhfMzE4NQ_48ca5486-248a-4978-a667-f98c88f60022"
      unitRef="shares">7223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1OGQ2NmY4MDRkMDQ4Nzg4M2RiYTM2NjJiNDZjMTgzL3NlYzo1NThkNjZmODA0ZDA0ODc4ODNkYmEzNjYyYjQ2YzE4M181NS9mcmFnOjZiMjIzOTE2MzAyOTQ0NjZiNDkwNjI1MzFiZTIwMzUzL3RleHRyZWdpb246NmIyMjM5MTYzMDI5NDQ2NmI0OTA2MjUzMWJlMjAzNTNfMzcw_74094f9b-8d35-424a-a2a6-f5cc313c3245">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M* P WJ^DU$\W9H#F+'KZ+U!+ P04    " !Z.6=5,URBA6T,   3?   &
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M*II 19-8:&8CT"8 \;L "'-BXLKWL3U83?W%&$PHJA. BB:QT$Q"M1E _&Z
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M(M"GNP@4<!%(S&)[(=0?8C 'J"X"*IKLKQ&3!NT/T'/\@;]M*K^R]*,/GBJ
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MR\.71[.C'B@/D[V^(\/&  $2TY=Y6@4,7BT>@,3-"L,CNX/N:Q^N*6E41&'
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M2%A*=ADH=I&S*N)5YL*2P UUDL#K-2,5EXL&^S+W;J+S)GS(A6/8Y296$-?
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M<<1?!G>@/R&T=L/@]O0C5@&,QP7P_<:Y(?Z"!Z2_*?7J_P%02P,$%     @
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MCAFVF"FY 671Q&8'SE5G3>*XL$EY-HIV.=F9Q0UKF"@1GET%W,JVDP*%T;/
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MTF';/>;T=X.:!>C]6BF[7["!_G]I\3=02P,$%     @ >CEG5=R+.%Z=!P
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MP+RTDH;(WYC\O#-O#-;F[?'H_N%&CLZ'6^/C=I4>M<(G6B^$W@=\S;:T[_:
MG\?0+[S:Z4=A^[[1K[$:(_>2V]N_:6__/9 %-"9,:;%,[3YNBEK1=3L2)WT3
MU-WO63_Z:,#&T#?X7M? P(Z'1@@46QSU0&YDQ5&R73DLTE##,K-F.S+M)/?
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M_VK4P0Z>I9-<_7A)\,S"CZC+Y\_9K<P/6.JGR5(_/6AB/]APS2?^"*I$ZC"
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;-566V_;-A3^*P=NT-F
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*56;6_C-@S^*X1W&%K
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M#VILV-":9[G]%??Y.(*5;+7[A.UHFY4>5(,VLMN#B4''Q?C-=OLZO ,4X7<
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MH$7)10F5%K)B"N:7O8E_?A7;^W3ABX"M/E@SJ\E,R@?[<9-?]CPK$!20&8O
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M@[(!QK^4$E\,.P#Z>9_]!E!+ P04    " !Z.6=5[Z"MK)0#  # $   &0
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MYP'+8<UKB7=Z]PE:/R/'EVEI_2_;M;%1P++:HBY;,"DHA6J^?-_FH0<@GN.
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M3931Z7M299JVU$Q05_YEKS12G_##@CHY&!= ^VNM\3!Q!W3_#>EO4$L#!!0
M   ( 'HY9U55(QV>8 0  (P7   9    >&PO=V]R:W-H965T<R]S:&5E=#(W
M+GAM;*U879.B.!3]*REV:JN[:EH@ H*K5K6?N+4]U35N[SQ'B4HU$#<).OOO
M-P&:43=2.)L7)>&<DWO)X9)D<"+TG>TQYN![FF1L:.PY/_1-DVWV.$6L0PXX
M$W>VA*:(BR;=F>Q ,8H*4IJ8T+(\,T5Q9HP&1=\K'0U(SI,XPZ\4L#Q-$?UG
MC!-R&AJV\='Q-=[MN>PP1X,#VN$5YF^'5RI:9JT2Q2G.6$PR0/%V:#S;_64@
M\07@KQB?V-DUD)FL"7F7C64T-"P9$$[PADL%)/Z.>(*31 J),/ZN-(UZ2$D\
MO_Y0GQ>YBUS6B.$)2;[%$=\/#=\ $=ZB/.%?R2G$53ZNU-N0A!6_X%1A+0-L
M<L9)6I%%!&F<E?_H>_4<S@A"1TV %0%>$YP;A&Y%Z+8E.!7!:4MP*X+;EN!5
M!*\MH5<1>FV?DE\1_+8C!!6A\)=9SE\Q^5/$T6A R0E0B19J\J)P4,$6<QYG
MTNLK3L7=6/#XZ(MXG?X@C(%73,%JCR@&SYS3>)USM$XPX 1,2)H*6ZXXV;SO
M21)ARL 36(FW+LH%@FS!&+%X U 6@6F<Y!Q'0"$K;\O66Q9S\##%',7)HQ!Z
M6TW!PZ='\ F8@$DD W%6H-AGT2FN_]R3G DZ&YA<I"P#-S=5>N,R/7@CO2YX
M(1G?,S#+(API^&$S/VC@F^)1U\\;?CSO,6P47.%#!W2MSP!:$"KBF333?\^S
M1OJTF?Z"J*#;-^FS]L';"OJ\?? J^J)]\"IZ^/^>_/*G<[\P0K=^\;J%7O?6
MBY>GF").:%_EZI+KJ+GR^]=G![3!0T-\X!BF1VR,?OW%]JS?5);2*3;5*3;3
M*3;7*;;0*1;J%%MJ$KLPK5.;UFE2+[X6B2CK*LN63*]@RA76<?0$ ]^U!N;Q
MW(PJF&];_B5LJH Y0>"YE["9 F:[KA]<PN8JF-?UNI>PA5+-M^$E+%3!K%X
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ML]+=%T0WL*IN#^&=LGBDMY<'_.H"[0)POE3*/@W<N3Y\QZW^ U!+ P04
M" !Z.6=5HH-]\DD1   J%0$ &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6RUW6MSXLBAQO&OTN6D3B55SAB)B^TY,Z[R6/?KU,[FG!>GS@L-R$990$02
MZSB5#Q\),'*#W ;G[S<[-J9_+6[/2LV#^/*8%[^5TS2MQ#_FLT7Y]6Q:5<O/
M%Q?E>)K.D_)3ODP7]5_N\V*>5/6OQ<-%N2S29+(>-)]=Z+W>Z&*>9(NSFR_K
MR[X7-U_R537+%NGW0I2K^3PIGKZEL_SQZYEV]GS!+]G#M&HNN+CYLDP>TA]I
M]=?E]Z+^[6*G3+)YNBBS?"&*]/[KV:WV.1ZM!ZRO\3]9^EB^^%DT-^5GGO_6
M_.).OI[UFBU*9^FX:HBD_N?W]"Z=S1JIWHZ_;]&SW9S-P)<_/^O6^L;7-^9G
M4J9W^>Q_LTDU_7IV=28FZ7VRFE6_Y(].NKU!P\8;Y[-R_5_QN+UN[TR,5V65
MS[>#ZRV89XO-O\D_MG?$BP&Z_LH ?3M /W9 ?SN@?^R P7; 8'_ Z)4!P^V
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M5(M0+:8T.83:%K'V1HTX+])Q4G;G#-H;1C4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M7R:J:;T9TWS6>=(@]60G9]/UX3O=O<.S^1OHK":J6:AFHYJ#:BZJ>:CFHUJ
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M_3[/J^=?F@F:S_RN;\[-OP%02P,$%     @ >CEG5?I4\Z\V P  ?0L  !D
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M\[Y.GRAZO6*@>&;;I057NOFREXGNCT&8"?KYBG/U,C =6-5Q1W\!4$L#!!0
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M<VAE970S-2YX;6RM5EUOVC 4_2M65DV=U#6?I, @4@M,F[1J55F[AVD/)KF
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M<9KE6OWJ0*X-U/,E8_)EHR^H?\>,_@=02P,$%     @ >CEG5;([!SX'!
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M%FKR0M%7UH)7DLN%LN14/$V$'0^6G$0O-S.!.D9SDHGUQ[":P1NT%(LR+E)
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M4$L! A0#%     @ >CEG59"CO"H( P  +PH  !@              ("!"!0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'HY9U4?+O8[
M: 4  )<6   8              " @487  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !Z.6=5,URBA6T,   3?   &
M@('D'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >CEG
M5=C_Y*2L!@  $QP  !@              ("!ARD  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( 'HY9U5MG *K, @  +$2   8
M      " @6DP  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !Z.6=5TG$N!ZX8  !?2@  &               @('/.   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ >CEG50WY9"X/!    0H  !@
M             ("!LU$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( 'HY9U5PVRZJP 0  /(+   9              " @?A5  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ >CEG569S/W?X P
M0PD  !D              ("![UH  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !Z.6=5GXMP<+D4   #/   &0              @($>
M7P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'HY9U7U
M^XSB[P0  #L-   9              " @0YT  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ >CEG5=R+.%Z=!P  H1@  !D
M     ("!-'D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'HY9U7RB>;JB 0  '8+   9              "
M@52B  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ >CEG
M5;BS-RC5 P  XP@  !D              ("!$Z<  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !Z.6=5OA&U^TT$  !P"@  &0
M        @($?JP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( 'HY9U5MR3VU'08  )L0   9              " @:.O  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ >CEG578N&_ET @  ^P4
M !D              ("!][4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !Z.6=5[Z"MK)0#  # $   &0              @(&BN
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'HY9U7G"[4E
M3@0  $,@   9              " @6V\  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ >CEG5;<Z94ZC @  )P8  !D
M ("!\L   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !Z
M.6=552,=GF $  ",%P  &0              @(',PP  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'HY9U7*_O?*90D  "Y0   9
M          " @6/(  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ >CEG5>\$4$L,!   #Q0  !D              ("!_]$  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !Z.6=5V3!3P*0"  #H
M!P  &0              @(%"U@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( 'HY9U4SP1F./P,  -,)   9              " @1W9
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ >CEG5:*#
M??))$0  *A4! !D              ("!D]P  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " !Z.6=5^E3SKS8#  !]"P  &0
M    @($3[@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M 'HY9U7UM[=75 ,  "4)   9              " @8#Q  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ >CEG51MI!GK] @  NPD  !D
M             ("!"_4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !Z.6=53HRY'>T%   J+0  &0              @($_^   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'HY9U5JQ91;OP@
M $91   9              " @6/^  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ >CEG56F&1WP3!0  @Q@  !D              ("!
M60<! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !Z.6=5
M=PWUKX4$   D'   &0              @(&C# $ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( 'HY9U7/@I[]M@,  -,,   9
M      " @5\1 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ >CEG5;([!SX'!   1A8  !D              ("!3!4! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !Z.6=5>Y$]!3<#  #6$P
M#0              @ &*&0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( 'HY
M9U67BKL<P    !,"   +              "  >P< 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( 'HY9U5P,7MB@@,  -\;   /              "  =4= 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !Z.6=5*5V(H),!  #B&   &@
M            @ &$(0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !Z.6=5B(RI-Z4!   O&0  $P              @ %/(P$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     ,0 Q $X-   E)0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>218</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krys-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  krys-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="krys-20220930.htm">krys-20220930.htm</File>
    <File>krys-20220930.xsd</File>
    <File>krys-20220930_cal.xml</File>
    <File>krys-20220930_def.xml</File>
    <File>krys-20220930_lab.xml</File>
    <File>krys-20220930_pre.xml</File>
    <File>krys-20220930ex311.htm</File>
    <File>krys-20220930ex312.htm</File>
    <File>krys-20220930ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="603">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 218,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 372,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 30,
   "keyStandard": 213,
   "memberCustom": 19,
   "memberStandard": 26,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Instruments",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Components",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Capitalization",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock-Based Compensation",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Subsequent Events",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Fair Value Instruments (Tables)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "id2aebf72749342469c8fe09700344c6b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "id2aebf72749342469c8fe09700344c6b_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9b7872ff13c54442a94e52d5702cac2a_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9b7872ff13c54442a94e52d5702cac2a_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i4a9c29f2cd0b44559649153e923cfb6e_I20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Capitalization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i29d32cac848944e583d90cca3a8fbc3f_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i06dfdd468a0b4f669b11ecad09c55f82_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "id108621ccf904c55942c6ee24593df70_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i9c9e5fe2bf2d44bc8ec0f46c39af78f6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "iade30e9ded214e8db1cda0100c6e970e_D20220701-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i0046fa99d7c941b0bbb5d5b667ccac30_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i56a7d3cd42a84d85bbe195262e9b7687_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "ia512091aa9cc474e8677a732ef039459_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i8627db24c8ef4f7e8eb028920efbc320_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220930.htm",
      "contextRef": "i7d81f609cb1f40d9ac7e2fc220fb302c_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASTRA facility.",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "ASTRA Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress current.",
        "label": "Accrued Construction In Progress Current",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedFinancingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Financing Fees, Current",
        "label": "Accrued Financing Fees, Current",
        "terseLabel": "Accrued financing costs"
       }
      }
     },
     "localname": "AccruedFinancingFeesCurrent",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AdditionalAreaOfRealEstatePropertyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of real estate property leased.",
        "label": "Additional Area Of Real Estate Property Leased",
        "terseLabel": "Additional area of real estate property leased"
       }
      }
     },
     "localname": "AdditionalAreaOfRealEstatePropertyLeased",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "krys_BostonMassachusettsLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston, Massachusetts Lease",
        "label": "Boston, Massachusetts Lease [Member]",
        "terseLabel": "Boston, Massachusetts Lease"
       }
      }
     },
     "localname": "BostonMassachusettsLeaseMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CostOfWorkPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Work, Percentage",
        "label": "Cost Of Work, Percentage",
        "terseLabel": "Cost of work, percentage"
       }
      }
     },
     "localname": "CostOfWorkPercentage",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClausePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Percent",
        "label": "Cumulative Escalation Clause, Percent",
        "terseLabel": "Cumulative escalation clause"
       }
      }
     },
     "localname": "CumulativeEscalationClausePercent",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClauseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Term",
        "label": "Cumulative Escalation Clause, Term",
        "terseLabel": "Cumulative escalation clause, term"
       }
      }
     },
     "localname": "CumulativeEscalationClauseTerm",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "label": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "terseLabel": "Lessor, operating lease, liability, annual lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementMilestonePaymentsSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "label": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "terseLabel": "Litigation settlement, milestone payments, sales threshold"
       }
      }
     },
     "localname": "LitigationSettlementMilestonePaymentsSalesThreshold",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Total Consideration",
        "label": "Litigation Settlement, Total Consideration",
        "terseLabel": "Litigation settlement, total consideration"
       }
      }
     },
     "localname": "LitigationSettlementTotalConsideration",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LossContingencyGuaranteedMaximumPriceToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "label": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "terseLabel": "Loss contingency, guaranteed maximum price to be paid"
       }
      }
     },
     "localname": "LossContingencyGuaranteedMaximumPriceToBePaid",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones [Domain]",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Milestones",
        "label": "Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestones",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "krys_OtherContractualObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other contractual obligations.",
        "label": "Other Contractual Obligations [Member]",
        "terseLabel": "Other Contractual Obligations"
       }
      }
     },
     "localname": "OtherContractualObligationsMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PaymentToEscrowForReducingLeaseRentals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to escrow for reducing lease rentals.",
        "label": "Payment To Escrow For Reducing Lease Rentals",
        "terseLabel": "Cash contribution"
       }
      }
     },
     "localname": "PaymentToEscrowForReducingLeaseRentals",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PaymentsForSuitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Suit Liability",
        "label": "Payments For Suit Liability",
        "negatedTerseLabel": "Repayment of ASTRA build to suit liability"
       }
      }
     },
     "localname": "PaymentsForSuitLiability",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PeriphaGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PeriphaGen",
        "label": "PeriphaGen [Member]",
        "terseLabel": "PeriphaGen"
       }
      }
     },
     "localname": "PeriphaGenMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PurchasePriceOfPotentialBuildingPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Potential Building Purchase",
        "label": "Purchase Price Of Potential Building Purchase",
        "terseLabel": "Purchase price of potential purchase"
       }
      }
     },
     "localname": "PurchasePriceOfPotentialBuildingPurchase",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Sale of stock, aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Sale of stock, remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_ShortTermAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Amendment",
        "label": "Short-Term Amendment [Member]",
        "terseLabel": "Short-Term Amendment"
       }
      }
     },
     "localname": "ShortTermAmendmentMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_SwitzerlandLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Switzerland Lease",
        "label": "Switzerland Lease [Member]",
        "terseLabel": "Switzerland Lease"
       }
      }
     },
     "localname": "SwitzerlandLeaseMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_TwoThousandSixteenLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen lease agreement.",
        "label": "Two Thousand Sixteen Lease Agreement [Member]",
        "terseLabel": "2016 Lease Agreement"
       }
      }
     },
     "localname": "TwoThousandSixteenLeaseAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220930",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r189",
      "r196",
      "r221",
      "r223",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r391",
      "r392",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r189",
      "r196",
      "r221",
      "r223",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r391",
      "r392",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r165",
      "r172",
      "r173",
      "r174",
      "r175",
      "r189",
      "r196",
      "r212",
      "r221",
      "r223",
      "r256",
      "r257",
      "r258",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r391",
      "r392",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r165",
      "r172",
      "r173",
      "r174",
      "r175",
      "r189",
      "r196",
      "r212",
      "r221",
      "r223",
      "r256",
      "r257",
      "r258",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r391",
      "r392",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r82",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r82",
      "r87",
      "r171",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r82",
      "r87",
      "r171",
      "r222",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r128",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r12",
      "r13",
      "r277",
      "r366",
      "r381"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r9",
      "r160"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r33",
      "r34",
      "r35",
      "r383",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r282",
      "r323",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r268",
      "r269",
      "r270",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r225",
      "r273",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r71",
      "r113",
      "r121",
      "r125",
      "r142",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r280",
      "r283",
      "r301",
      "r325",
      "r327",
      "r365",
      "r380"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r71",
      "r142",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r280",
      "r283",
      "r301",
      "r325",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r133",
      "r149"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r130",
      "r134",
      "r149",
      "r369"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r132",
      "r149"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r73",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r63"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r64",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r58",
      "r63",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r302"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r371",
      "r387"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r176",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized a September\u00a030, 2022 and December\u00a031, 2021; 25,709,664 shares issued and outstanding at September\u00a030, 2022; and 25,207,985 shares issued and outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r37",
      "r39",
      "r40",
      "r46",
      "r373",
      "r389"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r104",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress, gross"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r61",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r61",
      "r158"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r263",
      "r264",
      "r266",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r88",
      "r90",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r290",
      "r291",
      "r374",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r47",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r90",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r290",
      "r291",
      "r374",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r101",
      "r143",
      "r209",
      "r210",
      "r268",
      "r269",
      "r270",
      "r278",
      "r279",
      "r289",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r323",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r370",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r292",
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r293",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r190",
      "r213",
      "r214",
      "r219",
      "r220",
      "r293",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r213",
      "r214",
      "r219",
      "r220",
      "r293",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r312",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r191",
      "r207",
      "r287",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "negatedTerseLabel": "Loss on disposals of fixed assets"
       }
      }
     },
     "localname": "GainsLossesOnSalesOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r61",
      "r157",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r163",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r44",
      "r112",
      "r309",
      "r310",
      "r376"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future minimum operating lease payments",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r71",
      "r122",
      "r142",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r281",
      "r283",
      "r284",
      "r301",
      "r325",
      "r326"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r71",
      "r142",
      "r301",
      "r327",
      "r368",
      "r385"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r71",
      "r142",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r281",
      "r283",
      "r284",
      "r301",
      "r325",
      "r326",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r38",
      "r43",
      "r45",
      "r62",
      "r71",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r91",
      "r113",
      "r120",
      "r123",
      "r124",
      "r126",
      "r142",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r291",
      "r301",
      "r372",
      "r388"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r120",
      "r123",
      "r124",
      "r126"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r315",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability",
        "totalLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r318",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities and currency translation adjustment",
        "verboseLabel": "Unrealized gain (loss) on investments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r50",
      "r52",
      "r131"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.00001 par value; 20,000,000 shares authorized at \u00a0\u00a0 September\u00a030, 2022 and December\u00a031, 2021; 2,061,773 \u00a0\u00a0 shares issued, and no shares outstanding at September\u00a030, 2022 \u00a0\u00a0 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from insurance settlement, operating activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r8",
      "r159"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r161",
      "r327",
      "r378",
      "r386"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r276",
      "r362",
      "r411"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r210",
      "r327",
      "r384",
      "r396",
      "r398"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r143",
      "r268",
      "r269",
      "r270",
      "r278",
      "r279",
      "r289",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r317",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r260",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r224",
      "r226",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r247",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Surrendered or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Surrendered or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Restricted stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r231",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at September 30, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r29",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r101",
      "r143",
      "r209",
      "r210",
      "r268",
      "r269",
      "r270",
      "r278",
      "r279",
      "r289",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r323",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r101",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net, (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r209",
      "r210",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r209",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r71",
      "r129",
      "r142",
      "r301",
      "r327"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r210",
      "r211",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r14",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r14",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r191",
      "r207",
      "r287",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r72",
      "r213",
      "r220",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r316",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r89",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r88",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r415": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r416": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r417": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r418": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r419": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r421": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r422": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r423": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r424": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001711279-22-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-22-000058-xbrl.zip
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M'##3TMG(L%/2:"LP)4(LH%*4(7<P!Z"QXE9[Q@!*!FJA@Z2$^$2/>0#6O'A
MSSYW,'M4E>8^<IJR0KP(4 FS0F'J$"=*,SRB:=4'<X:Y _'+Q6\WR__ !=$@
M;40:%,X@:R03GC+"28P&JX6!9DZY@PG!A**1#J7U*QB#;8P*1VE#=%:%X(%(
M+ Y,\\\=3 @RB$V!T44AL' ,-,D Q2.I<#EX:CV1"P/9K','D[)\V!G"2'2*
M$J8-T00%&90AH%&&1C<[?.8U I8GVZ&=X=PSBYTF:;5+H(A2R;PD<RA:K;)_
MGG\U+>5"8BN-""0RGV8#I'(.,6PCUB#CBP?HW'('LP<7*)I3#"O04P4QL 1
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M(.^QL$Q@K8I-*8T@G$AG0@7J*1:?[CHA&+-2I"PHP]8HAA37R#B2]D7BH]W
MRWS2V[(BZK9TX(F=LL9QM$(9%;3WC&"IK8R,:2JC1\2/*--2.I95$W.13A*Y
M"R0$8&.><:N,](YRH;T6" 7/RR^=SPDMY1GVR'#P-($)Y+74U$5KE<>8*T'*
MC]92MV<G+9YSR1GETEK*F! *@_!X;9'2T4((7WYI*55YP^2 D3(=$B.D5](S
MPY0AU&"'>)0H(L39LP.FRK'>!*V[PLR*P#P1E!%)04N]L(HJXXQ1@I9?+,J0
M7%M,DR&B$@P<O4%I@Y6T]9P&V<!4"Q8XY;[\LE'*<H;) 62"P$(X2;EFS AI
MHK+&<T98)%2RYPO0TK87<99P2&AN.9$(#+PQ%C'CJ4Q1%ZBR*[]X5,.V5]F$
M<",=#H%HQA&3E!G$L>%@[14RT=,*^/_R541-#AU,B4F;B&HK-0N&I70\QL@Y
MRH&@V0KD\4I:];( UMU#^*8T\P$G=L:5LLX%^#"=.V4=703G_QPKHB8H()A3
MBX"_.Z(8+O;[QC%50EN#(C6R @)2^J*%"7)Y81V)45.F.%-2I7HH085@GAMA
M7*7)VK(B:L*!N<-4<:0)<A"*:ZZT=$8P1BF'\+P*IK\,Q/X9"0P66DAA%#:>
M,2V-(1Y3!D(3B9.!QRH+S!PKHB:9R4G'':JH "068SH\@!@G**'$*QLJ,&VR
MV%P;A> \!,4!HF1EN)*!8NNXY#AX&D.5X5D4NANH=@C(K6,HK0*T2A!X[:+B
MQ".@P<^Y:NV'39C^UL'E=[<37*P4(P=2YKRFC@EGE=281I).=@^6XF==0/E+
MHCC9O8B?DRC&R*B($/QSD>HQB*:62X4]T+ZT6JH"B^9_\B",(I7DDKSN=."G
M1[W0KTI-+Y>,,>6$)\PQ@Z7QPD;NB#5@0)12Y6<99<=J<FP#N<"T#1ZGPT@@
MH#+2$% Q&KP.R*,*+$KZ*:S>!-,/Q]V6WVF?];J?0Y66,Q",J+6$RJ@Q@Q!8
M,:R9M(9R&%6'*D#>2P[5)/,43*;I"RV48!$B+8,9@6!+>"R"4G+!M&HVYQQ,
M9S,>)6T(T@D'2@4O=:2<^<A!P60":\&4:N9(34ZGJ";*8\D(YYP9:C1 90T)
MUD4A>16"D;(=A38=+^4EJ(]@6($2@?DS@)*7U%/-.'5"+YA"S1:FR6F3%0J\
MDD:4<\(XQ/;(0W1E.8G$"$<719N&4;ZQ5=,BR:E5U$2A(=HESIN(@Q/@D8CE
M7IL*E#.5$)X)^B*EO4SSVTQRQCRR42%NK&": 6:RV'\3"\2)J#X\S2_=YG'W
MO&\Z?A\80PB=@IEO0I0;I@T9%AGB&1&_!MG70X/_'>^>&'P^Z*VG+\8_?O1I
MP1QKS6. 4$QYAHPS5*?U_MIQ$0@F%=A\]?'@7\]U;<+7OD(&5#&7RL@E!Y@8
M15SC:)$$/V>\5RQ68 ^V:FCH)'>^<M@RQB-&.C+'G(W8<^P%18QC%WEQXDTZ
M\(9GXQ<E..'\QJ$R*,/P/[\>TN\<*G/KTJ<<U&:EDB1&3!TX(T:,9H$3SR4B
MSKC1(GD8+E2&X?I&<HH10'P"DN,@YD",VDB]9=(AXPEVVA"FB!.>X?$(E$)@
M;H\ _L41N/9NG?.DQW?\V^@>\/*G/1QVF =$!5$:,\^HEL@8X[$G&BD7K\ML
MIC^>TS>>?W?[@VZG;OI]XX[/^V&0)L; >DZ?B?XJ\#>@8D11Q3@)$J!"H.U8
M&F&1XE(B*^@X?\_Q C#1_2_YX"KTX#H_?8A(8I[X%YGG+2IBHHTA^A!8@@LT
MB1*&K-$Q<HI&R> RQG)ISGI_ &XI7;_O0L= I[].9X\_>=7M!6?ZT^89$RNP
M"4P%CX$=0KC&B;-,^73\&L?2<NF&*5^ZQ./[>-")X:&QX5'SH)U!S-M@@G?,
M(@&L!E.+*G HWO[YV5GK,BV.S@=?5W\4-NME*^_DSK2&EU2.DA-/F?#4&LE8
M 'Z.)95*("](H%95Z0S@,F#4G_OYO\(2A0T0 ^'20CQAO48!3)^G7&GCJG#&
M>YD!G?W9O]YQ7J3RTWIY*I"Q,-;>!(J4T! )5NCLW](!.I=S?S%0=RP,D40*
MEG8O\1B4E&)%05TUJ]*YOV4$=/9G_B+L9 C:"DT-XPKH)C&>4.*(C='Q"IS5
M\1T<=P?'H?<2NMLS;G!N6KNVE1\55;95*0"AC(!VH90QXBQR;)6!:)HZ[R4"
M%AT7@^+,%*?YTQP2$#84>RV58R1&ZV6:[:8BA A@Z\6@.7,%=?94QP@, :)+
MFS=I)FFPVCF'HE58*:<%7PRJ,S]0YT)W3,04.<R"E)P%J@T/"FBK9(!IJB-:
M#+HS5U!G3WDP]4!T')4F1F:DM9Q:Y[B-6GL>0[4S.IO[S;W-5\;E+6AP14@.
M<0(CZH47H%D0(NJ !1$<24*M!$(ZG-!!&M-R39 5(HGI!$; 6ARXD=I$89@2
MP0IB5.#<*>VU'MD9@AA1V?A%V60SI7C?Y(.1X7B99OB_2N5;&(JS8_,Z=*;O
M^EE&U"-=_[>7/L&@1.U10$;Z$!PS1%M* PI,4TZY\RA6@,^5!KV9$+?KR>EV
MW@II@C7<F9\N.G[]]?@^CYZC=E)Q)Y@.:9]F+)!U'+B#PUXQ+J*L L4O1J ^
M'H'^-_)P_6'S2W<2ZU"?C^#=='O$%5Z/:V>9"%@K%#B5.&""M41\063DN!=^
M-!>^E)+O+%?UG%*J,?+>,:8ML"#-K>8F>$NM"(LA);N=I8S\NHPX1J4+'AFD
M%9.1:..8=)(PB6Q:BSF2$8I)-GZQE)&YRDBJ3WBDC'Q[Z1-D1"D4#:6*D2B9
MUTX[A"262GE"I2)X,61DD1C)[&4$&"LB)ABN$ '6JC1C!&.-++;2$;,@=F2Q
M&,GLI<1HC",61G"DF _64D,5)DXSZCS#J@)2\HS1(R;Z"+@!/1 LK?T'^X^=
M]I+R -^(435Z">L+OV8_;3_WN>E=[IM6V(W[@ZX[_1:_EG'#&L1C,^T%Y&AR
M=89,*,>] Q8GF$D5,Q(0$MI0JXP-^M940Z4!.K=PA]T8870Z1V6:8K@!YE,6
MO9!T( 3UT8*2\2B5MT&@&*)!DBM9@9U YXWA=([JL"P008D2!#&GG''@Q$C@
MS@G$I+D]G5=E?#:;]6*O)_.C_=PJJ5_(1<<"QL:BP(PVEN @A/44:XZ"<>/Y
M$L2S\8NJ CE38UG,B:!'K1"\=>E3JGX%F$F.&!/4,!V\T<)32J@C/#CE*[#)
MU[PQG,JL+'/!$S"78 <]A(7!I)5VAG!B/*)I85#Y$X^E,Y;SR2 +Q%40"MR>
M9Y%&$[6/SC(=E8XL#*<G8<PAPAB_J"J0,V:6.(5EC_9\7R]]2O$*YYIPX3&/
MD8E K+"$8"\%!],II%P,,,>7['X.O<U6JUM4N>R>I6!]$4'U"#$<F=*!4N:]
M-<0;(I%,)3$<?ST"LI)8SB5<0).HRB':T[1)@6(I$QJXHEXCYPPU*EI'YV$X
M*R'.0-YL9-(;*BV+/*CH@_*21*=P#(:.PBPRKIJ$%TNY?ERH11Y?+?GMI4\
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M(<%4.,Y;1!&8?SCI,5*"8.>B1LQQKAD!4Q\(XYKZ*-%S)&&/?N).QW7;X?J
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M/ C-C,4R$X0E 5;"!K:RH58)IR6*8I;YB)+2B*4FSTZ3+V]J,G(T2*Y9AI@
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M_I'T;L3?]1;=Q:[,9N[J29/!-]E;HU3=N,&%;L5&G,7CO-9BA665^7?;"]D
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M8MS68=P\HXE85N*LL8H:SU%(:QA77GOB4M3,&7\SR-W0/>HZM*N -@^@\2E
M"S02I04!';3)@,82.)?5MT24<$PR+WA6VJB<!;,Y9I]7'*LXMLDX1@5#)FS6
MSE1$[[PS1A'OC7+,6Q_%4G"L:FU+ SDQ!7(9Q+BU+H%-90I&S#:J"\* X(@^
MLJA]3!GDD"PX4*T"706ZU@'=/&/#94@AH-26.$Q2&D=I]*6-AQ<BZ6J4M@/>
M/L]T@PK,.<D].,^R5<H"!4.Y!>FC3<8P(438V1.&=X6:K61KJ56ZW%2B>PB!
M7L]^ST>CTQ(#+34LY\T3"WMT._UX<S2<7;O/;0QG<A^,HIP3QCA2ZXU)T64E
MBRN*(B4SW<V!_SBN68ZW''L,3T^'^>Q^S]L8G!78YBTV+XUJL'-9B'3P9";8
M*50Q]). Y)D$=(& ,T2#5D)9E(X2[K/"U44U9YQS==K3'/T5-H\ESX(N]6C7
MJEY)3IU/!BE)#C6SFI,H6+8IA:6>:/L#J+M!SYI%NO_:H]-X">BJ=C4/EDV[
M_*G,=CXF#<3%XO+/J&98F0531G]$%0,-*BM7%<@JD-6CK4>[H(P(5,:L  L:
M0T+.C,/BB%=.Y-\21425$6V0$3,6>.!!9Z67 +." "I>6C$3#EGB"TD%R::,
M68^0F#_%^.I$A;;;UQ.SKC,Z'0YC/\1AZ>4R&';&]G-).^XW/Z78&Y]^KX;E
MNSG'L^>Q&:AS<X3CO@SQYF-*8>5O@^$K^_FOWOBP> 7S,>9?G(^!BJ&4&<;^
MR)9%5K-\:3#U<L8LYRH3F8L$B5 +J,O(728)I$0L<=[P0$@VRTF7*[-(&.1:
M!%EMI..68V"VDM%OH[E5*JV;2O,$G)?N*7@<WI^.QDTSI3]C4\C\:G!K1*ZZ
MX3R@.^T_8!1IC#: \4QGU1 #:,TBB$BX9=H%8S+H2JR(NSF\7!&W4JE2Z?[E
MXM*](U4NWI\Q,NTS86BB,(Z )XD#<A'!*ID@*.F=ME2RB"T2C%N2C]#X \'9
M20?<;]>Y$S^7[V]N\[/)#MCJVZY'NWE'VQ*#\=7@6YNTXLQ[WC_KZM+(13<M
M%_^,_WO:&_7&\64<?NSY.(DW_!G]X%V_>4H3>J@)@4L3K;T9DY-'3);("#I*
M DB]RY*5J&R!HM/)F&B,S)*U*Q2M4>N*D?5HZ]&V+&I=Q<\&B9\9R\X['X.T
M6>J@SO*',P7..0^:N\"Y14%D6)O\V?: ^.O^,.8E?,WVW3O;ZW=^.BJ=YSJ#
M,A'E8SQCJB8R/BA-7A]63+RZ!"N5*I4JE1X.E>9QKW/)41+II4:"RCFK/0:.
MT5JCL]HV,UGU&C7NAH+GII_XE7;BD[ZHWX35_YNXV_^5159IE?JB_S+ZTV'6
MV.+H\3 K=/UWE],7#^+X17IE/U<];FEZW&QO"*>2-#QZH+2D"TD9P5)MP7!J
M')<H;6RJ> A?J&BZ D*%[4JE]49%*VQO+FS/)J,K3GA2&F(4'I"* %I(!M%R
MQZTV0E/:*MS>DM!JOMV=8FS7$&IUM-:CK4=;C[8>[<J5OVRJ.YJELW,I6^I.
M:ND%5R&@802%CW=7_K(XFVA[1;&K&MNR-+873V;ZD\60Z1>(A\"<*0H;@K;1
M 8H@%1,8O<H*&YJND;,5A#=I;)7W-MCPJKRW*MZ;L9:D"$RB%2!IU(!,:[#1
M<# \6>>\U=&[M3#?]@0J?SP<:-\._6&'+S0;:++[!ST;B$86!:,JF4B1N62M
MC3ZYH'5R/-+0-/"[?>ENG0VT"@R:K<N-D4CG. .M;);ZI36IR5(# O)(@K"6
M>]G,!J+&=(F>,VEB<599LZ=WM2R_P7U*Y]W^9B+=-?V8[P1S=3;0_2'<]&P@
M&FFFAK4@T"1 &S+"Q=)P7GHBO/?2>[:\V4 5WBJ\;3"\!1VCQV ]E3;_8QVU
M6@2'QMHDDTG+@K=J22Z$<=-5%XE&YTW,EJ.+$= ) H:55O,^":,B9HW.[^PI
M)%U!2,6XBG%;AW'S^,ZB98D';8SQ BVE.AAE9/#)6Y*B_0[(U9D:ZT"[F<%!
MC'&:S5;0B '04 =6H 8A8Y ZF[-$E5Y2V615BR<95)BK,->>?<\%<Y0XQA6E
MEBBDJ2G'E40SD8QVUN@*<^V"N>G07'(2L^G*@?K( ",J,()X<#9()1Q-INED
M;TA7+:-1106Z"G3MV?<\X[J3,=++Q*6R:+C2F!2AFAN?H@LQ5INU%? VVX3'
M\.1LDB 3D8 <$QB=\A?AO6#$3T:C9<6N*\1LMFA+C=;EYI.NDP/K]*#O!SPE
MD5Q8P6(@$I/0.L,-RABEU%EH8SK+P,#S# S)29T>U"I0VG_U>#R3P&Z%\HYJ
MX"YXP&1<!B4JP6DBLL85**=F9P\5ZRHRYSRSFA55DSW;=;1S*%F.(E$,8Q3)
MH:<A&R%9=I/HN#0J\? #M+OS<(BJ@"T/ZPZF>V5$7=QE IB3&I Z"3H% U%'
MA5QCUJG=SAXO]J6N4%>AKAYM/=H%376!!//_*3&3K?1@4M"$1*&YM\XK4J5(
M^Z7(_L1+F27)_I?]KX_%WXX)ERTA B8H#IF\'G0(#F3YR@-*K^/ZQ,@]I3*O
MDP'K'*(ES2%:$)[J'*+6P=6S&0-?:T>LQ%@L>@?(2ZM2Q31(ZU'$3'H=L]*K
MKDV4J9U%VLKHM;-(I5*E4J52I5*E4J725L8CZ_20ZK:J1[L11[O.N%)MW[XY
MUOGSF9"4LC03GR(D0P(@BQZL<+(D!N6+$2RC0N_LZ2[G:YAG_@ YN8)D/=K-
M.]IU1J2J_-DD^3,3S.*">X\1@3BC +VCX)@5X .+A(:@G YK$T /()951XBT
MV9M0?3Z52I5*E4HM".!?,T+$)Z:"D\12CT9YEY!ZK:QQDG(FY2U4N7OO15_5
MM3G4M?UQ:3E_V5U A-?,!PH4'0/DSH K8[TYT<18D:21:F>/7Y-W5$/Y;67Y
M"LR;0*5Y@'D)-G8%YG8#\XP=K5!)DF$8(K$AV]%*@)&!E"^<)>$)+STZ6H/,
MVQ,FK9- JL^T'FT]VGJT]6COS_2F6C@3$+,.AUFO,U%QQD)IIB:B0'MW#:].
M(UB1SO;'^,54[-TYE8+3'+2)"9":K+(184$X[;@A5'#'=_:8[E)R>ZVM,M\&
MFU>5^5;&?#,&4U1(E/0>C!,:L+"@,S&"H9Q1SRPEEJZ%^^YU%DCH?5S[0)!_
MG_9CAY.I>2#-RNI4D#F;Y&@C0LJ"@SHKFG[2#)W4E'LBF#9(SWISW;:0KDX%
M60D<O9ZIDF-&B9BO-$C/&: U"!F1**1$ O$,4V2T&0LB)7:9GNVSVM+V7+4'
M8>U!N(HTLKOA7!T+<I\0-QT[-#I*KQEHKDLA<)E\&#%?94PL&H(Q<E'G@E1\
MJ_B6P06S4<FC<HD8BL(29Q7*P)$)EI*E>EGX5LW*Q4!NNIY"1A'1*0E<&P)(
MM0'MC046BZCBE)D8=O:4,EVA>06Y"G);!W+S>-)(LLH3;B2A%)$D39-R,7FG
M8PQ)A9M1KG;,7P_<3>ETP2N5'+$0$_. Q$EPAADH1"5<:"2<ELD@ F\_3[?B
M7,6Y+<,YE8Q7)$E)I<>LO5F?#59JC(B!N\!4Q;F6X=QTJ"[H9#41 8)$"1B(
M >>"A7Q;F8M9>$E:W'-4=[6H,Y!^O(^'#',;A''S&*S46X8L><T9&LL,(U%%
M;5G6Y"Q/OAJL[4"VV0),HM&JR,%9%P&EUEF%TQRHSL:J\T$'97;VA#!=NOII
MY"W,+9W$2=? ?(O. [ETR#R?9!B<NJ-X2_3='"2Z-@KJ1#$?C;="!'34&Q9X
M")$3SA4&Q<XR--1YAH:IHT):!U5O9F*D**AP2(MUF4$*"4M@M1"0@A72ZB@P
M\IT]%%VNYHV/WHY5UI9/M56L?*MZHTJ0%F#K-7FG0BKJE)61)0QE9KG2WA.D
M+E&3U;X? &OM)]\"6)T.62!J0@F3H"2C@,(&,#H$B#QH+E6,U,5LVW:IFG/^
M4F7BBJJ5()4@+2'('&+.>!-%BLPE%A"=U]&3A-)S8Y/2258QUWXQ-^/HD)%H
M3$B 8YF^%90!ZY&"2]%::J*2P;=1SLV?#YX22?YN^>!KX,LE]!F^U1EL!DK=
ML1O#M21?;6C@ZD?>K1M#I=(F4&E3>V:LT["M;2DW1UGP,S9QU(H33PAHFQR@
M3 2,,@:"D]$%QVF2;F?/=*F9LRME.QKI5.A^*-!=J52IU H!NW23N@K831*P
M,]:X55F,,IV H5: *#1DY<N#B)A\B,FQP)<E89>'"MO3MFKY?9\W#[YJ,YMZ
MM/5HZ]'>:8Y2(EXCU=0;C48I@X808[50)5>8^[GUF=I:LQ6JRKN9&A>F@V2:
M)4!BLZ8BE (M,:LK*!)#;J)V<F=/S4XOKAQ:P6^#CG:=QEP%OY: WVS4-"AC
M'779,/,6T$M7TL,E""V35$%%CW0]Z+?M<=$Y&@MOD4NI.OXJE2J5*I4JE2J5
MVD2E><J]G5 6J8HN>(TAE=H4YJBW(6:UV0AZ"_6X-HB]7\WWPTS)MXFT3$)&
M(#SID@(@P*04@5EA>(K!8+0[>\QTM9A5?N>H^*Y\W%H^7H*96_GXOOEXQH+5
M1"II%0/B/ -,UH'%S,U2>J4L$<&PU"Y&7D4!<QL:/;^,)^-X[.+P#MV>)SG6
MDW.:2;-^T"V?N6=:\R2$5 F5"DX(9R6C)&;8TC&==5ZX18US;?F\,F!Z_WBF
MG-G3+$Q2))")+@$93V!4ABD1"]6B+O.OFY;/BIC2]OE.10F+,LS]^,_O@<G;
MEG]Q8S^9)9W!9@+<=4-F[X)NM='S?0+;5,!4D(#!:@Z"2 =(F0<3B (IHLW&
M<+:,K;IKH^>*:A75M@#5%)/:)&9H1(8L"!<%TS91G\V1J(-9%JI58W(Q:)NN
M"R&)"<VY X)< RI+P4J=K4KT,:&+6FC<V5.&=(VH"EN%MFV!MGF\9EG"6Z>2
MBDXH3"ZZP"7QI16ZID8H?C.VU6:GZP&YZ:;.)#A-I0054P*,TF;]S7M0ENCH
M73*!F=+4&=4<39TKNE5TVP9THU)0QQE&'7DV;82.BE)*.#-:&V-E1;>6H=MT
M7,]S(HPD'+B0%)"C F,D@J',E@JD++1*NRO4747F:.5<\:WB6UOQ;9XVSM9X
MEBU3'XA#%)E3T%#!HV'<)R=C-4S;@6HS44[GN#<\$M",JJRTZ>)THPR<=I$9
MHACE&=8$DJY2;*,LTR8:^O/8YD\\#Q3F+^>+.[;#=[W^^>(HRPQQ]JMF1>PJ
M+/F8[_HP/[EYW-0&,S<>V9-1?'3^S2^A-SHYLE\>]?H-4S5O^N7J)XJ3V8!K
M^;S)R[]\ZH7Q86'#73)AQ;.P[MDGG[V\V[PT=>R3UYC:%0)O?)GLTAM?^]YC
M]:[&F]_YO:=^_S7!;_[,NZY5[A+)-V2ME.PJ9)NR6+JKI-B4Q6[4R;)=@[>[
MLV?)'N=_<"ZXL='8[EB&5/]TB_YT$WL.7)\+=+V6<;$G<YL]321XFW;UI)G-
M,-E;H_;>N,&%[L1&G,6W/BR=TH@%>OV'?!C>GQZ?'MEQ#)VFP+%SI<*Q4X^F
M',T#/H57@[$]^J<;_KQWV5S^OU=.9'O0_Z?G_<[X<'":'Q%&W4[\[&.Q%YND
MPQFWVG6)[',8FNVF^R31<EE;O@57;,_1/3X>G/9OGGZT_9AQUMGL 9_ I'"B
M\U,IG;@-;FSK.3R-J>=[#YD7)H[E><3E!C4%^'$YQ;]M_]0.OW1H4TM!%^D3
M\* +**R@C!AJK?$>%48ME;**LY@(-R@FR7B$,DYK <5,S./XS:<7KSQ]^_2W
M]WDM(J_OZ.UQ7M_QG\=O_GKVY>W3UY]>_.OYE[?'!^^G8QYOWS\NS_VP_]?!
MX?[7#Y\._O7?X[=/W[&W_WI[^.;5OS\<O'J,;][_^_@-.T@7.<8OR=?]]_N?
M7OSQMX^"<>,<$*DT(/4"3& 4F&-,>,$]HWYGCYJNHMAE;,X.)8NSRIK+.%?+
M\AL3WUU\^YN)=+.AW;O!7*VDN#^$^SJ%<(:CH2D@1"RI*L(C.,H)T,@9"9YS
M%<E="RDJO%5XVRIXXXY);I5 A@[+^ [4D1,O1;"&:Q&7!6];F;ER?QA'IS!.
MDX#<"0+*NI*W8AVXD"QX+A1ST7)CV,X>E[S+S+QY*Q7C*L9M%<8Y1B273$D;
M"$83M)&:*(X:"09BZ2(85V%L'ACC4S#FM'62,@6<D @8G 9'1 *#/$6511-5
M?&=OWL&"%< J@+4?P.8IGP@T0U<,)!&;Y7X,VK,8E70^[S:CFK\9P6KYQ#IP
M3DSA7%*6JL0I.)WM4G0BFZ0. S O@L\JG*:LM .F749GZU_G;J94<:[B7'OV
M/0_,A92B-\2[A-D<3<XYXF3*NENTC#->C=%6H-OGZ9Y,(64@(TA!"I^M4<DL
MV*@0)"(R[KA3WI5><:Q+]+SU_6L#N56TDUL#^Y4AZ27VV1FD,B?Z>% 6D-FC
MV^G'FZ/@6SF1X=HPILZ&87 ,O8X)DXHZ.L*T820FYSDC3;=*2NBD6R4E_,?Q
MS.NGUD_"G'..K:]!SA\CTL&3F2!G5I:9SO8^Q. L8.(!'+,1I"*1!I&U:%J:
M5W91FZ[FL_6J=5!*G4&S04<[3W->)=$$9[+185&@SGOUE)DD7<8VB_@#N+M!
MUYI%NV88Z)Q@5]6O6X'=="S ED;+)!N7AH28P2Y8T"EH4()RC(JA%J7QB,C:
M%^<5ZBK4U:.M1[N8%,E XJU640FC4=EH@G%9U3*12.T8$56*M%Z*S!CQ27/?
MM%.6Q-/BH]1@D G@RF<=@:N$CJY1C&Q/BO+UW-=P #13UXN=?C%VO1,_E^]C
MG6=V:]=0BUS<E4J52NNFTCJMP\?A_>EH?!S[X]&KP;<RYU+E_+Q_5I35.,8:
MX'MR"??^C/][VAOUQO%E''[L^3A1"/Z,?O"NWSRET0VJ2K TE>#EC&$9G7<\
M\ #!8QFU8!@8H3ED6Y,X@CYZQHL7C5\S :9B0JLQH2)WI5*ETN;;S56^;I!\
MG3&YC2!,*V6 :Y\ I?%@1:3@!:=!&+2RF;'6,@&[)8'QU_UAS$OXFNWM=[;7
M[_Q4IH;_HY,9N-?_&,^8JF/[H3,H76BV,E1>O:GU:.O1UJ.]4U(R:L=5T@01
M"3**U@ECL]+B)0W4)7T+9>:&[.2F[=>5KE^3[B7?(/O_#8[*R?XK W=I:/*B
M_S+ZTV'66^+H\3"K-?UWE\,(!W'\(KVRGZO",H_"TILIUV!<19E9#R+C!M [
M#3HE <%PY3PU5#B_LS<;'+@I@[DR:<6_=AWM//BW!&.NXE^K\6_68,N6&!>>
M :/<GP&@% 2B8=X032))ZKX!<-L#H_GR=HII5@.@U?57J52I5*E4J52IM D*
M<F#>L9(WQABB,ZA9,%995,9XQUF\NX*<=8*)1ER4WQJC6)K*.UNY[$V401L-
MSJLRU5(9L%Y1D-0S@]PP(TG)"NQJ.MMG9N[*Y<K&+63CU=FYE8U7Q<:SV;T9
M>Q,U DIY(Z K(\^LUN!3="F;KU$DWRX^WK@PXX];#^_;H3_L\#DZ#S_D!L,A
M"YL890I>"[0.;7+.2!\2<\3[L[9-MRK(K0V&5P4U+V9K;ZW4/%G%P8I@ )GV
MX*16X+/*D#BJZ"7;V6.LRPAVB9BS^+;5,V&WO5/)PVM(<B<(JLU_[P]]IIO_
M(A+N4#A@DF4]AW@&Q@F?C19D7A+CB+5W;?Y;H:="S[U!CS8$I4K9T H!G>76
M4B02/094FB6W+.BIAM9"^#-=,^&XUHQ+!UR@!S19#])),0B><I\,(4[BSIZ@
MJBN5J/A3\:>M^$.4%"QPYVS*F!.UX8HGY)K90&R("^%/A9AY(&8F"XL9:@-J
M(#'Q##&>@/-"0I2!:LZ]$9Q<EX10P:6"2UM\RI&Y()3.MUA*9$0[BS%0;XV5
M4F<[ZV9TJ0UMUX%!TV$A)9TDI=ECC-P!BJC!&&= TV292HQ:YG?VM.H2-MN]
M^T9W<L6@BD'WIN!@])X))2WZA"0PJZ/D)E]=ABDZ*:N!U0KDF8EDR:2%]XF!
M9%$"6B4A"P\-UF&4S#JJM-[90TZZ68%MF1)T3[F:Z^3 1?O-;E&0?<YP%P^!
M)F=-"HA*1NN=UL(8$U52*JJS,#N>A]EEUO*7TXBVQKMN#T@O9^)=6F!"QBUH
M4=HOZI3 <B2@LX:+QII2UKNS9^;V]M0<F9J0>(]4\C&FM(%4FF?6G17.4&4I
M<H$J>)VM4$&<C903(5/Z <+>N6MA5?CFP==IC[KB4D=!$QCGLZFIA *;A21D
MDGF&Q!/4?&?OFKDI\S+N+ =L!.-6>*U4JE1ZV%2:0PBF;%D@S9B)6,97.\-E
M*(/$%$>)))HJ!-L@!&>\'IP$+S-Y( 47 *WPH-%F><BIC4$R:JU8BA1L:P+O
M.MEK";UY-P]3:I>!>K2;=[3K- =K,[Y-D;#[KQZ/#Z8D+-%"6,<)),*R7"7!
M@N&&@8M)E_P[IUC8V<,ND[0.4:D@68^V'FW+++$J?S9)_NQ/W)Q9!NU_V?_Z
M6/QME*2EUAJT1U%*K74V\5($)KS7B1-$MSX!]  BU\MO"+M%'J;J!ZQ4:AN5
M-C5D>4<JU?A4:].943OIF7?4:YN5N60IUU)[0A3#%&ZERM56D&U6UYZ-2U.-
M*S/O@W$R*VS B:. RDLP40J@TBH1:#"V--1@LP[YVA2GK1S_L*3GIE)I'EQ>
M@HE=<;G=N#QC1J/D(4B4X*+Q@#Q2<$XA$$4(,AY\:!,P;T^0=(X^O9L'.M5C
M6H^V'FT]VGJT[5+PO/0A9&4N).J1&'34H$DI2I:0&:'OKN#5WI0K4MF>CU],
M1=ZUC)$EJ8"'J &%#6 C$9#U=&^<=AZ]V=FCLLMEG2W3(N9;G755F6]ES#=C
M+^EDF=8^@J%H <LX2IL*R8(FW"JM8]/A^?ZY;_Z0X[4>\MMUA@V]CVMO#_OO
MTW[L<#+5';99V5T"(P^Z>2RC91:=TD(3BD0KQZ(P7'/JT"$UXJRZ_Q9%M+5Y
M[.K@:'\\G>>NHE*:1P:9=AQ0LP1.,03!C:+:.B.U..L>*[J$SUO@OS"OK-RU
M>Q7#;NI)LAJ>;YM+Z<9F)8MO?S.A;E8'NQO.U0ZU]PEQTY%#;G1,Q&2%2T1
MIAS8$+/6%;*J);B+B<F[MJBM^%;Q;:OPC9NHD_36<RM1YQ^<+1WD,7D1F;1A
M6?A6S<K%0&ZFFB(9I P)L!B;!G$,K&02*,% B4K&!+:S)QCM&D$JR%60VSJ0
MF\N3%EPDG"JJ)$.7J-8&4Q*<&&FHBO%FE)NC'69%M/D0;4IMDQ)E4$R#9=H"
M6D/ F.C!"=KT"V1:E[DFL[GY<^055!RK.+;).$9,RIP0M+$FJVB"FGP0QA$:
M LOJ6_B.ME;;^JX%Y*9#<3)1QXVCX)W7@!G2P"COP$C/H^(N*;0[>Y3P+M>F
M(MT/]_&086Z#,&Z>N2P$8QF"22+Q2!5Q!I$;Y($80J(RU2!M![+-Q#DII5$Z
M:Z D;P(J'<%QW2AQDB.W@G'<V4.JNP)7;I'6W-'E-@W^=LX\'V88G+JC>$L
MWAPPNC;0*8SCTN@8\XU&*X4A,GG-J59.!"[M61*&.D_",$MK&US#H,M"JS]F
MPJ"H%.56JPQ6.NMAF!0X2@+H9+GEGJ5HW<X>9UVS0(_S[['*VE*FMHJ5;U51
M5 G2 FR]1M$+01@C O4$,2BB6<S&$=6"*L[M17;;3<!ZYT:)50E<'JQ.1R6L
M9(;*8*&$( "ISSH@(H+Q:#G+:F#0*9NW7<'G;:18F;BB:B5()4@["#*/RY9I
MF15*DYA"%$Y:80,QEJ(QE(N8JIAKOYB;\74(ST+2@H/41@!J&L!8XH$Z)Y1.
M(23EVRCG[BGE>\-["6]1,7]MN5"I5*FT^;9M;3VY.?K"ZQFS. B&4ID(617,
M9C&7!%PHLZ555!&1$6+CSA[O*JQ#S#8,%"IT5RI5*FV^55T%["8)V-DB:\T=
MI<X#AA2R7+4ZR]K(P6MT3"IMM,#V2=CM23!8?F_GS8.OVK*F'FT]VGJT=RK#
M(]X9R:0V*:'GUO+@0G!2<VN$_V&6T:P^4_MGMD)5>3-;YJ*]L-8J$%:4S".G
MP!%,H$Q244ATJ92YJ#H"J6+?)A_M.FVYBGTMP;X9,TU99:QE"A@OW6>"1M"4
M:W"<>621:DW,6L#O 01&Y^@?O$4^I>KYJU2J5*I4JE2J5&H3E>:I^K8F>DNB
M"5PXU,KJ1)D11#ED/EKM;Z$@USZP]ZO[^IG*;T^S=8,T@4NRI,9;71HO*I#4
M$B550.;HSAX57;%8X7?EX];R\1(,W<K']\W'LV-DH_/2)PI:< 24FH$+EH-0
M:$UF8JJ:&I<6,?)RPXSMZ>?\,IZ,X[&+PSLT=9[D64_.:2;5^D%W=O;<9WTC
M,J-+*P83G.<TNM*XA"*F8,\:,-RBSKEV=EX=,+V;*6FF!'U6)F09ZR !L\*8
M$4H80..XD4&[2.RDLS-77:/O5IBP*,/<CP?]'IB\;=Z]&]O*+.D,-A/@KAEH
M<R=TJ_V<[Q/8IB*F3#NILSH$GJ28%2X1P%F3%:4D38K2>R;L7?LY5U2KJ+8%
MJ":T(Y3XA-H9)(RXJ(27Z/)O8D(>EX5JU9A<#-JF"T,8RZ:_IQYL1)ZA+:H,
M;8X!5Y0Z0SD3*$H79]7-?UFAK4+;ED#;/%XS0[P3U@N/T6'QE0G&K4W4AVSG
M,.-OQK;:NWEE.#:EHB'&*%$J4,$A8#9$P1*;;<^(DD;!' J]LT?GF E=T:NB
MUS:@ER0^&F5Y=":AY%RKTB%)>4N95":DI:!75=&6!VW3<3MK3#1)$:":2\!@
M6(8VZ4!JU)1$GJE8W/U4=XW2%=\JOFT^OLT#;R*#6V !B1 E&Z'4,$C)!%&$
M$ZNJX=D25)LMF&12.^8M&*9#AK7(P"GN@*E,+A'0IT1W]I#H$B[8*,NSB7;^
M/+;Y$\\#@?G+^>*.[?!=KS_Y>'85@WS,%WLX^4VO'_)/CSC=%0T4+I4+*3EG
MP^:)CTIM<<]_GS%98<Q7A[%C?>EJ9/M?\CEU^H-Q"84.\Z]+I>4XOAO:H\Z)
M'8Y+I^?Q81S%PJ^A-#XJD-]OCMN.\P^IU[=]W\M_/AKG7S0%FKM7XZ>7CNUL
M&<AV53Z07TX&HZ:T^=$P'MEQ[V/\Y5,OC _/\>/2&\]N ?GV%NOR(D['-[^E
M723Z+D'$5,#YTM>RH0::A-!!RJ0)!H)::<V#LSR#I$/ILU+Q-Q,[YV\Z''Z3
MQ>\BN&&T'\"FO.=']NB3_3+:^?GJ4>5SFB+-7*=ZW1GN_=,-\Z=<L[%+3YNA
MR<H),),.T!#@?X9?\O4]ZOS:RYS@#[N=YWU_\RUNRZJ?7+#DD\LL^?*"$0OW
M/K&CP\YO1X-/H];OYZ?3OCT-O;R'?]RXUH7NW^QSSG"E>=2E1XOK\"(_N!$'
M4P(JG\Z1/1G%1^??_!)ZHY,C^^51K]_LL7G3+U<_L'S =$),^;S)R]^X;Y=,
M./ L[>;LD\]>WFU>FA*;D]=4?J?1-[Y,=NF-KWWOL93M&B[N]-COOR;XS1^Z
MT&+5K1Z[BM2F>Q8D9TG;URE4%SLRM]G1F7"\%T/BQ\ PJ3G*O^GLYS\[''6>
M95X/#6]?R=NZLN=-:(AQRZW_]+R?%;#!:7Y&&,VX :Y+K)U#,6XYV;/-QY:U
MXQO3B;?UY.@\'+&LPL3[0+[K=_SB) ZS"9&-F<?9MOS8U.#>YNXL-/+L-I=J
MWAEFJUWDW/<@-?^U\1[,5YXZSP;7[%J\Y4YO/P'NNBVNR7-XR[W-$QI10=,D
MB?&.)B3!6*\B2YXQDAPG;%+6Q B=E$.P[2Z'.'AYYDA\_X[OO_)?#]C;HWVV
M__7@U9_'^7/%P5]OR)OW_ST\>/4,WQR_IF__>O;EPI'X_MV7_>-]?//U#3WX
M^AK?O/^S? 8>'/]VF)^?U_::OWW_F+U]^H>8=B2^>/K\RYNOA^_+W^3U]@[^
M5?;SCKWYZ[>\ES?LX%4XWG_Z]L/!TZ-TD9CWDGS=?[__Z<4??RO#,2E&P6KO
M 76TH)V-P&R^S8&ACYZ7>9:J:QA?H!KB>C1;:5G3U$?>>F1EQ:4-QR4?'/.<
M*ZD50R+16NIIQA]"7*))G#=OI@^B3&M#<.GK%"XEH;ASE(/G+@ FK< P(X%;
M@HJ*J$QB.WNHNDK.D92R2EC:(D7_>A:\U&&U,QYTAC$SG>\=Q3*"LM'\RF_+
M][XX/D^+=[37[PPNS .[%/.@+1; *I7\B;1ANTRT^3X\C2?Y#O0FPSE*9U![
M/,A+^]K\XDY-:FXK>=LGGNY7:[XJE"[3X7$_/+Y$A2JBEB6B+A*_OXDH070D
ME"J0UB)@#%E$.8; J4J)4A8BXLX>ZQHI%VU9W#[MN?+S$K7-RL_KX.=IE9-1
M2IP.&H(G$=!B:? 1.4C),TD=$=&I,A/,Z(5;D+=/[=P,E6,UL\%F#V3[4&KI
M6D?3'.#7Z5D*%:"6!E"]&84C4.DYM0RRWI$!*G$/+C("-C(;;% L,IX5#MZ5
MUR0RS]M.[&:46%D;HEL:9P^>EY>N<51>7CDO3RL;!!W302I(/@A D6FE=6*0
M4'.KN7=1QN)W[U(U;Z./5?+R@W)P%"=OF8!2LLH&H\P[):NOZ0O1L:-1'-^M
M$^^#,(I6%QHL+;]'A3*Q=/W.$#1ZD1XWU*B0- \D?0L%DOWWK]G!I[]93$)P
MX8"6#AT9GRQDA(I N2!>*:T\(:7_4(N,G^K,:+MJ\3UV;7F[G0UAXVG-0NN
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M[ED/T"G)S-8(3CZ<PH*3/9MNR'U&Y6]P'Y#NJ7& :@$( ][2+Q\/RHY-AB[
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M;(L-TK7SB6>>NW#FST7ZNL%PT#=?NL-)"KV_?/?WVUV$]=8O+5B/#Z= /T?
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M.LV=^W-0,U_/0O>Y7\5492^3#;IUSX'S69V&"\"(L^-A%%)I5AF#*ON-I0F
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MUB_KKWDY\+F/=VFB T_:^?"R704Z)%:;%NB81X-JVD#&D@7\>,PX"( [18H
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MW'*01)&F+,P];WJIOLU(ABJGY'&&,JPX88HR92J%;CMEU?BKE-F?!<E44K=
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M(X(*8Y1"<%0",8(QR-.4M.^$Y])9%;G])J'ZP]"@$:KW@@B&%1:G!'RN8X%
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M3(]R0C!FI5 V<H:M4:Q07!?&$>^YYN4<;XP)Q=<76R:LV.G[Y22I\4LS'%X
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MNW\^PKK=1>?877[ZYZ\(_UY\QLP)+B.HHCB">BI$@;2S!K&@"LET]-*QK1?
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M,)3+5A^&''/)XU9N,&&SMK0Z91)R:=R.A6W-#KJ]JOM3-X$(Q!8\A,\E<^T
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M/9DHJE^A0C]_/#=L5FG^>'K&:AUF];KE+G] >P4Q1J3H'-6!8PL"9*(5$@Q
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M%RO,HEM4K#F@LZ8IQ$.BTNXP[L.=#R]BYTO<*SOGLSZE>EC FF\DY:7"P6N
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M/6)(.6Z'I0"PPQK8:6#GJ<#.G<[$EX6=YY^.\F"81"8PZ7+O[5&R3%OE"$I
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MD_.<DG%V_!L]_]HB"XMVSZA3I4D/'VM8BFG7<84CI+E^)I[68U7]-'+)[U&
M5WD]'/0'P#3@.99X8IR?]_MB\K0FY^^Z"B(JDU*70BRO7WZ-/=_N5W^4Y)UF
MGA;-T[B 5OGK!5PI$]^A[92__\S!&;]\R ?WOS[8_'5BFMNHQ[,WP1T6D87'
MF-QQ%X]K6<ZZC/0UK&[[K-_V:S_2?]O.</WG\Y?79]-A_?U?IW>AE0X*&("X
MQ; 6-/+(]!JQ+;*  >=XIWP%>!CRZTQ2PDK)A+/^\W&O.SP+J)X)[V-,Z?<E
MD>"T'4(G/KQ!5!9\8MO-R:FC$G"U35]GX5\+E/3FR:CMFQ)U?CYHE59]K=%S
M3<X4;BV8KUX>ZB-M/(LG;,F8%AE2"%QJBQU/4AI'2/0V8..%2)K>OKO"#SK<
M)M:YRBY_UNZVDP^G7SL'IR_IAT_'&,8C]ND'>/WVXN#O=^W]/_;(WK<]_/&/
M5S"NG<L]NL=&OX%[#3_2O^2'PX_M@]VW[&#W,_OXZ2,\PX[X^,=KN,=?W_:^
MO?O\X>^]KWN[<+]O(>V]QU__/'PY@/]^V_NT=W'P]LBH4 KD(<:90AQKC4RB
M.B>CIY03-*PO5?,P9YM$79<3.JMV*U.U_&E1N=NKVG>@\T8<G"5/]PL9WR5;
MCX$8_WEOZ[C$^JT55%Y?Z.!N>$GO$2U'AL9.96*,K+"ZKUT#D\O Y+<9F*3$
M.$--0-QQ $?E);()6R22%-921KDP&]M"+:JZ\+PA<IEK+/-,3P(P%IX/!4HP
M\T*+R#A/B1B52_XKY[CWU%[3Z6Q%&1,WHL+8YS#A;CB,O5.Z,+<BIPTT@'$;
MP" S@!& 1.$4/*)$>@ ,%I"C"B-MHB+)1(.)WM@V5[TRYY)O&QK3T)@5TIB5
MT)?Y:A<KY"]C#UEQ0#V)4AA/!9W8##H)3*1F)J&$1>[G9B72. 047:YPDJ@Q
M,FUL,[+)V'5M3YX(G_GQH[<*\EC50?8&V(.G>R35_Z,**KZ%_^O9>[+N%)_3
MQ) ]67AKSSFUG!-< @%'2I>L!Q&1(<DBH&+6@%SDZNTEOTOHA8%HWT6X^\.J
M&^C;\R%BSX127>,9^D'\6=Y%U%\*?AHWT>J 9]9-Y!0G41N"6&(8<:[ ZE-"
MH*0,%Y%%;!VP$,FV,%MWT%G'K][CT6>%IW2+WH+E/>HQZ$A?;T/U;O7P3X0#
M_O+H)/"J9F/5=+B"TZKR]63 ]GB%&HZW,JB]G.-XR2D7/"-(V" 0%]@A(PQ'
M-M(0F+3PF=_8UGQ3J?DJHW,!57=!BS4]DWP^-/%VC[C>L/4<^.,(T!H*>0^X
M-DLA8PQ),T50R*<'7%N.-'$)>:TL-LKYJ,3&-I=;]+HZMT\8VY[Y-5;EC'P"
M-/5%KFG=Z<30ZO8R#4JQ_6S=DX]/37_0/_FJ6I\AC'7G;*+JWACP&R:[*L3?
M?S''9#WA@DL<D>;4YA \A1S&'(GH Q;2T)@K>W)"-[6AMZ:RC9NR<5.N%\W\
M41!J6.?J,&B6=7I%H[ TH&AB*:'HD..,HF1$=)%2&S#?V!9ZRZS]:<DZ?K5Q
M7&;')6ATX[9\:MRP88/WB<3S"1E@Y M#F$*>*(TX=< +K?+(<PY4, AL: (D
MWL1X/C*G<6NND^HW;LUU=VLV%/,>@6V68DHOK#9&H\@$1]QJCHQ3$6$6O? F
M>,_HQK;26V15669KA&[/_!JK+7"R=M1U)O5X7$^L-2J&>!M2^U-G%W-K/#6)
M^H =YT(8R0T1+!K*?'(REG#SAZ"S37;Q_6'^?" FE4FRW >4*9\Q7U%DC;4H
M2(J5=);HW*R8;7*C-P59-G7N<2+*;R*P/TDNS4^0,G,-D;T;EC69OT\#PF9I
MJX8%CD1XQ!B3B"L5 ,*(1@E3R;PTUDB[L2WQ%EOV/'Z]X&L1,[QNA,\G5_<Q
MNYLUN;J/I.*SN;J8)(:#RC6LG<]-,ABRF#%D@@Q,.)I22+F?LKY#KF[#%GX6
MMK 2EM DV#Y-2)E-L$V.&\4E0T(I@!0>,7)2@@E$=;(V81EE!,-';5*R9";(
MT\FC?195YVHN7>I@W]GU<T-.=%TCF\&"A>XPWVGT7!.+O>#3QFOT4%ZC"2EH
MO$8K!L_YU X7O>%..N0$%8C+W$0"XXAP<%0*9:SU+F?1J4U&Q&K+$ZQ"%=?\
M(/6^0>?ID-*'F*$G"L=K[_V:0.3&^[4Z*)[U?@47 O<^(0+_ 1[+"=*11*2)
M=T[RI"VA&]M<;RG> /%=SEI?O'CY\M6K%3_UDP"==?7'78\LU_GC2../^R'0
MF?7'49&X9=HCAIU#W 2+--86I2"DY80Y"JN^K;;(&M7.:^A40Z<>S3VX&K2;
M=@^2QC^X0HB;]0\R:J62P:! 74#<8XN<C@E)HI,4U!EB .((WZ3TV5NXU[H6
M_U$ZR2WH03+=Q@]^\[!]Z@C9TIS>I4^=R0DTM^M35SM71U^H<895C_N]X]KZ
M2:XYL9W:WFX]RW#;T150WI!^HV8BX:1NEXB(7GVW1'VK9HD3_5,>_.[3$Z.W
M9)F%<6.B5GL$JZTO&5=;O7C>B_T<GUR:.(9V2K$7SWQLN3BXB/&LO.T[W7X.
M-ZQZ.IYG6[;53:WNL =+?WK:/:L_@1?7-&@NS5#SI6)M$$]>Y2J>,:_P241P
MQ7@YZK0ZTPMUEF4]W8::@^[ =N96Y)<\2_84,'/0<I>MBY.V/RDSEVR[UX)'
M_!P']5?C5P#3T%\PK[_FB9WN5SOZ0OC!5MNM"]MO_><2Y,)X$T6*U"4:.'=>
M1X\3EYX9FQ1L,+45I:X)M4?BGKPU5Q5$#O-"W.4\4CY-OG'WQK>'.SR'*'BF
M8,$BPHZ9'(646\)'A@S(2331XJ "\(6MZPX309\ZI2LLR-TRDO2#21N-)*V5
M)(G]XR,J?:*1."0\2XAKDY!6C"#OM,A+"JL-+(QN75?WN9:DZ>;9FT6P?JP=
M]](HAZF6K!A1"BPH)ZW(Y<LMX<80)F*J^RRH:WK%KS[48G6R^42MJA^0S9=D
M[_A(& S"B4$BL8F(6PM6D0@6R9BD40J A^6#O^M<S:-.@$NCG ^.>L:4U(IR
M+.'&Q!- ,XQ=(DG,=NQH)&F])2G;U\DYPKE!T0F0I,@3,BY%!%0=6QN4%Q3V
M2UCN&T1I&N9F>/'3Y<$7HYZT=3O:UG$N$8Q"ME<*Z:W8[GD$^S/+:3$::E9[
M7%6:!R[=BJ?GG>YEC/W-%DPAFOBS; ?M'DQ<M]>_=_I[S5&E#9$!.X)+4\*C
M#H[X8$&+L9?1*!QOH,$K/[/\;AWF\N$N+, KF/]:P9_VV>4/Z/#>)3 5%ZPD
M+$B ?R\09Q3HKLVO A6P]3MBA-W8YF9+S">,WKP%7",S%%OJ<*(Z1L<9#U:
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M+<T$NK MU_;7&X';*.MO6XV\\TF686Y6QB,ES= FP&*U70V\[;!U][XXN=;
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ML6&&V.38FD$\PMV[(RK0*)&' 9"*DN%$D#;M/+S7#S0>.*YA69;C!(CHX!I
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M8Z)$"33F&$6$4!; ,:)5$+R>H^G'.8K(_YS_K>HD(3$'%B3:%:_5TO(XA@G
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MI:,>^"!\E$1P(*E 30PF8![D#.9?>^3P[1X*[;T#^,MK\%3@3S%U;),\PO%
M6R32GO@!ED'I[(0]AH#;' T,\ECHZSACEW1OWE$P=0EA=$O+HX/J)&'B&@5<
MF2PK0[6,7-1<P"S\I 0:\,-TK0,'7'/LTZP?@20#;Q6O#OY[ GN JI_\<P%,
MR#!@!.27A+GR$3S*(3AZ^Z,1,*O$?MA[^W%_[W45-_[2/>_> 1>Q]_X ?X+0
M8Q21J$%!B+3QN><P'8Z8VO("^!Z#<!@&B"D,]E,= (GT!+0P9AX@7A&_%FO=
MGUP";\C52KP"F?S,18XLK$OD-".V/(8WIH<IWODIHSL\BM"+Y7X![E#><X&+
M)U#3RE!]B>NHNW099XK9E.#JU?93\P=A9A8 Q!) 27DE[$PY'<0+K^KVX200
M@4]D<2.124AE6%YWP9OP!AXX!,]:6 (8DAC!B:7#"L[A<(*)%R RCF45P3YP
M3'BCO#H\WG^M?((/V1CQS]^!<YV,Q[RX*ZE]=32\PF0N&0O_A!TN*C2IN4=^
M4!PM6E55AE:!3U7$W2G6POIY*MIF4())@/T/6)G5/AGW8+=D>0*KZ)?"Z\?[
M^YUBGZ;72=$,L=(*S?!XGU+;/UL"F%/!MQ,(#_\9]B<8N^E4G#6G.B(36JM<
M.XRP [*=ZE\?0TI??#B^4T;C,VK$9? 0CSO-84E]HNV<PFDP$?@])0<F86_<
MNTE1AK_:HY_NG[T[0OW#%%P].FH4B"H$-+5X$E>Y))D'29Y+=,'!9$R!<IHE
MY60GPZZR#[\?1F#R_T(83+I*#%(5]R(#GQ(>_]0#F:_HOQM$S#>X;S"_% ;M
M"DD,TEI Q.)=TG"8XF5EA&*$53P9PXZB?!."48G2O+H$)7RF#M[_D0.;@;I%
M7T2>C#@L^ '%NE*)ER\!":]Y'X$B"K27B@'I)K8&N@AR,.(2ICT9#%![@# <
MI4,,?V(*0_'KJL9 2BT\WFB2%3E *&JE5 UOPGZ!SEB@W164$(+,!SD2)T%&
MAU>ZS!(3H5-OK5.[[,KK6T0X7&*/Y([7#F,:W@K?*W9JO40'K]?_(Z7_ 1:L
M]DMB;]*%]"KAI/$J>*Q<7U]WBTD*"*[N97HE&PN=O+NH(%#IGYJE6:YKSD,/
MWDH!8\T*F"+&+NGDGD+F_-/1R5_V76+FA*[*P'U7SF^&$; A7O+!J!0I%H"C
M\ZA@!3$BYU$*DJ]%4(!*G@5'X(V/I!-E"K.QC._'20:V38_U8YPU$=KC))89
M2YW<_?3;/%?L*:AOOB-V!H(MR0B[;"=XR=)<XB7,N 1" =)[->3@T:#&>KTF
MIL+\7K7/AY>H AJRFSAM )8H_"EZ98"[1T&S$B0.E/.[]Q=GX"G<P9:-L6?4
M>'\BL._1S[J=_?!]=!O:G?$1IO1P&=A#KZ''HLISP*T2NSME[@*'XM&1?_!J
M[^CD %95,T.)T0OC]6XVAXTY/=O_J.J_?SD7'\%P= \JCE(>[[#A,S7/ /<7
M?BB%!CEN90H561;_(Y*%I! Q%FFK->DJ6_-MPW*ZZ%))8%DRM*=<EJ9%5)[$
M6[!:X!EPK?XS ?Y0S@H I<-Q#YW7RC%)\&31&P7?N?3N2B<4[Y4%-2ZS__M?
M5MC_=^^[I:\0 )4#VX<9YV0<ET\BA?,AFHE$WO) FN\3MP9-@IDV;Q8<XBZ$
MQ?:!LWJ8LG"O(-^&">,BC0,=V#Y8UQCQD89Q43-15%V7&1:5V)6FPG0>1)D<
M(4F!+)"J+Q%E+&%B0;&-Y=V]<@4\@:^Z[@$%WJCI];">!72C_#=',[_:?Y%'
M!!Q!7V#(B_[R_^<4QQ,F?R.45^(AD2TWI5=$PT)@30RSH=$\_"Y;$"RG<1XY
M?7YAK'K^P;X[_6CNZ\^7T@^65Z4YQQ1"(9!PW$F16'(I]5_$,"P;"3JI-&0D
M;B7A&:1+DON=^N,E[=4:4@!I90R);X)): ,,_?R<2GR_&7'EZ.A(E%W"U+K*
MZ5 Y)E&->G:.MBVC4O"^-%;A_V,'+TR^I'PA%M[4'.-W:0_36HU21QWNGX'D
ME&*3/#H@OD=6999M:;ZFD17QV9!KDI4#-8S48F[EG(7;2:$_H0-D"C@ZRV7]
M%#V#Y:RR 1M]6?K)I6$DLI00'@G9K^9& WN""T_Y[:BB1'!"_!!)(!D7X,_]
M%,\+.%')6<SAU8,4-$V:493B:SV=M#@L:C(T%:.8F7@]<E9ORB::85#N4#[&
MWCZ%]C5FM*_8-N/U?&OP&N;WHR^SAV3F4=%>1! X:$2:$!O#E(*)O**7+GGM
MUI\A-@8-6T:WT=Z#G900W65H.DL&*!Q+<H25C-)$='9KKVU7NK8U=^O:=N/+
MG81"!TX#G^F*,"Q%7= <VV#9U)8%V2PB53[NBQ2'PAKI$:\'P*0[D5_\MB@=
M6L_]]$PEH^TM5<GXC.;LAE4RFH9@+M#$IV!C5C=?E9RG*IPD4D7LN1:,+BXD
M%UW(%1HA2GE>% V11P;&,]Y_*OO1%8;];FK>YX!7.'C(=?BS6M\J1D@%I-FH
M$/!0*/FB(/:XK(M6SB4N&[SZU=GA\7FA#I-\.K*P5/#-;.EL?736C!N!\9MF
MHU1<IS3J,&1,&>@F JOK;??O;J<T:T83^%5.URLE= G1:]6$$:2HN+'<">%9
M]D/Y0M5..Y%'FBIEX595<SJ_^4NS^G1>PY5ZL [%1\#YL*@>(*.<T@J+*SWR
M^JJBUPKZ?WHJM\Z@WDJF<N/P,<RO%Z6]R7");C&UYC)83S#.\7I<S@#70[PB
M+]+AG0D7SI^<FUH@BH+W#Z8>;D1C^-J%83W$)WR9ZSD[@PV;,2U&NC7U,R+Q
M+HL<R]VIV3)YV79'"-PI3.?&F744<<TH"^VH V(]G6%^+O$LP8 0@>>ODFR2
MEW/"RV4*:^>@6O9JI>.*JI2F"(6%LHDL(A7U@C2APDDK23&=C,FJKM>1B4I$
M61FBA C44!0;RN)FC*W+X<O2U)K9!UX1>+=EE]D%T(%5H6^QZAHA=O?66P+?
MG:,4EVRG:FUN.]7W)>38*E5NFZX4S@2VTRXH Q#/U%">ZMM(@&!>!=T\\#+G
M45P!U(J4*NQDY$HFTR/DS\<28I/N,(8W!1)6Q=OT W+*Y.@E<$X._"3K4I$-
M*5A5U?!V"F2!8OSIH0LN)FS8CI*E-R >*!([;'X'+^S+S,&8XP=5$GRGFLUD
M!.-B?PMV(Z,U,16,H^Q""9;2\F:QVHJARV!-/G5K7M2M3P.%"5T0]R=80CV6
M2RHN2N!5Q5_Q) 9B6ZGFN@E>4T((%#VS2)(-THF("^$OJ:<F[<1.F&AG];XD
M-6]6.928;+O IV>+FJ\4P'-4))WD8QGY@QD(*-5<-#%&'H]$Q/U*X$:0WEM@
M'-7;2@A\$=EZM6VQ^B2>6X%U5!YN>8(BOE])EB*;#6^HPG&C9+2.GYUWB$+
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MNP(;)T[Z]::;YX?O:+PB0\OPBKL]C"8(&ZAN)6-044)"#Z49.DX*X'",],M
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MK$]UXWF/<Y'#^1?HMC'K*V^3=,RQV.AH&'8[\,OF3VLYTPT4A=L&N7T4ZF3
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MQ#N9/>7SS$RY\0Y6FG7]%]8?LTB5C!_IJR0D7G\Z(_!N9L!LJ>L 8G((I\\
M"<Y>(*A_@##-3?W#@X[2RG-Y6_*ZI@7J$Z_\YB7G.!SIIA?3>9.DK[K</BOY
M9JJJOQ/U_^\C7N<9/.P(HC:P90HFS:E;ON3\C1ILT=PFR9=]5D,.^6*?\* #
MSSWS9"IO7X?I,]]^[D"@VAT^$.Q?"W4'>_H]AIX'7GDQS)K!IL.0>6_5)YDV
M_CZI4>K\;6KI"PU$=<#0?(-;J6U:4&ZF;#:&EMR-!N0-9;.>CUW]2$]5L1JW
MDL9UP.M;I'3I#N<%RM+95=1T2Y$%A91]1+A]!1V<.6>^*OY?D) ,J31O&110
MU#5 +RJRSE!(3_ZJBII0*:-0'VA7*M@:>=6Y* *_(?;-[A6OGHPK2>HP)55J
MR7A):MD)PPC["P?05^:HU1C5%N>B*UJZR14MEC73*BQJ4OZ\8^%(16OWF#\1
M?1?#?.O D.9:4-;!UC<:L:O2KMIYA\1I2*CZ7.(!\/Y[LH4RV=O-$Y0GJU1]
M?&&VM<=YRSK8R0,53VK[[#OX&BZ!1J;W/$_-,]^.N"9S/MZ^9Z'N"'CH[L!/
MUFO#E+<@K .22?AU0T-8-V!5NB%$)*<53"%;,4U=@S8=7LR"#4@!0D-N7MJ^
M#K"MS,[N:*ASJ=+C#[;46THGK+.Z=?;L-WH H+;%O<YC_Z%S@UT=.ZXVY,*F
M=;!A=1G5_!.EZ6\1AJ5>$N+=XU?U4:4N[:5[-^51=34N-<4S<_ZB,QIQ BL%
M_!X2-5$,158S94W[/#MH,O]NS7!*905%;9>==:/:)!.>87H;*J\IJ!N'NLD
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MN-/BQM[B$?F"D?-4:2WDCP;G(!:>0+*DBPTY"=?Z5'PW2K<<&G4O#G]K<!U
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M8ZR+[5GYM@". (G[2/=[U_@L*,:\FJ&KFL@!M])882($;@LHQSS]QB48SU-
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M+:&]-=%#/=Z2L;\)-3W=;IS"O<3NFEFCXCW$VN,6<.W9F=J2GTX3@T;4T\2
M=Z%N:P6+,<EEV;IC\ D$\?O2\3;2;-VM;=&W^MK?KH1=]P1TJ62/ :2WOO:M
M1HBQ*)"!-B@TV3FQV2CA=6\X?)!C'[%/6LNLL9'U=CBOA].+<1Y^'.;+,.I
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M-E\" *9/ P 4    :W)Y<RTR,#(R,#DS,%]G,2YJ<&?LO'=<4^^V-[CI(B6
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M4_ <4A#_A?H<LF;]0'O#]#1%0)2-(+>/_IJ%6IQ>W.A&CF6([/-E\=X?[UF
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MAF[LP'U_A;_X@\]X_X?^_Z'_+Z*O/M$@F(,*44E6;:Y0*F:=;1)FP6_#H2W
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M_4D6(@(M"K?QMQ5LF@V3.L"W+]J;,,:%YD5(*A<&UCT<[;4&6>0ER[ ^2_W
M*OX]+/[EOGR]12GWJ.[09G%QV\S H0 B@;_. TNL>\U19R<.Y9YA8B5R?K@H
MLR8\4>;L2C)8#!?EK*IEHVY9.GI"!_X=(Y>,IVJ6ADZ_ZP7,)ZFF]:D]1:=$
M*V$-HZFI9^P-T0.<(!^? X)66 J??7F9<IDCSS$-02<F\N5+U<_"?ZQ823Z
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M:QL&TM)]A8>OD9W'\*B-;[6,J5&]'*D:XC+;PX,0(N*9V%;@.6JSO"_!3TA
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MA-F2J>\EX\LXCO$]&XWR^=;WR:,#:I0M<-_7Z)"XB@X.P'4Z-]92++'\._Y
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MW<_,2UZPX7Q;A/G7RH 9[&EL]K+..K;;.(">$W+AWP7=3AJ@FKX#;3I:U6O
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MB\OK&0W%OV:RG,1S)^MQEA4:B[[0]@O-" 6\^+; YI)$\@)%V7#N50W9!5T
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M%\+FQ'?:SPE=%3&XDO_#.^3ZD3]XU7 0MB/"C6$/DW4D-CL2S,P%HA5K'UP
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M4,3">)S,&W0LZAL,4FT%TH,><".),G2<+P":'F12.XR?BK3@\J9\;=LOG#^
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MYRWU( T$36=*MK/>NGA$+FW5..G]*NWH7N_.?Z1[LUW+HR#YD#W-&<D5^'>
M\Q%%+Q[S>XGU:[JY\C#=&(5A>SD"X]!\?KH4FH=7'K>\ZV-^>:.7RNSHI4O;
MW2L906>,]7=':P5M0-9UY1\=QT)KORPUD7H[MPF2MK.AI;6SN)N#&51;:'LP
M652)%(L1Y&$<@8;$@;19LA]EM*BL63@LZ1-5U4M)*/71 2HUI)#WH:S36Q:L
M5:?ZIC>E9%[W;WY3D<!>X?3)L"2AB65KD4-*E 9NVYM![:?4E^7D(+-UO#+%
M7&<N[PR5L&Y4L/>$":WP8=5DHKF?#1<D'(QNP9<EU2+E"(Z1H&\-3LZ!PP\
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MM[Z+S=UTXEZMZ&\?=^\X%CYXUR#^K,N+T3.YC-WJ+X))_Z43DO#,LNK_-K#
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M/_&[<11FN]870)+6=F<,Y!:U6T-WH9PA[U.\KJ]+ G23:VLTT5/G43D&FA>
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M2Q"FG4V.QG4U=9RW)K9VHC?EU]YN(3&/W3YCCNW92ID;7R@2I/69$ILKYWY
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MNBX:/HGN;$"C0"G8G1+XS1[8SKP-Z@KXG]3_D_J?D-KF5V$Y#%;GQ9A78TZ
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MM 75WG(7^UFVZ&'?)PF/W*Z88^<(]EVE?#-[@QG.;\18]GQQ[LHRH]E^::=
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M7K@Y@QXZXF9I9U^5\<SVA_&*8@S>IN#G.0*\[_I-#A^!U+P@JXJ%<^P.UR6
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M#FA=Z53<U2=EX%OKM'FL>"+0B[6K=X# 8#MVS?6T0F6N1<9NG?T;M0 W(<]
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M$A?FOO$\'0%XK/Y7]]4_6"I3D7U3<KBKJM5A5$UOQM.[F\K;7,9J[][6_]X
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M5X_'3<J+_K75R+E5HB-9 2MC>@*T"%PG(DUUTB.V!-\Z3_MSY=UK8H6T0*_
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M4*@K3INB.L\*YB]?J#%X.E,M<H8)-RS2=AOWD:*#GV,+NNQF/A7<!2(9J3$
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MF.S:YBJY%A%1P4U'-OT':A N:TTJ*DB[]]8]MN+PK?_\FVZ.($)OM/-8C?W
MT[>V*WB"S]<T2_I\DF _WV5#FDK^>K)E>:&Q5;'%-3ZXJ$K[72"=Y&MXZ4T<
M]=(4: *(WD]0M 3U554"@"!S(P_8S2UT65C X>]A(\4J<ZO$X*+!W*A.QZ_1
M,:WI$6+Y,V?#4=QNUX+^4&W#)9'Y;N/@0H/M:P%JF^MNBCIF<CTP%N)<P?M4
MKY7K"]6#'-?6^1JR+T5Q7D5]*]_[QU]"'8#4>' +R8DUR. 1O&^Q*E3_H4EB
MD=-^/9SU  .R?)E+3^#\+B>OK#.,H9CA/R3GL:?)GRE/DUK6!HX/F5W0.14\
MEM<AMU0,/J>';W"+E<5VTCXT[C' )C><A+.%-W/[?DB"-)K%F[M877WL'<E1
M8*"4@(41C;@UCM#@:,/D/CZX\>89+?3MY+^MG/*M@9OPJ3!JN%-(W#R8R^3<
M6MDVMA-PZO%TP84Y[PN\+#JXUX-S7"K/QW'W7Y>NP2KN!B=-RG"%F?%8P=@7
M$7T]2BO2;85I)X\1Q*O0@O+J3=8\O"'1D[U6:6@)T]QR1F!D10OB6'.3'/Y2
M; I7S$?47OX8!IPA">/LQ^E OPS1E6%;JEA42:"EY$_?A.B,MG3)<QQ;?X[U
M ^@)"1?=O)5.KI5^F22?8N0M@[OQ7^EHWT1U&3.__]**NVH:_&XF6TF4W*O4
M74"G\=1$.R@5OB#R[B?:?'HK2/@N9)+D2]T'*MP(#4<$,SHQ.(H$E(N7_V_J
M8#6+5<RY&TC53UTB$_\>.E'NMC7,_3RJS"39H!#F"7\<)HA8O)OB;<6R^:C>
M;8:",:<431_E-X:H\2>&(X)Y&+/9M"!WJ=9"D<41RXL@;GJ@F@HVL[@"[X3@
M &14>..FS]CX.)Y9,0L*U92JYD5;"1(AOIYGTIQ.PXG0*S=_Z1#_7KJTP,+5
MDR7--0G_^]Q\+WM,^V?<3\] 2A(F'W^W%])S]J]^CX_$YN&#V2Q8MYA"<4B"
MA3PO0<1;PN0_"5HIP#/J5]P12Y;7! XVAG.1@X>"SKL3?OR-?["C.2NX[YC(
MC!4FMF.3SNZEQRB5Q>&(;#TQ,#W'RU7TQ]CLFGW7;)0)I\L.L'?-'=OQV A1
M/T^="6AH_'6A59VNE?/Y/9C@F 0Y_69BF!>399+VZQC\0U>B(D)^XJ9V8!J!
M(MG8*/%@A"1'&0>&<%#AK], 8VZH$.K[KC;==02^3(D_((TC"\Y\C^G-'XHG
M9ZI!E<%SUC"3?W'N"Q62:]HTC+YO*95LD.%"A4#S,6IH# XN)]"SX^U'OYHM
M1;CL+C<V_J<.Z/\)C2GS]#J,HB,#IQ6BO&2;LC#4S;P@;ANK4HYY70W5$/OW
M'!VB) E_9+*.0D5Z,-=#7,R]7,!W&+G<(2@+X)#3<^<-OEV]?\\+ =C^@3,<
M9G1OF<&'MV<>(XP%(C$%68OH^6Y\-L;[SBEM1DS3LS!P1OGT?2B().AWIA4J
M#MIS7#9Z06.\/\AC^ //]'2Q5BOM>/+OA"9<!?!-@=D<\ .Z$>9D/Y_9D-_O
MI0A%[BHP+W:0]L#\6!K$X(1.#Q;GS:*SR5578?Y.9[)I[#H-^_K^Y1\3FCD=
MKP<;D$NMK5072TU&7L_S.L6^&*GOV_AM%G_H?TCXAS-U_O:%Y50G**<WWF;(
M%7621E<M#=GZXI PBD2:^W;B_=+<1GM!3T! ZNBC@,Z4(@+F/96V[_V]Y0J4
MK_D)V*CY)^:?F']B_O^#F1/$,MP3;8(\?P(\7%*;HW]H_V3(0J. OJEY FZ@
MTVTG3AY/0-]O2;Y,OTS&S$B=)P"1-_/>%5ST?QK*HG@U'/Z'[67PP.A(V=+I
M87?MF)(HH<A)H,43<'Y:ZKNZ??X$1(T_ 4CJF4^ "#'X$<-.!'IH]S\81'KG
M3MW>F%F[#V"4<*<V4]R'O_]ONCC_6Q<:M)HNE/#9I8SQ\01B>R9RQN+\2Y]_
M!J570(%IF!ZXY!_9>0+(\O^;COX?CL+P?7P>CLGI-G\984SB6V=[>OD$Z*2X
M_?E_H[9% C!\ O[B!R/U3]#_6) VL7XT0E0<,[:>-*G_IVDWEHY[M(C9^Y>7
M_W!]]>^CZS4(X_[IS;:V)*5>/Q V@9!01,0LNB9Z20_X6"E7"2JM>5$06A07
M[LE.:MZ<CM*UD;R8[?!_3;F%#$O3^FJ2"V;'T3U>-[CC-BFSQ))#IF(WI343
M=T:QZ,L [F3[!@Q XMK4=_Q]1W#&Z.3H=OU<:FJS(4,N.%ICBD8]<>AYN!.E
M&MP%   '\&KQ:YA!&_4I\OSCSM([^(\N=<FD]N),XJ]3>$V1KP.><2YI1K_A
M9\$1"^BZ<N.Y&J4IN^9< J>("6S%YAFR(Q(91]MI ^=7T-HB7:CNG@8_DP6[
MP<=KXL@OD.L!YH6<"$XFA) 2; S5^QM8YJS[VGR'4YY;R-D30$P]E&^1C%]W
MG3SJB:^P0ON.B 9KK>ZFC4=+$D'2431_]9=(^[ES]([J-4]I[]Q176Q8GK\=
M,J$3K48*JZ!==3Q8-4;]W*-=#;6BVPGEOCD^JLB:*&BMS1!XO14]T*R9]871
M-Z'Q,(ZS,V$IR@U-$8[?KK>43*5':9?Q(75SU(LG\WFTBD8KMB0%&UV1;IY)
M;SO/F8>RJGF$+^J]=,N$($NAG'VR9_=^[JX3;M(:XC>ZGJXW.@[R"_5P28X8
M0.>9@D\^E/..0#G.BL5**?A]G 4]_WM**YLS; .X;E.@&K\]'LAXO5X->L2Q
MP+]2U :-[$:1Z#!)T$T*L)AQ2BH,3%5V>49]W1<E\BSL.<_6EL<H-BW<G>_6
M#ID,T[/T%WC>B_4Z9K'&,'#6=R?#S2'"28\W0-#"9OT)0'L"K/HV2VB&<-O,
MTG0E&GE>]M "=BH10>W]-'[N1=P4P4D:,\G)E<LKFGLXR_FW>@M<7H=;FF]%
M*$U,7RH^%P^B>'75>Y1:.&!>R *:ONPM667W"N^)$/2+[\#*81./PK47(08V
M5J&1);S!ZY 7)_<6-D5(" FQ*\$>\^:HQ,,\F QKB5&3E  OK1]1_+WLU*&)
MO+#\,YP*,AGG[=IHQ6$*04P.6;I7_BJH 6<(A-8([>BN;(%7E3_/+&S*]L[F
M&"*M<SURGX!0WZ2UC5=8A+3%:AW)'IT;V8;66MX"5;4I\]M>^_MWT(HGH";C
M;"WWG#[AS5B185$)+HWARY<7B,5\P-#8)[J5/;=Y9XU&7%?\:[=D?KNOX&4K
MT!3UFU6V))B0D%0,:>M+4;X2=0K";6+Y E#I1X.Y6Y>K=-;LCT;-.(./VL4?
MYUP9E!=:=5_U4_!T]3B?N&-T3I<MO6A@L2A:W(L],MW6^I(]==_F[#'R>>;S
MP/&P._V:H -43K[N%&UF1J4\R9JXTR/WU3PRWML<'E%DVJ*M;W4;O[8C\.L@
MZNR><I[+KX$X2UO7PEOQ1 E8;0C:D?5TMNMXA"*9&,<UV;MW.75=LH7,\-Q^
MN<+W?+.TQ/J]\>T;N39&HLC">;@(5[(2SAH_Y'9:D_M:!JBQ%7?Z@5MC;VFQ
M_F(>$C=)*#5..Y4O!TLJC2J)P?: 2OW#8=>S@LE'DCG-Q3XGNL=L+^?&F&E]
MJ^ W$PI7OC0Q18!>\Z$BNZ>A@RA1T@IV+;J2-<CY 86OUD-XYJI4RZZY?A5_
M(B1OCC[)+6[3!E[UN6,/D\C::'0%:UDS5>X/RJ3M8YF@(QV0[$/<NG?0TF9Y
M[_DWUZU6EW9#C_+/CT1SS)7R%L66VCZ#"BZ<"E:T1DNLM.=T(5M(LSJ$E AZ
MN6@8,G(40:YUKW[B;ZA/%4PZ*Q'5?4_N?Y4<*5L6T4E%99<J^)K4N5<"L(.&
MJS]VC-M67+5[)RZEE@:"0SU@G?H7J2,VTW#\[)';!=]GGGI<^I#SU3P(]RFU
MV>C<T=@D%='5<! V][BD29V_0-G9[+^IIS6\^O3BY("<82(RXES!)O1#!M_A
MM[>Q R2EN>CMQ5T,KPW%CI@HWD/M3(TI4^3%%5L;^./V*AP<3Y/BC)#"?_M<
MN4=%A$+LK[/0T!4VU,KCUZ4FRG'D(A9T=>:6)&^K0"NI#.^^L@Q[)'&?$S#+
MX@1UICG5;D03R:RQO.'%&G(@]91_N-,I"PFE\GLKRO=F3J ?CATV+6B#8*&C
M@,S3YWV7UI1S3V,B?6,5^#D7 486Z_8YM9EN24EZ1 OG3(I;F"".\?H ZM*0
M Q$/K[;OD9;4T0X2Z5GA-@F"@$L_%TS $X#*?S3HL3YU(5']RB?*\4/S^9OY
M1>GQLL@S-'Z.^T$.8).O1'NG]RM74Y=ES*X]Y^)B#WQO92E+8G,QS-M8\->%
M[7.M&$I$*L(X?@T5WU4A7F4?Z46N(VYT;JZ&9'O@;<$;(O>U-O?%.XR7*??<
M-37?Q]<F:^6EY)HFJ=QIIECF7Z2H.J+YB]%:1S8DO!)PBNWE$ .R\[V5?_VO
M@Y7'#VL6Y.CTY!3DH+_DEVT86Z9>6!E/<U%6M6)8' T!,6U:!!,ZJ1LO=3+=
M6TMJ/^13/&"IW;ME@DT9Y3K\.4L7,.[%@5LE6U*]F-%'Y8_*S]<SL/*,W-3V
MRANPHEXH<WQ7HBK;\P&S:9L>I</I_O5ZL6]G4]B"0A"A"^I0KJD'RT,$KP)A
M%",9G0%SE21AWQU$,*XK.C5"$9X-_5YJJG8HQVSLT.: =J(79$>K'1-G'AHZ
M6Q[$_?8#PGN3EP(X_I)T?3U##U9=K=2//7KX-AKO=#P$#T4T"%Q;=<M$J<4P
M5^ )<1G' C(LD[M6@L"01I_M<*]\/0M^NL<4FUK"PJC.%W&.>&*?#X7- "*.
M2>S%"F7MIK=08^N3?>ISS6D7U'1U")-,>:&[^EO-H00&;&X)RH9'4E*T@!^B
MC'N?!%O'+L-+=4K9^)^  W5))B36Q"Q>G%%F,;5AV553,7.^&RGDV'/:%6P7
M 0^5]\EBP7?N>W*%W"4&\<"*[;D40T(W\AL"Q$TXH^\D $]2]LGVJ/KY5O.4
M"_*Q:1T8?&?[,T[M(YV%\3?77MS7;J-+\_8(B^:L55 W4RONVN'KF9GK4X,G
MP$)HJTMJ6X$A,%NQ0TF50;)=5>TGIK(C3*3OJ=Y!,R="/EUYHI'357BXUOIT
M[9>:SZ:!<V0T"=D<V*J)-P EMFP:K'FG,+T=#K3GF#+)9;+\7L3(![TFRC4[
M3F9 P,FO&QXN^BA:MI*M\XZMAJZGH+1X=^:97)V%30;+CV2.4-.(HT@_O7;#
M(@S@;IHNLTL G>?':Q9N=-FIOL+YW7 NSI)^:K"KB8#_PT9]T(&4D2C!O0MH
M*!OZ2;(V?G"*-3]J<*3NJ/OL^]O7'?UP1\*#5M%UI\*Y/L9K2$=LIOP1Q!?S
M9CGCC\>C'[/JX:K*$4@L92*,8S^WET]V+Z---!N]R. .-VVKK4HLU&$<UT<F
MS1;5(R2;19N]YCM@8NU;TP_,VT-V*'P[;XWLF>(_JU7FL, \A-JI2:G/RW0&
MLUDDW  4KAG@*.3?XU7.'$6D)([415X-".Z^O_GV@5G,*3X^JE#(LB#WE$0)
M'*1I5U,W85MM[( X9X>M0HNS6/:6[V.(.M%-HC@:1>+Y.7JZ><?VT)IZ[EHZ
MK8SS?MZ0L64U?W#,U[ BEL[--*?VDJLV-!;::M]#="GEEL8$[6B>=>FA-S&R
M=%%T\WYXRWQFBSN"E:M^*%>9..6;K5(-X_@+DC;O-V0)<LZ],ZSE*3&WX.XB
MMS8$P BOYR4)SV8,2+)/I8)<9JVW*NLR;+#/;@?E>=5UPHM<I6)W<HK.:+L8
M 4[#(*)^HEUOQI-UZ:/"INDC-I07%5X^"%\G)"%S<5JN\IU' Y&/NSZY?$Q-
M*1-U4 >RUE"OG+JF4H6<1:T!8[(O!8N@FG<\D5'4Y\AJJW9F&^4?8:D^4:YH
M+H\8PR>DY$^E)! [,SDYQTJ675'[+'S1\=\DW?%RE!Y%5KO$C'30G+?896E-
M+MQ+QG0C'=^[;9S7>0OYI;/!?^V5BYN=?X86$0\F+,\0"6YT]LPQ""UOWFJ-
M5D1M<;T)M;FR%SY>FALM]]H(^]Q*/-]#ZS1KV9B4Z)U,H!(^I((J$QXJ.$##
M1&L=R&M#PQ1;XS1#24).=LH"#A5D,RY_0RR@4VK:@#)+)T9$$U6_4ZCKH#M,
M@54K>7*OW;U,$<E2"P-,Q F<' N\6S/6"NK8(N6HG#<!$#9C8%TA5P5,A(<[
M*7(3E5\\"E$;]=FU_/T:A$Z G:SR]_\QK4B44>&42:4VENN&"^E]LPO=9 I$
M2)S=^T1P@"&A%_D=*V8_X6\"S_%3!/OX4N"0GVD)10#5JVDHG7=8YY@;LH=%
M94\P!'2_E0^FY?',(H7D)W<U,6F!RLU;6]O:PIZ .YEC5F(1#H^W+"A!*&'9
M;WB>Y52(>L9_RSHA"RS5:I1WU)Y4:IBF61P:KD86+[[Y]/,\%;8"-GX1]NMW
M:!_[A VWC<Z;Q]')BII=%U1Q]-4,C;-I.<FARC=)2V=K4:(W=>1,4H_X+W(+
M1E@*JG/$38N8M&H<%@R(-MR/6/&?+0Q+B].0)BX$]))D<#;CG&2\OJ<K6' /
MLMHOGI'C03<2'/]Z"!>6HT1""1>GZCB\X!#8OEXGU46B579LW +AUI.]VJ(4
M*UJ4>9X!@WH3:SU'G#7_!/#(IO<=VQ+BPN#GGQ)OKRAF=(Y*ZS3E0PBD0V3<
MMFA>U=R)QD9UU4JZQL"\AHO(3"I=\):=XI:HJIV\8-B>WKPSF >9MIYM^.G(
M4L>;9&@MR\76X"F*#>&"A$366A(CA]TX#/8(P'+%Z&K;]<XLM$^ ^1D?BA_\
MPH]I6,0"1-P^J+E)50]W07ZQQ36CT-2(4%ELL'-]_' 230*-D;6A'Y%K!#L?
M+6PFU&EC?ZB4#>GC>0A=0].$45/2OG*;27TF%=B#J;)Y6Z_!+MV>D-RJYC0X
M5&0-;WSDR!KG.ISB6XD!2V*5N6!SOF;45X )6WH5+3;1^.0'I%?HV:+E?,*\
M;1@-#P3[!H'CM%@M]NM;6I9S\V#8J*_](#L<=WT1['#$.Y?E5#=CD7F6\K)A
MKXT/$<%;L61(+P_X5&8BB(%MY[8P#7*JFI-S"V*UELU;\/QGEB(8.ZS/G=)O
MPTGLE)UJ_<_/3F!H-28>N68M,UC"910.5EYXS=5 _2TMKSNEK[?R:E$3(K[.
M(BPKO)2-.!W[*8+I_ 1@#A0,H(]L'AO.V$8Z4%<Z.=!_HW*J,<](%SI7WA5&
MYR<OIKW2_I&+D7$NPS?A *MC%Y/DC8.5\&Q8Y]F[9^X;8<#0:7!WTDGPU?Q
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M3M(OY;VWA*Z*9'$K[[5>X+T\J5#9$952A7^%J% 6.O/6[;>*]_;6;Z6KBW#
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MQ:&&1MLK"CU(]C#<N9>],277!LF06,O2^6R2V>R,-:IMC:8,K(_059[B/GL
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MEK]G<-@V&V[AVJ@)@^D)D0\-\GV-YH[E"M.89WM6\D1);$#4 TBS_[/2@<I
M)\BAQ'#7@>+-I#T/X8FS&MHB?O#9V_OW=S34768+9"FE1%K\<T"7R0^<':G.
MP:TJ5B=F3O'\"F;D.ZQN"3(Z.UMB -5X "2;<?ILOA[XS#=+I5[,"1S;]53J
M/!U';54@3(.$E56:*QS9&.S!*.Q8U-3>TI9QJ>?X8AT+4)LZBJAWKO[#\DJD
M)O(B*_\.VX:8^?(UB2YR):NPHI+!D:V1SK%VZ<V8LUB#6C'08;1:(*0NI,ZJ
MRG^WT!BL-%[FH>HG8G=$=V$31]HP*TK15Z/<FD+W*J:TVC234)Y@$*!QSQE_
M]]*@J-MCRJF<0L6.I[ NUB)TXPY?.FORD"=O:)K#(T]N_$[Q$?D"%)Y&DAJS
MP]5(>X%C?B$/3]G'C!D"F@R>D]34%YNLSVF>X9@K2UEH]:]3!17OXZHVMMFT
M"JHZB1H.5:>;<[-%*+]C<:F/&UF B5HPS'C+//D=MJKEZ]72E#&Z4 &IK%IZ
MFOW<I9W<XGK/!BCD&\Y\]CCP.>8V=-V0SF_'=4H)/835U[?-85CA3E6?\'(>
M_Y*:J#,+Q&\Z[7\],-?^:"P/Q'LZD&!/WFU1W"5T+3+>24O-0\M%Z#O_XWL,
M',>\Y]N'-5V+0HQB]33/66LZ8.JPDMNZS0V<; A1)8UIAB$!&L[HS0K%!X3X
M+ C,6\02S&]YWU35X5[N9[6+8?'#Y;OE#>P+C[D>6:\]IP=)(6QQ8Q !84[G
M(WPZDTN#C.DM-1!C@QWUML8,;]84XQ^6D)2M#U1L.)>.] B\(0??GAP">I/F
M:0[JV0K><YKCD>Q<LXN?NHL?F4^VHG^9/G>!,,0\-R'F^CDNI5*$RH#9G?VQ
M-",LI+7(QF=.Y0 P5C)$E17=99(;8#X3+I%C"LC%\.1T^P2$PZ?J#4&%DTX5
MA<-Z).S*19XV,8IQK0^6[B1\$KF>FBQR#F\)RQ$N7XDME[<J[G*FW&JI%NQE
MT_YE#=-X_5E Y/DM]V#-ELS@Q U6_XQ8W/7)^DP77>:50?Z[=3-"L.2^N?5'
M4IID_B=RC!*G_2]S87NS5Q4%%X/A%P;<S^>[Z]U.BH[9V-Q.^?LF00O9Y\W_
MN;N\_//J=O'K 0]VF02G-FIFRU*O9L5?#=/7<A+C !!*UK)9'W5$H\"&A2!1
M];C+]^G?&Y,T'];DNC4%RW4P1=FO%3Q]0C28K&)BR#"&X33%"1AOQKN^3ONG
M/*1'?('0WT8A-S?#6$"OMBP<#!*]":8(6!/*@2MA^.+O8P'C+YPQ]Y,Q7(WS
M&[*III%C8^%'4!PL )$+OH<%O-@$7EZ8_I5*HM%^!PO(=25!H_FP ,HW6$ H
M<FWUZH$:%A X&1 *1+1+T6,!\OA0!)TZ(N^?BHIP@Z,K.P+^EZ^(\T)L;"MM
MG0'EOX\ 8@$/J3M,SWCEL8  *RQ@O?CV @C6^*ZHF;$ : T6@'PWAC)E(L("
MOG]>11%QH#2Q (*-3N@9:286@)-_>[9TG. ?*U2X#+ %@W=+,$,1U-<$"0&K
M"P%_);>\0!'<A [('A] ,>\%;ZC[0P)^LXC>X*K\M>DM"N%\?9<="^BPD^V*
MMXBYT?=G^;N+_NZBO[OH/^XB I^ 3M-[=@:A]8>%(82B.I-E$\I/$E(\F$NV
M6DFY&BOHWZ*FX&JZ&O4U#>TI1[Q6>A;:3FM4Y@!:UC@U+^$1'<H/<_5J/IDO
M-!R6&@<X?T1UC/^[):'IA\7J"<0/;8P1ZO0*CS=C?A*2)1[8VW/BCD'($!ES
M<+[0<U4@7JM:@/N-ZV#9@#%!((!HJQ0N-R:?[3,[%B=%#XP9#2%:;LO:BLW^
MSEM17DDJ\3J85AM'F3EKM"CG]1[G=Y)GJ"!$H\X<3T7=",F!IP%;1L""8SDK
MM*DJ;/2%4:LW*>]@]Y%F.#/O5.<@GKGZ??M:4,O5"5O]Y-G^3Y4/3;9\!5]6
MFA64EP]_V4<,AYS^I&(&@'97)N08*H+@OI%"Y:3[9H?U/")/(MC32I>BO6
MPB&IJC]]GBW?;&B%TXI0H@:&C%2CO_4>VQFT&N=7C1Y8!_YI>O+&PN$& 6YF
M#?;RK+BZU:TDCS#22.H(*0VGV"4!/?8"&V]<E9)EQ<=A')$9P)KBDV])<5V*
M;%N!'1V/I[,)D>0HAQXFVL^[ 0M>B:;7V<CMY#'K)MZA>!JU8LI\\4\C"7E;
MM!L3MM^)=3N8*%L0;W-D$K?[99(I_J0JN0@J GG8G)3_!+J^KGX2\9%)45VZ
M ,714VLKX17N03EY<!:MFM^4NC>[I[+=_"YS1 _3$'GW0X+ 8F:@',.FC_$C
MG&TZ8#=]&["'R7+VTY[.\Y4E4T,CM4H3]KZ$5DXTTVPX\X#N)ZE@0]KUW%K$
M_?I"V.+PL\6%^=VK2&C(ZWI(!DK^05VJ0$)M7XR*UUV%P%(\O&^ZI1-R0!FP
MI#Y8#8Z^OD./]K,^.>UVM''V92IAG-3C[?A)N,L(\5<Q_],IP'\R;WDX>"9+
M"@(:M4"@+5-\'QJ3'"7Z?I'4J1#(IDC%/_..:,TCCJ^3V I3Z;_3=B<*<'+(
M 5^!YMM>'@+G\Z>?S,)GS!J;IBMLU"(9E"U\(\GR.38_BDPM!HI1.X-)ROO7
MZ;/\A]$RAA,E!6<B:10MKWY_G%UY94.65/: NXRR">"2'/_J5FP#B5$D6E,>
M(Z+O6C.F?]W/XUGZ5.NHSVL9.6,Q%%,:,<#MF>3=,8AS<V^\'D@\\F-75$3$
MF2G]1P$$EM2G6E?00=;+TJ?]0#],XJ#BZ'\BGYNZS\#(IS_<J3R_.E,+R!;M
M[.BR^4:?0>#KYE*K$>G#K Y+PL39AN+OQ"2=&1P19VV\VWL:1>^ATZGZB[J<
M-B+1]8" VIOC$;)*>AF3]!WV'"1%IQ<3YTR=:L]$G;'_2J^-/K='R4-%U<^P
M[DN!F-BB8D:?.3<%@/=%\QJCDI%O:PJ5A..PW7-#6#]AS*ZCUZ-R;DO&Z"\Z
MBZ,X'5(/BU>)A8=]:6(+KDOW8O.68>J>![>AYM*%VU6J5.1Z_&4"B13G)5/Z
M;7%80%@[[3)*MB?#^#"UWJ5X_F51%J^#[WGHPQ=?;<%0]D>#6C3@/_#!,0M/
M8+A((Y/ 3'V;LO#0B,O=BRJ>Z16M.I?2L"2&B(40WG<)/1](Y7$9LQ[A[)!A
MN!VDK=5\1B4?2,D)%[511Q48."BQF-#2\*H/Z 6ZXM[;G:USDB+QEN[AG304
M<J@4*1[ZM=1E;KEXZ7^A_O;KL7'](YPMF&E7F];0D')1>V-3$N/;\07,Z%T#
M/\BZ\KI40%FGRV]_$]"(*:(RZ%A*>GWDQ8TZ"<C_I8>OB^S%I-%S*-E ;[ C
M6E9LS6*D3_;9V3-.W/#6"8BVQ;JCY[%RB(JOHZ89@9NWU[-!IX%, F\N,G(+
M\?ZOS7T"$G.B?@BG]3Y5T,$[!Q$EU1"UIK -P];)2V_?DYV#O2ZY=<6AJ@T&
MBB2\"DTY)HM*L.3,.=>AB]#OLKIH^D/>]<$&>T%EWN5<O74[,_[0F K9V:?6
MS !7"==/>^%JJ$0W1V&8R8]]D0TTH3U9KZO5R>.(MZDK\DFO-$^/3E,^%31@
M(.B91S@=BR@"K3#IYP315KZFI,9[OQ8LT"7^$W4XC:E,KIN?Q*2N-E V\*((
MQ_-<OY_+W=PY"Z)TX-H >V,3H9.!":"8$B?^ TEZ_OZ.-<L8BYGB[R0"TS(,
M^R9L$V<_C14.N*WK)RK.!NEF;=*]FCXK;KC;):)_Z+^5V. HE]5 R$9 WER*
MPKY/'CA_U7O)V);5D]2[U>U>.W!P2)<U$DSIN69QS-C/E*( <$TU(*XM (7H
MM]7Y4H5H3>=F*WQMMFHT=(_MZ.A(=G69-F]I^=]8SOW_"T#R+I*P@$2Z_ILN
M?BS@=XG#S/Z0K!W?'[*R@ -6X$U4:BL">/S\7+Q:MC/QU..1INGWG.>/="=7
M20\MD**AQT)/(@TNIE1#M.IQ7/OM/JSY/\3#/,Q#Z=L PR"B%OE2K_D\N/#/
M)6/B7FQ1/0]8X[FB0P;4I=7L;,VB30LOYX^OBJ##(T5NVS"N<:&<N[_IG$,.
M,/+KT6WRK- O_0Z.A:7.'6Q4YALT:\BS?<-4Z'VA7:F/+1;VHB0%QG9]-[.[
M(N$,@;B6'X*^(>,>[!HG]6E%>^WZ9S4^?\?!97C5O.FN6P@*@.^$8_1+38<+
MC/8F?V=8XE30#^HV-7U)[>HJE2 5$! \'%509P*+UX^#)6TJ=B-+#6&JHHD\
MA=4/XD"+=\/6<$)"KMS>5;M_FY$I,^D#0Y9)9'ZTDH2N$-4B^R,XIHZM,QZD
MSFSK!@9ZW?ENPXP<<;!GNH.XR%UK4S) '%Y?][18_I!,:8M];Z4EMQ1(&#3J
MS;;F>N]=M1!<UOIR"CFOF?=4*3U 1VH[ZIR/%BR*V D_YCZ+YAIYO6,R_8I]
MEOT$\_7RN9;51]R04PO<&#>#8X2L:NKVCG*C(\B^JKO9 [_\SKSR&FX=@\UB
MY;H#L%)34\NK]F1W:6IOAG=2RB#JF,^?L5/V,T:\U,[9Y<G(]=R\TT;ZES)M
M*A@ 0$@8,IW]HZZ>!("R4$=FY^;[Y1FTJ8I9R%I7!:J["(6GPEX<OM?0+3Z>
MK;N:D1U#>++.CUV=2JV,]NUHM:@ZJ'H[5;#!64()6EVR 9M3',&J^OEAMK"G
M>>:WROM]2OA=4A^ZBW)@AV<V$2IY;3$3GT]FN)B[@GF:%5_J#:LX(8 !TQWC
M*9R&U_U5ZN5/4*W1=%@>3VQ[@1 9;/?YGS1!&<RW.P\ EOZ0&+?XN9(5+,!Z
M-?;00OWGT.P^%G!G)UG3I-(-$=S'1P5R6K::MI@X#W6KV:+B*J9]EU2>TN?C
M>7XUK0LEP@B[%*(RI%FUIJUGW)_8?%EZS"T >/LB4#"Q+B9YKN'93:L";&YN
M>!2&&;R"G-] QGA^M'GU&9B&E/O3_J;6-#!]Z>+R"&J5(0;79TL(&//L>[U3
M*-[KO1H"%N2+D5*QR._E2')B"$NFG?].WL^(NE]?%!&K_#I/YS7Z#]FSMP*:
M!HU77Z=U_<I!ZEV7$E]\1,.=SVD]@GP:/C8.M+]I?J*?4#P B+MEO<[]B-8N
M+]CY:NBAL.,;5-C*8_ ?S7L_!^Z_#KQ_=-,6S_Y#;\A%U^YRL2C@10J^J)4S
MY.09UV09&!?>"L350X68M$U_]^:U;$A:&=&,?FX-X%4:#LQ/4MGM-7(.T<E!
MY,A\%<8/"TM]J>D;ACM"YKXX13NP'Y=5(F7%MGQE6N38O7<ZN3HS)A"O"DGM
M4MVLRSK(^Q#O6ET=J[<!:'A.PAKOPW?6.O+L5=S%I*\XX]VH-+(:*NV)0-;$
M8Y-&#^)0ZDYC$,I__<1!!!I1L_HX4C.$N4\W^$$GT&!7,;S(&*PW57;>[%0_
MF/E:MY&Z6@Z)!0RK=7;(?R.6[W.;GI/L=UUN^EVY_\-TV_'<88&C#4J?(PNS
M\\KXK#WH8"?]RW._W29,Q(4."_".8""6R"@W@<);I454^9B )*;V#3K/YRFX
M1>\0#J'2GGTJPH_[RGSB73;O#T19R$^=\:%4*L_9IH5#]5GC.K6'@^AI>/7(
M?>*R,5[EJ0)2(RH^O*U&8_.2[-#RC]XIE/M4IGCN^WX6O3H^#7DNA'1O^)<4
M/.Z$?)T7M$J[FP3HPV'8KCU7#S=X<I0"/]26G^;=J)X^5HC)@<F+]O0DMFYU
M]./%_!4NOAC6!$C:E4(WU6>V4[" BO[,"9,@I&#'E6C(.WEK#W>(R@LJ:"0X
M.A2F LI2L@B4W\DXO?I=H"/\O8@QI@COK5'9,@*(B9=AQ *J8J$WL09HWG:A
M?_>+A<0-FS2)!1_*\I&F AB^%_J?^LW\_X'P5CI\@@4\%HZ__FR!!4QHS?V<
MPT'F=1GDQ$!X'*P*7M0N*?G4"M1^IG^AC#\H4\;5>(^SFPQ?9<%HIX?CF9;R
M'X.H,R!*XT;@5F^"95$40-3$K<0$]IF>D83?AIS;(NG0\15F6,#..GKB=*6K
M\@3:--N$ZOS0+C/AT>K@"ZTVU"/@*LY7(-[@R<ISN6M9LAGW11]C4F4:D5'1
MZG)O]0(\RSXT^V""H _**R *N/^2"7]?7Q:1B[G5OG*H  2[+/)62<O&0'\#
M26[N]M\(=PX'-O8U-%R+2GA7RPY=MG?FHQ:[K])"/D)DUWW5Y">[M)_4CV8,
M0N\FO0]9L\CQ7^8WI(+2<LO"A22^-(B2VFG8C13!#+OKEQ7E[]7('>[/>^SK
M_34)\/]4H=#6^5-1[W+GN?8+\JNN^CR4YS.P,"J(.GA1JP$2M:U*].)YDO27
M=B/D\U%:8B6I[(W&R7@&4+?:K'L3M_M^):E):-J(]WGK%(><XDP,>=O-I<GR
MWBJ&,X V8%P&B,&/Q]C>ACJ2#;XKO&XL(.B6<L3:C85<9,_!N*X2ATV3DU,6
MQUO1TJ12+J[* ^B[S4 $6^E54;R4;!%(5&,<(VKAYW3UI4NUJ,W#C(9&DC0D
M2:Q?3&S,($T=);IQR&XA'.-HQ:\5INJ[%1N5G<?2\M[T?PRFZ5^#.>N:2N61
MI?).9TKUXLC@?=Z]>WAS1:[0V';FSG+0E.J<>U-A_ '_BSO+G'<A'PU1>@A7
MR3GU4K#1>#U7I# 97U0NQ'WG;;@6_\)1G]BSQ< KG+,RDG_L+<#IC*@= SNH
MG*F>6KMN9:(#W*:72++SRG$KKM;!Q1?7Z,D,-*ETD8U19:F;D;JH36EM-8JJ
MQ;@_DK@L;2++"M+M72A0WJ.6*J;5XW+J<1@_]!]XI^M5S+?,C,MR/U]\/_.G
M3ZB+$EO]D%Z*34B2SY46X>] 0BX"O^84+#,TAB@-/8_3XP3<XB#OI4G6>V,K
M,6PBHM&E\D7VHC4F\FZ%OQZW?*X>E;F0P%EE])GU^H=#J,1[?PFR?WP*W7Z/
MI(9RH=L5FF[8[$3:^<<]'BP:M55/Q<2RM:3,Y4B%SC$\=?P9;RZX6J UZ<]L
M-RLJ(Y:D[!2UGSB4NJCI&AJ="-W>."9.+PKH"D>F7>/"L8".KUA 7_R_:O5L
M6J?!RH3?C1=F$ NP74VY7M%YW(),#2T#2TR=&2NN:JAIJY'[I1H:9ZM2B=-?
M,FQ,XRQ6"H^!^'K)0:(]LP9U+OB8,,D?'/1?@A^,6808B_YC_Z1K4N[3N(@:
MO?8]>AGJ.=UL/)>P;-&;35D_0ZV'. _+;VEN,^R:&PWFK.I-UWSW+1BT\[U\
M%67 ]*AZS@FC;E9@;XI(-'JE.Y@U=5 ]('<O",\%TSRXIL/Q#VLUOREZ8J,]
MO+Z[.#[AZU$G>R>U<B/:6!W>D/7]ZQ%QWKW]956N9W\^TC2O[8C_";??H]]@
MS\@6;)S6&=ISY#^KGZK(37@VX,U6 X^0C614?]WS;\L'_JL04,17HJ(_XK&_
MZL)7QO/.]&U6I(<Z/<A\M<,G+5Q(E?$UBXL+P[[T!BLURY>L>5G>.X'/B7UG
M0W=Z1\3;V>R86((G=\L./_:630R4UC#1D#>9RT9XL!;9#_WC2@MN>LOW.'S/
MCRVQ !8LH,X]WBDKFDI&##$:"HQFGOHP0]1>:;>E<)$24_/::T?,B7J;9@\D
MS"U+*L57L=M"C6%K\<^_BHN+9G T']P:_1F#MR3/*.E["BOYA\XS%:#M=#-E
M@H$=.@_(!C2R9^<(G&",&MN;D"DCUW6[[+7V/.46G[FXY;@XEU28\A)(_+D>
M ^GL>-:DJ>5;:YN;'=24#G4?/GB5Q-KZK(Q>O-N'I%S_'[>S,/NAI!I/RX4.
M)O1F_#(:W6[9SH\*S=^3(8SNAFG,..51WPFH<^"-0W+2/ A5V?A#&'>^(_S[
M'ST4ZI_-&_!OQ2I<IH]FV<<=\1V)_S6S.W *7T4_6+Q5<3.5-?O;J_@8*J1)
MRGH6T\5V'UMC0UN8'8T1"\O[3@[ :4=E_L^=6ONZO5'B;\E3N7L?S#@5C88Z
M%1[I!OO(_U=D /^-O_$W_L;?^!O_#,I-4Z"L727!S6AC.WX]\DE8I2]'M,?[
MB8.W*81:#[;-OPNU;K[A&!4W[J]\A+-?]Z\R'$SDT6]NIDW(KE.DZ(M \;T-
ML(I<XES_%K_RN&A"-V-5%L6/H=ZDCCAOWQYMQ-GBSOVNX%B#]A[B;?1W,^+U
M^].* N=;?O%P/_4LK55\O\#(]MX:)R4E")#8;W!8#/@1-8#TBA:JO ,RU$4R
M-7M<,-*KU"==7.P,>TL56VB-+FI0?02\?43N^Q P]P,2T&M:UQ]6A@589SEL
M*'W& M8K$8?9Z2(%MJ66M>@/L5$IOQ*/XK>U!+19&8G<90$W7'S]?"'^%,B]
MW7!%NO.HE0";= P6P)PD;RIH?[3I 9/Y@K,ZH2!@E[I"G?JRGDR5OU].7 AP
MQ35RPX#Q1P3TQ8?[5,;X,YH.KE]+]!8%LE%-&0[R]"C3=%%9ZBRY?F>PV&:T
MKSQ81;KUY-#=T/6OFU*")6?::>S+O7B:QSV26;X]MO@(E=(4F1WLTW"7]AG'
M*_FG!;),/-!R8'<$%G"PBFA\ASR.XCDG: .J@RR2B'C9DN P?2KAAQ6_V_1L
MN,7N0V2[H0BML; Y&#3<$:P.5X\ $GV4>EF+YC) I@9=J,F<^B\7L*L GWD]
M78T-?/XD<#M0IOX'Q%\]-ONI*<R ).PG FH0@*]2< U!802O@ZQ@ZHGQ'-8'
M@=!]+\OK)3>3SO^N]RE/^X,"'.S 'LB-#;QN5=/[0QR(>QE+_=Z46$ Z>_$6
M#EF9C,;)( ?@^".RUQ-:&] [1@YV0#D (\'O$<<Z*+/2^J6&'?G9-V&?(F-K
M,,A7BX8<M/+CY_MR3 7_Y?[_?QA,[P9T:D$WS:\S;UT =*LX7X:U7U:F@#W0
ME*CX=2R@'TB"ZEX']@Z/48!$NWUZ,OHBU^;=Z7V%Z\WWD'V7FNV[*9[,PX7K
M.)M.;(%@-/J=_P03+S+\,*@<_*R^&57MN!9/L)MH9&2 H:XC*3=:5DX42](7
M>"CW0Z,]'3>DE1GEA33<>!]_D(Y6AH%*_!_;SJ[0USCDX*$R^U*U=S,V%@?8
MZ)F<1 >!J9];6DFMI#9L@<I@V^OH([ =\@<P&DHL\W@/^-#_<?WWZK9IQ[/?
M]?0.\R]"[ZAZT[YKF)$?9-U\V<@J/ >RN7"9/O:G0HUUR5+<L#H$4!0A/Q(Y
M%IL:R1-]UE"TX%^?7&'6(FZ%1G/C".&<4O=51MX(3$+7DF5HD7YIT1[#LE0C
MA;8G*I6&>]I/T+5+BHPQ\,:DC@05J6"W][=R=8P1K)BYT7A0 L\A "O,23T&
MO_]!XT&0:6?@GI+-V:W*1KQB5 ,8J<\GJH]P^M%0KXYBQXL$*R ^8OAGH;8\
M;IJ(N(QU=1*[G/E/_?="O LBFWI:CP)UK!1XHSYO$H+K#V5$KN.P #@_JAZA
MU(<%(-+\DF\H"TH7_<+1H@$7J92Z7ND[)%Q'9[!K6]P>?_+]%<'K;-FU[R0(
MU\MU]6@99A2K(6+8@8R$>M6O?0]FI?LQ\G7P=V\!HN([B<Q#23A 4;N<.J5;
M/0F3&.N[$4+;'#[(Z+KM'+BO::B$70"Q?BFGK07D86>A7X\SHV>"JUN=?Y0]
MM*;%'MK 'H]<AKS1V(51V [#D68)FY%*&3:G8NO:)W_\6N8R?F,!5:;1,A2@
MG!Y=X#T9<?L 0BF^2N/,_3'B03C:V(!S4]9WP/NK]TL@IZ3J!UY5QT<X!] :
MV1B(V\;JPD8G;*PGZ_'I*V1=ZLG+$H,]*G4;22DMB -7UU !G8)"0B#@#PI@
MWOX6=8KDZLPAEUW+RZ9 0&,QVM]_R]Q#V>0/%B]5M!7+V]WK*Y)XJM?]>H@V
M>-!I45'Y9'6E'8$*@*M 2-9&..2;YH1ER9?T.AXGZ\Y:DR\OBZCPL0($5&2^
M$1+/G!YW!<Q3=V93(XMZG*G K\)?HNHK0=VZCLKJ%2A/*C5I LD'YOHF'TER
M[@49?9:/3PV44K_!MT)2JR-&ZY'Q:TMT6]F-!2 ;O<QWXY4?>5.W5WRI76,F
M)%+O"53+WCWE/\[X@P6\N?XAPW$S,>LOBBQ:E+5]-4M^M4Y" ,,\G5)%N8YH
MOGS)N*9#)'C$"MJO"TG.RCNZYKN@')>B1NO\#J"!X!7;W=R?/!2:FZK$L.3_
M3NQU\&MFTX)ON.N=MK S*R[PXV:#MNL"YOEZ<_ AZNM<\<$Y#/6R84S4<Q4C
MYSOAEHCKBO)'KL"V3:E?4KGQ7Q@+JJB?-$0!3G*B<\AO??N8S'\0>K_^^J4*
M$AJ^F71D*\/"]_G 8*K'P?E1H=AVE(C<>#H9DZ*51FXZR0,73=@2R' #[T -
M6<B'C_%!A6[PR*I.;4[#^GM$@Z6=WR1)>D<;&/_2=I\]I>Q\X]CU7 <]<\X1
M&V"3 S0!:7<VF."C]M<#\%$AW1<GB^KE]CH)>_NED0]3?7]Z>^8-/,3$8G"^
M$M='(YPO6"=NF%!>Z^XFSY!O<S?&*, J4<I2*A5J=_2]!W[O1GQX4Z9W:K3#
M,\@(Z 6 DQ$V<!L,:P[B-19 !QJ^N6T8I7W.8C9%>_P-V;6J]FE=EJS5=)Y'
M>?O$EJ#C,&,_6X[!EA-$% E<&\-07,*Q@-N[CAACAPQM^)E?D%Z'V*10(HYF
M+$MC,NBZ&&I*#_J8]J4!GECG8FH(EKT.E7J_!@WT%T;)^B)3-XP1UI6%:D6V
ML[4@5YJX^.VA2:G06>/+NT?H@B_$G^Y_DB"AN;F]]1"I_KTMIATDJ#<WPQ<T
M/&98P.=H-)\_%L#N(N(_MD-H0X,%Z+G,97_!.3T^]$#KH/I-4*$(+_A%"%_L
MV0AUSPI]2 ]L#RQ01P$*\T@5M0R;3O[RT.))A-13MATGHOB%N/UU:)S4>Z02
MO**1K^^:%:Z3ETL_0MTK(U.?U-U#YS<D);^N.EE69NJ;(."OUT?I_Q$-[1V;
MMQY>ORM+Y%%)C%K41(CV!.#8C=MEV$0=.&H%"-",\RZ4+P2:9>W0!UYOA#0Q
MZ'['4*+$-Z"X>P:%)4B2]8MRI)(6I-%0&9[\IG'R# WJIEIJJ-IZ$RXF0)$D
M=CLNTEC W6J4@W!E!Y &H]"(K(PNK^!V\C 4PT@2ES0J65-55S4Y.$)&\>&7
M 0\VHG8@7&ACL#+*[?:TP2F,+EY4/:-VO\%.U/;XX?FA_5:E34/,D6OG#K>8
MWE#L$B\F+N6\L8-O/M[@.OL<2+E+1]WK,)P31K< 297%6[*MHF[, /68O_2&
MM'Y\#^1\1Q24[?HV(!2Z]FV%KNXZ<0M%NQY KKY.X#%M->,HO&_(8B-</LR0
M5V:M@@,C>'JOW<J:@8$4![H&7&A<%^T<(7@W>R8;RR2 Q (B=A#7DP$6J"&D
M\T?V:1CS[$EWZ_UE*CEYXU\/&_!I=K8J%TS7'?<P!HCV3*3N!K!W[ [&(EES
MT0\>3_<!Y:NODU"Y<,C"2?5XO_[]B8P%&K+Y\*H1OGH 1;Y\.>7L?DSK/V'"
MAC0.O^"&R61D.*7<3WR2BNKB&5:EEQP1P$GQ^AB2/%AAOWI!AW2.:6<&29J@
MVI!0;51F 4CFW(.17MGXSN+KIQ(IG%-J%%1I]RC$ =\\:!\'TF(!]TRP@&16
M9/RUO]WJE3XE>!!)!O9%.V)P4$\1OIU0?+ 5',W#X[Z8I=W'Q#UU+RX[4<%A
M\T_#J-&?WUU*_L][GL'?'LF@KW]";9!H=3#9K#]3ECO*&:UHZ!U0IU $@T"?
M624SF9R->FX<$UJW5H;]]:%6J#?BN.N&"FUZ$7[!GNY8>%TY=((Y9G\2[_\K
MJWGQF^6&M!H ' N,A:@780&=6N[QN$61]6YP&C IVTT/^F/P8,$[YY6ON!_Y
M^E?Z_/8'9:V.'V*TKDL+48N%]CF,4F[P+/KN=HZV<%5C:FWW%FKB7Z0JG] Y
M!Q-E#A&LEG=;&:*NK@(6+-70YH88+R;V9^;C<5'NN&992\]/P5B 8'S;);A]
MV0$.G9];$XUKYW0 UE'N!-WP.I@^/,[LG?.Q^MTX]0-:W_(94A;@OD7H]M3I
MB1+A]\15(9S[D6@_L.8X%K"6DY'ZD[T"%M[#94J%!70!'=;Q656VGW^5.I8L
MG/O":4GH]NTG8S][PPT5:G\#+T1&'"R8UD47<,BZ3H2K-?VX&ND'[2VGTQ<Z
M#]-])4IUT'HS2N$&%>OK':9<(IG6646\K0RKOAF61>1OYVAD#U9@ ?6FIO>H
MSO:D9:8Z%KMN#I[B70;PJOSYJ0TW/1A#6G1)7(:O]F(!=4YM&WQ$MD[Q#C\,
M;3UA#NK5KW\8&^5)I>$'"Y3YFPNH 4#4'9DE90%.6,#BG>T5Q;!UQB>6<:_$
M+,WH$N3/[^HF+6 <49&W@3&]%1F$/([,[/VY'@28R]1K$NWBJV,^P5RC+]82
M&\4Z*YL@%&B6HI ;2; Y*A8+P-<VX>B19+%VAQY<AW5O/C0<.55/GQ*;;_/)
M.(T(6/O6KGY@)=LAB]+3/_4(.%1'*0=42_B?6Y[<C%W$?W0ZE3S[3D*#^E,,
MUKI.+[MY"/Z@'FOR_/8IL!YK,K1H,GZ.GV?\6+DP0GG0V?+G5H\(%[OWQZS.
M$,L9*"SO(@+I%2/[D<@!_KY\K#?:^2[(]$W4^OK<6MMW/_OMO5>1/4F#"5KW
MR$//!A@8%X!O_2=6JR=OQ@,(;QA \A@#=S:$?ZX->,ZAR._[R@,6_D<$VY5I
MK>*CADQA)9C_E[14"&<XH%,2XXPT-:A'A<"/(S),XW3E)XYSD[OI^GMX>%6E
M=;8G385H"JUI4J:&7^@),@QX]XW+]%8*HU@1W;VR1&=M:A K)(<.*JUR3YNM
MUG1U4<'&^<%[&/G*+%\2I;3RW<U3DY3_^M>W?^-O_(U_"!I7D.ZOQ$RTZ7OC
M?DF='8 O\5,HXC:P3MOH8 $=E3?U_WT'['_Y"_!O^]_VO^W_\W8FO[4<XKU&
MC7T.G>GS8@-IG3U)9X&UV-E;;>?9S9K+V$\Y<<O-.+  S2Q#+. .]&I&M\.$
MK17))K&_'-%9,\M[8'XR';_<A]:5.N_7-E9PU!?6+"RS4=?[^1_4K)?Q7]WT
M?V-WBX<OZ]Y0L>EL:,]"JT:_G BMVDK*3.QP$GRSD!1E\*B4KS!1)S>N[/GM
M#F!%$_P^,:6H.SZ]^SODVUDW$[^AEMK*T)6@^!G4=0[S.."<=@:*X,("RI7^
MY8'AM Y[&,D_,&O<_R^RXF4Y,#'.LJ*"X#]]C54-_*@,#6?;TIUH2I7;E9+P
M^W#$DVG/Q"IR;LADKV+V5E&46,!LJ<1.%)\0%A#)1#G^@\PO6KL6FNTZI'H4
M/K!0MQ.$GAUC2IG5.:?0#)U3GSFRH:KD,YWXCUR"[C][R'.(,9*E*R"^UYE&
MT^<__=YOL*^+\SZL:=B8)LO^>CO@IO#X2%Z,\9HT4*^=++JU.'J 1>MGPB\Q
M6IF4&O4%E475RNF1Q2P^CBLJ*)P""R@>+<<"@DRO[67_U='*CVJAYP'_\ ^!
M_\GV'2D^^++.A@%2RYXNNYXR7R+J28ATYQUE_Q%\[F:&^.<#8AO,<]_G^.!
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M15S>/&1$'/>;""+FPH\PDAO.]XJB@,.(B^KU-HH# _^JMR)^&6:L3D3-(DD
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MTP,5P2]L+B17XB!)'"<?:0([_*-!;$FU*DJ>1]#554OB5??MC6-)A]03H7!
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MD!5,=HU#K'($Z([]Y:.86,>G7=J7G\G\6)?[Y%O2WR7%@$7\1&##XR@<,[8
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M-E]9V;N]IM[[&!0I&Q)\M*3_%+VKP18@$^PLA&$&N8HDB'&$3YT>=:,*3;H
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M%[0L.M&;_2.7&29*@%,LO2<F8'#QE$\X19NNDR5G@#$?2(X%$.D6 L36S+)
MI_2@]]UF7?O5!4A25YSY(?8'*I-GA#(,T719/P>,T#Q&(FX1F0G*830 AH$@
MA)[L:%,!C]ZB=E2[)LL>[X)BV'O:Q2YOX=S41@=M.1L$EW_0/:SKFLR0$!U\
MQ2I,<)!R^:/9U'*EJG^T&GBR6RS,W-A;<NJ0<<1*XWQ# WWI7 !BM"AZJ<0'
M7S+D 2L6Z:-A,/D)4NYN<Y(2F&TD+R]_A>>2_,8-QT">=<89D;>KP'+=UHU(
M&H!?DVV*%(+):]H0@;"@JCR'1N0<!\Y4$C3FHF2F7-'CE+Z:<YO#HMX;4T*
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M"I7LL'&T*JW1_5VA:],_:Z O8RJ1AW/M0KC2!^)Y'A\B-Z-LI=YS],BZML"
M^-$U177@,9@@1;O_Z7"=BR(']Q),;/!]/=YZ55K!80BT/CLOD'Q=;Q/:!3-6
MT7ZP0+UR@%0WPAA&TP "5Y!"B\!R]I),4HO5UX;/J1B-[OM+JCGEW6WW#\R/
M%0":[E)#Q-V8#%= /(?FIMD\!>GF*[(,'NY9=*+%='<_(Q3S\_YX2Q4ZQL!+
MHA,@-KSN7?AT%YK:'-IWE2&*%+S;J"PJ '?F>)E2U<PQMM%* QP^B^\M(**X
M2 B3'T]^@.8JCN?,/(RLM-HXMI*A-W5H3T]\N_G/MT\O>/EK\(%/0?RPFP$I
M$PK6L9JRLV =KKT.8?SA@,O6O!XUJ)>H"J@S9A*^!C,EWC1U#T!^[TM=.-KN
MXS@W/K<OM% IG5F4.Q@CLY$W63"XL_=:<,K4&GZ3[J<_,3-MMZV0#Z)XX4>)
M.7CF->89&H#%ED36&_3,AP*Q;,PZB)XAD\D4'?/W")57(9*30G. Q;:D533=
M4R]!V)PF[*YED2]2[N%'0^D6Q??&,E9_Y<'1]GL=N9,N V>;.Q5K&LVCBK^1
M'!Z=_"STPK6G[EJ#[,''"D2@)OL/3492+28*PFI1.JQH[=-J<7N)Z ?E:[JA
M93]+W3.+ P H$=ZOXU%9=(MB 1FNR4Z*6$)568W"F(<UQ['GW09OQH/.&5Y^
M$-/R_)XE=W*RSQMQ!QUL/<'8= 854:AYG-HZD@AC');=86-H]5:V&.)TYI:I
M>?ZXQE?NX;DG1_#62 'U#-=MBR@ 90N_T#3-):Q,7$G9:-S/&X=JRZ*=X@VR
M.^==W-^Y'6-]\N"RW.;+9]\F3!LN?*+P$WC#FY _4P;Z&E-R&CZ\I[N**Q;!
M;&+:27>/*QN>[7K9?:V!M0PGF= #BZ:;W?$V_P=<5DMRG-',PTRC<407(#[4
M%8B/@=AAR&@#K_P6XN+V]XJX^Z\-O%]'U,T] 3SBESQRC=%TBDZF)K\R4@'1
M\Z ,)@]!F9*TL!N14R*DH,=V[ D?(:9WK'6_<=TL[02Y?PU/$!2R+VWGNGLR
M8%RI@9V$<"7K4QX3Y,/46=P_3$U!SY=7_,!4EXN.]2]+"SU]%O\DF%GA\WC5
M.J4NL&+7FN?0'C.^#[/;)L\#?4(Z5+@"$R#-P3\ZP<Y4@;DF2%@F:MO@K,33
M<A+O9:&3,>MO7F4=Y9CB)9:L)LQ,PEO@HC2 <[VNZ8\=67G#88HAR#W/>@JM
M=]RT-"+[",8;<.O]ZZYXE9+\Q?^$.Z'GYPD]=2?TN :]E*3:]"R?A83$J>3"
MFP- -,"UG@<TP"'X_O:AP7ZK#HKDR/3V\6$@GI\&*-']3>V:L 9O]]_]YW]!
M_"^(_P7Q+X$ 9!S&3TZ'84;OK[8;K)?Z!/ GME+7=2>^XD+B,FNBML!'2%W$
M7N%'+B-^=6OG\CUDBTFLH"KY=T/V>,":-?]ONK,T 0V!:I,'!\Z+YV5^19 ,
MBU"+ I_@,_(T@,UO:Z575/VDW]%U]?XX-2@ECWJ8!MA9_+LJPS^ $?B? F)N
M%C\Y#KT;;LL$_)R+.!LI&$<#7.R-N]IQY_S"%10>:0G_<?DA#=!H2ZWW*,%)
M3Y/,C*Q9-6S)1YW!)V[,"J.<MMZ$C:<Y/GJ<@DYP(7KW)_=9^F4D:'N(_N:O
MOZT]<?+<-E6@:_2=J@,&14/*$1I@I?^WU1_,AO\Q#,!_"0A&BX70#46.2!'>
MT2<* =%WRE#!S[MOK*=^&RNW>TW.[=-\.V*:[$)50*5V- A]K2@;'M0.&]D!
M?^#D+!'WU=03OWIU7-(F6;-B\+=<MU.O,_'89W#'/[E-^OM=5.8_G,D5AAO_
M-=Q /4ERVVC69.C?]L<)U)9'9(?QR7R5Z0@)6M'_+6E&U?"[[::5(L<'UG;&
M-6QP)G&7Y,[&'U[MJ<9)I&4H6)X[>/-VOV2HIR1 S1/^8>G*/Z#TR+GP_Q83
MSFQHA7H)5?;YL#)UL:Y:X9T7R$!NC:@@<;HB6+PVCGTQ%=\F_YLU;[41IO[4
M%U0$R370Z3--' C0LA\<?B\C'K+Z(_\>RXQO])G&'<EZD$&%0/8^[&.O9<?^
MHI_!/Q!*.Y$?_EO(QG\(@LMUBK]NJ$$,8FCYLE5FNUH^*^TRYVQW*2-:H6]"
M96&@IFM+UK5=>0NRTF*JE.A7X_2C!2*/X>0L[B[=DXB9F0E?&53\G[(T_G\,
MHLIS4LM+7VK]OLIC\\LODY6JF\1?D^X=^225&7CLGR[%#PP(H\3P-D-.DO*J
M)?"+)^BR*=DQ&:F\YC'=-K?:(:C9DC:[T-W.-'6-;XL*E*0!BF,IRZ=2_LWW
M/WP0Z3^KS-=QE%BO_%@Q\'Z8:F"QW"M;@)AL)UGMI_D4)Y:JRV(-27IV0].K
MTPYDO@\:<<KKTW.5DP=,EY?&1RI77- /_2R_]2*;*ZI_;8=Y_[N=!E?V=]"4
M6^':1V#-:/TIKJKY+<9O(<@[)]H\*R*F),9QMRA (AB55[&+5MYNC4I5PAT4
M+FC4F SM-"31I55+<E]NY=!X9I3TB6N_.X00)<60- +5\K4CL+:HJM\)[J(.
M[#LW694ZU<6^TT"-*"]9:S]VL9&B]A'"PC\$I'93!ZMJD&LB#NHHR2Z<F\KD
M_'X,:"-#V=4/>5QCW'EW>>= 4\=]RF+:ME:;!F"G.^:/G'Z33>^!*H\64PQF
M8B4?-EP8-55(?)6Y)C"ARX#_129^.IGT*?)Y*Z(.9$GT#U0""C:A<'(R*"/C
M[1<J3WI-$>Q $_XAE312+[IT .VID<HLO?([MIFODRZQ7D8O1,NZ'7M7/JDM
M6T0L/GH#Q!BNF><9:RW[Q$E$@CHQK*[E2(2+D\_M/-O=F)R?/YHS&<.&6G&/
M@ZW[8ROS\'WZ2[LN*$R#PXLI51K 1&DQ,ZKU=\_._2IS.WV<-F80<O/^'>TC
M&1_85GJ/S45&/CD?,KZ1LBS-^I"@2P1'>\J>6)UR)&:;7O*E.JB72)QIG_!(
MIV:=W+"LJ#<,$UDK)^_X49'B5S=DP263F31 .'T@GW\_LG^O+%U![#&WD6B
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M)Y7VHPMY8G5;^C^*X1@7&Z>"4S1 LT;N;2]25]5D=;HYH[;[#V7DZ=VGA33
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M@-9111K@F&.;[19.E,HH^:<'Z/Y-;<<JO Z.EZ0^7E-H@/M0&')H@+"7U33
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MM5I!KO5QT;?5/BK3?R;]?Y2!]$N:^W6EY\;!LZ>L'K?I1M>OS=*/7/[IO."
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MMT8!Y$'71.O(1YJW]I1L!R0-.K'XOA_1'DE>L ,BA'PU@FCW(\A%$4@FR5
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MS]=Q"CEIP@"D_I1TL.S[18'//FVD.8^.&R+'/UC(7[W; :X2CC- 4Y=!ALO
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M,?""4AB^23LS]D;P[T.Q_KX/+$Y2 /9$;"/YPKY%[$$4V!.R#1%5@B3/;-0
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M8.5Y#@@W+63%WS_Y]??)RDX\)\A<A2&$S\LWJ+]VR4RL^5_HS2RKBML\8.#
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M?\N!4&:]T^ZB9WWG?>E$RP\75]P7:*J<@^FQU5 W[6><*BB+!<\Y@;JQ;^+
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M%YJ'[<.L.4PL37I<8CM8"S/P7/\)6_=_U3K^J];Q7[6._[A:1QJ#%8R?ZCG
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MY>DHDKL6!<T["](V'(#'=!(//"EEND+NIUXFC&[VIY%JK6?7VZ;_9M1O?7=
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M_SU,@W^-@QM@WLPJF.25Y.U?A=6OPG\%47*3!>0F35'SR%QO*LSC]$VMU&9
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M(>+F.":!-(C-<8R,A2!!*'D\6RU7=&[' 7M/=_KRMV,,]T)KX8#>WSI: ON
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MK0Y'J8S:HQ\:C6^:R&;'4[Q!WPW7+<OSSOAS[USZ3/9F-S/,F< 8$^-]?S.
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M), I8U1ED$<QA2B,,D@9%5!&/(XIXRP-K?9(EP::VIYH(R>H! 6-I*Z%K,Z
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M+7+K1+6NMZ^%>+PQ;LCO4F\7KBFZ;S$[=OPP).8#D\A18?XM_AOQ6Z=_U17
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MP:M]%,&7NZH.^B![)'N8/-&(Q8"C<HL] (>$XW!G3WNA*;3^9EF86G"?I5Y
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M],:U*_1QX1,<Q@&1&L] :7LAHQ)2DJ0P04S_H7\ITP;9UPLQ&J[-6$/NW,5
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M3R89TG96IG>P>"#GCWJV>!KN 8\7SPSHN0.'Z0?Z:OE(\\6,$4:" ,60QXQ
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MR2#%)MV!4Y(($<J06=E,3J-.C2@;N<"3$=PX69X:T<'3YG=.P:.6X%ML6X>
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MX/[P>;.6G 48V7CJ"]"Q+=7[2=?V5SF=E]L*KRM-J:HZH;<LUX_USPX:=K!
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M]7W0 WH3M("3+>*0;_XH?=S] 9]:OXWR->:>7V-^[FN\_=Y>['R?[^KX[T&
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M4!CNJ<T"]V G1L.3E;85-FU*C5<MNAGX,@Q\C#-<%T__>&:[\-^S_LP13,M
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M<5[]\]>UDO.-_6DF:2H9$06 N+1E$QD'),\)R%"622JDAA2'S94NMC4U#3J
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MT)N&H1<)#M@@6X/G;8ZU!CA\^+AS_K.&G<SQSU_5>W=@];+<5!_8#QN^:[3
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M;)W(>246J^IE[9)-&JU)U+8K7NJN6+0O-G.FQ<K_%4Y?IZ]YP./&\T$/M_'
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MX/'$*)BK2,+DW^ZH(A5,Q[%@A3^@=U1<.[]JBJ^=U#EJ<D,J(F19Z-)(%BL
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MG'SZ!=_%4;I?.,:B<2%[#@'K>%/:$(1Z=QF"XLR(FF=I'0CL2.)VF3#V3X#
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M%DB-<\A(_D(HC*%LG2K8CK+17],<%W%M)=6#07QX5YNF;=>;<E:HY$P&K;0
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ME :YX;M-QKA%<EVC\%"A=: +-UMX@#^7";RKI-Y$E(*8C8' 2WWP6AME.5G
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MS+.XPO\ZHP_[^>N^>;![G]&L%N$IVAIIR+N+7&'+LYSK^$Q(H=9TIAQK'E6
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MUCG?NBKA"7)&'N@Y#*9:L;\'))V_[__>^_^[K5LVQV<BHRVUSRJDJ"ET3:F
M3UK4&TX6F*,CQ5I?4QU"[[A-'8;"XK$$V %8KXH2WY:+U[-A=J/R]F)3A<4D
M=8G B^&TJ5CKJ84$%Y+UKHA0L/5SF:T(&[=APT#P:R^2#G#VZ)R)>V&O<LEK
MX^G ,-J7XPZ\"P*T=<D5&3QSS:<R;$G;5FASSPQM@PBF \"]/OU"YZANY.WR
MY73U9;$*L[?ES:(.*ON*^7PZZ+WP.>OBB5D06%2USWH=%$7_M)B#-'32B*&-
MP;</G5L!T3\S( XNL Y ^09I%[AI$W%O*Y9B)9=2!L-3;3&-$KQ, AQ*7I1R
M$9LG/YX@9[O,*WMF&&O%_PZ@1.XH$@&?7^)7G"TV&GM3UGCZY8P6^; HZ]^)
MTW<WJ3Q32EM-S#/U7CU&\)%%*+55E,[)A]"Z-&PO0K>#WW/+_ \OLPZ ^7 C
M\K>7[2I>;^)\TNC5X;AT9@,F$>H-;>26U?:-#*(NE@Y@4,F;D")KGK[;G<SM
M0/E<+A6.):\.(%DWML3/M#?:!VUH<8H/YRQ5B($<6P'&U>=]@L<Z-%>"4-)Z
MZ;TQH77%QK:T;0>^YW8W,8AD.D#<K_C[#8XM%W/Z,N&-^/WN_HIBOA3!H%B5
M*+H*"$&Y#+:$0B?+%%2M#?.N-&Z'P.=VF3&HI)Y[<=''VMMCP-*BB\\_:F'1
M0WL:OJPH69N%MQ*,D60QE>'DQ D#NO8(C"Q[U_R"LGU9T:8.X?(F.?^VPG(V
MJ\%YK6;9A.<;WMY0VB893!PAFN) U8=;/F8$JQ&9<]XPL]W ENW7[+9B:!<
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MEC5FSZ/-?HAVT@^0TBFD]A7Y UVD#^5_!S"Z2[X/2?-(OH,5G(*B+#*0D^^
M-+N--CBEFH\=W <V@Y7P# V;0_C= 5Q>G2WGTW5]D3K/KZ9_U*]6%SL)UGKK
MR $0-AK2S[2)Z)0#R4D]&Q.2T*TCE<>I&?=UPM @:B2%$?&T6JXG[\/\TX5I
M%\9S4Q\TZZ)!H5801'+@>$G>28GH<1OHT*?>@ W]ZQHRMQ8<5\4,ZESOS]@>
MT'!I0ZV3FBD./&]*_*4ELCG]P9.RFF?,?*O:[6WP,*:O<H"P[HI[#\Z-+/!?
MIO/IZ=GI!>%".">)>A"&*U*'.A'AL1#AW"8OA2G;N:W?$?FM14<6^CXB6[3@
MW]B"#W_<(!QY+L+;2'%<*81Z<I5CD DPD1GTI/Y0;.4V?$_P-Q<=1_\W$_S>
M_.O @7S4Y%W?_*!3D3/'(-K:QC8G02ZQK[9/,<DU0Z];CZ/^/E7C.I3CYN/V
M$TW/8+M1PV B\:4.>0JVU)XWC'2FLQETC"7ZZ$OPK<O;NJTM&0H)>Y26["*6
M?B]G=QRXT?A%2\/5QQE <NPW+H].E$B$-\.R!ZL4&5EF OA P3IC61MTW@??
MVB0--97D9+Z>YCK"8OH5/]3V[9O6LC__D69GQ,!7I O.,YL733SND7%:[Q\G
M2G/+Z80"USZ"\HC@K,F EB>662R2;Q6Q[W(MW8+P3B>6[(*ON]KT^ +]I]&W
MEV[5HFR&NX2KX2YW/H=^0%_6I@1'4\9[DS:.IF[#R:'5.,H@E%>UIBRY6J\:
MP2>*N"Q36B4E;<RMRTJ&4N._UHZA=71IY>[)5V+EIDO& Z(YGUMTR0).AQ&S
MM>"5(+_*BT@>%KE9R67GC#0"=?-*U_U([515[X*A^W,_AQ=:!V'7K6U.N,XE
M!K)M!5TBVU9]>A<2,!39^524O_M@MBWBQL71443^%,QVXO_>X/F*R[AH=27]
MX."U*U<)+=-U &Y$3JZ2S.0JN<! T;G+(B95S-"N^.YJ:K"[I$'45#L!=*",
M_H;33Y_)$3DAB(9/>/G^8+.QU=NS-7D^\WPQP2I-3$"5,A;07M&6F-?@,^-@
M8AUO*G3QS<L?=B*P+Z-X # 6QY)2OQ"\\)#O[7$2)$\^N_H2H>:^M"C@8I2
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MO$BM0!*AH$1"LJW:0S%:.:^*$FJKBK7GU5=H)V$]TE=H%\Z-W5[F=E\<K<@
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MQ;"HY0Q;)-OH_IPS]&>@^R.AN&EV_\DWV+M?U'_JL\9__9?_!U!+ P04
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MFCCL=,)>&/ NM/SN010?!M"/_58OZG>Z!R$$_VZAD4WL[F2T6:;PNI:)O)$
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M;RMSFAHQ4?.W:ZYY7,]$9TFQB-N.;?]:T4-/NA%+A9R/2_[BM1!S2Y@@-\)
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M     &MR>7,M,C R,C Y,S N:'1M4$L! A0#%     @ >CEG5:2<;:,-#@
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M,#(R,#DS,%]G,2YJ<&=02P$"% ,4    " !Z.6=5L_\6MDJK  !Z1P< %0
M            @ &[4@0 :W)Y<RTR,#(R,#DS,%]L86(N>&UL4$L! A0#%
M  @ >CEG5=G,<L/:8P  7)($ !4              ( !./X$ &MR>7,M,C R
M,C Y,S!?<')E+GAM;%!+ 0(4 Q0    ( 'HY9U4_S5CWV@<  *TI   6
M          "  45B!0!K<GES+3(P,C(P.3,P97@S,3$N:'1M4$L! A0#%
M  @ >CEG5<*)3!O&!P  B"D  !8              ( !4VH% &MR>7,M,C R
M,C Y,S!E>#,Q,BYH=&U02P$"% ,4    " !Z.6=50A6MDD$%  "1*P  %@
M            @ %-<@4 :W)Y<RTR,#(R,#DS,&5X,S(Q+FAT;5!+!08
.."@ * )@"  #"=P4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
